   Abstract
          There is disclosed compositions and methods relating to or derived from anti-PD-LI
   antibodies. More specifically, there is disclosed fully human antibodies that bind PD-Li,
   PD-Li-binding fragments and derivatives of such antibodies, and PD-Li -binding
 5 polypeptides comprising such fragments. Further still, there is disclosed nucleic acids
   encoding such antibodies, antibody fragments and derivatives and polypeptides, cells
   comprising such polynucleotides, methods of making such antibodies, antibody fragments
   and derivatives and polypeptides, and methods of using such antibodies, antibody fragments
   and derivatives and polypeptides, including methods of treating or diagnosing subjects
10 having PD-Li related disorders or conditions, including various inflammatory disorders and
   various cancers.
                                                  134

                             Antigen Binding Proteins that Bind PD-Li
   Related Applications
           This is a divisional of Australian Patent Application No. 2013267161, which is the
   Australian National Phase of PCT/US2013/043775, which claims priority from United
 5 States patent application USSN 61/654,022, filed 31 May 2012 and USSN 61/739982, filed
   20 December 2012. The contents of each application listed in this paragraph are fully
   incorporated by reference herein.
   Technical Field
10         The present disclosure provides compositions and methods relating to or derived
   from anti-PD-Li antibodies. More specifically, the present disclosure provides human
   antibodies that bind PD-L1, PD-Li -binding fragments and derivatives of such antibodies,
   and PD-Li -binding polypeptides comprising such fragments. Further still, the present
   disclosure provides nucleic acids encoding such antibodies, antibody fragments and
15 derivatives and polypeptides, cells comprising such polynucleotides, methods of making
   such antibodies, antibody fragments and derivatives and polypeptides, and methods of using
   such antibodies, antibody fragments and derivatives and polypeptides, including methods of
   treating or diagnosing subjects having PD-Li related disorders or conditions, including
   various inflammatory disorders and various cancers.
20 Background
           Programmed death ligand 1 (PD-Li) is a 40 kDa type 1 transmembrane protein.
   PD-Li (human PD-Li cDNA is composed of the base sequence shown by EMBL/GenBank
   Acc. No. NM_001267706 and mouse PD-LI cDNA is composed of the base sequence
   shown by NM_021893) that is a ligand of PD-lis expressed in so-called antigen-presenting
25 cells such as activated monocytes and dendritic cells. These cells present interaction
   molecules that induce a variety of immuno-inductive signals to T lymphocytes, and PD-Li
   is one of these molecules that induce the inhibitory signal by ligating PD-1. It has been
   revealed that PD-Li ligation suppressed the activation (cellular proliferation and induction
   of various cytokine productions) of PD-I expressing T lymphocytes. PD-LI expression has
30 been confirmed in not only immunocompetent cells but also a certain kind of tumor cell
   lines (cell lines derived from monocytic leukemia, cell lines derived from mast cells, cell
                                                   I

   lines derived from hepatic carcinomas, cell lines derived from neuroblasts, and cell lines
   derived from breast carcinomas) (Nature Immunology (2001), vol. 2, issue 3, p. 261-267.).
            Programmed death 1 (PD-1) is a member of the CD28 family of receptors, which
   includes CD28, CTLA-4, ICOS, PD-Li, and BTLA. The initial member of the family,
 5 CD28, was discovered by functional effect on augmenting T cell proliferation following the
   addition of monoclonal antibodies (Hutloff et al. (1999) Nature 397:263-266; Hansen et al.
   (1980) Immunogenics 10:247-260). Two cell surface glycoprotein ligands for PD-I have
   been identified, PD-LI and PDL-2, and have been shown to down-regulate T cell activation
   and cytokine secretion occur upon binding to PD-I (Freeman et al. (2000) J Exp. Med.
10 192:1027-34; Latchman et al. (2001) Nat. Immunol. 2:261-8; Carter et al. (2002) Eur.J
   Immunol. 32:634-43; Ohigashi et al. (2005) Clin. Cancer Res. 11:2947-53). Both PD-Li
   (B7-H I) and PD-L2 (B7-DC) are B7 homologs that bind to PD-1. Expression of PD-LI on
   the cell surface has also been shown to be upregulated through IFN-y stimulation.
            PD-Li expression has been found in several murine and human cancers, including
15 human lung, ovarian and colon carcinoma and various myelomas (Iwai et al. (2002) Proc.
   Natl. Acad. Sci. USA 99:12293-7; Ohigashi et al. (2005) Clin. CancerRes. 11:2947-53). PD
   LI has been suggested to play a role in tumor immunity by increasing apoptosis of antigen
   specific T-cell clones (Dong et al. (2002) Nat. Med. 8:793-800). It has also been suggested
   that PD-Li might be involved in intestinal mucosal inflammation and inhibition of PD-Li
20 suppresses wasting disease associated with colitis (Kanai et al. (2003) J Immunol.
   171:4156-63).
            Summary
            The present disclosure provides a fully human antibody of an IgG class that binds to
   a PD-LI epitope with a binding affinity of at least 10-6 M, which has a heavy chain variable
25 domain sequence that is at least 95% identical to the amino acid sequences selected from the
   group consisting of SEQ ID NO. 1, SEQ ID NO. 3, SEQ ID NO. 5, SEQ ID NO. 7, SEQ ID
   NO. 9, SEQ ID NO. 11, SEQ ID NO. 13, SEQ ID NO. 15, SEQ ID NO. 17, SEQ ID NO.
   19, SEQ ID NO. 21, SEQ ID NO. 23, SEQ ID NO. 25, SEQ ID NO. 27, SEQ ID NO. 29,
   SEQ ID NO. 31, SEQ ID NO. 33, SEQ ID NO. 35, SEQ ID NO. 37, SEQ ID NO. 39, SEQ
30 ID NO. 41, SEQ ID NO. 43, SEQ ID NO. 45, SEQ ID NO. 47, SEQ ID NO. 49, SEQ ID
   NO. 51, SEQ ID NO. 53, SEQ ID NO. 55, SEQ ID NO. 57, SEQ ID NO. 59, SEQ ID NO.
                                                   2

   61, SEQ ID NO. 63, SEQ ID NO. 65, SEQ ID NO. 67, SEQ ID NO. 69, SEQ ID NO. 71,
   SEQ ID NO. 73, SEQ ID NO. 75, SEQ ID NO. 77, SEQ ID NO. 79, SEQ ID NO. 81, SEQ
   ID NO. 83, SEQ ID NO. 85, SEQ ID NO. 87, SEQ ID NO. 89, SEQ ID NO. 91, SEQ ID
   NO. 93, SEQ ID NO. 95, SEQ ID NO. 97, SEQ ID NO. 99, SEQ ID NO. 101, SEQ ID NO.
 5 103, SEQ ID NO. 105, SEQ ID NO. 107, SEQ ID NO. 109, SEQ ID NO. 111, SEQ ID NO.
   113, SEQ ID NO. 115, SEQ ID NO. 117, SEQ ID NO. 119, SEQ ID NO. 121, SEQ ID NO.
   123, SEQ ID NO. 125, SEQ ID NO. 127, SEQ ID NO. 129, SEQ ID NO. 131, SEQ ID NO.
   133, SEQ ID NO. 135, SEQ ID NO. 137, SEQ ID NO. 139, SEQ ID NO. 141, SEQ ID NO.
   143, SEQ ID NO. 145, SEQ ID NO. 147, SEQ ID NO. 149, SEQ ID NO. 151, SEQ ID NO.
10 153, SEQ ID NO. 155, SEQ ID NO. 157, SEQ ID NO. 159, SEQ ID NO. 161, SEQ ID NO.
   163, SEQ ID NO. 165, SEQ ID NO. 167, SEQ ID NO. 169, SEQ ID NO. 171, SEQ ID NO.
   173, SEQ ID NO. 175, SEQ ID NO. 177, SEQ ID NO. 179, SEQ ID NO. 181, SEQ ID NO.
   183, SEQ ID NO. 185, SEQ ID NO. 187, SEQ ID NO. 189, SEQ ID NO. 191, SEQ ID NO.
   193, SEQ ID NO. 195, SEQ ID NO. 197, SEQ ID NO. 199, SEQ ID NO. 201, SEQ ID NO.
15 203, SEQ ID NO. 205, SEQ ID NO. 207, SEQ ID NO. 209, SEQ ID NO. 211, SEQ ID NO.
   213, SEQ ID NO. 215, SEQ ID NO. 217, SEQ ID NO. 219, SEQ ID NO. 221, SEQ ID NO.
   223, SEQ ID NO. 225, SEQ ID NO. 227, SEQ ID NO. 229, SEQ ID NO. 231, SEQ ID NO.
   233, SEQ ID NO. 235, SEQ ID NO. 237, SEQ ID NO. 239, SEQ ID NO. 241, and
   combinations thereof, and that has a light chain variable domain sequence that is at least
20 95% identical to the amino acid sequences selected from the group consisting of SEQ ID
   NO. 2, SEQ ID NO. 4, SEQ ID NO. 6, SEQ ID NO. 8, SEQ ID NO. 10, SEQ ID NO. 12,
   SEQ ID NO. 14, SEQ ID NO. 16, SEQ ID NO. 18, SEQ ID NO. 20, SEQ ID NO. 22, SEQ
   ID NO. 24, SEQ ID NO. 26, SEQ ID NO. 28, SEQ ID NO. 30, SEQ ID NO. 32, SEQ ID
   NO. 34, SEQ ID NO. 36, SEQ ID NO. 38, SEQ ID NO. 40, SEQ ID NO. 42, SEQ ID NO.
25 44, SEQ ID NO. 46, SEQ ID NO. 48, SEQ ID NO. 50, SEQ ID NO. 52, SEQ ID NO. 54,
   SEQ ID NO. 56, SEQ ID NO. 58, SEQ ID NO. 60, SEQ ID NO. 62, SEQ ID NO. 64, SEQ
   ID NO. 66, SEQ ID NO. 68, SEQ ID NO. 70, SEQ ID NO. 72, SEQ ID NO. 74, SEQ ID
   NO. 76, SEQ ID NO. 78, SEQ ID NO. 80, SEQ ID NO. 82, SEQ ID NO. 84, SEQ ID NO.
   86, SEQ ID NO. 88, SEQ ID NO. 90, SEQ ID NO. 92, SEQ ID NO. 94, SEQ ID NO. 96,
30 SEQ ID NO. 98, SEQ ID NO. 100, SEQ ID NO. 102, SEQ ID NO. 104, SEQ ID NO. 106,
   SEQ ID NO. 108, SEQ ID NO. 110, SEQ ID NO. 112, SEQ ID NO. 114, SEQ ID NO. 116,
                                                  3

   SEQ ID NO. 118, SEQ ID NO. 120, SEQ ID NO. 122, SEQ ID NO. 124, SEQ ID NO. 126,
   SEQ ID NO. 128, SEQ ID NO. 130, SEQ ID NO. 132, SEQ ID NO. 134, SEQ ID NO. 136,
   SEQ ID NO. 138, SEQ ID NO. 140, SEQ ID NO. 142, SEQ ID NO. 144, SEQ ID NO. 146,
   SEQ ID NO. 148, SEQ ID NO. 150, SEQ ID NO. 152, SEQ ID NO. 154, SEQ ID NO. 156,
 5 SEQ ID NO. 158, SEQ ID NO. 160, SEQ ID NO. 162, SEQ ID NO. 164, SEQ ID NO. 166,
   SEQ ID NO. 168, SEQ ID NO. 170, SEQ ID NO. 172, SEQ ID NO. 174, SEQ ID NO. 176,
   SEQ ID NO. 178, SEQ ID NO. 180, SEQ ID NO. 182, SEQ ID NO. 184, SEQ ID NO. 186,
   SEQ ID NO. 188, SEQ ID NO. 190, SEQ ID NO. 192, SEQ ID NO. 194, SEQ ID NO. 196,
   SEQ ID NO. 198, SEQ ID NO. 200, SEQ ID NO. 202, SEQ ID NO. 204, SEQ ID NO. 206,
10 SEQ ID NO. 208, SEQ ID NO. 210, SEQ ID NO. 212, SEQ ID NO. 214, SEQ ID NO. 216,
   SEQ ID NO. 218, SEQ ID NO. 220, SEQ ID NO. 222, SEQ ID NO. 224, SEQ ID NO. 226,
   SEQ ID NO. 228, SEQ ID NO. 230, SEQ ID NO. 232, SEQ ID NO. 234, SEQ ID NO. 236,
   SEQ ID NO. 238, SEQ ID NO. 240, SEQ ID NO. 242, and combinations thereof.
   Preferably, the fully human antibody has both a heavy chain and a light chain wherein the
15 antibody has a heavy chain/light chain variable domain sequence selected from the group
   consisting of SEQ ID NO. 1/SEQ ID NO. 2 (called E6 herein), SEQ ID NO. 3/SEQ ID NO.
   4 (called E7 herein), SEQ ID NO. 5/SEQ ID NO. 6 (called E9 herein), SEQ ID NO. 7/SEQ
   ID NO. 8 (called EI1 herein), SEQ ID NO. 9/SEQ ID NO. 10 (called Fl herein), SEQ ID
   NO. 11/SEQ ID NO. 12 (called F4 herein), SEQ ID NO. 13/SEQ ID NO. 14 (called F7
20 herein), SEQ ID NO. 15/SEQ ID NO. 16 (called F8 herein), SEQ ID NO. 17/SEQ ID NO.
   18 (called F 11 herein), SEQ ID NO. 19/SEQ ID NO. 20 (called G4 herein), SEQ ID NO.
   21/SEQ ID NO. 22 (called G9 herein), SEQ ID NO. 23/SEQ ID NO. 24 (called G 11 herein),
   SEQ ID NO. 25/SEQ ID NO. 26 (called G12 herein), SEQ ID NO. 27/SEQ ID NO. 28
   (called H1 herein), SEQ ID NO. 29/SEQ ID NO. 30 (called H3 herein), SEQ ID NO.
25 31/SEQ ID NO. 32 (called H4 herein), SEQ ID NO. 33/SEQ ID NO. 34 (called H5 herein),
   SEQ ID NO. 35/SEQ ID NO. 36 (called H6 herein), SEQ ID NO. 37/SEQ ID NO. 38 (called
   H1O herein), SEQ ID NO. 39/SEQ ID NO. 40 (called H12 herein), SEQ ID NO. 41/SEQ ID
   NO. 42 (called PDL-D2 herein), SEQ ID NO. 43/SEQ ID NO. 44 (called PDL-D 11 herein),
   SEQ ID NO. 45/SEQ ID NO. 46 (called PDL-Hl herein), SEQ ID NO. 47/SEQ ID NO. 48
30 (called RB4 herein), SEQ ID NO. 49/SEQ ID NO. 50 (called RB 11 herein), SEQ ID NO.
   51/SEQ ID NO. 52 (called RC5 herein), SEQ ID NO. 53/SEQ ID NO. 54 (called RF5
                                                 4

   herein), SEQ ID NO. 55/SEQ ID NO. 56 (called RG9 herein), SEQ ID NO. 57/SEQ ID NO.
   58 (called RD1 herein), SEQ ID NO. 59/SEQ ID NO. 60 (called RF1 1 herein), SEQ ID NO.
   61/SEQ ID NO. 62 (called RH 11 herein), SEQ ID NO. 63/SEQ ID NO. 64 (called RD9
   herein), SEQ ID NO. 65/SEQ ID NO. 66 (called RE10 herein), SEQ ID NO. 67/SEQ ID
 5 NO. 68 (called RA3 herein), SEQ ID NO. 69/SEQ ID NO. 70 (called RG1 herein), SEQ ID
   NO. 71/SEQ ID NO. 72 (called RB1 herein), SEQ ID NO. 73/SEQ ID NO. 74 (called RG7
   herein), SEQ ID NO. 75/SEQ ID NO. 76 (called RA6 herein), SEQ ID NO. 77/SEQ ID NO.
   78 (called RA8 herein), SEQ ID NO. 79/SEQ ID NO. 80 (called RA9 herein), SEQ ID NO.
   81/SEQ ID NO. 82 (called RB5 herein), SEQ ID NO. 83/SEQ ID NO. 84 (called RB8
10 herein), SEQ ID NO. 85/SEQ ID NO. 86 (called RC8 herein), SEQ ID NO. 87/SEQ ID NO.
   88 (called RC1O herein), SEQ ID NO. 89/SEQ ID NO. 90 (called RD2 herein), SEQ ID NO.
   91/SEQ ID NO. 92 (called RE8 herein), SEQ ID NO. 93/SEQ ID NO. 94 (called RE9
   herein), SEQ ID NO. 95/SEQ ID NO. 96 (called RG12 herein), SEQ ID NO. 97/SEQ ID
   NO. 98 (called RSA1 herein), SEQ ID NO. 99/SEQ ID NO. 100 (called R2A7 herein), SEQ
15 ID NO. 101/SEQ ID NO. 102 (called R2B12 herein), SEQ ID NO. 103/SEQ ID NO. 104
   (called R2C9 herein), SEQ ID NO. 105/SEQ ID NO. 106 (called R2D5 herein), SEQ ID
   NO. 107/SEQ ID NO. 108 (called R2D7 herein), SEQ ID NO. 109/SEQ ID NO. 110 (called
   R2F4 herein), SEQ ID NO. 111/SEQ ID NO. 112 (called R2A10 herein), SEQ ID NO.
   113/SEQ ID NO. 114 (called R2E2 herein), SEQ ID NO. 115/SEQ ID NO. 116 (called
20 R3B8 herein), SEQ ID NO. 117/SEQ ID NO. 118 (called R3C3 herein), SEQ ID NO.
   119/SEQ ID NO. 120 (called R3E9 herein), SEQ ID NO. 121/SEQ ID NO. 122 (called
   R3E1O herein), SEQ ID NO. 123/SEQ ID NO. 124 (called R3F7 herein), SEQ ID NO.
   125/SEQ ID NO. 126 (called R3F10 herein), SEQ ID NO. 127/SEQ ID NO. 128 (called
   R4B1O herein), SEQ ID NO. 129/SEQ ID NO. 130 (called R4H1 herein), SEQ ID NO.
25 131/SEQ ID NO. 132 (called R4A1 1 herein), SEQ ID NO. 133/SEQ ID NO. 134 (called
   R3D2 herein), SEQ ID NO. 135/SEQ ID NO. 136 (called R5B8 herein), SEQ ID NO.
   137/SEQ ID NO. 138 (called SH1A1Q herein), SEQ ID NO. 139/SEQ ID NO. 140 (called
   SH1B7B(K) herein), SEQ ID NO. 141/SEQ ID NO. 142 (called SHICI herein), SEQ ID
   NO. 143/SEQ ID NO. 144 (called SH1C8 herein), SEQ ID NO. 145/SEQ ID NO. 146
30 (called SHIE10 herein), SEQ ID NO. 147/SEQ ID NO. 148 (called SH1E2 herein), SEQ ID
   NO. 149/SEQ ID NO. 150 (called SH1A9 herein), SEQ ID NO. 151/SEQ ID NO. 152
                                              5

   (called SHIB 11 herein), SEQ ID NO. 153/SEQ ID NO. 154 (called SH1E4 herein), SEQ ID
   NO. 155/SEQ ID NO. 156 (called SH1B3 herein), SEQ ID NO. 157/SEQ ID NO. 158
   (called SHID1 herein), SEQ ID NO. 159/SEQ ID NO. 160 (called SH1D2 herein), SEQ ID
   NO. 161/SEQ ID NO. 162 (called SH1D12 herein), SEQ ID NO. 163/SEQ ID NO. 164
 5 (called SHIE1 herein), SEQ ID NO. 165/SEQ ID NO. 166 (called SH1G9 herein), SEQ ID
   NO. 167/SEQ ID NO. 168 (called SHIA 1 herein), SEQ ID NO. 169/SEQ ID NO. 170
   (called SH1C2 herein), SEQ ID NO. 171/SEQ ID NO. 172 (called SH1G8 herein), SEQ ID
   NO. 173/SEQ ID NO. 174 (called SH1H2 herein), SEQ ID NO. 175/SEQ ID NO. 176
   (called SHIB10 herein), SEQ ID NO. 177/SEQ ID NO. 178 (called SH1B7A(L) herein),
10 SEQ ID NO. 179/SEQ ID NO. 180 (called SH1E6 herein), SEQ ID NO. 181/SEQ ID NO.
   182 (called SHIC 11 herein), SEQ ID NO. 183/SEQ ID NO. 184 (called SH1A2 herein),
   SEQ ID NO. 185/SEQ ID NO. 186 (called SHIBI herein), SEQ ID NO. 187/SEQ ID NO.
   188 (called R6B2 herein), SEQ ID NO. 189/SEQ ID NO. 190 (called R6B7 herein), SEQ ID
   NO. 191/SEQ ID NO. 192 (called R6B1 1 herein), SEQ ID NO. 193/SEQ ID NO. 194
15 (called R6D1 herein), SEQ ID NO. 195/SEQ ID NO. 196 (called R6C8 herein), SEQ ID
   NO. 197/SEQ ID NO. 198 (called R9G8 herein), SEQ ID NO. 199/SEQ ID NO. 200 (called
   R7D1 herein), SEQ ID NO. 201/SEQ ID NO. 202 (called R7D2 herein), SEQ ID NO.
   203/SEQ ID NO. 204 (called R7E7 herein), SEQ ID NO. 205/SEQ ID NO. 206 (called
   R7F2 herein), SEQ ID NO. 207/SEQ ID NO. 208 (called R7F7 herein), SEQ ID NO.
20 209/SEQ ID NO. 210 (called R9H2 herein), SEQ ID NO. 211/SEQ ID NO. 212 (called
   R9H6 herein), SEQ ID NO. 213/SEQ ID NO. 214 (called H6B1L herein), SEQ ID NO.
   215/SEQ ID NO. 216 (called H6A1 herein), SEQ ID NO. 217/SEQ ID NO. 218 (called
   H6B1 herein), SEQ ID NO. 219/SEQ ID NO. 220 (called H6B2 herein), SEQ ID NO.
   221/SEQ ID NO. 222 (called H19C herein), SEQ ID NO. 223/SEQ ID NO. 224 (called
25 H1 OD herein), SEQ ID NO. 225/SEQ ID NO. 226 (called H I1F herein), SEQ ID NO.
   227/SEQ ID NO. 228 (called HiCi herein), SEQ ID NO. 229/SEQ ID NO. 230 (called
   GPGiA2 herein), SEQ ID NO. 231/SEQ ID NO. 232 (called GPGG8 herein), SEQ ID NO.
   233/SEQ ID NO. 234 (called GPGG1O herein), SEQ ID NO. 235/SEQ ID NO. 236 (called
   GPGH7 herein), SEQ ID NO. 237/SEQ ID NO. 238 (called GPGH1O herein), SEQ ID NO.
30 239/SEQ ID NO. 240 (called GPGH1 1 herein), SEQ ID NO. 241/SEQ ID NO. 242 (called
   GPGH1OP herein), and combinations thereof.
                                              6

           The present disclosure provides a Fab fully human antibody fragment, having a
   variable domain region from a heavy chain and a variable domain region from a light chain,
   wherein the heavy chain variable domain sequence that is at least 95% identical to the
   amino acid sequences selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 3,
 5 SEQ ID NO. 5, SEQ ID NO. 7, SEQ ID NO. 9, SEQ ID NO. 11, SEQ ID NO. 13, SEQ ID
   NO. 15, SEQ ID NO. 17, SEQ ID NO. 19, SEQ ID NO. 21, SEQ ID NO. 23, SEQ ID NO.
   25, SEQ ID NO. 27, SEQ ID NO. 29, SEQ ID NO. 31, SEQ ID NO. 33, SEQ ID NO. 35,
   SEQ ID NO. 37, SEQ ID NO. 39, SEQ ID NO. 41, SEQ ID NO. 43, SEQ ID NO. 45, SEQ
   ID NO. 47, SEQ ID NO. 49, SEQ ID NO. 51, SEQ ID NO. 53, SEQ ID NO. 55, SEQ ID
10 NO. 57, SEQ ID NO. 59, SEQ ID NO. 61, SEQ ID NO. 63, SEQ ID NO. 65, SEQ ID NO.
   67, SEQ ID NO. 69, SEQ ID NO. 71, SEQ ID NO. 73, SEQ ID NO. 75, SEQ ID NO. 77,
   SEQ ID NO. 79, SEQ ID NO. 81, SEQ ID NO. 83, SEQ ID NO. 85, SEQ ID NO. 87, SEQ
   ID NO. 89, SEQ ID NO. 91, SEQ ID NO. 93, SEQ ID NO. 95, SEQ ID NO. 97, SEQ ID
   NO. 99, SEQ ID NO. 101, SEQ ID NO. 103, SEQ ID NO. 105, SEQ ID NO. 107, SEQ ID
15 NO. 109, SEQ ID NO. 111, SEQ ID NO. 113, SEQ ID NO. 115, SEQ ID NO. 117, SEQ ID
   NO. 119, SEQ ID NO. 121, SEQ ID NO. 123, SEQ ID NO. 125, SEQ ID NO. 127, SEQ ID
   NO. 129, SEQ ID NO. 131, SEQ ID NO. 133, SEQ ID NO. 135, SEQ ID NO. 137, SEQ ID
   NO. 139, SEQ ID NO. 141, SEQ ID NO. 143, SEQ ID NO. 145, SEQ ID NO. 147, SEQ ID
   NO. 149, SEQ ID NO. 151, SEQ ID NO. 153, SEQ ID NO. 155, SEQ ID NO. 157, SEQ ID
20 NO. 159, SEQ ID NO. 161, SEQ ID NO. 163, SEQ ID NO. 165, SEQ ID NO. 167, SEQ ID
   NO. 169, SEQ ID NO. 171, SEQ ID NO. 173, SEQ ID NO. 175, SEQ ID NO. 177, SEQ ID
   NO. 179, SEQ ID NO. 181, SEQ ID NO. 183, SEQ ID NO. 185, SEQ ID NO. 187, SEQ ID
   NO. 189, SEQ ID NO. 191, SEQ ID NO. 193, SEQ ID NO. 195, SEQ ID NO. 197, SEQ ID
   NO. 199, SEQ ID NO. 201, SEQ ID NO. 203, SEQ ID NO. 205, SEQ ID NO. 207, SEQ ID
25 NO. 209, SEQ ID NO. 211, SEQ ID NO. 213, SEQ ID NO. 215, SEQ ID NO. 217, SEQ ID
   NO. 219, SEQ ID NO. 221, SEQ ID NO. 223, SEQ ID NO. 225, SEQ ID NO. 227, SEQ ID
   NO. 229, SEQ ID NO. 231, SEQ ID NO. 233, SEQ ID NO. 235, SEQ ID NO. 237, SEQ ID
   NO. 239, SEQ ID NO. 241, and combinations thereof, and that has a light chain variable
   domain sequence that is at least 95% identical to the amino acid sequences selected from the
30 group consisting of SEQ ID NO. 2, SEQ ID NO. 4, SEQ ID NO. 6, SEQ ID NO. 8, SEQ ID
   NO. 10, SEQ ID NO. 12, SEQ ID NO. 14, SEQ ID NO. 16, SEQ ID NO. 18, SEQ ID NO.
                                                 7

   20, SEQ ID NO. 22, SEQ ID NO. 24, SEQ ID NO. 26, SEQ ID NO. 28, SEQ ID NO. 30,
   SEQ ID NO. 32, SEQ ID NO. 34, SEQ ID NO. 36, SEQ ID NO. 38, SEQ ID NO. 40, SEQ
   ID NO. 42, SEQ ID NO. 44, SEQ ID NO. 46, SEQ ID NO. 48, SEQ ID NO. 50, SEQ ID
   NO. 52, SEQ ID NO. 54, SEQ ID NO. 56, SEQ ID NO. 58, SEQ ID NO. 60, SEQ ID NO.
 5 62, SEQ ID NO. 64, SEQ ID NO. 66, SEQ ID NO. 68, SEQ ID NO. 70, SEQ ID NO. 72,
   SEQ ID NO. 74, SEQ ID NO. 76, SEQ ID NO. 78, SEQ ID NO. 80, SEQ ID NO. 82, SEQ
   ID NO. 84, SEQ ID NO. 86, SEQ ID NO. 88, SEQ ID NO. 90, SEQ ID NO. 92, SEQ ID
   NO. 94, SEQ ID NO. 96, SEQ ID NO. 98, SEQ ID NO. 100, SEQ ID NO. 102, SEQ ID
   NO. 104, SEQ ID NO. 106, SEQ ID NO. 108, SEQ ID NO. 110, SEQ ID NO. 112, SEQ ID
10 NO. 114, SEQ ID NO. 116, SEQ ID NO. 118, SEQ ID NO. 120, SEQ ID NO. 122, SEQ ID
   NO. 124, SEQ ID NO. 126, SEQ ID NO. 128, SEQ ID NO. 130, SEQ ID NO. 132, SEQ ID
   NO. 134, SEQ ID NO. 136, SEQ ID NO. 138, SEQ ID NO. 140, SEQ ID NO. 142, SEQ ID
   NO. 144, SEQ ID NO. 146, SEQ ID NO. 148, SEQ ID NO. 150, SEQ ID NO. 152, SEQ ID
   NO. 154, SEQ ID NO. 156, SEQ ID NO. 158, SEQ ID NO. 160, SEQ ID NO. 162, SEQ ID
15 NO. 164, SEQ ID NO. 166, SEQ ID NO. 168, SEQ ID NO. 170, SEQ ID NO. 172, SEQ ID
   NO. 174, SEQ ID NO. 176, SEQ ID NO. 178, SEQ ID NO. 180, SEQ ID NO. 182, SEQ ID
   NO. 184, SEQ ID NO. 186, SEQ ID NO. 188, SEQ ID NO. 190, SEQ ID NO. 192, SEQ ID
   NO. 194, SEQ ID NO. 196, SEQ ID NO. 198, SEQ ID NO. 200, SEQ ID NO. 202, SEQ ID
   NO. 204, SEQ ID NO. 206, SEQ ID NO. 208, SEQ ID NO. 210, SEQ ID NO. 212, SEQ ID
20 NO. 214, SEQ ID NO. 216, SEQ ID NO. 218, SEQ ID NO. 220, SEQ ID NO. 222, SEQ ID
   NO. 224, SEQ ID NO. 226, SEQ ID NO. 228, SEQ ID NO. 230, SEQ ID NO. 232, SEQ ID
   NO. 234, SEQ ID NO. 236, SEQ ID NO. 238, SEQ ID NO. 240, SEQ ID NO. 242, and
   combinations thereof. Preferably, the fully human antibody Fab fragment has both a heavy
   chain variable domain region and a light chain variable domain region wherein the antibody
25 has a heavy chain/light chain variable domain sequence selected from the group consisting
   of SEQ ID NO. 1/SEQ ID NO. 2, SEQ ID NO. 3/SEQ ID NO. 4, SEQ ID NO. 5/SEQ ID
   NO. 6, SEQ ID NO. 7/SEQ ID NO. 8, SEQ ID NO. 9/SEQ ID NO. 10, SEQ ID NO. 11/SEQ
   ID NO. 12, SEQ ID NO. 13/SEQ ID NO. 14, SEQ ID NO. 15/SEQ ID NO. 16, SEQ ID NO.
   17/SEQ ID NO. 18, SEQ ID NO. 19/SEQ ID NO. 20, SEQ ID NO. 21/SEQ ID NO. 22,
30 SEQ ID NO. 23/SEQ ID NO. 24, SEQ ID NO. 25/SEQ ID NO. 26, SEQ ID NO. 27/SEQ ID
   NO. 28, SEQ ID NO. 29/SEQ ID NO. 30, SEQ ID NO. 31/SEQ ID NO. 32, SEQ ID NO.
                                                 8

   33/SEQ ID NO. 34, SEQ ID NO. 35/SEQ ID NO. 36, SEQ ID NO. 37/SEQ ID NO. 38,
   SEQ ID NO. 39/SEQ ID NO. 40, SEQ ID NO. 41/SEQ ID NO. 42, SEQ ID NO. 43/SEQ ID
   NO. 44, SEQ ID NO. 45/SEQ ID NO. 46, SEQ ID NO. 47/SEQ ID NO. 48, SEQ ID NO.
   49/SEQ ID NO. 50, SEQ ID NO. 51/SEQ ID NO. 52, SEQ ID NO. 53/SEQ ID NO. 54,
 5 SEQ ID NO. 55/SEQ ID NO. 56, SEQ ID NO. 57/SEQ ID NO. 58, SEQ ID NO. 59/SEQ ID
   NO. 60, SEQ ID NO. 61/SEQ ID NO. 62, SEQ ID NO. 63/SEQ ID NO. 64, SEQ ID NO.
   65/SEQ ID NO. 66, SEQ ID NO. 67/SEQ ID NO. 68, SEQ ID NO. 69/SEQ ID NO. 70,
   SEQ ID NO. 71/SEQ ID NO. 72, SEQ ID NO. 73/SEQ ID NO. 74, SEQ ID NO. 75/SEQ ID
   NO. 76, SEQ ID NO. 77/SEQ ID NO. 78, SEQ ID NO. 79/SEQ ID NO. 80, SEQ ID NO.
10 81/SEQ ID NO. 82, SEQ ID NO. 83/SEQ ID NO. 84, SEQ ID NO. 85/SEQ ID NO. 86,
   SEQ ID NO. 87/SEQ ID NO. 88, SEQ ID NO. 89/SEQ ID NO. 90, SEQ ID NO. 91/SEQ ID
   NO. 92, SEQ ID NO. 93/SEQ ID NO. 94, SEQ ID NO. 95/SEQ ID NO. 96, SEQ ID NO.
   97/SEQ ID NO. 98, SEQ ID NO. 99/SEQ ID NO. 100, SEQ ID NO. 101/SEQ ID NO. 102,
   SEQ ID NO. 103/SEQ ID NO. 104, SEQ ID NO. 105/SEQ ID NO. 106, SEQ ID NO.
15 107/SEQ ID NO. 108, SEQ ID NO. 109/SEQ ID NO. 110, SEQ ID NO. 111/SEQ ID NO.
   112, SEQ ID NO. 113/SEQ ID NO. 114, SEQ ID NO. 115/SEQ ID NO. 116, SEQ ID NO.
   117/SEQ ID NO. 118, SEQ ID NO. 119/SEQ ID NO. 120, SEQ ID NO. 121/SEQ ID NO.
   122, SEQ ID NO. 123/SEQ ID NO. 124, SEQ ID NO. 125/SEQ ID NO. 126, SEQ ID NO.
   127/SEQ ID NO. 128, SEQ ID NO. 129/SEQ ID NO. 130, SEQ ID NO. 131/SEQ ID NO.
20 132, SEQ ID NO. 133/SEQ ID NO. 134, SEQ ID NO. 135/SEQ ID NO. 136, SEQ ID NO.
   137/SEQ ID NO. 138, SEQ ID NO. 139/SEQ ID NO. 140, SEQ ID NO. 141/SEQ ID NO.
   142, SEQ ID NO. 143/SEQ ID NO. 144, SEQ ID NO. 145/SEQ ID NO. 146, SEQ ID NO.
   147/SEQ ID NO. 148, SEQ ID NO. 149/SEQ ID NO. 150, SEQ ID NO. 151/SEQ ID NO.
   152, SEQ ID NO. 153/SEQ ID NO. 154, SEQ ID NO. 155/SEQ ID NO. 156, SEQ ID NO.
25 157/SEQ ID NO. 158, SEQ ID NO. 159/SEQ ID NO. 160, SEQ ID NO. 161/SEQ ID NO.
   162, SEQ ID NO. 163/SEQ ID NO. 164, SEQ ID NO. 165/SEQ ID NO. 166, SEQ ID NO.
   167/SEQ ID NO. 168, SEQ ID NO. 169/SEQ ID NO. 170, SEQ ID NO. 171/SEQ ID NO.
   172, SEQ ID NO. 173/SEQ ID NO. 174, SEQ ID NO. 175/SEQ ID NO. 176, SEQ ID NO.
   177/SEQ ID NO. 178, SEQ ID NO. 179/SEQ ID NO. 180, SEQ ID NO. 181/SEQ ID NO.
30 182, SEQ ID NO. 183/SEQ ID NO. 184, SEQ ID NO. 185/SEQ ID NO. 186, SEQ ID NO.
   187/SEQ ID NO. 188, SEQ ID NO. 189/SEQ ID NO. 190, SEQ ID NO. 191/SEQ ID NO.
                                          9

   192, SEQ ID NO. 193/SEQ ID NO. 194, SEQ ID NO. 195/SEQ ID NO. 196, SEQ ID NO.
   197/SEQ ID NO. 198, SEQ ID NO. 199/SEQ ID NO. 200, SEQ ID NO. 201/SEQ ID NO.
   202, SEQ ID NO. 203/SEQ ID NO. 204, SEQ ID NO. 205/SEQ ID NO. 206, SEQ ID NO.
   207/SEQ ID NO. 208, SEQ ID NO. 209/SEQ ID NO. 210, SEQ ID NO. 211/SEQ ID NO.
 5 212, SEQ ID NO. 213/SEQ ID NO. 214, SEQ ID NO. 215/SEQ ID NO. 216, SEQ ID NO.
   217/SEQ ID NO. 218, SEQ ID NO. 219/SEQ ID NO. 220, SEQ ID NO. 221/SEQ ID NO.
   222, SEQ ID NO. 223/SEQ ID NO. 224, SEQ ID NO. 225/SEQ ID NO. 226, SEQ ID NO.
   227/SEQ ID NO. 228, SEQ ID NO. 229/SEQ ID NO. 230, SEQ ID NO. 231/SEQ ID NO.
   232, SEQ ID NO. 233/SEQ ID NO. 234, SEQ ID NO. 235/SEQ ID NO. 236, SEQ ID NO.
10 237/SEQ ID NO. 238, SEQ ID NO. 239/SEQ ID NO. 240, SEQ ID NO. 241/SEQ ID NO.
   242, and combinations thereof.
          The present disclosure provides a single chain human antibody, having a variable
   domain region from a heavy chain and a variable domain region from a light chain and a
   peptide linker connection the heavy chain and light chain variable domain regions, wherein
15 the heavy chain variable domain sequence that is at least 95% identical to the amino acid
   sequences selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 3, SEQ ID
   NO. 5, SEQ ID NO. 7, SEQ ID NO. 9, SEQ ID NO. 11, SEQ ID NO. 13, SEQ ID NO. 15,
   SEQ ID NO. 17, SEQ ID NO. 19, SEQ ID NO. 21, SEQ ID NO. 23, SEQ ID NO. 25, SEQ
   ID NO. 27, SEQ ID NO. 29, SEQ ID NO. 31, SEQ ID NO. 33, SEQ ID NO. 35, SEQ ID
20 NO. 37, SEQ ID NO. 39, SEQ ID NO. 41, SEQ ID NO. 43, SEQ ID NO. 45, SEQ ID NO.
   47, SEQ ID NO. 49, SEQ ID NO. 51, SEQ ID NO. 53, SEQ ID NO. 55, SEQ ID NO. 57,
   SEQ ID NO. 59, SEQ ID NO. 61, SEQ ID NO. 63, SEQ ID NO. 65, SEQ ID NO. 67, SEQ
   ID NO. 69, SEQ ID NO. 71, SEQ ID NO. 73, SEQ ID NO. 75, SEQ ID NO. 77, SEQ ID
   NO. 79, SEQ ID NO. 81, SEQ ID NO. 83, SEQ ID NO. 85, SEQ ID NO. 87, SEQ ID NO.
25 89, SEQ ID NO. 91, SEQ ID NO. 93, SEQ ID NO. 95, SEQ ID NO. 97, SEQ ID NO. 99,
   SEQ ID NO. 101, SEQ ID NO. 103, SEQ ID NO. 105, SEQ ID NO. 107, SEQ ID NO. 109,
   SEQ ID NO. 111, SEQ ID NO. 113, SEQ ID NO. 115, SEQ ID NO. 117, SEQ ID NO. 119,
   SEQ ID NO. 121, SEQ ID NO. 123, SEQ ID NO. 125, SEQ ID NO. 127, SEQ ID NO. 129,
   SEQ ID NO. 131, SEQ ID NO. 133, SEQ ID NO. 135, SEQ ID NO. 137, SEQ ID NO. 139,
30 SEQ ID NO. 141, SEQ ID NO. 143, SEQ ID NO. 145, SEQ ID NO. 147, SEQ ID NO. 149,
   SEQ ID NO. 151, SEQ ID NO. 153, SEQ ID NO. 155, SEQ ID NO. 157, SEQ ID NO. 159,
                                                10

   SEQ ID NO. 161, SEQ ID NO. 163, SEQ ID NO. 165, SEQ ID NO. 167, SEQ ID NO. 169,
   SEQ ID NO. 171, SEQ ID NO. 173, SEQ ID NO. 175, SEQ ID NO. 177, SEQ ID NO. 179,
   SEQ ID NO. 181, SEQ ID NO. 183, SEQ ID NO. 185, SEQ ID NO. 187, SEQ ID NO. 189,
   SEQ ID NO. 191, SEQ ID NO. 193, SEQ ID NO. 195, SEQ ID NO. 197, SEQ ID NO. 199,
 5 SEQ ID NO. 201, SEQ ID NO. 203, SEQ ID NO. 205, SEQ ID NO. 207, SEQ ID NO. 209,
   SEQ ID NO. 211, SEQ ID NO. 213, SEQ ID NO. 215, SEQ ID NO. 217, SEQ ID NO. 219,
   SEQ ID NO. 221, SEQ ID NO. 223, SEQ ID NO. 225, SEQ ID NO. 227, SEQ ID NO. 229,
   SEQ ID NO. 231, SEQ ID NO. 233, SEQ ID NO. 235, SEQ ID NO. 237, SEQ ID NO. 239,
   SEQ ID NO. 241, and combinations thereof, and that has a light chain variable domain
10 sequence that is at least 95% identical to the amino acid sequences selected from the group
   consisting of SEQ ID NO. 2, SEQ ID NO. 4, SEQ ID NO. 6, SEQ ID NO. 8, SEQ ID NO.
   10, SEQ ID NO. 12, SEQ ID NO. 14, SEQ ID NO. 16, SEQ ID NO. 18, SEQ ID NO. 20,
   SEQ ID NO. 22, SEQ ID NO. 24, SEQ ID NO. 26, SEQ ID NO. 28, SEQ ID NO. 30, SEQ
   ID NO. 32, SEQ ID NO. 34, SEQ ID NO. 36, SEQ ID NO. 38, SEQ ID NO. 40, SEQ ID
15 NO. 42, SEQ ID NO. 44, SEQ ID NO. 46, SEQ ID NO. 48, SEQ ID NO. 50, SEQ ID NO.
   52, SEQ ID NO. 54, SEQ ID NO. 56, SEQ ID NO. 58, SEQ ID NO. 60, SEQ ID NO. 62,
   SEQ ID NO. 64, SEQ ID NO. 66, SEQ ID NO. 68, SEQ ID NO. 70, SEQ ID NO. 72, SEQ
   ID NO. 74, SEQ ID NO. 76, SEQ ID NO. 78, SEQ ID NO. 80, SEQ ID NO. 82, SEQ ID
   NO. 84, SEQ ID NO. 86, SEQ ID NO. 88, SEQ ID NO. 90, SEQ ID NO. 92, SEQ ID NO.
20 94, SEQ ID NO. 96, SEQ ID NO. 98, SEQ ID NO. 100, SEQ ID NO. 102, SEQ ID NO.
   104, SEQ ID NO. 106, SEQ ID NO. 108, SEQ ID NO. 110, SEQ ID NO. 112, SEQ ID NO.
   114, SEQ ID NO. 116, SEQ ID NO. 118, SEQ ID NO. 120, SEQ ID NO. 122, SEQ ID NO.
   124, SEQ ID NO. 126, SEQ ID NO. 128, SEQ ID NO. 130, SEQ ID NO. 132, SEQ ID NO.
   134, SEQ ID NO. 136, SEQ ID NO. 138, SEQ ID NO. 140, SEQ ID NO. 142, SEQ ID NO.
25 144, SEQ ID NO. 146, SEQ ID NO. 148, SEQ ID NO. 150, SEQ ID NO. 152, SEQ ID NO.
   154, SEQ ID NO. 156, SEQ ID NO. 158, SEQ ID NO. 160, SEQ ID NO. 162, SEQ ID NO.
   164, SEQ ID NO. 166, SEQ ID NO. 168, SEQ ID NO. 170, SEQ ID NO. 172, SEQ ID NO.
   174, SEQ ID NO. 176, SEQ ID NO. 178, SEQ ID NO. 180, SEQ ID NO. 182, SEQ ID NO.
   184, SEQ ID NO. 186, SEQ ID NO. 188, SEQ ID NO. 190, SEQ ID NO. 192, SEQ ID NO.
30 194, SEQ ID NO. 196, SEQ ID NO. 198, SEQ ID NO. 200, SEQ ID NO. 202, SEQ ID NO.
   204, SEQ ID NO. 206, SEQ ID NO. 208, SEQ ID NO. 210, SEQ ID NO. 212, SEQ ID NO.
                                                   11

   214, SEQ ID NO. 216, SEQ ID NO. 218, SEQ ID NO. 220, SEQ ID NO. 222, SEQ ID NO.
   224, SEQ ID NO. 226, SEQ ID NO. 228, SEQ ID NO. 230, SEQ ID NO. 232, SEQ ID NO.
   234, SEQ ID NO. 236, SEQ ID NO. 238, SEQ ID NO. 240, SEQ ID NO. 242, and
   combinations thereof. Preferably, the fully human single chain antibody has both a heavy
 5 chain variable domain region and a light chain variable domain region, wherein the single
   chain fully human antibody has a heavy chain/light chain variable domain sequence selected
   from the group consisting of SEQ ID NO. 1/SEQ ID NO. 2, SEQ ID NO. 3/SEQ ID NO. 4,
   SEQ ID NO. 5/SEQ ID NO. 6, SEQ ID NO. 7/SEQ ID NO. 8, SEQ ID NO. 9/SEQ ID NO.
   10, SEQ ID NO. 11/SEQ ID NO. 12, SEQ ID NO. 13/SEQ ID NO. 14, SEQ ID NO.
10 15/SEQ ID NO. 16, SEQ ID NO. 17/SEQ ID NO. 18, SEQ ID NO. 19/SEQ ID NO. 20,
   SEQ ID NO. 21/SEQ ID NO. 22, SEQ ID NO. 23/SEQ ID NO. 24, SEQ ID NO. 25/SEQ ID
   NO. 26, SEQ ID NO. 27/SEQ ID NO. 28, SEQ ID NO. 29/SEQ ID NO. 30, SEQ ID NO.
   31/SEQ ID NO. 32, SEQ ID NO. 33/SEQ ID NO. 34, SEQ ID NO. 35/SEQ ID NO. 36,
   SEQ ID NO. 37/SEQ ID NO. 38, SEQ ID NO. 39/SEQ ID NO. 40, SEQ ID NO. 41/SEQ ID
15 NO. 42, SEQ ID NO. 43/SEQ ID NO. 44, SEQ ID NO. 45/SEQ ID NO. 46, SEQ ID NO.
   47/SEQ ID NO. 48, SEQ ID NO. 49/SEQ ID NO. 50, SEQ ID NO. 51/SEQ ID NO. 52,
   SEQ ID NO. 53/SEQ ID NO. 54, SEQ ID NO. 55/SEQ ID NO. 56, SEQ ID NO. 57/SEQ ID
   NO. 58, SEQ ID NO. 59/SEQ ID NO. 60, SEQ ID NO. 61/SEQ ID NO. 62, SEQ ID NO.
   63/SEQ ID NO. 64, SEQ ID NO. 65/SEQ ID NO. 66, SEQ ID NO. 67/SEQ ID NO. 68,
20 SEQ ID NO. 69/SEQ ID NO. 70, SEQ ID NO. 71/SEQ ID NO. 72, SEQ ID NO. 73/SEQ ID
   NO. 74, SEQ ID NO. 75/SEQ ID NO. 76, SEQ ID NO. 77/SEQ ID NO. 78, SEQ ID NO.
   79/SEQ ID NO. 80, SEQ ID NO. 81/SEQ ID NO. 82, SEQ ID NO. 83/SEQ ID NO. 84,
   SEQ ID NO. 85/SEQ ID NO. 86, SEQ ID NO. 87/SEQ ID NO. 88, SEQ ID NO. 89/SEQ ID
   NO. 90, SEQ ID NO. 91/SEQ ID NO. 92, SEQ ID NO. 93/SEQ ID NO. 94, SEQ ID NO.
25 95/SEQ ID NO. 96, SEQ ID NO. 97/SEQ ID NO. 98, SEQ ID NO. 99/SEQ ID NO. 100,
   SEQ ID NO. 101/SEQ ID NO. 102, SEQ ID NO. 103/SEQ ID NO. 104, SEQ ID NO.
   105/SEQ ID NO. 106, SEQ ID NO. 107/SEQ ID NO. 108, SEQ ID NO. 109/SEQ ID NO.
   110, SEQ ID NO. 111/SEQ ID NO. 112, SEQ ID NO. 113/SEQ ID NO. 114, SEQ ID NO.
   115/SEQ ID NO. 116, SEQ ID NO. 117/SEQ ID NO. 118, SEQ ID NO. 119/SEQ ID NO.
30 120, SEQ ID NO. 121/SEQ ID NO. 122, SEQ ID NO. 123/SEQ ID NO. 124, SEQ ID NO.
   125/SEQ ID NO. 126, SEQ ID NO. 127/SEQ ID NO. 128, SEQ ID NO. 129/SEQ ID NO.
                                                 12

   130, SEQ ID NO. 131/SEQ ID NO. 132, SEQ ID NO. 133/SEQ ID NO. 134, SEQ ID NO.
   135/SEQ ID NO. 136, SEQ ID NO. 137/SEQ ID NO. 138, SEQ ID NO. 139/SEQ ID NO.
   140, SEQ ID NO. 141/SEQ ID NO. 142, SEQ ID NO. 143/SEQ ID NO. 144, SEQ ID NO.
   145/SEQ ID NO. 146, SEQ ID NO. 147/SEQ ID NO. 148, SEQ ID NO. 149/SEQ ID NO.
 5 150, SEQ ID NO. 151/SEQ ID NO. 152, SEQ ID NO. 153/SEQ ID NO. 154, SEQ ID NO.
   155/SEQ ID NO. 156, SEQ ID NO. 157/SEQ ID NO. 158, SEQ ID NO. 159/SEQ ID NO.
   160, SEQ ID NO. 161/SEQ ID NO. 162, SEQ ID NO. 163/SEQ ID NO. 164, SEQ ID NO.
   165/SEQ ID NO. 166, SEQ ID NO. 167/SEQ ID NO. 168, SEQ ID NO. 169/SEQ ID NO.
   170, SEQ ID NO. 171/SEQ ID NO. 172, SEQ ID NO. 173/SEQ ID NO. 174, SEQ ID NO.
10 175/SEQ ID NO. 176, SEQ ID NO. 177/SEQ ID NO. 178, SEQ ID NO. 179/SEQ ID NO.
   180, SEQ ID NO. 181/SEQ ID NO. 182, SEQ ID NO. 183/SEQ ID NO. 184, SEQ ID NO.
   185/SEQ ID NO. 186, SEQ ID NO. 187/SEQ ID NO. 188, SEQ ID NO. 189/SEQ ID NO.
   190, SEQ ID NO. 191/SEQ ID NO. 192, SEQ ID NO. 193/SEQ ID NO. 194, SEQ ID NO.
   195/SEQ ID NO. 196, SEQ ID NO. 197/SEQ ID NO. 198, SEQ ID NO. 199/SEQ ID NO.
15 200, SEQ ID NO. 201/SEQ ID NO. 202, SEQ ID NO. 203/SEQ ID NO. 204, SEQ ID NO.
   205/SEQ ID NO. 206, SEQ ID NO. 207/SEQ ID NO. 208, SEQ ID NO. 209/SEQ ID NO.
   210, SEQ ID NO. 211/SEQ ID NO. 212, SEQ ID NO. 213/SEQ ID NO. 214, SEQ ID NO.
   215/SEQ ID NO. 216, SEQ ID NO. 217/SEQ ID NO. 218, SEQ ID NO. 219/SEQ ID NO.
   220, SEQ ID NO. 221/SEQ ID NO. 222, SEQ ID NO. 223/SEQ ID NO. 224, SEQ ID NO.
20 225/SEQ ID NO. 226, SEQ ID NO. 227/SEQ ID NO. 228, SEQ ID NO. 229/SEQ ID NO.
   230, SEQ ID NO. 231/SEQ ID NO. 232, SEQ ID NO. 233/SEQ ID NO. 234, SEQ ID NO.
   235/SEQ ID NO. 236, SEQ ID NO. 237/SEQ ID NO. 238, SEQ ID NO. 239/SEQ ID NO.
   240, SEQ ID NO. 241/SEQ ID NO. 242, and combinations thereof.
           The present disclosure further provides a method for treating a broad spectrum of
25 mammalian cancers or a broad-spectrum of inflammatory diseases and autoimmune
   diseases, comprising administering an effective amount of an anti-PD-Li polypeptide,
   wherein the anti-PD-LI polypeptide is selected from the group consisting of a fully human
   antibody of an IgG class that binds to a PD-LI epitope with a binding affinity of at least 10
   6M,  a Fab fully human antibody fragment, having a variable domain region from a heavy
30 chain and a variable domain region from a light chain, a single chain human antibody,
   having a variable domain region from a heavy chain and a variable domain region from a
                                                 13

   light chain and a peptide linker connection the heavy chain and light chain variable domain
   regions, and combinations thereof;
            wherein the fully human antibody has a heavy chain variable domain sequence that
   is at least 95% identical to the amino acid sequences selected from the group consisting of
 5 SEQ ID NO. 1, SEQ ID NO. 3, SEQ ID NO. 5, SEQ ID NO. 7, SEQ ID NO. 9, SEQ ID NO.
   11, SEQ ID NO. 13, SEQ ID NO. 15, SEQ ID NO. 17, SEQ ID NO. 19, SEQ ID NO. 21,
   SEQ ID NO. 23, SEQ ID NO. 25, SEQ ID NO. 27, SEQ ID NO. 29, SEQ ID NO. 31, SEQ
   ID NO. 33, SEQ ID NO. 35, SEQ ID NO. 37, SEQ ID NO. 39, SEQ ID NO. 41, SEQ ID
   NO. 43, SEQ ID NO. 45, SEQ ID NO. 47, SEQ ID NO. 49, SEQ ID NO. 51, SEQ ID NO.
10 53, SEQ ID NO. 55, SEQ ID NO. 57, SEQ ID NO. 59, SEQ ID NO. 61, SEQ ID NO. 63,
   SEQ ID NO. 65, SEQ ID NO. 67, SEQ ID NO. 69, SEQ ID NO. 71, SEQ ID NO. 73, SEQ
   ID NO. 75, SEQ ID NO. 77, SEQ ID NO. 79, SEQ ID NO. 81, SEQ ID NO. 83, SEQ ID
   NO. 85, SEQ ID NO. 87, SEQ ID NO. 89, SEQ ID NO. 91, SEQ ID NO. 93, SEQ ID NO.
   95, SEQ ID NO. 97, SEQ ID NO. 99, SEQ ID NO. 101, SEQ ID NO. 103, SEQ ID NO.
15 105, SEQ ID NO. 107, SEQ ID NO. 109, SEQ ID NO. 111, SEQ ID NO. 113, SEQ ID NO.
   115, SEQ ID NO. 117, SEQ ID NO. 119, SEQ ID NO. 121, SEQ ID NO. 123, SEQ ID NO.
   125, SEQ ID NO. 127, SEQ ID NO. 129, SEQ ID NO. 131, SEQ ID NO. 133, SEQ ID NO.
   135, SEQ ID NO. 137, SEQ ID NO. 139, SEQ ID NO. 141, SEQ ID NO. 143, SEQ ID NO.
   145, SEQ ID NO. 147, SEQ ID NO. 149, SEQ ID NO. 151, SEQ ID NO. 153, SEQ ID NO.
20 155, SEQ ID NO. 157, SEQ ID NO. 159, SEQ ID NO. 161, SEQ ID NO. 163, SEQ ID NO.
   165, SEQ ID NO. 167, SEQ ID NO. 169, SEQ ID NO. 171, SEQ ID NO. 173, SEQ ID NO.
   175, SEQ ID NO. 177, SEQ ID NO. 179, SEQ ID NO. 181, SEQ ID NO. 183, SEQ ID NO.
   185, SEQ ID NO. 187, SEQ ID NO. 189, SEQ ID NO. 191, SEQ ID NO. 193, SEQ ID NO.
   195, SEQ ID NO. 197, SEQ ID NO. 199, SEQ ID NO. 201, SEQ ID NO. 203, SEQ ID NO.
25 205, SEQ ID NO. 207, SEQ ID NO. 209, SEQ ID NO. 211, SEQ ID NO. 213, SEQ ID NO.
   215, SEQ ID NO. 217, SEQ ID NO. 219, SEQ ID NO. 221, SEQ ID NO. 223, SEQ ID NO.
   225, SEQ ID NO. 227, SEQ ID NO. 229, SEQ ID NO. 231, SEQ ID NO. 233, SEQ ID NO.
   235, SEQ ID NO. 237, SEQ ID NO. 239, SEQ ID NO. 241, and combinations thereof, and
   that has a light chain variable domain sequence that is at least 95% identical to the amino
30 acid sequences selected from the group consisting of SEQ ID NO. 2, SEQ ID NO. 4, SEQ
   ID NO. 6, SEQ ID NO. 8, SEQ ID NO. 10, SEQ ID NO. 12, SEQ ID NO. 14, SEQ ID NO.
                                                  14

   16, SEQ ID NO. 18, SEQ ID NO. 20, SEQ ID NO. 22, SEQ ID NO. 24, SEQ ID NO. 26,
   SEQ ID NO. 28, SEQ ID NO. 30, SEQ ID NO. 32, SEQ ID NO. 34, SEQ ID NO. 36, SEQ
   ID NO. 38, SEQ ID NO. 40, SEQ ID NO. 42, SEQ ID NO. 44, SEQ ID NO. 46, SEQ ID
   NO. 48, SEQ ID NO. 50, SEQ ID NO. 52, SEQ ID NO. 54, SEQ ID NO. 56, SEQ ID NO.
 5 58, SEQ ID NO. 60, SEQ ID NO. 62, SEQ ID NO. 64, SEQ ID NO. 66, SEQ ID NO. 68,
   SEQ ID NO. 70, SEQ ID NO. 72, SEQ ID NO. 74, SEQ ID NO. 76, SEQ ID NO. 78, SEQ
   ID NO. 80, SEQ ID NO. 82, SEQ ID NO. 84, SEQ ID NO. 86, SEQ ID NO. 88, SEQ ID
   NO. 90, SEQ ID NO. 92, SEQ ID NO. 94, SEQ ID NO. 96, SEQ ID NO. 98, SEQ ID NO.
   100, SEQ ID NO. 102, SEQ ID NO. 104, SEQ ID NO. 106, SEQ ID NO. 108, SEQ ID NO.
10 110, SEQ ID NO. 112, SEQ ID NO. 114, SEQ ID NO. 116, SEQ ID NO. 118, SEQ ID NO.
   120, SEQ ID NO. 122, SEQ ID NO. 124, SEQ ID NO. 126, SEQ ID NO. 128, SEQ ID NO.
   130, SEQ ID NO. 132, SEQ ID NO. 134, SEQ ID NO. 136, SEQ ID NO. 138, SEQ ID NO.
   140, SEQ ID NO. 142, SEQ ID NO. 144, SEQ ID NO. 146, SEQ ID NO. 148, SEQ ID NO.
   150, SEQ ID NO. 152, SEQ ID NO. 154, SEQ ID NO. 156, SEQ ID NO. 158, SEQ ID NO.
15 160, SEQ ID NO. 162, SEQ ID NO. 164, SEQ ID NO. 166, SEQ ID NO. 168, SEQ ID NO.
   170, SEQ ID NO. 172, SEQ ID NO. 174, SEQ ID NO. 176, SEQ ID NO. 178, SEQ ID NO.
   180, SEQ ID NO. 182, SEQ ID NO. 184, SEQ ID NO. 186, SEQ ID NO. 188, SEQ ID NO.
   190, SEQ ID NO. 192, SEQ ID NO. 194, SEQ ID NO. 196, SEQ ID NO. 198, SEQ ID NO.
   200, SEQ ID NO. 202, SEQ ID NO. 204, SEQ ID NO. 206, SEQ ID NO. 208, SEQ ID NO.
20 210, SEQ ID NO. 212, SEQ ID NO. 214, SEQ ID NO. 216, SEQ ID NO. 218, SEQ ID NO.
   220, SEQ ID NO. 222, SEQ ID NO. 224, SEQ ID NO. 226, SEQ ID NO. 228, SEQ ID NO.
   230, SEQ ID NO. 232, SEQ ID NO. 234, SEQ ID NO. 236, SEQ ID NO. 238, SEQ ID NO.
   240, SEQ ID NO. 242, and combinations thereof;
           wherein the Fab fully human antibody fragment has the heavy chain variable domain
25 sequence that is at least 95% identical to the amino acid sequences selected from the group
   consisting of SEQ ID NO. 1, SEQ ID NO. 3, SEQ ID NO. 5, SEQ ID NO. 7, SEQ ID NO. 9,
   SEQ ID NO. 11, SEQ ID NO. 13, SEQ ID NO. 15, SEQ ID NO. 17, SEQ ID NO. 19, SEQ
   ID NO. 21, SEQ ID NO. 23, SEQ ID NO. 25, SEQ ID NO. 27, SEQ ID NO. 29, SEQ ID
   NO. 31, SEQ ID NO. 33, SEQ ID NO. 35, SEQ ID NO. 37, SEQ ID NO. 39, SEQ ID NO.
30 41, SEQ ID NO. 43, SEQ ID NO. 45, SEQ ID NO. 47, SEQ ID NO. 49, SEQ ID NO. 51,
   SEQ ID NO. 53, SEQ ID NO. 55, SEQ ID NO. 57, SEQ ID NO. 59, SEQ ID NO. 61, SEQ
                                                   15

   ID NO. 63, SEQ ID NO. 65, SEQ ID NO. 67, SEQ ID NO. 69, SEQ ID NO. 71, SEQ ID
   NO. 73, SEQ ID NO. 75, SEQ ID NO. 77, SEQ ID NO. 79, SEQ ID NO. 81, SEQ ID NO.
   83, SEQ ID NO. 85, SEQ ID NO. 87, SEQ ID NO. 89, SEQ ID NO. 91, SEQ ID NO. 93,
   SEQ ID NO. 95, SEQ ID NO. 97, SEQ ID NO. 99, SEQ ID NO. 101, SEQ ID NO. 103,
 5 SEQ ID NO. 105, SEQ ID NO. 107, SEQ ID NO. 109, SEQ ID NO. 111, SEQ ID NO. 113,
   SEQ ID NO. 115, SEQ ID NO. 117, SEQ ID NO. 119, SEQ ID NO. 121, SEQ ID NO. 123,
   SEQ ID NO. 125, SEQ ID NO. 127, SEQ ID NO. 129, SEQ ID NO. 131, SEQ ID NO. 133,
   SEQ ID NO. 135, SEQ ID NO. 137, SEQ ID NO. 139, SEQ ID NO. 141, SEQ ID NO. 143,
   SEQ ID NO. 145, SEQ ID NO. 147, SEQ ID NO. 149, SEQ ID NO. 151, SEQ ID NO. 153,
10 SEQ ID NO. 155, SEQ ID NO. 157, SEQ ID NO. 159, SEQ ID NO. 161, SEQ ID NO. 163,
   SEQ ID NO. 165, SEQ ID NO. 167, SEQ ID NO. 169, SEQ ID NO. 171, SEQ ID NO. 173,
   SEQ ID NO. 175, SEQ ID NO. 177, SEQ ID NO. 179, SEQ ID NO. 181, SEQ ID NO. 183,
   SEQ ID NO. 185, SEQ ID NO. 187, SEQ ID NO. 189, SEQ ID NO. 191, SEQ ID NO. 193,
   SEQ ID NO. 195, SEQ ID NO. 197, SEQ ID NO. 199, SEQ ID NO. 201, SEQ ID NO. 203,
15 SEQ ID NO. 205, SEQ ID NO. 207, SEQ ID NO. 209, SEQ ID NO. 211, SEQ ID NO. 213,
   SEQ ID NO. 215, SEQ ID NO. 217, SEQ ID NO. 219, SEQ ID NO. 221, SEQ ID NO. 223,
   SEQ ID NO. 225, SEQ ID NO. 227, SEQ ID NO. 229, SEQ ID NO. 231, SEQ ID NO. 233,
   SEQ ID NO. 235, SEQ ID NO. 237, SEQ ID NO. 239, SEQ ID NO. 241, and combinations
   thereof, and that has the light chain variable domain sequence that is at least 95% identical
20 to the amino acid sequences selected from the group consisting of SEQ ID NO. 2, SEQ ID
   NO. 4, SEQ ID NO. 6, SEQ ID NO. 8, SEQ ID NO. 10, SEQ ID NO. 12, SEQ ID NO. 14,
   SEQ ID NO. 16, SEQ ID NO. 18, SEQ ID NO. 20, SEQ ID NO. 22, SEQ ID NO. 24, SEQ
   ID NO. 26, SEQ ID NO. 28, SEQ ID NO. 30, SEQ ID NO. 32, SEQ ID NO. 34, SEQ ID
   NO. 36, SEQ ID NO. 38, SEQ ID NO. 40, SEQ ID NO. 42, SEQ ID NO. 44, SEQ ID NO.
25 46, SEQ ID NO. 48, SEQ ID NO. 50, SEQ ID NO. 52, SEQ ID NO. 54, SEQ ID NO. 56,
   SEQ ID NO. 58, SEQ ID NO. 60, SEQ ID NO. 62, SEQ ID NO. 64, SEQ ID NO. 66, SEQ
   ID NO. 68, SEQ ID NO. 70, SEQ ID NO. 72, SEQ ID NO. 74, SEQ ID NO. 76, SEQ ID
   NO. 78, SEQ ID NO. 80, SEQ ID NO. 82, SEQ ID NO. 84, SEQ ID NO. 86, SEQ ID NO.
   88, SEQ ID NO. 90, SEQ ID NO. 92, SEQ ID NO. 94, SEQ ID NO. 96, SEQ ID NO. 98,
30 SEQ ID NO. 100, SEQ ID NO. 102, SEQ ID NO. 104, SEQ ID NO. 106, SEQ ID NO. 108,
   SEQ ID NO. 110, SEQ ID NO. 112, SEQ ID NO. 114, SEQ ID NO. 116, SEQ ID NO. 118,
                                                   16

   SEQ ID NO. 120, SEQ ID NO. 122, SEQ ID NO. 124, SEQ ID NO. 126, SEQ ID NO. 128,
   SEQ ID NO. 130, SEQ ID NO. 132, SEQ ID NO. 134, SEQ ID NO. 136, SEQ ID NO. 138,
   SEQ ID NO. 140, SEQ ID NO. 142, SEQ ID NO. 144, SEQ ID NO. 146, SEQ ID NO. 148,
   SEQ ID NO. 150, SEQ ID NO. 152, SEQ ID NO. 154, SEQ ID NO. 156, SEQ ID NO. 158,
 5 SEQ ID NO. 160, SEQ ID NO. 162, SEQ ID NO. 164, SEQ ID NO. 166, SEQ ID NO. 168,
   SEQ ID NO. 170, SEQ ID NO. 172, SEQ ID NO. 174, SEQ ID NO. 176, SEQ ID NO. 178,
   SEQ ID NO. 180, SEQ ID NO. 182, SEQ ID NO. 184, SEQ ID NO. 186, SEQ ID NO. 188,
   SEQ ID NO. 190, SEQ ID NO. 192, SEQ ID NO. 194, SEQ ID NO. 196, SEQ ID NO. 198,
   SEQ ID NO. 200, SEQ ID NO. 202, SEQ ID NO. 204, SEQ ID NO. 206, SEQ ID NO. 208,
10 SEQ ID NO. 210, SEQ ID NO. 212, SEQ ID NO. 214, SEQ ID NO. 216, SEQ ID NO. 218,
   SEQ ID NO. 220, SEQ ID NO. 222, SEQ ID NO. 224, SEQ ID NO. 226, SEQ ID NO. 228,
   SEQ ID NO. 230, SEQ ID NO. 232, SEQ ID NO. 234, SEQ ID NO. 236, SEQ ID NO. 238,
   SEQ ID NO. 240, SEQ ID NO. 242, and combinations thereof; and
           wherein the single chain human antibody has the heavy chain variable domain
15 sequence that is at least 95% identical to the amino acid sequences selected from the group
   consisting of SEQ ID NO. 1, SEQ ID NO. 3, SEQ ID NO. 5, SEQ ID NO. 7, SEQ ID NO. 9,
   SEQ ID NO. 11, SEQ ID NO. 13, SEQ ID NO. 15, SEQ ID NO. 17, SEQ ID NO. 19, SEQ
   ID NO. 21, SEQ ID NO. 23, SEQ ID NO. 25, SEQ ID NO. 27, SEQ ID NO. 29, SEQ ID
   NO. 31, SEQ ID NO. 33, SEQ ID NO. 35, SEQ ID NO. 37, SEQ ID NO. 39, SEQ ID NO.
20 41, SEQ ID NO. 43, SEQ ID NO. 45, SEQ ID NO. 47, SEQ ID NO. 49, SEQ ID NO. 51,
   SEQ ID NO. 53, SEQ ID NO. 55, SEQ ID NO. 57, SEQ ID NO. 59, SEQ ID NO. 61, SEQ
   ID NO. 63, SEQ ID NO. 65, SEQ ID NO. 67, SEQ ID NO. 69, SEQ ID NO. 71, SEQ ID
   NO. 73, SEQ ID NO. 75, SEQ ID NO. 77, SEQ ID NO. 79, SEQ ID NO. 81, SEQ ID NO.
   83, SEQ ID NO. 85, SEQ ID NO. 87, SEQ ID NO. 89, SEQ ID NO. 91, SEQ ID NO. 93,
25 SEQ ID NO. 95, SEQ ID NO. 97, SEQ ID NO. 99, SEQ ID NO. 101, SEQ ID NO. 103,
   SEQ ID NO. 105, SEQ ID NO. 107, SEQ ID NO. 109, SEQ ID NO. 111, SEQ ID NO. 113,
   SEQ ID NO. 115, SEQ ID NO. 117, SEQ ID NO. 119, SEQ ID NO. 121, SEQ ID NO. 123,
   SEQ ID NO. 125, SEQ ID NO. 127, SEQ ID NO. 129, SEQ ID NO. 131, SEQ ID NO. 133,
   SEQ ID NO. 135, SEQ ID NO. 137, SEQ ID NO. 139, SEQ ID NO. 141, SEQ ID NO. 143,
30 SEQ ID NO. 145, SEQ ID NO. 147, SEQ ID NO. 149, SEQ ID NO. 151, SEQ ID NO. 153,
   SEQ ID NO. 155, SEQ ID NO. 157, SEQ ID NO. 159, SEQ ID NO. 161, SEQ ID NO. 163,
                                                   17

   SEQ ID NO. 165, SEQ ID NO. 167, SEQ ID NO. 169, SEQ ID NO. 171, SEQ ID NO. 173,
   SEQ ID NO. 175, SEQ ID NO. 177, SEQ ID NO. 179, SEQ ID NO. 181, SEQ ID NO. 183,
   SEQ ID NO. 185, SEQ ID NO. 187, SEQ ID NO. 189, SEQ ID NO. 191, SEQ ID NO. 193,
   SEQ ID NO. 195, SEQ ID NO. 197, SEQ ID NO. 199, SEQ ID NO. 201, SEQ ID NO. 203,
 5 SEQ ID NO. 205, SEQ ID NO. 207, SEQ ID NO. 209, SEQ ID NO. 211, SEQ ID NO. 213,
   SEQ ID NO. 215, SEQ ID NO. 217, SEQ ID NO. 219, SEQ ID NO. 221, SEQ ID NO. 223,
   SEQ ID NO. 225, SEQ ID NO. 227, SEQ ID NO. 229, SEQ ID NO. 231, SEQ ID NO. 233,
   SEQ ID NO. 235, SEQ ID NO. 237, SEQ ID NO. 239, SEQ ID NO. 241, and combinations
   thereof, and that has the light chain variable domain sequence that is at least 95% identical
10 to the amino acid sequences selected from the group consisting of SEQ ID NO. 2, SEQ ID
   NO. 4, SEQ ID NO. 6, SEQ ID NO. 8, SEQ ID NO. 10, SEQ ID NO. 12, SEQ ID NO. 14,
   SEQ ID NO. 16, SEQ ID NO. 18, SEQ ID NO. 20, SEQ ID NO. 22, SEQ ID NO. 24, SEQ
   ID NO. 26, SEQ ID NO. 28, SEQ ID NO. 30, SEQ ID NO. 32, SEQ ID NO. 34, SEQ ID
   NO. 36, SEQ ID NO. 38, SEQ ID NO. 40, SEQ ID NO. 42, SEQ ID NO. 44, SEQ ID NO.
15 46, SEQ ID NO. 48, SEQ ID NO. 50, SEQ ID NO. 52, SEQ ID NO. 54, SEQ ID NO. 56,
   SEQ ID NO. 58, SEQ ID NO. 60, SEQ ID NO. 62, SEQ ID NO. 64, SEQ ID NO. 66, SEQ
   ID NO. 68, SEQ ID NO. 70, SEQ ID NO. 72, SEQ ID NO. 74, SEQ ID NO. 76, SEQ ID
   NO. 78, SEQ ID NO. 80, SEQ ID NO. 82, SEQ ID NO. 84, SEQ ID NO. 86, SEQ ID NO.
   88, SEQ ID NO. 90, SEQ ID NO. 92, SEQ ID NO. 94, SEQ ID NO. 96, SEQ ID NO. 98,
20 SEQ ID NO. 100, SEQ ID NO. 102, SEQ ID NO. 104, SEQ ID NO. 106, SEQ ID NO. 108,
   SEQ ID NO. 110, SEQ ID NO. 112, SEQ ID NO. 114, SEQ ID NO. 116, SEQ ID NO. 118,
   SEQ ID NO. 120, SEQ ID NO. 122, SEQ ID NO. 124, SEQ ID NO. 126, SEQ ID NO. 128,
   SEQ ID NO. 130, SEQ ID NO. 132, SEQ ID NO. 134, SEQ ID NO. 136, SEQ ID NO. 138,
   SEQ ID NO. 140, SEQ ID NO. 142, SEQ ID NO. 144, SEQ ID NO. 146, SEQ ID NO. 148,
25 SEQ ID NO. 150, SEQ ID NO. 152, SEQ ID NO. 154, SEQ ID NO. 156, SEQ ID NO. 158,
   SEQ ID NO. 160, SEQ ID NO. 162, SEQ ID NO. 164, SEQ ID NO. 166, SEQ ID NO. 168,
   SEQ ID NO. 170, SEQ ID NO. 172, SEQ ID NO. 174, SEQ ID NO. 176, SEQ ID NO. 178,
   SEQ ID NO. 180, SEQ ID NO. 182, SEQ ID NO. 184, SEQ ID NO. 186, SEQ ID NO. 188,
   SEQ ID NO. 190, SEQ ID NO. 192, SEQ ID NO. 194, SEQ ID NO. 196, SEQ ID NO. 198,
30 SEQ ID NO. 200, SEQ ID NO. 202, SEQ ID NO. 204, SEQ ID NO. 206, SEQ ID NO. 208,
   SEQ ID NO. 210, SEQ ID NO. 212, SEQ ID NO. 214, SEQ ID NO. 216, SEQ ID NO. 218,
                                                   18

   SEQ ID NO. 220, SEQ ID NO. 222, SEQ ID NO. 224, SEQ ID NO. 226, SEQ ID NO. 228,
   SEQ ID NO. 230, SEQ ID NO. 232, SEQ ID NO. 234, SEQ ID NO. 236, SEQ ID NO. 238,
   SEQ ID NO. 240, SEQ ID NO. 242, and combinations thereof.
           Preferably, the fully human antibody has both a heavy chain and a light chain
 5 wherein the antibody has a heavy chain/light chain variable domain sequence selected from
   the group consisting of SEQ ID NO. 1/SEQ ID NO. 2 (called E6 herein), SEQ ID NO.
   3/SEQ ID NO. 4 (called E7 herein), SEQ ID NO. 5/SEQ ID NO. 6 (called E9 herein), SEQ
   ID NO. 7/SEQ ID NO. 8 (called EI1 herein), SEQ ID NO. 9/SEQ ID NO. 10 (called Fl
   herein), SEQ ID NO. 11/SEQ ID NO. 12 (called F4 herein), SEQ ID NO. 13/SEQ ID NO.
10 14 (called F7 herein), SEQ ID NO. 15/SEQ ID NO. 16 (called F8 herein), SEQ ID NO.
   17/SEQ ID NO. 18 (called F 11 herein), SEQ ID NO. 19/SEQ ID NO. 20 (called G4 herein),
   SEQ ID NO. 21/SEQ ID NO. 22 (called G9 herein), SEQ ID NO. 23/SEQ ID NO. 24 (called
   G 11 herein), SEQ ID NO. 25/SEQ ID NO. 26 (called G12 herein), SEQ ID NO. 27/SEQ ID
   NO. 28 (called H1 herein), SEQ ID NO. 29/SEQ ID NO. 30 (called H3 herein), SEQ ID
15 NO. 31/SEQ ID NO. 32 (called H4 herein), SEQ ID NO. 33/SEQ ID NO. 34 (called H5
   herein), SEQ ID NO. 35/SEQ ID NO. 36 (called H6 herein), SEQ ID NO. 37/SEQ ID NO.
   38 (called H10 herein), SEQ ID NO. 39/SEQ ID NO. 40 (called H12 herein), SEQ ID NO.
   41/SEQ ID NO. 42 (called PDL-D2 herein), SEQ ID NO. 43/SEQ ID NO. 44 (called PDL
   D 11 herein), SEQ ID NO. 45/SEQ ID NO. 46 (called PDL-H1 herein), SEQ ID NO.
20 47/SEQ ID NO. 48 (called RB4 herein), SEQ ID NO. 49/SEQ ID NO. 50 (called RB 11
   herein), SEQ ID NO. 51/SEQ ID NO. 52 (called RC5 herein), SEQ ID NO. 53/SEQ ID NO.
   54 (called RF5 herein), SEQ ID NO. 55/SEQ ID NO. 56 (called RG9 herein), SEQ ID NO.
   57/SEQ ID NO. 58 (called RD1 herein), SEQ ID NO. 59/SEQ ID NO. 60 (called RF 11
   herein), SEQ ID NO. 61/SEQ ID NO. 62 (called RH 11 herein), SEQ ID NO. 63/SEQ ID
25 NO. 64 (called RD9 herein), SEQ ID NO. 65/SEQ ID NO. 66 (called RE10 herein), SEQ ID
   NO. 67/SEQ ID NO. 68 (called RA3 herein), SEQ ID NO. 69/SEQ ID NO. 70 (called RG1
   herein), SEQ ID NO. 71/SEQ ID NO. 72 (called RB1 herein), SEQ ID NO. 73/SEQ ID NO.
   74 (called RG7 herein), SEQ ID NO. 75/SEQ ID NO. 76 (called RA6 herein), SEQ ID NO.
   77/SEQ ID NO. 78 (called RA8 herein), SEQ ID NO. 79/SEQ ID NO. 80 (called RA9
30 herein), SEQ ID NO. 81/SEQ ID NO. 82 (called RB5 herein), SEQ ID NO. 83/SEQ ID NO.
   84 (called RB8 herein), SEQ ID NO. 85/SEQ ID NO. 86 (called RC8 herein), SEQ ID NO.
                                                19

   87/SEQ ID NO. 88 (called RC10 herein), SEQ ID NO. 89/SEQ ID NO. 90 (called RD2
   herein), SEQ ID NO. 91/SEQ ID NO. 92 (called RE8 herein), SEQ ID NO. 93/SEQ ID NO.
   94 (called RE9 herein), SEQ ID NO. 95/SEQ ID NO. 96 (called RG12 herein), SEQ ID NO.
   97/SEQ ID NO. 98 (called RSA1 herein), SEQ ID NO. 99/SEQ ID NO. 100 (called R2A7
 5 herein), SEQ ID NO. 101/SEQ ID NO. 102 (called R2B12 herein), SEQ ID NO. 103/SEQ
   ID NO. 104 (called R2C9 herein), SEQ ID NO. 105/SEQ ID NO. 106 (called R2D5 herein),
   SEQ ID NO. 107/SEQ ID NO. 108 (called R2D7 herein), SEQ ID NO. 109/SEQ ID NO.
   110 (called R2F4 herein), SEQ ID NO. 111/SEQ ID NO. 112 (called R2A10 herein), SEQ
   ID NO. 113/SEQ ID NO. 114 (called R2E2 herein), SEQ ID NO. 115/SEQ ID NO. 116
10 (called R3B8 herein), SEQ ID NO. 117/SEQ ID NO. 118 (called R3C3 herein), SEQ ID
   NO. 119/SEQ ID NO. 120 (called R3E9 herein), SEQ ID NO. 121/SEQ ID NO. 122 (called
   R3E1O herein), SEQ ID NO. 123/SEQ ID NO. 124 (called R3F7 herein), SEQ ID NO.
   125/SEQ ID NO. 126 (called R3F10 herein), SEQ ID NO. 127/SEQ ID NO. 128 (called
   R4B10 herein), SEQ ID NO. 129/SEQ ID NO. 130 (called R4H1 herein), SEQ ID NO.
15 131/SEQ ID NO. 132 (called R4A1 1 herein), SEQ ID NO. 133/SEQ ID NO. 134 (called
   R3D2 herein), SEQ ID NO. 135/SEQ ID NO. 136 (called R5B8 herein), SEQ ID NO.
   137/SEQ ID NO. 138 (called SH1A1Q herein), SEQ ID NO. 139/SEQ ID NO. 140 (called
   SH1B7B(K) herein), SEQ ID NO. 141/SEQ ID NO. 142 (called SHICI herein), SEQ ID
   NO. 143/SEQ ID NO. 144 (called SH1C8 herein), SEQ ID NO. 145/SEQ ID NO. 146
20 (called SHIE10 herein), SEQ ID NO. 147/SEQ ID NO. 148 (called SH1E2 herein), SEQ ID
   NO. 149/SEQ ID NO. 150 (called SH1A9 herein), SEQ ID NO. 151/SEQ ID NO. 152
   (called SHIB 11 herein), SEQ ID NO. 153/SEQ ID NO. 154 (called SH1E4 herein), SEQ ID
   NO. 155/SEQ ID NO. 156 (called SH1B3 herein), SEQ ID NO. 157/SEQ ID NO. 158
   (called SHID1 herein), SEQ ID NO. 159/SEQ ID NO. 160 (called SH1D2 herein), SEQ ID
25 NO. 161/SEQ ID NO. 162 (called SH1D12 herein), SEQ ID NO. 163/SEQ ID NO. 164
   (called SHIE1 herein), SEQ ID NO. 165/SEQ ID NO. 166 (called SH1G9 herein), SEQ ID
   NO. 167/SEQ ID NO. 168 (called SHIA 1 herein), SEQ ID NO. 169/SEQ ID NO. 170
   (called SH1C2 herein), SEQ ID NO. 171/SEQ ID NO. 172 (called SH1G8 herein), SEQ ID
   NO. 173/SEQ ID NO. 174 (called SH1H2 herein), SEQ ID NO. 175/SEQ ID NO. 176
30 (called SHIB10 herein), SEQ ID NO. 177/SEQ ID NO. 178 (called SH1B7A(L) herein),
   SEQ ID NO. 179/SEQ ID NO. 180 (called SH1E6 herein), SEQ ID NO. 181/SEQ ID NO.
                                             20

   182 (called SHIC 11 herein), SEQ ID NO. 183/SEQ ID NO. 184 (called SH1A2 herein),
   SEQ ID NO. 185/SEQ ID NO. 186 (called SHIBI herein), SEQ ID NO. 187/SEQ ID NO.
   188 (called R6B2 herein), SEQ ID NO. 189/SEQ ID NO. 190 (called R6B7 herein), SEQ ID
   NO. 191/SEQ ID NO. 192 (called R6B1 1 herein), SEQ ID NO. 193/SEQ ID NO. 194
 5 (called R6D1 herein), SEQ ID NO. 195/SEQ ID NO. 196 (called R6C8 herein), SEQ ID
   NO. 197/SEQ ID NO. 198 (called R9G8 herein), SEQ ID NO. 199/SEQ ID NO. 200 (called
   R7D1 herein), SEQ ID NO. 201/SEQ ID NO. 202 (called R7D2 herein), SEQ ID NO.
   203/SEQ ID NO. 204 (called R7E7 herein), SEQ ID NO. 205/SEQ ID NO. 206 (called
   R7F2 herein), SEQ ID NO. 207/SEQ ID NO. 208 (called R7F7 herein), SEQ ID NO.
10 209/SEQ ID NO. 210 (called R9H2 herein), SEQ ID NO. 211/SEQ ID NO. 212 (called
   R9H6 herein), SEQ ID NO. 213/SEQ ID NO. 214 (called H6B1L herein), SEQ ID NO.
   215/SEQ ID NO. 216 (called H6A1 herein), SEQ ID NO. 217/SEQ ID NO. 218 (called
   H6B1 herein), SEQ ID NO. 219/SEQ ID NO. 220 (called H6B2 herein), SEQ ID NO.
   221/SEQ ID NO. 222 (called H19C herein), SEQ ID NO. 223/SEQ ID NO. 224 (called
15 H1 OD herein), SEQ ID NO. 225/SEQ ID NO. 226 (called H I1F herein), SEQ ID NO.
   227/SEQ ID NO. 228 (called HiCi herein), SEQ ID NO. 229/SEQ ID NO. 230 (called
   GPG1A2 herein), SEQ ID NO. 231/SEQ ID NO. 232 (called GPGG8 herein), SEQ ID NO.
   233/SEQ ID NO. 234 (called GPGG1O herein), SEQ ID NO. 235/SEQ ID NO. 236 (called
   GPGH7 herein), SEQ ID NO. 237/SEQ ID NO. 238 (called GPGH1O herein), SEQ ID NO.
20 239/SEQ ID NO. 240 (called GPGH1 1 herein), SEQ ID NO. 241/SEQ ID NO. 242 (called
   GPGH 1OP herein), and combinations thereof. Preferably, the fully human antibody Fab
   fragment has both a heavy chain variable domain region and a light chain variable domain
   region wherein the antibody has a heavy chain/light chain variable domain sequence
   selected from the group consisting of SEQ ID NO. 1/SEQ ID NO. 2 (called E6 herein), SEQ
25 ID NO. 3/SEQ ID NO. 4 (called E7 herein), SEQ ID NO. 5/SEQ ID NO. 6 (called E9
   herein), SEQ ID NO. 7/SEQ ID NO. 8 (called EI1 herein), SEQ ID NO. 9/SEQ ID NO. 10
   (called Fl herein), SEQ ID NO. I1/SEQ ID NO. 12 (called F4 herein), SEQ ID NO. 13/SEQ
   ID NO. 14 (called F7 herein), SEQ ID NO. 15/SEQ ID NO. 16 (called F8 herein), SEQ ID
   NO. 17/SEQ ID NO. 18 (called F 11 herein), SEQ ID NO. 19/SEQ ID NO. 20 (called G4
30 herein), SEQ ID NO. 21/SEQ ID NO. 22 (called G9 herein), SEQ ID NO. 23/SEQ ID NO.
   24 (called GIl herein), SEQ ID NO. 25/SEQ ID NO. 26 (called G12 herein), SEQ ID NO.
                                               21

   27/SEQ ID NO. 28 (called HI herein), SEQ ID NO. 29/SEQ ID NO. 30 (called H3 herein),
   SEQ ID NO. 31/SEQ ID NO. 32 (called H4 herein), SEQ ID NO. 33/SEQ ID NO. 34 (called
   H5 herein), SEQ ID NO. 35/SEQ ID NO. 36 (called H6 herein), SEQ ID NO. 37/SEQ ID
   NO. 38 (called H10 herein), SEQ ID NO. 39/SEQ ID NO. 40 (called H12 herein), SEQ ID
 5 NO. 41/SEQ ID NO. 42 (called PDL-D2 herein), SEQ ID NO. 43/SEQ ID NO. 44 (called
   PDL-D1 1 herein), SEQ ID NO. 45/SEQ ID NO. 46 (called PDL-H1 herein), SEQ ID NO.
   47/SEQ ID NO. 48 (called RB4 herein), SEQ ID NO. 49/SEQ ID NO. 50 (called RB1 1
   herein), SEQ ID NO. 51/SEQ ID NO. 52 (called RC5 herein), SEQ ID NO. 53/SEQ ID NO.
   54 (called RF5 herein), SEQ ID NO. 55/SEQ ID NO. 56 (called RG9 herein), SEQ ID NO.
10 57/SEQ ID NO. 58 (called RD1 herein), SEQ ID NO. 59/SEQ ID NO. 60 (called RF1 1
   herein), SEQ ID NO. 61/SEQ ID NO. 62 (called RH 11 herein), SEQ ID NO. 63/SEQ ID
   NO. 64 (called RD9 herein), SEQ ID NO. 65/SEQ ID NO. 66 (called RE10 herein), SEQ ID
   NO. 67/SEQ ID NO. 68 (called RA3 herein), SEQ ID NO. 69/SEQ ID NO. 70 (called RG1
   herein), SEQ ID NO. 71/SEQ ID NO. 72 (called RB1 herein), SEQ ID NO. 73/SEQ ID NO.
15 74 (called RG7 herein), SEQ ID NO. 75/SEQ ID NO. 76 (called RA6 herein), SEQ ID NO.
   77/SEQ ID NO. 78 (called RA8 herein), SEQ ID NO. 79/SEQ ID NO. 80 (called RA9
   herein), SEQ ID NO. 81/SEQ ID NO. 82 (called RB5 herein), SEQ ID NO. 83/SEQ ID NO.
   84 (called RB8 herein), SEQ ID NO. 85/SEQ ID NO. 86 (called RC8 herein), SEQ ID NO.
   87/SEQ ID NO. 88 (called RC1O herein), SEQ ID NO. 89/SEQ ID NO. 90 (called RD2
20 herein), SEQ ID NO. 91/SEQ ID NO. 92 (called RE8 herein), SEQ ID NO. 93/SEQ ID NO.
   94 (called RE9 herein), SEQ ID NO. 95/SEQ ID NO. 96 (called RG12 herein), SEQ ID NO.
   97/SEQ ID NO. 98 (called RSA1 herein), SEQ ID NO. 99/SEQ ID NO. 100 (called R2A7
   herein), SEQ ID NO. 101/SEQ ID NO. 102 (called R2B12 herein), SEQ ID NO. 103/SEQ
   ID NO. 104 (called R2C9 herein), SEQ ID NO. 105/SEQ ID NO. 106 (called R2D5 herein),
25 SEQ ID NO. 107/SEQ ID NO. 108 (called R2D7 herein), SEQ ID NO. 109/SEQ ID NO.
   110 (called R2F4 herein), SEQ ID NO. 111/SEQ ID NO. 112 (called R2A10 herein), SEQ
   ID NO. 113/SEQ ID NO. 114 (called R2E2 herein), SEQ ID NO. 115/SEQ ID NO. 116
   (called R3B8 herein), SEQ ID NO. 117/SEQ ID NO. 118 (called R3C3 herein), SEQ ID
   NO. 119/SEQ ID NO. 120 (called R3E9 herein), SEQ ID NO. 121/SEQ ID NO. 122 (called
30 R3E1O herein), SEQ ID NO. 123/SEQ ID NO. 124 (called R3F7 herein), SEQ ID NO.
   125/SEQ ID NO. 126 (called R3F1O herein), SEQ ID NO. 127/SEQ ID NO. 128 (called
                                             22

   R4B1O herein), SEQ ID NO. 129/SEQ ID NO. 130 (called R4H1 herein), SEQ ID NO.
   131/SEQ ID NO. 132 (called R4A1 1 herein), SEQ ID NO. 133/SEQ ID NO. 134 (called
   R3D2 herein), SEQ ID NO. 135/SEQ ID NO. 136 (called R5B8 herein), SEQ ID NO.
   137/SEQ ID NO. 138 (called SH1A1Q herein), SEQ ID NO. 139/SEQ ID NO. 140 (called
 5 SH1B7B(K) herein), SEQ ID NO. 141/SEQ ID NO. 142 (called SHICI herein), SEQ ID
   NO. 143/SEQ ID NO. 144 (called SH1C8 herein), SEQ ID NO. 145/SEQ ID NO. 146
   (called SHIE10 herein), SEQ ID NO. 147/SEQ ID NO. 148 (called SH1E2 herein), SEQ ID
   NO. 149/SEQ ID NO. 150 (called SH1A9 herein), SEQ ID NO. 151/SEQ ID NO. 152
   (called SHIB 11 herein), SEQ ID NO. 153/SEQ ID NO. 154 (called SH1E4 herein), SEQ ID
10 NO. 155/SEQ ID NO. 156 (called SH1B3 herein), SEQ ID NO. 157/SEQ ID NO. 158
   (called SHID1 herein), SEQ ID NO. 159/SEQ ID NO. 160 (called SH1D2 herein), SEQ ID
   NO. 161/SEQ ID NO. 162 (called SH1D12 herein), SEQ ID NO. 163/SEQ ID NO. 164
   (called SHIE1 herein), SEQ ID NO. 165/SEQ ID NO. 166 (called SH1G9 herein), SEQ ID
   NO. 167/SEQ ID NO. 168 (called SHIA 1 herein), SEQ ID NO. 169/SEQ ID NO. 170
15 (called SH1C2 herein), SEQ ID NO. 171/SEQ ID NO. 172 (called SH1G8 herein), SEQ ID
   NO. 173/SEQ ID NO. 174 (called SH1H2 herein), SEQ ID NO. 175/SEQ ID NO. 176
   (called SHIB10 herein), SEQ ID NO. 177/SEQ ID NO. 178 (called SH1B7A(L) herein),
   SEQ ID NO. 179/SEQ ID NO. 180 (called SH1E6 herein), SEQ ID NO. 181/SEQ ID NO.
   182 (called SHIC 11 herein), SEQ ID NO. 183/SEQ ID NO. 184 (called SH1A2 herein),
20 SEQ ID NO. 185/SEQ ID NO. 186 (called SHIBI herein), SEQ ID NO. 187/SEQ ID NO.
   188 (called R6B2 herein), SEQ ID NO. 189/SEQ ID NO. 190 (called R6B7 herein), SEQ ID
   NO. 191/SEQ ID NO. 192 (called R6B1 1 herein), SEQ ID NO. 193/SEQ ID NO. 194
   (called R6D1 herein), SEQ ID NO. 195/SEQ ID NO. 196 (called R6C8 herein), SEQ ID
   NO. 197/SEQ ID NO. 198 (called R9G8 herein), SEQ ID NO. 199/SEQ ID NO. 200 (called
25 R7D1 herein), SEQ ID NO. 201/SEQ ID NO. 202 (called R7D2 herein), SEQ ID NO.
   203/SEQ ID NO. 204 (called R7E7 herein), SEQ ID NO. 205/SEQ ID NO. 206 (called
   R7F2 herein), SEQ ID NO. 207/SEQ ID NO. 208 (called R7F7 herein), SEQ ID NO.
   209/SEQ ID NO. 210 (called R9H2 herein), SEQ ID NO. 211/SEQ ID NO. 212 (called
   R9H6 herein), SEQ ID NO. 213/SEQ ID NO. 214 (called H6B1L herein), SEQ ID NO.
30 215/SEQ ID NO. 216 (called H6A1 herein), SEQ ID NO. 217/SEQ ID NO. 218 (called
   H6B1 herein), SEQ ID NO. 219/SEQ ID NO. 220 (called H6B2 herein), SEQ ID NO.
                                             23

   221/SEQ ID NO. 222 (called H19C herein), SEQ ID NO. 223/SEQ ID NO. 224 (called
   H1 OD herein), SEQ ID NO. 225/SEQ ID NO. 226 (called H I1F herein), SEQ ID NO.
   227/SEQ ID NO. 228 (called HiCi herein), SEQ ID NO. 229/SEQ ID NO. 230 (called
   GPG1A2 herein), SEQ ID NO. 231/SEQ ID NO. 232 (called GPGG8 herein), SEQ ID NO.
 5 233/SEQ ID NO. 234 (called GPGG1O herein), SEQ ID NO. 235/SEQ ID NO. 236 (called
   GPGH7 herein), SEQ ID NO. 237/SEQ ID NO. 238 (called GPGH1O herein), SEQ ID NO.
   239/SEQ ID NO. 240 (called GPGH1 1 herein), SEQ ID NO. 241/SEQ ID NO. 242 (called
   GPGH OP herein), and combinations thereof. Preferably, the fully human single chain
   antibody has both a heavy chain variable domain region and a light chain variable domain
10 region, wherein the single chain fully human antibody has a heavy chain/light chain variable
   domain sequence selected from the group consisting of SEQ ID NO. 1/SEQ ID NO. 2, SEQ
   ID NO. 3/SEQ ID NO. 4, SEQ ID NO. 5/SEQ ID NO. 6, SEQ ID NO. 7/SEQ ID NO. 8,
   SEQ ID NO. 9/SEQ ID NO. 10, SEQ ID NO. 11/SEQ ID NO. 12, SEQ ID NO. 13/SEQ ID
   NO. 14, SEQ ID NO. 15/SEQ ID NO. 16, SEQ ID NO. 17/SEQ ID NO. 18, SEQ ID NO.
15 19/SEQ ID NO. 20, SEQ ID NO. 21/SEQ ID NO. 22, SEQ ID NO. 23/SEQ ID NO. 24,
   SEQ ID NO. 25/SEQ ID NO. 26, SEQ ID NO. 27/SEQ ID NO. 28, SEQ ID NO. 29/SEQ ID
   NO. 30, SEQ ID NO. 31/SEQ ID NO. 32, SEQ ID NO. 33/SEQ ID NO. 34, SEQ ID NO.
   35/SEQ ID NO. 36, SEQ ID NO. 37/SEQ ID NO. 38, SEQ ID NO. 39/SEQ ID NO. 40,
   SEQ ID NO. 41/SEQ ID NO. 42, SEQ ID NO. 43/SEQ ID NO. 44, SEQ ID NO. 45/SEQ ID
20 NO. 46, SEQ ID NO. 47/SEQ ID NO. 48, SEQ ID NO. 49/SEQ ID NO. 50, SEQ ID NO.
   51/SEQ ID NO. 52, SEQ ID NO. 53/SEQ ID NO. 54, SEQ ID NO. 55/SEQ ID NO. 56,
   SEQ ID NO. 57/SEQ ID NO. 58, SEQ ID NO. 59/SEQ ID NO. 60, SEQ ID NO. 61/SEQ ID
   NO. 62, SEQ ID NO. 63/SEQ ID NO. 64, SEQ ID NO. 65/SEQ ID NO. 66, SEQ ID NO.
   67/SEQ ID NO. 68, SEQ ID NO. 69/SEQ ID NO. 70, SEQ ID NO. 71/SEQ ID NO. 72,
25 SEQ ID NO. 73/SEQ ID NO. 74, SEQ ID NO. 75/SEQ ID NO. 76, SEQ ID NO. 77/SEQ ID
   NO. 78, SEQ ID NO. 79/SEQ ID NO. 80, SEQ ID NO. 81/SEQ ID NO. 82, SEQ ID NO.
   83/SEQ ID NO. 84, SEQ ID NO. 85/SEQ ID NO. 86, SEQ ID NO. 87/SEQ ID NO. 88,
   SEQ ID NO. 89/SEQ ID NO. 90, SEQ ID NO. 91/SEQ ID NO. 92, SEQ ID NO. 93/SEQ ID
   NO. 94, SEQ ID NO. 95/SEQ ID NO. 96, SEQ ID NO. 97/SEQ ID NO. 98, SEQ ID NO.
30 99/SEQ ID NO. 100, SEQ ID NO. 101/SEQ ID NO. 102, SEQ ID NO. 103/SEQ ID NO.
   104, SEQ ID NO. 105/SEQ ID NO. 106, SEQ ID NO. 107/SEQ ID NO. 108, SEQ ID NO.
                                                24

   109/SEQ ID NO. 110, SEQ ID NO. 111/SEQ ID NO. 112, SEQ ID NO. 113/SEQ ID NO.
   114, SEQ ID NO. 115/SEQ ID NO. 116, SEQ ID NO. 117/SEQ ID NO. 118, SEQ ID NO.
   119/SEQ ID NO. 120, SEQ ID NO. 121/SEQ ID NO. 122, SEQ ID NO. 123/SEQ ID NO.
   124, SEQ ID NO. 125/SEQ ID NO. 126, SEQ ID NO. 127/SEQ ID NO. 128, SEQ ID NO.
 5 129/SEQ ID NO. 130, SEQ ID NO. 131/SEQ ID NO. 132, SEQ ID NO. 133/SEQ ID NO.
   134, SEQ ID NO. 135/SEQ ID NO. 136, SEQ ID NO. 137/SEQ ID NO. 138, SEQ ID NO.
   139/SEQ ID NO. 140, SEQ ID NO. 141/SEQ ID NO. 142, SEQ ID NO. 143/SEQ ID NO.
   144, SEQ ID NO. 145/SEQ ID NO. 146, SEQ ID NO. 147/SEQ ID NO. 148, SEQ ID NO.
   149/SEQ ID NO. 150, SEQ ID NO. 151/SEQ ID NO. 152, SEQ ID NO. 153/SEQ ID NO.
10 154, SEQ ID NO. 155/SEQ ID NO. 156, SEQ ID NO. 157/SEQ ID NO. 158, SEQ ID NO.
   159/SEQ ID NO. 160, SEQ ID NO. 161/SEQ ID NO. 162, SEQ ID NO. 163/SEQ ID NO.
   164, SEQ ID NO. 165/SEQ ID NO. 166, SEQ ID NO. 167/SEQ ID NO. 168, SEQ ID NO.
   169/SEQ ID NO. 170, SEQ ID NO. 171/SEQ ID NO. 172, SEQ ID NO. 173/SEQ ID NO.
   174, SEQ ID NO. 175/SEQ ID NO. 176, SEQ ID NO. 177/SEQ ID NO. 178, SEQ ID NO.
15 179/SEQ ID NO. 180, SEQ ID NO. 181/SEQ ID NO. 182, SEQ ID NO. 183/SEQ ID NO.
   184, SEQ ID NO. 185/SEQ ID NO. 186, SEQ ID NO. 187/SEQ ID NO. 188, SEQ ID NO.
   189/SEQ ID NO. 190, SEQ ID NO. 191/SEQ ID NO. 192, SEQ ID NO. 193/SEQ ID NO.
   194, SEQ ID NO. 195/SEQ ID NO. 196, SEQ ID NO. 197/SEQ ID NO. 198, SEQ ID NO.
   199/SEQ ID NO. 200, SEQ ID NO. 201/SEQ ID NO. 202, SEQ ID NO. 203/SEQ ID NO.
20 204, SEQ ID NO. 205/SEQ ID NO. 206, SEQ ID NO. 207/SEQ ID NO. 208, SEQ ID NO.
   209/SEQ ID NO. 210, SEQ ID NO. 211/SEQ ID NO. 212, SEQ ID NO. 213/SEQ ID NO.
   214, SEQ ID NO. 215/SEQ ID NO. 216, SEQ ID NO. 217/SEQ ID NO. 218, SEQ ID NO.
   219/SEQ ID NO. 220, SEQ ID NO. 221/SEQ ID NO. 222, SEQ ID NO. 223/SEQ ID NO.
   224, SEQ ID NO. 225/SEQ ID NO. 226, SEQ ID NO. 227/SEQ ID NO. 228, SEQ ID NO.
25 229/SEQ ID NO. 230, SEQ ID NO. 231/SEQ ID NO. 232, SEQ ID NO. 233/SEQ ID NO.
   234, SEQ ID NO. 235/SEQ ID NO. 236, SEQ ID NO. 237/SEQ ID NO. 238, SEQ ID NO.
   239/SEQ ID NO. 240, SEQ ID NO. 241/SEQ ID NO. 242, and combinations thereof.
           Preferably, the broad spectrum of mammalian cancers to be treated is selected from
   the group consisting of ovarian, colon, breast, lung cancers, myelomas, neuroblastic-derived
30 CNS tumors, monocytic leukemias, B-cell derived leukemias, T-cell derived leukemias, B
   cell derived lymphomas, T-cell derived lymphomas, mast cell derived tumors, and
                                                 25

   combinations thereof. Preferably, the autoimmune disease or inflammatory disease is
   selected from the group consisting of intestinal mucosal inflammation, wasting disease
   associated with colitis, multiple sclerosis, systemic lupus erythematosus, viral infections,
   rheumatoid arthritis, osteoarthritis, psoriasis, Cohn's disease, and inflammatory bowel
 5 disease.
   Brief Description of the Figures
            Figure 1 shows anti-PD-LI antibodies H6 and H10 binding to human PD-LI
   expressed on human lymphocytes and the EC 50 determination in the 100 pM range
            Figure 2 shows disclosed anti-PD-Li antibodies binding to human lymphocytes by
10 FACSAria analysis.
            Figure 3 shows disclosed anti-PD-LI antibodies H1, H6 and H10 inhibit lymphocyte
   proliferation.
            Figure 4 shows disclosed anti-PD-LI antibody H10 inhibit NK cell proliferation.
            Figure 5 shows disclosed anti-PD-LI antibodies H6 and H10 enhance cell activation
15 and that the responsive lymphocyte population is the NK cell.
            Figure 6 shows effect of anti-PD-LI antibodies H6 and H10 on the progression of
   disease in a murine model of multiple sclerosis (MS)
            Figure 7 shows the results of EC50 cell binding flow cytometry experiments,
   demonstrating that anti-PD-Li antibody G12 binds the cell surface of CHO cells transfected
20 with full length PD-Li in a concentration dependent manner.
            Figure 8 shows the results of EC50 cell binding flow cytometry experiments,
   demonstrating that anti-PD-LI antibody G12 binds in a concentration dependent manner to
   the cell surface of ES-2 ovarian carcinoma cells induced with IFNy to increase the level of
   PD-LI expression on these cells.
25          Figure 9 shows IC50 data for the blocking of the interaction between recombinant
   human PD-land human PD-Li expressed on CHO cells by anti-PD-Li antibody G12.
            Figure 10 shows a mixed lymphocyte reaction (MLR) to evaluate the effect of the
   antibodies on lymphocyte activity in lymphocyte effector cells. IL-2 secretion was measured
   in the presence or absence of the anti-PD-Li human monoclonal antibody. The antibodies
30 used were the disclosed G12 antibody as compared to prior disclosed antibodies IOA5 and
   12A4 (Bristol-Myers/Medarex) that were obtained via in-house production from prior
                                                    26

   disclosed antibody sequences (U.S. Patent Application 2009/0055944 the disclosure of
   which is incorporated by reference herein).
           Figure II shows a mixed lymphocyte reaction (MLR) was employed to demonstrate
   the effect of blocking the PD-Li/PD-1 pathway by the listed anti-PD-Li antibodies on
 5 lymphocyte effector cells. IFN-y secretion was measured in the presence or absence of the
   anti-PD-Li human monoclonal antibody. The antibodies used were the disclosed G12
   antibody as compared to prior disclosed antibody I 0A5 (Bristol-Myers/Medarex) that was
   obtained via in-house production from prior-disclosed antibody sequences (see U.S. Patent
   Application 2009/0055944, the disclosure of which is incorporated by reference herein).
10         Figure 12 shows a mixed lymphocyte reaction (MLR) was employed to evaluate the
   effect of the antibodies on lymphocyte activity by the anti-PD-LI antibodies on lymphocyte
   effector cells. T cell activation was measured in the presence or absence of the anti-PD-LI
   human monoclonal antibody. The antibodies used were the disclosed G12 antibody as
   compared to prior disclosed antibodies I 0A5 and 12A4 (Bristol-Myers/Medarex) that were
15 obtained via in-house production from prior-disclosed antibody sequences (U.S. Patent
   Application 2009/0055944 the disclosure of which is incorporated by reference herein).
           Figure 13 shows a mixed lymphocyte reaction (MLR) was employed to evaluate the
   effect of the antibodies on lymphocyte activity by the anti-PD-LI antibodies on lymphocyte
   effector cells. T cell activation was measured in the presence or absence of the anti-PD-LI
20 human monoclonal antibody. The antibodies used were the disclosed H6BIL, RSAI, RA3,
   RC5, SHIE2, SHIE4, SHIB 11, and SHIC8 as compared to prior disclosed antibodies IOA5
   (Bristol-Myers-Squibb/Medarex) and YW243.55S70 (Roche/Genentech) that were obtained
   via in-house production from prior-disclosed antibody sequences (U.S. Patent Application
   2009/0055944 and U.S. Patent Application US 2010/0203056; the disclosure of which are
25 incorporated by reference herein).
           Figure 14 shows a mixed lymphocyte reaction (MLR) to evaluate the effect of the
   antibodies on lymphocyte activity in lymphocyte effector cells. IL-2 secretion was measured
   in the presence or absence of the anti-PD-Li human monoclonal antibody. The antibodies
   used were the disclosed H6BiL, RSAi, RA3, RC5, SHiE2, SHiE4, SHiB 1i, and SHiC8
30 as compared to prior disclosed antibodies IOA5 (Bristol-Myers-Squibb/Medarex) and
   YW243.55S70 (Roche/Genentech) that were obtained via in-house production from prior
                                                 27

   disclosed antibody sequences (U.S. Patent Application 2009/0055944 and U.S. Patent
   Application US 2010/0203056; the disclosure of which are incorporated by reference
   herein).
            Figure 15 shows a mixed lymphocyte reaction (MLR) was employed to demonstrate
 5 the effect of blocking the PD-Li/PD-1 pathway by the listed anti-PD-Li antibodies on
   lymphocyte effector cells. IFN-y secretion was measured in the presence or absence of the
   anti-PD-Li human monoclonal antibody. The antibodies used were the disclosed H6BiL,
   RSAi, RA3, RC5, SHiE2, SHiE4, SHiB 1i, and SHiC8 as compared to prior disclosed
   antibodies i0A5 (Bristol-Myers-Squibb/Medarex) and YW243.55S70 (Roche/Genentech)
10 that were obtained via in-house production from prior-disclosed antibody sequences (U.S.
   Patent Application 2009/0055944 and U.S. Patent Application US 2010/0203056; the
   disclosure of which are incorporated by reference herein).
   Detailed Description
            The present disclosure provides a fully human antibody of an IgG class that binds to
15 a PD-LI epitope with a binding affinity of 10-6M or less, that has a heavy chain variable
   domain sequence that is at least 95% identical to the amino acid sequences selected from the
   group consisting of SEQ ID NO. 1, SEQ ID NO. 3, SEQ ID NO. 5, SEQ ID NO. 7, SEQ ID
   NO. 9, SEQ ID NO. 11, SEQ ID NO. 13, SEQ ID NO. 15, SEQ ID NO. 17, SEQ ID NO.
   19, SEQ ID NO. 21, SEQ ID NO. 23, SEQ ID NO. 25, SEQ ID NO. 27, SEQ ID NO. 29,
20 SEQ ID NO. 31, SEQ ID NO. 33, SEQ ID NO. 35, SEQ ID NO. 37, SEQ ID NO. 39, SEQ
   ID NO. 41, SEQ ID NO. 43, SEQ ID NO. 45, SEQ ID NO. 47, SEQ ID NO. 49, SEQ ID
   NO. 51, SEQ ID NO. 53, SEQ ID NO. 55, SEQ ID NO. 57, SEQ ID NO. 59, SEQ ID NO.
   61, SEQ ID NO. 63, SEQ ID NO. 65, SEQ ID NO. 67, SEQ ID NO. 69, SEQ ID NO. 71,
   SEQ ID NO. 73, SEQ ID NO. 75, SEQ ID NO. 77, SEQ ID NO. 79, SEQ ID NO. 81, SEQ
25 ID NO. 83, SEQ ID NO. 85, SEQ ID NO. 87, SEQ ID NO. 89, SEQ ID NO. 91, SEQ ID
   NO. 93, SEQ ID NO. 95, SEQ ID NO. 97, SEQ ID NO. 99, SEQ ID NO. 101, SEQ ID NO.
   103, SEQ ID NO. 105, SEQ ID NO. 107, SEQ ID NO. 109, SEQ ID NO. 111, SEQ ID NO.
   113, SEQ ID NO. 115, SEQ ID NO. 117, SEQ ID NO. 119, SEQ ID NO. 121, SEQ ID NO.
   123, SEQ ID NO. 125, SEQ ID NO. 127, SEQ ID NO. 129, SEQ ID NO. 131, SEQ ID NO.
30 133, SEQ ID NO. 135, SEQ ID NO. 137, SEQ ID NO. 139, SEQ ID NO. 141, SEQ ID NO.
   143, SEQ ID NO. 145, SEQ ID NO. 147, SEQ ID NO. 149, SEQ ID NO. 151, SEQ ID NO.
                                                  28

   153, SEQ ID NO. 155, SEQ ID NO. 157, SEQ ID NO. 159, SEQ ID NO. 161, SEQ ID NO.
   163, SEQ ID NO. 165, SEQ ID NO. 167, SEQ ID NO. 169, SEQ ID NO. 171, SEQ ID NO.
   173, SEQ ID NO. 175, SEQ ID NO. 177, SEQ ID NO. 179, SEQ ID NO. 181, SEQ ID NO.
   183, SEQ ID NO. 185, SEQ ID NO. 187, SEQ ID NO. 189, SEQ ID NO. 191, SEQ ID NO.
 5 193, SEQ ID NO. 195, SEQ ID NO. 197, SEQ ID NO. 199, SEQ ID NO. 201, SEQ ID NO.
   203, SEQ ID NO. 205, SEQ ID NO. 207, SEQ ID NO. 209, SEQ ID NO. 211, SEQ ID NO.
   213, SEQ ID NO. 215, SEQ ID NO. 217, SEQ ID NO. 219, SEQ ID NO. 221, SEQ ID NO.
   223, SEQ ID NO. 225, SEQ ID NO. 227, SEQ ID NO. 229, SEQ ID NO. 231, SEQ ID NO.
   233, SEQ ID NO. 235, SEQ ID NO. 237, SEQ ID NO. 239, SEQ ID NO. 241, and
10 combinations thereof, and that has a light chain variable domain sequence that is at least
   95% identical to the amino acid sequences selected from the group consisting of SEQ ID
   NO. 2, SEQ ID NO. 4, SEQ ID NO. 6, SEQ ID NO. 8, SEQ ID NO. 10, SEQ ID NO. 12,
   SEQ ID NO. 14, SEQ ID NO. 16, SEQ ID NO. 18, SEQ ID NO. 20, SEQ ID NO. 22, SEQ
   ID NO. 24, SEQ ID NO. 26, SEQ ID NO. 28, SEQ ID NO. 30, SEQ ID NO. 32, SEQ ID
15 NO. 34, SEQ ID NO. 36, SEQ ID NO. 38, SEQ ID NO. 40, SEQ ID NO. 42, SEQ ID NO.
   44, SEQ ID NO. 46, SEQ ID NO. 48, SEQ ID NO. 50, SEQ ID NO. 52, SEQ ID NO. 54,
   SEQ ID NO. 56, SEQ ID NO. 58, SEQ ID NO. 60, SEQ ID NO. 62, SEQ ID NO. 64, SEQ
   ID NO. 66, SEQ ID NO. 68, SEQ ID NO. 70, SEQ ID NO. 72, SEQ ID NO. 74, SEQ ID
   NO. 76, SEQ ID NO. 78, SEQ ID NO. 80, SEQ ID NO. 82, SEQ ID NO. 84, SEQ ID NO.
20 86, SEQ ID NO. 88, SEQ ID NO. 90, SEQ ID NO. 92, SEQ ID NO. 94, SEQ ID NO. 96,
   SEQ ID NO. 98, SEQ ID NO. 100, SEQ ID NO. 102, SEQ ID NO. 104, SEQ ID NO. 106,
   SEQ ID NO. 108, SEQ ID NO. 110, SEQ ID NO. 112, SEQ ID NO. 114, SEQ ID NO. 116,
   SEQ ID NO. 118, SEQ ID NO. 120, SEQ ID NO. 122, SEQ ID NO. 124, SEQ ID NO. 126,
   SEQ ID NO. 128, SEQ ID NO. 130, SEQ ID NO. 132, SEQ ID NO. 134, SEQ ID NO. 136,
25 SEQ ID NO. 138, SEQ ID NO. 140, SEQ ID NO. 142, SEQ ID NO. 144, SEQ ID NO. 146,
   SEQ ID NO. 148, SEQ ID NO. 150, SEQ ID NO. 152, SEQ ID NO. 154, SEQ ID NO. 156,
   SEQ ID NO. 158, SEQ ID NO. 160, SEQ ID NO. 162, SEQ ID NO. 164, SEQ ID NO. 166,
   SEQ ID NO. 168, SEQ ID NO. 170, SEQ ID NO. 172, SEQ ID NO. 174, SEQ ID NO. 176,
   SEQ ID NO. 178, SEQ ID NO. 180, SEQ ID NO. 182, SEQ ID NO. 184, SEQ ID NO. 186,
30 SEQ ID NO. 188, SEQ ID NO. 190, SEQ ID NO. 192, SEQ ID NO. 194, SEQ ID NO. 196,
   SEQ ID NO. 198, SEQ ID NO. 200, SEQ ID NO. 202, SEQ ID NO. 204, SEQ ID NO. 206,
                                                 29

   SEQ ID NO. 208, SEQ ID NO. 210, SEQ ID NO. 212, SEQ ID NO. 214, SEQ ID NO. 216,
   SEQ ID NO. 218, SEQ ID NO. 220, SEQ ID NO. 222, SEQ ID NO. 224, SEQ ID NO. 226,
   SEQ ID NO. 228, SEQ ID NO. 230, SEQ ID NO. 232, SEQ ID NO. 234, SEQ ID NO. 236,
   SEQ ID NO. 238, SEQ ID NO. 240, SEQ ID NO. 242, and combinations thereof.
 5 Preferably, the fully human antibody has both a heavy chain and a light chain wherein the
   antibody has a heavy chain/light chain variable domain sequence selected from the group
   consisting of SEQ ID NO. 1/SEQ ID NO. 2 (called E6 herein), SEQ ID NO. 3/SEQ ID NO.
   4 (called E7 herein), SEQ ID NO. 5/SEQ ID NO. 6 (called E9 herein), SEQ ID NO. 7/SEQ
   ID NO. 8 (called EI1 herein), SEQ ID NO. 9/SEQ ID NO. 10 (called Fl herein), SEQ ID
10 NO. 11/SEQ ID NO. 12 (called F4 herein), SEQ ID NO. 13/SEQ ID NO. 14 (called F7
   herein), SEQ ID NO. 15/SEQ ID NO. 16 (called F8 herein), SEQ ID NO. 17/SEQ ID NO.
   18 (called F 11 herein), SEQ ID NO. 19/SEQ ID NO. 20 (called G4 herein), SEQ ID NO.
   21/SEQ ID NO. 22 (called G9 herein), SEQ ID NO. 23/SEQ ID NO. 24 (called G 11 herein),
   SEQ ID NO. 25/SEQ ID NO. 26 (called G12 herein), SEQ ID NO. 27/SEQ ID NO. 28
15 (called H1 herein), SEQ ID NO. 29/SEQ ID NO. 30 (called H3 herein), SEQ ID NO.
   31/SEQ ID NO. 32 (called H4 herein), SEQ ID NO. 33/SEQ ID NO. 34 (called H5 herein),
   SEQ ID NO. 35/SEQ ID NO. 36 (called H6 herein), SEQ ID NO. 37/SEQ ID NO. 38 (called
   H1O herein), SEQ ID NO. 39/SEQ ID NO. 40 (called H12 herein), SEQ ID NO. 41/SEQ ID
   NO. 42 (called PDL-D2 herein), SEQ ID NO. 43/SEQ ID NO. 44 (called PDL-D 11 herein),
20 SEQ ID NO. 45/SEQ ID NO. 46 (called PDL-Hl herein), SEQ ID NO. 47/SEQ ID NO. 48
   (called RB4 herein), SEQ ID NO. 49/SEQ ID NO. 50 (called RB 11 herein), SEQ ID NO.
   51/SEQ ID NO. 52 (called RC5 herein), SEQ ID NO. 53/SEQ ID NO. 54 (called RF5
   herein), SEQ ID NO. 55/SEQ ID NO. 56 (called RG9 herein), SEQ ID NO. 57/SEQ ID NO.
   58 (called RD1 herein), SEQ ID NO. 59/SEQ ID NO. 60 (called RF 11 herein), SEQ ID NO.
25 61/SEQ ID NO. 62 (called RH 11 herein), SEQ ID NO. 63/SEQ ID NO. 64 (called RD9
   herein), SEQ ID NO. 65/SEQ ID NO. 66 (called RE10 herein), SEQ ID NO. 67/SEQ ID
   NO. 68 (called RA3 herein), SEQ ID NO. 69/SEQ ID NO. 70 (called RG1 herein), SEQ ID
   NO. 71/SEQ ID NO. 72 (called RB1 herein), SEQ ID NO. 73/SEQ ID NO. 74 (called RG7
   herein), SEQ ID NO. 75/SEQ ID NO. 76 (called RA6 herein), SEQ ID NO. 77/SEQ ID NO.
30 78 (called RA8 herein), SEQ ID NO. 79/SEQ ID NO. 80 (called RA9 herein), SEQ ID NO.
   81/SEQ ID NO. 82 (called RB5 herein), SEQ ID NO. 83/SEQ ID NO. 84 (called RB8
                                                30

   herein), SEQ ID NO. 85/SEQ ID NO. 86 (called RC8 herein), SEQ ID NO. 87/SEQ ID NO.
   88 (called RC10 herein), SEQ ID NO. 89/SEQ ID NO. 90 (called RD2 herein), SEQ ID NO.
   91/SEQ ID NO. 92 (called RE8 herein), SEQ ID NO. 93/SEQ ID NO. 94 (called RE9
   herein), SEQ ID NO. 95/SEQ ID NO. 96 (called RG12 herein), SEQ ID NO. 97/SEQ ID
 5 NO. 98 (called RSA1 herein), SEQ ID NO. 99/SEQ ID NO. 100 (called R2A7 herein), SEQ
   ID NO. 101/SEQ ID NO. 102 (called R2B12 herein), SEQ ID NO. 103/SEQ ID NO. 104
   (called R2C9 herein), SEQ ID NO. 105/SEQ ID NO. 106 (called R2D5 herein), SEQ ID
   NO. 107/SEQ ID NO. 108 (called R2D7 herein), SEQ ID NO. 109/SEQ ID NO. 110 (called
   R2F4 herein), SEQ ID NO. 111/SEQ ID NO. 112 (called R2A10 herein), SEQ ID NO.
10 113/SEQ ID NO. 114 (called R2E2 herein), SEQ ID NO. 115/SEQ ID NO. 116 (called
   R3B8 herein), SEQ ID NO. 117/SEQ ID NO. 118 (called R3C3 herein), SEQ ID NO.
   119/SEQ ID NO. 120 (called R3E9 herein), SEQ ID NO. 121/SEQ ID NO. 122 (called
   R3E1O herein), SEQ ID NO. 123/SEQ ID NO. 124 (called R3F7 herein), SEQ ID NO.
   125/SEQ ID NO. 126 (called R3F10 herein), SEQ ID NO. 127/SEQ ID NO. 128 (called
15 R4B10 herein), SEQ ID NO. 129/SEQ ID NO. 130 (called R4H1 herein), SEQ ID NO.
   131/SEQ ID NO. 132 (called R4A1 1 herein), SEQ ID NO. 133/SEQ ID NO. 134 (called
   R3D2 herein), SEQ ID NO. 135/SEQ ID NO. 136 (called R5B8 herein), SEQ ID NO.
   137/SEQ ID NO. 138 (called SH1A1Q herein), SEQ ID NO. 139/SEQ ID NO. 140 (called
   SH1B7B(K) herein), SEQ ID NO. 141/SEQ ID NO. 142 (called SHICI herein), SEQ ID
20 NO. 143/SEQ ID NO. 144 (called SH1C8 herein), SEQ ID NO. 145/SEQ ID NO. 146
   (called SHIE10 herein), SEQ ID NO. 147/SEQ ID NO. 148 (called SH1E2 herein), SEQ ID
   NO. 149/SEQ ID NO. 150 (called SH1A9 herein), SEQ ID NO. 151/SEQ ID NO. 152
   (called SHIB 11 herein), SEQ ID NO. 153/SEQ ID NO. 154 (called SH1E4 herein), SEQ ID
   NO. 155/SEQ ID NO. 156 (called SH1B3 herein), SEQ ID NO. 157/SEQ ID NO. 158
25 (called SHID1 herein), SEQ ID NO. 159/SEQ ID NO. 160 (called SH1D2 herein), SEQ ID
   NO. 161/SEQ ID NO. 162 (called SH1D12 herein), SEQ ID NO. 163/SEQ ID NO. 164
   (called SHIE1 herein), SEQ ID NO. 165/SEQ ID NO. 166 (called SH1G9 herein), SEQ ID
   NO. 167/SEQ ID NO. 168 (called SHIA 1 herein), SEQ ID NO. 169/SEQ ID NO. 170
   (called SH1C2 herein), SEQ ID NO. 171/SEQ ID NO. 172 (called SH1G8 herein), SEQ ID
30 NO. 173/SEQ ID NO. 174 (called SH1H2 herein), SEQ ID NO. 175/SEQ ID NO. 176
   (called SHIB1O herein), SEQ ID NO. 177/SEQ ID NO. 178 (called SH1B7A(L) herein),
                                             31

   SEQ ID NO. 179/SEQ ID NO. 180 (called SH1E6 herein), SEQ ID NO. 181/SEQ ID NO.
   182 (called SHIC 11 herein), SEQ ID NO. 183/SEQ ID NO. 184 (called SH1A2 herein),
   SEQ ID NO. 185/SEQ ID NO. 186 (called SHIBI herein), SEQ ID NO. 187/SEQ ID NO.
   188 (called R6B2 herein), SEQ ID NO. 189/SEQ ID NO. 190 (called R6B7 herein), SEQ ID
 5 NO. 191/SEQ ID NO. 192 (called R6B1 1 herein), SEQ ID NO. 193/SEQ ID NO. 194
   (called R6D1 herein), SEQ ID NO. 195/SEQ ID NO. 196 (called R6C8 herein), SEQ ID
   NO. 197/SEQ ID NO. 198 (called R9G8 herein), SEQ ID NO. 199/SEQ ID NO. 200 (called
   R7D1 herein), SEQ ID NO. 201/SEQ ID NO. 202 (called R7D2 herein), SEQ ID NO.
   203/SEQ ID NO. 204 (called R7E7 herein), SEQ ID NO. 205/SEQ ID NO. 206 (called
10 R7F2 herein), SEQ ID NO. 207/SEQ ID NO. 208 (called R7F7 herein), SEQ ID NO.
   209/SEQ ID NO. 210 (called R9H2 herein), SEQ ID NO. 211/SEQ ID NO. 212 (called
   R9H6 herein), SEQ ID NO. 213/SEQ ID NO. 214 (called H6B1L herein), SEQ ID NO.
   215/SEQ ID NO. 216 (called H6A1 herein), SEQ ID NO. 217/SEQ ID NO. 218 (called
   H6B1 herein), SEQ ID NO. 219/SEQ ID NO. 220 (called H6B2 herein), SEQ ID NO.
15 221/SEQ ID NO. 222 (called H19C herein), SEQ ID NO. 223/SEQ ID NO. 224 (called
   H1 OD herein), SEQ ID NO. 225/SEQ ID NO. 226 (called H I1F herein), SEQ ID NO.
   227/SEQ ID NO. 228 (called HiCi herein), SEQ ID NO. 229/SEQ ID NO. 230 (called
   GPG1A2 herein), SEQ ID NO. 231/SEQ ID NO. 232 (called GPGG8 herein), SEQ ID NO.
   233/SEQ ID NO. 234 (called GPGG1O herein), SEQ ID NO. 235/SEQ ID NO. 236 (called
20 GPGH7 herein), SEQ ID NO. 237/SEQ ID NO. 238 (called GPGH1O herein), SEQ ID NO.
   239/SEQ ID NO. 240 (called GPGH1 1 herein), SEQ ID NO. 241/SEQ ID NO. 242 (called
   GPGH1OP herein), and combinations thereof.
           The present disclosure provides a Fab fully human antibody fragment, having a
   variable domain region from a heavy chain and a variable domain region from a light chain,
25 wherein the heavy chain variable domain sequence that is at least 95% identical to the
   amino acid sequences selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 3,
   SEQ ID NO. 5, SEQ ID NO. 7, SEQ ID NO. 9, SEQ ID NO. 11, SEQ ID NO. 13, SEQ ID
   NO. 15, SEQ ID NO. 17, SEQ ID NO. 19, SEQ ID NO. 21, SEQ ID NO. 23, SEQ ID NO.
   25, SEQ ID NO. 27, SEQ ID NO. 29, SEQ ID NO. 31, SEQ ID NO. 33, SEQ ID NO. 35,
30 SEQ ID NO. 37, SEQ ID NO. 39, SEQ ID NO. 41, SEQ ID NO. 43, SEQ ID NO. 45, SEQ
   ID NO. 47, SEQ ID NO. 49, SEQ ID NO. 51, SEQ ID NO. 53, SEQ ID NO. 55, SEQ ID
                                                32

   NO. 57, SEQ ID NO. 59, SEQ ID NO. 61, SEQ ID NO. 63, SEQ ID NO. 65, SEQ ID NO.
   67, SEQ ID NO. 69, SEQ ID NO. 71, SEQ ID NO. 73, SEQ ID NO. 75, SEQ ID NO. 77,
   SEQ ID NO. 79, SEQ ID NO. 81, SEQ ID NO. 83, SEQ ID NO. 85, SEQ ID NO. 87, SEQ
   ID NO. 89, SEQ ID NO. 91, SEQ ID NO. 93, SEQ ID NO. 95, SEQ ID NO. 97, SEQ ID
 5 NO. 99, SEQ ID NO. 101, SEQ ID NO. 103, SEQ ID NO. 105, SEQ ID NO. 107, SEQ ID
   NO. 109, SEQ ID NO. 111, SEQ ID NO. 113, SEQ ID NO. 115, SEQ ID NO. 117, SEQ ID
   NO. 119, SEQ ID NO. 121, SEQ ID NO. 123, SEQ ID NO. 125, SEQ ID NO. 127, SEQ ID
   NO. 129, SEQ ID NO. 131, SEQ ID NO. 133, SEQ ID NO. 135, SEQ ID NO. 137, SEQ ID
   NO. 139, SEQ ID NO. 141, SEQ ID NO. 143, SEQ ID NO. 145, SEQ ID NO. 147, SEQ ID
10 NO. 149, SEQ ID NO. 151, SEQ ID NO. 153, SEQ ID NO. 155, SEQ ID NO. 157, SEQ ID
   NO. 159, SEQ ID NO. 161, SEQ ID NO. 163, SEQ ID NO. 165, SEQ ID NO. 167, SEQ ID
   NO. 169, SEQ ID NO. 171, SEQ ID NO. 173, SEQ ID NO. 175, SEQ ID NO. 177, SEQ ID
   NO. 179, SEQ ID NO. 181, SEQ ID NO. 183, SEQ ID NO. 185, SEQ ID NO. 187, SEQ ID
   NO. 189, SEQ ID NO. 191, SEQ ID NO. 193, SEQ ID NO. 195, SEQ ID NO. 197, SEQ ID
15 NO. 199, SEQ ID NO. 201, SEQ ID NO. 203, SEQ ID NO. 205, SEQ ID NO. 207, SEQ ID
   NO. 209, SEQ ID NO. 211, SEQ ID NO. 213, SEQ ID NO. 215, SEQ ID NO. 217, SEQ ID
   NO. 219, SEQ ID NO. 221, SEQ ID NO. 223, SEQ ID NO. 225, SEQ ID NO. 227, SEQ ID
   NO. 229, SEQ ID NO. 231, SEQ ID NO. 233, SEQ ID NO. 235, SEQ ID NO. 237, SEQ ID
   NO. 239, SEQ ID NO. 241, and combinations thereof, and that has a light chain variable
20 domain sequence that is at least 95% identical to the amino acid sequences selected from the
   group consisting of SEQ ID NO. 2, SEQ ID NO. 4, SEQ ID NO. 6, SEQ ID NO. 8, SEQ ID
   NO. 10, SEQ ID NO. 12, SEQ ID NO. 14, SEQ ID NO. 16, SEQ ID NO. 18, SEQ ID NO.
   20, SEQ ID NO. 22, SEQ ID NO. 24, SEQ ID NO. 26, SEQ ID NO. 28, SEQ ID NO. 30,
   SEQ ID NO. 32, SEQ ID NO. 34, SEQ ID NO. 36, SEQ ID NO. 38, SEQ ID NO. 40, SEQ
25 ID NO. 42, SEQ ID NO. 44, SEQ ID NO. 46, SEQ ID NO. 48, SEQ ID NO. 50, SEQ ID
   NO. 52, SEQ ID NO. 54, SEQ ID NO. 56, SEQ ID NO. 58, SEQ ID NO. 60, SEQ ID NO.
   62, SEQ ID NO. 64, SEQ ID NO. 66, SEQ ID NO. 68, SEQ ID NO. 70, SEQ ID NO. 72,
   SEQ ID NO. 74, SEQ ID NO. 76, SEQ ID NO. 78, SEQ ID NO. 80, SEQ ID NO. 82, SEQ
   ID NO. 84, SEQ ID NO. 86, SEQ ID NO. 88, SEQ ID NO. 90, SEQ ID NO. 92, SEQ ID
30 NO. 94, SEQ ID NO. 96, SEQ ID NO. 98, SEQ ID NO. 100, SEQ ID NO. 102, SEQ ID
   NO. 104, SEQ ID NO. 106, SEQ ID NO. 108, SEQ ID NO. 110, SEQ ID NO. 112, SEQ ID
                                                33

   NO. 114, SEQ ID NO. 116, SEQ ID NO. 118, SEQ ID NO. 120, SEQ ID NO. 122, SEQ ID
   NO. 124, SEQ ID NO. 126, SEQ ID NO. 128, SEQ ID NO. 130, SEQ ID NO. 132, SEQ ID
   NO. 134, SEQ ID NO. 136, SEQ ID NO. 138, SEQ ID NO. 140, SEQ ID NO. 142, SEQ ID
   NO. 144, SEQ ID NO. 146, SEQ ID NO. 148, SEQ ID NO. 150, SEQ ID NO. 152, SEQ ID
 5 NO. 154, SEQ ID NO. 156, SEQ ID NO. 158, SEQ ID NO. 160, SEQ ID NO. 162, SEQ ID
   NO. 164, SEQ ID NO. 166, SEQ ID NO. 168, SEQ ID NO. 170, SEQ ID NO. 172, SEQ ID
   NO. 174, SEQ ID NO. 176, SEQ ID NO. 178, SEQ ID NO. 180, SEQ ID NO. 182, SEQ ID
   NO. 184, SEQ ID NO. 186, SEQ ID NO. 188, SEQ ID NO. 190, SEQ ID NO. 192, SEQ ID
   NO. 194, SEQ ID NO. 196, SEQ ID NO. 198, SEQ ID NO. 200, SEQ ID NO. 202, SEQ ID
10 NO. 204, SEQ ID NO. 206, SEQ ID NO. 208, SEQ ID NO. 210, SEQ ID NO. 212, SEQ ID
   NO. 214, SEQ ID NO. 216, SEQ ID NO. 218, SEQ ID NO. 220, SEQ ID NO. 222, SEQ ID
   NO. 224, SEQ ID NO. 226, SEQ ID NO. 228, SEQ ID NO. 230, SEQ ID NO. 232, SEQ ID
   NO. 234, SEQ ID NO. 236, SEQ ID NO. 238, SEQ ID NO. 240, SEQ ID NO. 242, and
   combinations thereof. Preferably, the fully human antibody Fab fragment has both a heavy
15 chain variable domain region and a light chain variable domain region wherein the antibody
   has a heavy chain/light chain variable domain sequence selected from the group consisting
   of SEQ ID NO. 1/SEQ ID NO. 2, SEQ ID NO. 3/SEQ ID NO. 4, SEQ ID NO. 5/SEQ ID
   NO. 6, SEQ ID NO. 7/SEQ ID NO. 8, SEQ ID NO. 9/SEQ ID NO. 10, SEQ ID NO. 11/SEQ
   ID NO. 12, SEQ ID NO. 13/SEQ ID NO. 14, SEQ ID NO. 15/SEQ ID NO. 16, SEQ ID NO.
20 17/SEQ ID NO. 18, SEQ ID NO. 19/SEQ ID NO. 20, SEQ ID NO. 21/SEQ ID NO. 22,
   SEQ ID NO. 23/SEQ ID NO. 24, SEQ ID NO. 25/SEQ ID NO. 26, SEQ ID NO. 27/SEQ ID
   NO. 28, SEQ ID NO. 29/SEQ ID NO. 30, SEQ ID NO. 31/SEQ ID NO. 32, SEQ ID NO.
   33/SEQ ID NO. 34, SEQ ID NO. 35/SEQ ID NO. 36, SEQ ID NO. 37/SEQ ID NO. 38,
   SEQ ID NO. 39/SEQ ID NO. 40, SEQ ID NO. 41/SEQ ID NO. 42, SEQ ID NO. 43/SEQ ID
25 NO. 44, SEQ ID NO. 45/SEQ ID NO. 46, SEQ ID NO. 47/SEQ ID NO. 48, SEQ ID NO.
   49/SEQ ID NO. 50, SEQ ID NO. 51/SEQ ID NO. 52, SEQ ID NO. 53/SEQ ID NO. 54,
   SEQ ID NO. 55/SEQ ID NO. 56, SEQ ID NO. 57/SEQ ID NO. 58, SEQ ID NO. 59/SEQ ID
   NO. 60, SEQ ID NO. 61/SEQ ID NO. 62, SEQ ID NO. 63/SEQ ID NO. 64, SEQ ID NO.
   65/SEQ ID NO. 66, SEQ ID NO. 67/SEQ ID NO. 68, SEQ ID NO. 69/SEQ ID NO. 70,
30 SEQ ID NO. 71/SEQ ID NO. 72, SEQ ID NO. 73/SEQ ID NO. 74, SEQ ID NO. 75/SEQ ID
   NO. 76, SEQ ID NO. 77/SEQ ID NO. 78, SEQ ID NO. 79/SEQ ID NO. 80, SEQ ID NO.
                                                 34

   81/SEQ ID NO. 82, SEQ ID NO. 83/SEQ ID NO. 84, SEQ ID NO. 85/SEQ ID NO. 86,
   SEQ ID NO. 87/SEQ ID NO. 88, SEQ ID NO. 89/SEQ ID NO. 90, SEQ ID NO. 91/SEQ ID
   NO. 92, SEQ ID NO. 93/SEQ ID NO. 94, SEQ ID NO. 95/SEQ ID NO. 96, SEQ ID NO.
   97/SEQ ID NO. 98, SEQ ID NO. 99/SEQ ID NO. 100, SEQ ID NO. 101/SEQ ID NO. 102,
 5 SEQ ID NO. 103/SEQ ID NO. 104, SEQ ID NO. 105/SEQ ID NO. 106, SEQ ID NO.
   107/SEQ ID NO. 108, SEQ ID NO. 109/SEQ ID NO. 110, SEQ ID NO. 111/SEQ ID NO.
   112, SEQ ID NO. 113/SEQ ID NO. 114, SEQ ID NO. 115/SEQ ID NO. 116, SEQ ID NO.
   117/SEQ ID NO. 118, SEQ ID NO. 119/SEQ ID NO. 120, SEQ ID NO. 121/SEQ ID NO.
   122, SEQ ID NO. 123/SEQ ID NO. 124, SEQ ID NO. 125/SEQ ID NO. 126, SEQ ID NO.
10 127/SEQ ID NO. 128, SEQ ID NO. 129/SEQ ID NO. 130, SEQ ID NO. 131/SEQ ID NO.
   132, SEQ ID NO. 133/SEQ ID NO. 134, SEQ ID NO. 135/SEQ ID NO. 136, SEQ ID NO.
   137/SEQ ID NO. 138, SEQ ID NO. 139/SEQ ID NO. 140, SEQ ID NO. 141/SEQ ID NO.
   142, SEQ ID NO. 143/SEQ ID NO. 144, SEQ ID NO. 145/SEQ ID NO. 146, SEQ ID NO.
   147/SEQ ID NO. 148, SEQ ID NO. 149/SEQ ID NO. 150, SEQ ID NO. 151/SEQ ID NO.
15 152, SEQ ID NO. 153/SEQ ID NO. 154, SEQ ID NO. 155/SEQ ID NO. 156, SEQ ID NO.
   157/SEQ ID NO. 158, SEQ ID NO. 159/SEQ ID NO. 160, SEQ ID NO. 161/SEQ ID NO.
   162, SEQ ID NO. 163/SEQ ID NO. 164, SEQ ID NO. 165/SEQ ID NO. 166, SEQ ID NO.
   167/SEQ ID NO. 168, SEQ ID NO. 169/SEQ ID NO. 170, SEQ ID NO. 171/SEQ ID NO.
   172, SEQ ID NO. 173/SEQ ID NO. 174, SEQ ID NO. 175/SEQ ID NO. 176, SEQ ID NO.
20 177/SEQ ID NO. 178, SEQ ID NO. 179/SEQ ID NO. 180, SEQ ID NO. 181/SEQ ID NO.
   182, SEQ ID NO. 183/SEQ ID NO. 184, SEQ ID NO. 185/SEQ ID NO. 186, SEQ ID NO.
   187/SEQ ID NO. 188, SEQ ID NO. 189/SEQ ID NO. 190, SEQ ID NO. 191/SEQ ID NO.
   192, SEQ ID NO. 193/SEQ ID NO. 194, SEQ ID NO. 195/SEQ ID NO. 196, SEQ ID NO.
   197/SEQ ID NO. 198, SEQ ID NO. 199/SEQ ID NO. 200, SEQ ID NO. 201/SEQ ID NO.
25 202, SEQ ID NO. 203/SEQ ID NO. 204, SEQ ID NO. 205/SEQ ID NO. 206, SEQ ID NO.
   207/SEQ ID NO. 208, SEQ ID NO. 209/SEQ ID NO. 210, SEQ ID NO. 211/SEQ ID NO.
   212, SEQ ID NO. 213/SEQ ID NO. 214, SEQ ID NO. 215/SEQ ID NO. 216, SEQ ID NO.
   217/SEQ ID NO. 218, SEQ ID NO. 219/SEQ ID NO. 220, SEQ ID NO. 221/SEQ ID NO.
   222, SEQ ID NO. 223/SEQ ID NO. 224, SEQ ID NO. 225/SEQ ID NO. 226, SEQ ID NO.
30 227/SEQ ID NO. 228, SEQ ID NO. 229/SEQ ID NO. 230, SEQ ID NO. 231/SEQ ID NO.
   232, SEQ ID NO. 233/SEQ ID NO. 234, SEQ ID NO. 235/SEQ ID NO. 236, SEQ ID NO.
                                          35

   237/SEQ ID NO. 238, SEQ ID NO. 239/SEQ ID NO. 240, SEQ ID NO. 241/SEQ ID NO.
   242, and combinations thereof.
          The present disclosure provides a single chain human antibody, having a variable
   domain region from a heavy chain and a variable domain region from a light chain and a
 5 peptide linker connection the heavy chain and light chain variable domain regions, wherein
   the heavy chain variable domain sequence that is at least 95% identical to the amino acid
   sequences selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 3, SEQ ID
   NO. 5, SEQ ID NO. 7, SEQ ID NO. 9, SEQ ID NO. 11, SEQ ID NO. 13, SEQ ID NO. 15,
   SEQ ID NO. 17, SEQ ID NO. 19, SEQ ID NO. 21, SEQ ID NO. 23, SEQ ID NO. 25, SEQ
10 ID NO. 27, SEQ ID NO. 29, SEQ ID NO. 31, SEQ ID NO. 33, SEQ ID NO. 35, SEQ ID
   NO. 37, SEQ ID NO. 39, SEQ ID NO. 41, SEQ ID NO. 43, SEQ ID NO. 45, SEQ ID NO.
   47, SEQ ID NO. 49, SEQ ID NO. 51, SEQ ID NO. 53, SEQ ID NO. 55, SEQ ID NO. 57,
   SEQ ID NO. 59, SEQ ID NO. 61, SEQ ID NO. 63, SEQ ID NO. 65, SEQ ID NO. 67, SEQ
   ID NO. 69, SEQ ID NO. 71, SEQ ID NO. 73, SEQ ID NO. 75, SEQ ID NO. 77, SEQ ID
15 NO. 79, SEQ ID NO. 81, SEQ ID NO. 83, SEQ ID NO. 85, SEQ ID NO. 87, SEQ ID NO.
   89, SEQ ID NO. 91, SEQ ID NO. 93, SEQ ID NO. 95, SEQ ID NO. 97, SEQ ID NO. 99,
   SEQ ID NO. 101, SEQ ID NO. 103, SEQ ID NO. 105, SEQ ID NO. 107, SEQ ID NO. 109,
   SEQ ID NO. 111, SEQ ID NO. 113, SEQ ID NO. 115, SEQ ID NO. 117, SEQ ID NO. 119,
   SEQ ID NO. 121, SEQ ID NO. 123, SEQ ID NO. 125, SEQ ID NO. 127, SEQ ID NO. 129,
20 SEQ ID NO. 131, SEQ ID NO. 133, SEQ ID NO. 135, SEQ ID NO. 137, SEQ ID NO. 139,
   SEQ ID NO. 141, SEQ ID NO. 143, SEQ ID NO. 145, SEQ ID NO. 147, SEQ ID NO. 149,
   SEQ ID NO. 151, SEQ ID NO. 153, SEQ ID NO. 155, SEQ ID NO. 157, SEQ ID NO. 159,
   SEQ ID NO. 161, SEQ ID NO. 163, SEQ ID NO. 165, SEQ ID NO. 167, SEQ ID NO. 169,
   SEQ ID NO. 171, SEQ ID NO. 173, SEQ ID NO. 175, SEQ ID NO. 177, SEQ ID NO. 179,
25 SEQ ID NO. 181, SEQ ID NO. 183, SEQ ID NO. 185, SEQ ID NO. 187, SEQ ID NO. 189,
   SEQ ID NO. 191, SEQ ID NO. 193, SEQ ID NO. 195, SEQ ID NO. 197, SEQ ID NO. 199,
   SEQ ID NO. 201, SEQ ID NO. 203, SEQ ID NO. 205, SEQ ID NO. 207, SEQ ID NO. 209,
   SEQ ID NO. 211, SEQ ID NO. 213, SEQ ID NO. 215, SEQ ID NO. 217, SEQ ID NO. 219,
   SEQ ID NO. 221, SEQ ID NO. 223, SEQ ID NO. 225, SEQ ID NO. 227, SEQ ID NO. 229,
30 SEQ ID NO. 231, SEQ ID NO. 233, SEQ ID NO. 235, SEQ ID NO. 237, SEQ ID NO. 239,
   SEQ ID NO. 241, and combinations thereof, and that has a light chain variable domain
                                                36

   sequence that is at least 95% identical to the amino acid sequences selected from the group
   consisting of SEQ ID NO. 2, SEQ ID NO. 4, SEQ ID NO. 6, SEQ ID NO. 8, SEQ ID NO.
   10, SEQ ID NO. 12, SEQ ID NO. 14, SEQ ID NO. 16, SEQ ID NO. 18, SEQ ID NO. 20,
   SEQ ID NO. 22, SEQ ID NO. 24, SEQ ID NO. 26, SEQ ID NO. 28, SEQ ID NO. 30, SEQ
 5 ID NO. 32, SEQ ID NO. 34, SEQ ID NO. 36, SEQ ID NO. 38, SEQ ID NO. 40, SEQ ID
   NO. 42, SEQ ID NO. 44, SEQ ID NO. 46, SEQ ID NO. 48, SEQ ID NO. 50, SEQ ID NO.
   52, SEQ ID NO. 54, SEQ ID NO. 56, SEQ ID NO. 58, SEQ ID NO. 60, SEQ ID NO. 62,
   SEQ ID NO. 64, SEQ ID NO. 66, SEQ ID NO. 68, SEQ ID NO. 70, SEQ ID NO. 72, SEQ
   ID NO. 74, SEQ ID NO. 76, SEQ ID NO. 78, SEQ ID NO. 80, SEQ ID NO. 82, SEQ ID
10 NO. 84, SEQ ID NO. 86, SEQ ID NO. 88, SEQ ID NO. 90, SEQ ID NO. 92, SEQ ID NO.
   94, SEQ ID NO. 96, SEQ ID NO. 98, SEQ ID NO. 100, SEQ ID NO. 102, SEQ ID NO.
   104, SEQ ID NO. 106, SEQ ID NO. 108, SEQ ID NO. 110, SEQ ID NO. 112, SEQ ID NO.
   114, SEQ ID NO. 116, SEQ ID NO. 118, SEQ ID NO. 120, SEQ ID NO. 122, SEQ ID NO.
   124, SEQ ID NO. 126, SEQ ID NO. 128, SEQ ID NO. 130, SEQ ID NO. 132, SEQ ID NO.
15 134, SEQ ID NO. 136, SEQ ID NO. 138, SEQ ID NO. 140, SEQ ID NO. 142, SEQ ID NO.
   144, SEQ ID NO. 146, SEQ ID NO. 148, SEQ ID NO. 150, SEQ ID NO. 152, SEQ ID NO.
   154, SEQ ID NO. 156, SEQ ID NO. 158, SEQ ID NO. 160, SEQ ID NO. 162, SEQ ID NO.
   164, SEQ ID NO. 166, SEQ ID NO. 168, SEQ ID NO. 170, SEQ ID NO. 172, SEQ ID NO.
   174, SEQ ID NO. 176, SEQ ID NO. 178, SEQ ID NO. 180, SEQ ID NO. 182, SEQ ID NO.
20 184, SEQ ID NO. 186, SEQ ID NO. 188, SEQ ID NO. 190, SEQ ID NO. 192, SEQ ID NO.
   194, SEQ ID NO. 196, SEQ ID NO. 198, SEQ ID NO. 200, SEQ ID NO. 202, SEQ ID NO.
   204, SEQ ID NO. 206, SEQ ID NO. 208, SEQ ID NO. 210, SEQ ID NO. 212, SEQ ID NO.
   214, SEQ ID NO. 216, SEQ ID NO. 218, SEQ ID NO. 220, SEQ ID NO. 222, SEQ ID NO.
   224, SEQ ID NO. 226, SEQ ID NO. 228, SEQ ID NO. 230, SEQ ID NO. 232, SEQ ID NO.
25 234, SEQ ID NO. 236, SEQ ID NO. 238, SEQ ID NO. 240, SEQ ID NO. 242, and
   combinations thereof. Preferably, the fully human single chain antibody has both a heavy
   chain variable domain region and a light chain variable domain region, wherein the single
   chain fully human antibody has a heavy chain/light chain variable domain sequence selected
   from the group consisting of SEQ ID NO. 1/SEQ ID NO. 2, SEQ ID NO. 3/SEQ ID NO. 4,
30 SEQ ID NO. 5/SEQ ID NO. 6, SEQ ID NO. 7/SEQ ID NO. 8, SEQ ID NO. 9/SEQ ID NO.
   10, SEQ ID NO. 11/SEQ ID NO. 12, SEQ ID NO. 13/SEQ ID NO. 14, SEQ ID NO.
                                                  37

   15/SEQ ID NO. 16, SEQ ID NO. 17/SEQ ID NO. 18, SEQ ID NO. 19/SEQ ID NO. 20,
   SEQ ID NO. 21/SEQ ID NO. 22, SEQ ID NO. 23/SEQ ID NO. 24, SEQ ID NO. 25/SEQ ID
   NO. 26, SEQ ID NO. 27/SEQ ID NO. 28, SEQ ID NO. 29/SEQ ID NO. 30, SEQ ID NO.
   31/SEQ ID NO. 32, SEQ ID NO. 33/SEQ ID NO. 34, SEQ ID NO. 35/SEQ ID NO. 36,
 5 SEQ ID NO. 37/SEQ ID NO. 38, SEQ ID NO. 39/SEQ ID NO. 40, SEQ ID NO. 41/SEQ ID
   NO. 42, SEQ ID NO. 43/SEQ ID NO. 44, SEQ ID NO. 45/SEQ ID NO. 46, SEQ ID NO.
   47/SEQ ID NO. 48, SEQ ID NO. 49/SEQ ID NO. 50, SEQ ID NO. 51/SEQ ID NO. 52,
   SEQ ID NO. 53/SEQ ID NO. 54, SEQ ID NO. 55/SEQ ID NO. 56, SEQ ID NO. 57/SEQ ID
   NO. 58, SEQ ID NO. 59/SEQ ID NO. 60, SEQ ID NO. 61/SEQ ID NO. 62, SEQ ID NO.
10 63/SEQ ID NO. 64, SEQ ID NO. 65/SEQ ID NO. 66, SEQ ID NO. 67/SEQ ID NO. 68,
   SEQ ID NO. 69/SEQ ID NO. 70, SEQ ID NO. 71/SEQ ID NO. 72, SEQ ID NO. 73/SEQ ID
   NO. 74, SEQ ID NO. 75/SEQ ID NO. 76, SEQ ID NO. 77/SEQ ID NO. 78, SEQ ID NO.
   79/SEQ ID NO. 80, SEQ ID NO. 81/SEQ ID NO. 82, SEQ ID NO. 83/SEQ ID NO. 84,
   SEQ ID NO. 85/SEQ ID NO. 86, SEQ ID NO. 87/SEQ ID NO. 88, SEQ ID NO. 89/SEQ ID
15 NO. 90, SEQ ID NO. 91/SEQ ID NO. 92, SEQ ID NO. 93/SEQ ID NO. 94, SEQ ID NO.
   95/SEQ ID NO. 96, SEQ ID NO. 97/SEQ ID NO. 98, SEQ ID NO. 99/SEQ ID NO. 100,
   SEQ ID NO. 101/SEQ ID NO. 102, SEQ ID NO. 103/SEQ ID NO. 104, SEQ ID NO.
   105/SEQ ID NO. 106, SEQ ID NO. 107/SEQ ID NO. 108, SEQ ID NO. 109/SEQ ID NO.
   110, SEQ ID NO. 111/SEQ ID NO. 112, SEQ ID NO. 113/SEQ ID NO. 114, SEQ ID NO.
20 115/SEQ ID NO. 116, SEQ ID NO. 117/SEQ ID NO. 118, SEQ ID NO. 119/SEQ ID NO.
   120, SEQ ID NO. 121/SEQ ID NO. 122, SEQ ID NO. 123/SEQ ID NO. 124, SEQ ID NO.
   125/SEQ ID NO. 126, SEQ ID NO. 127/SEQ ID NO. 128, SEQ ID NO. 129/SEQ ID NO.
   130, SEQ ID NO. 131/SEQ ID NO. 132, SEQ ID NO. 133/SEQ ID NO. 134, SEQ ID NO.
   135/SEQ ID NO. 136, SEQ ID NO. 137/SEQ ID NO. 138, SEQ ID NO. 139/SEQ ID NO.
25 140, SEQ ID NO. 141/SEQ ID NO. 142, SEQ ID NO. 143/SEQ ID NO. 144, SEQ ID NO.
   145/SEQ ID NO. 146, SEQ ID NO. 147/SEQ ID NO. 148, SEQ ID NO. 149/SEQ ID NO.
   150, SEQ ID NO. 151/SEQ ID NO. 152, SEQ ID NO. 153/SEQ ID NO. 154, SEQ ID NO.
   155/SEQ ID NO. 156, SEQ ID NO. 157/SEQ ID NO. 158, SEQ ID NO. 159/SEQ ID NO.
   160, SEQ ID NO. 161/SEQ ID NO. 162, SEQ ID NO. 163/SEQ ID NO. 164, SEQ ID NO.
30 165/SEQ ID NO. 166, SEQ ID NO. 167/SEQ ID NO. 168, SEQ ID NO. 169/SEQ ID NO.
   170, SEQ ID NO. 171/SEQ ID NO. 172, SEQ ID NO. 173/SEQ ID NO. 174, SEQ ID NO.
                                          38

   175/SEQ ID NO. 176, SEQ ID NO. 177/SEQ ID NO. 178, SEQ ID NO. 179/SEQ ID NO.
   180, SEQ ID NO. 181/SEQ ID NO. 182, SEQ ID NO. 183/SEQ ID NO. 184, SEQ ID NO.
   185/SEQ ID NO. 186, SEQ ID NO. 187/SEQ ID NO. 188, SEQ ID NO. 189/SEQ ID NO.
   190, SEQ ID NO. 191/SEQ ID NO. 192, SEQ ID NO. 193/SEQ ID NO. 194, SEQ ID NO.
 5 195/SEQ ID NO. 196, SEQ ID NO. 197/SEQ ID NO. 198, SEQ ID NO. 199/SEQ ID NO.
   200, SEQ ID NO. 201/SEQ ID NO. 202, SEQ ID NO. 203/SEQ ID NO. 204, SEQ ID NO.
   205/SEQ ID NO. 206, SEQ ID NO. 207/SEQ ID NO. 208, SEQ ID NO. 209/SEQ ID NO.
   210, SEQ ID NO. 211/SEQ ID NO. 212, SEQ ID NO. 213/SEQ ID NO. 214, SEQ ID NO.
   215/SEQ ID NO. 216, SEQ ID NO. 217/SEQ ID NO. 218, SEQ ID NO. 219/SEQ ID NO.
10 220, SEQ ID NO. 221/SEQ ID NO. 222, SEQ ID NO. 223/SEQ ID NO. 224, SEQ ID NO.
   225/SEQ ID NO. 226, SEQ ID NO. 227/SEQ ID NO. 228, SEQ ID NO. 229/SEQ ID NO.
   230, SEQ ID NO. 231/SEQ ID NO. 232, SEQ ID NO. 233/SEQ ID NO. 234, SEQ ID NO.
   235/SEQ ID NO. 236, SEQ ID NO. 237/SEQ ID NO. 238, SEQ ID NO. 239/SEQ ID NO.
   240, SEQ ID NO. 241/SEQ ID NO. 242, and combinations thereof.
15          The present disclosure further provides a method for treating a broad spectrum of
   mammalian cancers or inflammatory diseases or autoimmune diseases, comprising
   administering an effective amount of an anti-PD-LI polypeptide, wherein the anti-PD-LI
   polypeptide is selected from the group consisting of a fully human antibody of an IgG class
   that binds to a PD-Li epitope with a binding affinity of at least 10-6M, a Fab fully human
20 antibody fragment, having a variable domain region from a heavy chain and a variable
   domain region from a light chain, a single chain human antibody, having a variable domain
   region from a heavy chain and a variable domain region from a light chain and a peptide
   linker connection the heavy chain and light chain variable domain regions, and
   combinations thereof;
25          wherein the fully human antibody has a heavy chain variable domain sequence that
   is at least 95% identical to the amino acid sequences selected from the group consisting of
   SEQ ID NO. 1, SEQ ID NO. 3, SEQ ID NO. 5, SEQ ID NO. 7, SEQ ID NO. 9, SEQ ID NO.
   11, SEQ ID NO. 13, SEQ ID NO. 15, SEQ ID NO. 17, SEQ ID NO. 19, SEQ ID NO. 21,
   SEQ ID NO. 23, SEQ ID NO. 25, SEQ ID NO. 27, SEQ ID NO. 29, SEQ ID NO. 31, SEQ
30 ID NO. 33, SEQ ID NO. 35, SEQ ID NO. 37, SEQ ID NO. 39, SEQ ID NO. 41, SEQ ID
   NO. 43, SEQ ID NO. 45, SEQ ID NO. 47, SEQ ID NO. 49, SEQ ID NO. 51, SEQ ID NO.
                                                  39

   53, SEQ ID NO. 55, SEQ ID NO. 57, SEQ ID NO. 59, SEQ ID NO. 61, SEQ ID NO. 63,
   SEQ ID NO. 65, SEQ ID NO. 67, SEQ ID NO. 69, SEQ ID NO. 71, SEQ ID NO. 73, SEQ
   ID NO. 75, SEQ ID NO. 77, SEQ ID NO. 79, SEQ ID NO. 81, SEQ ID NO. 83, SEQ ID
   NO. 85, SEQ ID NO. 87, SEQ ID NO. 89, SEQ ID NO. 91, SEQ ID NO. 93, SEQ ID NO.
 5 95, SEQ ID NO. 97, SEQ ID NO. 99, SEQ ID NO. 101, SEQ ID NO. 103, SEQ ID NO.
   105, SEQ ID NO. 107, SEQ ID NO. 109, SEQ ID NO. 111, SEQ ID NO. 113, SEQ ID NO.
   115, SEQ ID NO. 117, SEQ ID NO. 119, SEQ ID NO. 121, SEQ ID NO. 123, SEQ ID NO.
   125, SEQ ID NO. 127, SEQ ID NO. 129, SEQ ID NO. 131, SEQ ID NO. 133, SEQ ID NO.
   135, SEQ ID NO. 137, SEQ ID NO. 139, SEQ ID NO. 141, SEQ ID NO. 143, SEQ ID NO.
10 145, SEQ ID NO. 147, SEQ ID NO. 149, SEQ ID NO. 151, SEQ ID NO. 153, SEQ ID NO.
   155, SEQ ID NO. 157, SEQ ID NO. 159, SEQ ID NO. 161, SEQ ID NO. 163, SEQ ID NO.
   165, SEQ ID NO. 167, SEQ ID NO. 169, SEQ ID NO. 171, SEQ ID NO. 173, SEQ ID NO.
   175, SEQ ID NO. 177, SEQ ID NO. 179, SEQ ID NO. 181, SEQ ID NO. 183, SEQ ID NO.
   185, SEQ ID NO. 187, SEQ ID NO. 189, SEQ ID NO. 191, SEQ ID NO. 193, SEQ ID NO.
15 195, SEQ ID NO. 197, SEQ ID NO. 199, SEQ ID NO. 201, SEQ ID NO. 203, SEQ ID NO.
   205, SEQ ID NO. 207, SEQ ID NO. 209, SEQ ID NO. 211, SEQ ID NO. 213, SEQ ID NO.
   215, SEQ ID NO. 217, SEQ ID NO. 219, SEQ ID NO. 221, SEQ ID NO. 223, SEQ ID NO.
   225, SEQ ID NO. 227, SEQ ID NO. 229, SEQ ID NO. 231, SEQ ID NO. 233, SEQ ID NO.
   235, SEQ ID NO. 237, SEQ ID NO. 239, SEQ ID NO. 241, and combinations thereof, and
20 that has a light chain variable domain sequence that is at least 95% identical to the amino
   acid sequences selected from the group consisting of SEQ ID NO. 2, SEQ ID NO. 4, SEQ
   ID NO. 6, SEQ ID NO. 8, SEQ ID NO. 10, SEQ ID NO. 12, SEQ ID NO. 14, SEQ ID NO.
   16, SEQ ID NO. 18, SEQ ID NO. 20, SEQ ID NO. 22, SEQ ID NO. 24, SEQ ID NO. 26,
   SEQ ID NO. 28, SEQ ID NO. 30, SEQ ID NO. 32, SEQ ID NO. 34, SEQ ID NO. 36, SEQ
25 ID NO. 38, SEQ ID NO. 40, SEQ ID NO. 42, SEQ ID NO. 44, SEQ ID NO. 46, SEQ ID
   NO. 48, SEQ ID NO. 50, SEQ ID NO. 52, SEQ ID NO. 54, SEQ ID NO. 56, SEQ ID NO.
   58, SEQ ID NO. 60, SEQ ID NO. 62, SEQ ID NO. 64, SEQ ID NO. 66, SEQ ID NO. 68,
   SEQ ID NO. 70, SEQ ID NO. 72, SEQ ID NO. 74, SEQ ID NO. 76, SEQ ID NO. 78, SEQ
   ID NO. 80, SEQ ID NO. 82, SEQ ID NO. 84, SEQ ID NO. 86, SEQ ID NO. 88, SEQ ID
30 NO. 90, SEQ ID NO. 92, SEQ ID NO. 94, SEQ ID NO. 96, SEQ ID NO. 98, SEQ ID NO.
   100, SEQ ID NO. 102, SEQ ID NO. 104, SEQ ID NO. 106, SEQ ID NO. 108, SEQ ID NO.
                                                40

   110, SEQ ID NO. 112, SEQ ID NO. 114, SEQ ID NO. 116, SEQ ID NO. 118, SEQ ID NO.
   120, SEQ ID NO. 122, SEQ ID NO. 124, SEQ ID NO. 126, SEQ ID NO. 128, SEQ ID NO.
   130, SEQ ID NO. 132, SEQ ID NO. 134, SEQ ID NO. 136, SEQ ID NO. 138, SEQ ID NO.
   140, SEQ ID NO. 142, SEQ ID NO. 144, SEQ ID NO. 146, SEQ ID NO. 148, SEQ ID NO.
 5 150, SEQ ID NO. 152, SEQ ID NO. 154, SEQ ID NO. 156, SEQ ID NO. 158, SEQ ID NO.
   160, SEQ ID NO. 162, SEQ ID NO. 164, SEQ ID NO. 166, SEQ ID NO. 168, SEQ ID NO.
   170, SEQ ID NO. 172, SEQ ID NO. 174, SEQ ID NO. 176, SEQ ID NO. 178, SEQ ID NO.
   180, SEQ ID NO. 182, SEQ ID NO. 184, SEQ ID NO. 186, SEQ ID NO. 188, SEQ ID NO.
   190, SEQ ID NO. 192, SEQ ID NO. 194, SEQ ID NO. 196, SEQ ID NO. 198, SEQ ID NO.
10 200, SEQ ID NO. 202, SEQ ID NO. 204, SEQ ID NO. 206, SEQ ID NO. 208, SEQ ID NO.
   210, SEQ ID NO. 212, SEQ ID NO. 214, SEQ ID NO. 216, SEQ ID NO. 218, SEQ ID NO.
   220, SEQ ID NO. 222, SEQ ID NO. 224, SEQ ID NO. 226, SEQ ID NO. 228, SEQ ID NO.
   230, SEQ ID NO. 232, SEQ ID NO. 234, SEQ ID NO. 236, SEQ ID NO. 238, SEQ ID NO.
   240, SEQ ID NO. 242, and combinations thereof;
15         wherein the Fab fully human antibody fragment has the heavy chain variable domain
   sequence that is at least 95% identical to the amino acid sequences selected from the group
   consisting of SEQ ID NO. 1, SEQ ID NO. 3, SEQ ID NO. 5, SEQ ID NO. 7, SEQ ID NO. 9,
   SEQ ID NO. 11, SEQ ID NO. 13, SEQ ID NO. 15, SEQ ID NO. 17, SEQ ID NO. 19, SEQ
   ID NO. 21, SEQ ID NO. 23, SEQ ID NO. 25, SEQ ID NO. 27, SEQ ID NO. 29, SEQ ID
20 NO. 31, SEQ ID NO. 33, SEQ ID NO. 35, SEQ ID NO. 37, SEQ ID NO. 39, SEQ ID NO.
   41, SEQ ID NO. 43, SEQ ID NO. 45, SEQ ID NO. 47, SEQ ID NO. 49, SEQ ID NO. 51,
   SEQ ID NO. 53, SEQ ID NO. 55, SEQ ID NO. 57, SEQ ID NO. 59, SEQ ID NO. 61, SEQ
   ID NO. 63, SEQ ID NO. 65, SEQ ID NO. 67, SEQ ID NO. 69, SEQ ID NO. 71, SEQ ID
   NO. 73, SEQ ID NO. 75, SEQ ID NO. 77, SEQ ID NO. 79, SEQ ID NO. 81, SEQ ID NO.
25 83, SEQ ID NO. 85, SEQ ID NO. 87, SEQ ID NO. 89, SEQ ID NO. 91, SEQ ID NO. 93,
   SEQ ID NO. 95, SEQ ID NO. 97, SEQ ID NO. 99, SEQ ID NO. 101, SEQ ID NO. 103,
   SEQ ID NO. 105, SEQ ID NO. 107, SEQ ID NO. 109, SEQ ID NO. 111, SEQ ID NO. 113,
   SEQ ID NO. 115, SEQ ID NO. 117, SEQ ID NO. 119, SEQ ID NO. 121, SEQ ID NO. 123,
   SEQ ID NO. 125, SEQ ID NO. 127, SEQ ID NO. 129, SEQ ID NO. 131, SEQ ID NO. 133,
30 SEQ ID NO. 135, SEQ ID NO. 137, SEQ ID NO. 139, SEQ ID NO. 141, SEQ ID NO. 143,
   SEQ ID NO. 145, SEQ ID NO. 147, SEQ ID NO. 149, SEQ ID NO. 151, SEQ ID NO. 153,
                                                  41

   SEQ ID NO. 155, SEQ ID NO. 157, SEQ ID NO. 159, SEQ ID NO. 161, SEQ ID NO. 163,
   SEQ ID NO. 165, SEQ ID NO. 167, SEQ ID NO. 169, SEQ ID NO. 171, SEQ ID NO. 173,
   SEQ ID NO. 175, SEQ ID NO. 177, SEQ ID NO. 179, SEQ ID NO. 181, SEQ ID NO. 183,
   SEQ ID NO. 185, SEQ ID NO. 187, SEQ ID NO. 189, SEQ ID NO. 191, SEQ ID NO. 193,
 5 SEQ ID NO. 195, SEQ ID NO. 197, SEQ ID NO. 199, SEQ ID NO. 201, SEQ ID NO. 203,
   SEQ ID NO. 205, SEQ ID NO. 207, SEQ ID NO. 209, SEQ ID NO. 211, SEQ ID NO. 213,
   SEQ ID NO. 215, SEQ ID NO. 217, SEQ ID NO. 219, SEQ ID NO. 221, SEQ ID NO. 223,
   SEQ ID NO. 225, SEQ ID NO. 227, SEQ ID NO. 229, SEQ ID NO. 231, SEQ ID NO. 233,
   SEQ ID NO. 235, SEQ ID NO. 237, SEQ ID NO. 239, SEQ ID NO. 241, and combinations
10 thereof, and that has the light chain variable domain sequence that is at least 95% identical
   to the amino acid sequences selected from the group consisting of SEQ ID NO. 2, SEQ ID
   NO. 4, SEQ ID NO. 6, SEQ ID NO. 8, SEQ ID NO. 10, SEQ ID NO. 12, SEQ ID NO. 14,
   SEQ ID NO. 16, SEQ ID NO. 18, SEQ ID NO. 20, SEQ ID NO. 22, SEQ ID NO. 24, SEQ
   ID NO. 26, SEQ ID NO. 28, SEQ ID NO. 30, SEQ ID NO. 32, SEQ ID NO. 34, SEQ ID
15 NO. 36, SEQ ID NO. 38, SEQ ID NO. 40, SEQ ID NO. 42, SEQ ID NO. 44, SEQ ID NO.
   46, SEQ ID NO. 48, SEQ ID NO. 50, SEQ ID NO. 52, SEQ ID NO. 54, SEQ ID NO. 56,
   SEQ ID NO. 58, SEQ ID NO. 60, SEQ ID NO. 62, SEQ ID NO. 64, SEQ ID NO. 66, SEQ
   ID NO. 68, SEQ ID NO. 70, SEQ ID NO. 72, SEQ ID NO. 74, SEQ ID NO. 76, SEQ ID
   NO. 78, SEQ ID NO. 80, SEQ ID NO. 82, SEQ ID NO. 84, SEQ ID NO. 86, SEQ ID NO.
20 88, SEQ ID NO. 90, SEQ ID NO. 92, SEQ ID NO. 94, SEQ ID NO. 96, SEQ ID NO. 98,
   SEQ ID NO. 100, SEQ ID NO. 102, SEQ ID NO. 104, SEQ ID NO. 106, SEQ ID NO. 108,
   SEQ ID NO. 110, SEQ ID NO. 112, SEQ ID NO. 114, SEQ ID NO. 116, SEQ ID NO. 118,
   SEQ ID NO. 120, SEQ ID NO. 122, SEQ ID NO. 124, SEQ ID NO. 126, SEQ ID NO. 128,
   SEQ ID NO. 130, SEQ ID NO. 132, SEQ ID NO. 134, SEQ ID NO. 136, SEQ ID NO. 138,
25 SEQ ID NO. 140, SEQ ID NO. 142, SEQ ID NO. 144, SEQ ID NO. 146, SEQ ID NO. 148,
   SEQ ID NO. 150, SEQ ID NO. 152, SEQ ID NO. 154, SEQ ID NO. 156, SEQ ID NO. 158,
   SEQ ID NO. 160, SEQ ID NO. 162, SEQ ID NO. 164, SEQ ID NO. 166, SEQ ID NO. 168,
   SEQ ID NO. 170, SEQ ID NO. 172, SEQ ID NO. 174, SEQ ID NO. 176, SEQ ID NO. 178,
   SEQ ID NO. 180, SEQ ID NO. 182, SEQ ID NO. 184, SEQ ID NO. 186, SEQ ID NO. 188,
30 SEQ ID NO. 190, SEQ ID NO. 192, SEQ ID NO. 194, SEQ ID NO. 196, SEQ ID NO. 198,
   SEQ ID NO. 200, SEQ ID NO. 202, SEQ ID NO. 204, SEQ ID NO. 206, SEQ ID NO. 208,
                                                   42

   SEQ ID NO. 210, SEQ ID NO. 212, SEQ ID NO. 214, SEQ ID NO. 216, SEQ ID NO. 218,
   SEQ ID NO. 220, SEQ ID NO. 222, SEQ ID NO. 224, SEQ ID NO. 226, SEQ ID NO. 228,
   SEQ ID NO. 230, SEQ ID NO. 232, SEQ ID NO. 234, SEQ ID NO. 236, SEQ ID NO. 238,
   SEQ ID NO. 240, SEQ ID NO. 242, and combinations thereof; and
 5         wherein the single chain human antibody has the heavy chain variable domain
   sequence that is at least 95% identical to the amino acid sequences selected from the group
   consisting of SEQ ID NO. 1, SEQ ID NO. 3, SEQ ID NO. 5, SEQ ID NO. 7, SEQ ID NO. 9,
   SEQ ID NO. 11, SEQ ID NO. 13, SEQ ID NO. 15, SEQ ID NO. 17, SEQ ID NO. 19, SEQ
   ID NO. 21, SEQ ID NO. 23, SEQ ID NO. 25, SEQ ID NO. 27, SEQ ID NO. 29, SEQ ID
10 NO. 31, SEQ ID NO. 33, SEQ ID NO. 35, SEQ ID NO. 37, SEQ ID NO. 39, SEQ ID NO.
   41, SEQ ID NO. 43, SEQ ID NO. 45, SEQ ID NO. 47, SEQ ID NO. 49, SEQ ID NO. 51,
   SEQ ID NO. 53, SEQ ID NO. 55, SEQ ID NO. 57, SEQ ID NO. 59, SEQ ID NO. 61, SEQ
   ID NO. 63, SEQ ID NO. 65, SEQ ID NO. 67, SEQ ID NO. 69, SEQ ID NO. 71, SEQ ID
   NO. 73, SEQ ID NO. 75, SEQ ID NO. 77, SEQ ID NO. 79, SEQ ID NO. 81, SEQ ID NO.
15 83, SEQ ID NO. 85, SEQ ID NO. 87, SEQ ID NO. 89, SEQ ID NO. 91, SEQ ID NO. 93,
   SEQ ID NO. 95, SEQ ID NO. 97, SEQ ID NO. 99, SEQ ID NO. 101, SEQ ID NO. 103,
   SEQ ID NO. 105, SEQ ID NO. 107, SEQ ID NO. 109, SEQ ID NO. 111, SEQ ID NO. 113,
   SEQ ID NO. 115, SEQ ID NO. 117, SEQ ID NO. 119, SEQ ID NO. 121, SEQ ID NO. 123,
   SEQ ID NO. 125, SEQ ID NO. 127, SEQ ID NO. 129, SEQ ID NO. 131, SEQ ID NO. 133,
20 SEQ ID NO. 135, SEQ ID NO. 137, SEQ ID NO. 139, SEQ ID NO. 141, SEQ ID NO. 143,
   SEQ ID NO. 145, SEQ ID NO. 147, SEQ ID NO. 149, SEQ ID NO. 151, SEQ ID NO. 153,
   SEQ ID NO. 155, SEQ ID NO. 157, SEQ ID NO. 159, SEQ ID NO. 161, SEQ ID NO. 163,
   SEQ ID NO. 165, SEQ ID NO. 167, SEQ ID NO. 169, SEQ ID NO. 171, SEQ ID NO. 173,
   SEQ ID NO. 175, SEQ ID NO. 177, SEQ ID NO. 179, SEQ ID NO. 181, SEQ ID NO. 183,
25 SEQ ID NO. 185, SEQ ID NO. 187, SEQ ID NO. 189, SEQ ID NO. 191, SEQ ID NO. 193,
   SEQ ID NO. 195, SEQ ID NO. 197, SEQ ID NO. 199, SEQ ID NO. 201, SEQ ID NO. 203,
   SEQ ID NO. 205, SEQ ID NO. 207, SEQ ID NO. 209, SEQ ID NO. 211, SEQ ID NO. 213,
   SEQ ID NO. 215, SEQ ID NO. 217, SEQ ID NO. 219, SEQ ID NO. 221, SEQ ID NO. 223,
   SEQ ID NO. 225, SEQ ID NO. 227, SEQ ID NO. 229, SEQ ID NO. 231, SEQ ID NO. 233,
30 SEQ ID NO. 235, SEQ ID NO. 237, SEQ ID NO. 239, SEQ ID NO. 241, and combinations
   thereof, and that has the light chain variable domain sequence that is at least 95% identical
                                                   43

   to the amino acid sequences selected from the group consisting of SEQ ID NO. 2, SEQ ID
   NO. 4, SEQ ID NO. 6, SEQ ID NO. 8, SEQ ID NO. 10, SEQ ID NO. 12, SEQ ID NO. 14,
   SEQ ID NO. 16, SEQ ID NO. 18, SEQ ID NO. 20, SEQ ID NO. 22, SEQ ID NO. 24, SEQ
   ID NO. 26, SEQ ID NO. 28, SEQ ID NO. 30, SEQ ID NO. 32, SEQ ID NO. 34, SEQ ID
 5 NO. 36, SEQ ID NO. 38, SEQ ID NO. 40, SEQ ID NO. 42, SEQ ID NO. 44, SEQ ID NO.
   46, SEQ ID NO. 48, SEQ ID NO. 50, SEQ ID NO. 52, SEQ ID NO. 54, SEQ ID NO. 56,
   SEQ ID NO. 58, SEQ ID NO. 60, SEQ ID NO. 62, SEQ ID NO. 64, SEQ ID NO. 66, SEQ
   ID NO. 68, SEQ ID NO. 70, SEQ ID NO. 72, SEQ ID NO. 74, SEQ ID NO. 76, SEQ ID
   NO. 78, SEQ ID NO. 80, SEQ ID NO. 82, SEQ ID NO. 84, SEQ ID NO. 86, SEQ ID NO.
10 88, SEQ ID NO. 90, SEQ ID NO. 92, SEQ ID NO. 94, SEQ ID NO. 96, SEQ ID NO. 98,
   SEQ ID NO. 100, SEQ ID NO. 102, SEQ ID NO. 104, SEQ ID NO. 106, SEQ ID NO. 108,
   SEQ ID NO. 110, SEQ ID NO. 112, SEQ ID NO. 114, SEQ ID NO. 116, SEQ ID NO. 118,
   SEQ ID NO. 120, SEQ ID NO. 122, SEQ ID NO. 124, SEQ ID NO. 126, SEQ ID NO. 128,
   SEQ ID NO. 130, SEQ ID NO. 132, SEQ ID NO. 134, SEQ ID NO. 136, SEQ ID NO. 138,
15 SEQ ID NO. 140, SEQ ID NO. 142, SEQ ID NO. 144, SEQ ID NO. 146, SEQ ID NO. 148,
   SEQ ID NO. 150, SEQ ID NO. 152, SEQ ID NO. 154, SEQ ID NO. 156, SEQ ID NO. 158,
   SEQ ID NO. 160, SEQ ID NO. 162, SEQ ID NO. 164, SEQ ID NO. 166, SEQ ID NO. 168,
   SEQ ID NO. 170, SEQ ID NO. 172, SEQ ID NO. 174, SEQ ID NO. 176, SEQ ID NO. 178,
   SEQ ID NO. 180, SEQ ID NO. 182, SEQ ID NO. 184, SEQ ID NO. 186, SEQ ID NO. 188,
20 SEQ ID NO. 190, SEQ ID NO. 192, SEQ ID NO. 194, SEQ ID NO. 196, SEQ ID NO. 198,
   SEQ ID NO. 200, SEQ ID NO. 202, SEQ ID NO. 204, SEQ ID NO. 206, SEQ ID NO. 208,
   SEQ ID NO. 210, SEQ ID NO. 212, SEQ ID NO. 214, SEQ ID NO. 216, SEQ ID NO. 218,
   SEQ ID NO. 220, SEQ ID NO. 222, SEQ ID NO. 224, SEQ ID NO. 226, SEQ ID NO. 228,
   SEQ ID NO. 230, SEQ ID NO. 232, SEQ ID NO. 234, SEQ ID NO. 236, SEQ ID NO. 238,
25 SEQ ID NO. 240, SEQ ID NO. 242, and combinations thereof.
           Preferably, the fully human antibody has both a heavy chain and a light chain
   wherein the antibody has a heavy chain/light chain variable domain sequence selected from
   the group consisting of SEQ ID NO. 1/SEQ ID NO. 2, SEQ ID NO. 3/SEQ ID NO. 4, SEQ
   ID NO. 5/SEQ ID NO. 6, SEQ ID NO. 7/SEQ ID NO. 8, SEQ ID NO. 9/SEQ ID NO. 10,
30 SEQ ID NO. 11/SEQ ID NO. 12, SEQ ID NO. 13/SEQ ID NO. 14, SEQ ID NO. 15/SEQ ID
   NO. 16, SEQ ID NO. 17/SEQ ID NO. 18, SEQ ID NO. 19/SEQ ID NO. 20, SEQ ID NO.
                                                44

   21/SEQ ID NO. 22, SEQ ID NO. 23/SEQ ID NO. 24, SEQ ID NO. 25/SEQ ID NO. 26,
   SEQ ID NO. 27/SEQ ID NO. 28, SEQ ID NO. 29/SEQ ID NO. 30, SEQ ID NO. 31/SEQ ID
   NO. 32, SEQ ID NO. 33/SEQ ID NO. 34, SEQ ID NO. 35/SEQ ID NO. 36, SEQ ID NO.
   37/SEQ ID NO. 38, SEQ ID NO. 39/SEQ ID NO. 40, SEQ ID NO. 41/SEQ ID NO. 42,
 5 SEQ ID NO. 43/SEQ ID NO. 44, SEQ ID NO. 45/SEQ ID NO. 46, SEQ ID NO. 47/SEQ ID
   NO. 48, SEQ ID NO. 49/SEQ ID NO. 50, SEQ ID NO. 51/SEQ ID NO. 52, SEQ ID NO.
   53/SEQ ID NO. 54, SEQ ID NO. 55/SEQ ID NO. 56, SEQ ID NO. 57/SEQ ID NO. 58,
   SEQ ID NO. 59/SEQ ID NO. 60, SEQ ID NO. 61/SEQ ID NO. 62, SEQ ID NO. 63/SEQ ID
   NO. 64, SEQ ID NO. 65/SEQ ID NO. 66, SEQ ID NO. 67/SEQ ID NO. 68, SEQ ID NO.
10 69/SEQ ID NO. 70, SEQ ID NO. 71/SEQ ID NO. 72, SEQ ID NO. 73/SEQ ID NO. 74,
   SEQ ID NO. 75/SEQ ID NO. 76, SEQ ID NO. 77/SEQ ID NO. 78, SEQ ID NO. 79/SEQ ID
   NO. 80, SEQ ID NO. 81/SEQ ID NO. 82, SEQ ID NO. 83/SEQ ID NO. 84, SEQ ID NO.
   85/SEQ ID NO. 86, SEQ ID NO. 87/SEQ ID NO. 88, SEQ ID NO. 89/SEQ ID NO. 90,
   SEQ ID NO. 91/SEQ ID NO. 92, SEQ ID NO. 93/SEQ ID NO. 94, SEQ ID NO. 95/SEQ ID
15 NO. 96, SEQ ID NO. 97/SEQ ID NO. 98, SEQ ID NO. 99/SEQ ID NO. 100, SEQ ID NO.
   101/SEQ ID NO. 102, SEQ ID NO. 103/SEQ ID NO. 104, SEQ ID NO. 105/SEQ ID NO.
   106, SEQ ID NO. 107/SEQ ID NO. 108, SEQ ID NO. 109/SEQ ID NO. 110, SEQ ID NO.
   111/SEQ ID NO. 112, SEQ ID NO. 113/SEQ ID NO. 114, SEQ ID NO. 115/SEQ ID NO.
   116, SEQ ID NO. 117/SEQ ID NO. 118, SEQ ID NO. 119/SEQ ID NO. 120, SEQ ID NO.
20 121/SEQ ID NO. 122, SEQ ID NO. 123/SEQ ID NO. 124, SEQ ID NO. 125/SEQ ID NO.
   126, SEQ ID NO. 127/SEQ ID NO. 128, SEQ ID NO. 129/SEQ ID NO. 130, SEQ ID NO.
   131/SEQ ID NO. 132, SEQ ID NO. 133/SEQ ID NO. 134, SEQ ID NO. 135/SEQ ID NO.
   136, SEQ ID NO. 137/SEQ ID NO. 138, SEQ ID NO. 139/SEQ ID NO. 140, SEQ ID NO.
   141/SEQ ID NO. 142, SEQ ID NO. 143/SEQ ID NO. 144, SEQ ID NO. 145/SEQ ID NO.
25 146, SEQ ID NO. 147/SEQ ID NO. 148, SEQ ID NO. 149/SEQ ID NO. 150, SEQ ID NO.
   151/SEQ ID NO. 152, SEQ ID NO. 153/SEQ ID NO. 154, SEQ ID NO. 155/SEQ ID NO.
   156, SEQ ID NO. 157/SEQ ID NO. 158, SEQ ID NO. 159/SEQ ID NO. 160, SEQ ID NO.
   161/SEQ ID NO. 162, SEQ ID NO. 163/SEQ ID NO. 164, SEQ ID NO. 165/SEQ ID NO.
   166, SEQ ID NO. 167/SEQ ID NO. 168, SEQ ID NO. 169/SEQ ID NO. 170, SEQ ID NO.
30 171/SEQ ID NO. 172, SEQ ID NO. 173/SEQ ID NO. 174, SEQ ID NO. 175/SEQ ID NO.
   176, SEQ ID NO. 177/SEQ ID NO. 178, SEQ ID NO. 179/SEQ ID NO. 180, SEQ ID NO.
                                          45

   181/SEQ ID NO. 182, SEQ ID NO. 183/SEQ ID NO. 184, SEQ ID NO. 185/SEQ ID NO.
   186, SEQ ID NO. 187/SEQ ID NO. 188, SEQ ID NO. 189/SEQ ID NO. 190, SEQ ID NO.
   191/SEQ ID NO. 192, SEQ ID NO. 193/SEQ ID NO. 194, SEQ ID NO. 195/SEQ ID NO.
   196, SEQ ID NO. 197/SEQ ID NO. 198, SEQ ID NO. 199/SEQ ID NO. 200, SEQ ID NO.
 5 201/SEQ ID NO. 202, SEQ ID NO. 203/SEQ ID NO. 204, SEQ ID NO. 205/SEQ ID NO.
   206, SEQ ID NO. 207/SEQ ID NO. 208, SEQ ID NO. 209/SEQ ID NO. 210, SEQ ID NO.
   211/SEQ ID NO. 212, SEQ ID NO. 213/SEQ ID NO. 214, SEQ ID NO. 215/SEQ ID NO.
   216, SEQ ID NO. 217/SEQ ID NO. 218, SEQ ID NO. 219/SEQ ID NO. 220, SEQ ID NO.
   221/SEQ ID NO. 222, SEQ ID NO. 223/SEQ ID NO. 224, SEQ ID NO. 225/SEQ ID NO.
10 226, SEQ ID NO. 227/SEQ ID NO. 228, SEQ ID NO. 229/SEQ ID NO. 230, SEQ ID NO.
   231/SEQ ID NO. 232, SEQ ID NO. 233/SEQ ID NO. 234, SEQ ID NO. 235/SEQ ID NO.
   236, SEQ ID NO. 237/SEQ ID NO. 238, SEQ ID NO. 239/SEQ ID NO. 240, SEQ ID NO.
   241/SEQ ID NO. 242, and combinations thereof. Preferably, the fully human antibody Fab
   fragment has both a heavy chain variable domain region and a light chain variable domain
15 region wherein the antibody has a heavy chain/light chain variable domain sequence
   selected from the group consisting of SEQ ID NO. 1/SEQ ID NO. 2, SEQ ID NO. 3/SEQ ID
   NO. 4, SEQ ID NO. 5/SEQ ID NO. 6, SEQ ID NO. 7/SEQ ID NO. 8, SEQ ID NO. 9/SEQ
   ID NO. 10, SEQ ID NO. 11/SEQ ID NO. 12, SEQ ID NO. 13/SEQ ID NO. 14, SEQ ID NO.
   15/SEQ ID NO. 16, SEQ ID NO. 17/SEQ ID NO. 18, SEQ ID NO. 19/SEQ ID NO. 20,
20 SEQ ID NO. 21/SEQ ID NO. 22, SEQ ID NO. 23/SEQ ID NO. 24, SEQ ID NO. 25/SEQ ID
   NO. 26, SEQ ID NO. 27/SEQ ID NO. 28, SEQ ID NO. 29/SEQ ID NO. 30, SEQ ID NO.
   31/SEQ ID NO. 32, SEQ ID NO. 33/SEQ ID NO. 34, SEQ ID NO. 35/SEQ ID NO. 36,
   SEQ ID NO. 37/SEQ ID NO. 38, SEQ ID NO. 39/SEQ ID NO. 40, SEQ ID NO. 41/SEQ ID
   NO. 42, SEQ ID NO. 43/SEQ ID NO. 44, SEQ ID NO. 45/SEQ ID NO. 46, SEQ ID NO.
25 47/SEQ ID NO. 48, SEQ ID NO. 49/SEQ ID NO. 50, SEQ ID NO. 51/SEQ ID NO. 52,
   SEQ ID NO. 53/SEQ ID NO. 54, SEQ ID NO. 55/SEQ ID NO. 56, SEQ ID NO. 57/SEQ ID
   NO. 58, SEQ ID NO. 59/SEQ ID NO. 60, SEQ ID NO. 61/SEQ ID NO. 62, SEQ ID NO.
   63/SEQ ID NO. 64, SEQ ID NO. 65/SEQ ID NO. 66, SEQ ID NO. 67/SEQ ID NO. 68,
   SEQ ID NO. 69/SEQ ID NO. 70, SEQ ID NO. 71/SEQ ID NO. 72, SEQ ID NO. 73/SEQ ID
30 NO. 74, SEQ ID NO. 75/SEQ ID NO. 76, SEQ ID NO. 77/SEQ ID NO. 78, SEQ ID NO.
   79/SEQ ID NO. 80, SEQ ID NO. 81/SEQ ID NO. 82, SEQ ID NO. 83/SEQ ID NO. 84,
                                               46

   SEQ ID NO. 85/SEQ ID NO. 86, SEQ ID NO. 87/SEQ ID NO. 88, SEQ ID NO. 89/SEQ ID
   NO. 90, SEQ ID NO. 91/SEQ ID NO. 92, SEQ ID NO. 93/SEQ ID NO. 94, SEQ ID NO.
   95/SEQ ID NO. 96, SEQ ID NO. 97/SEQ ID NO. 98, SEQ ID NO. 99/SEQ ID NO. 100,
   SEQ ID NO. 101/SEQ ID NO. 102, SEQ ID NO. 103/SEQ ID NO. 104, SEQ ID NO.
 5 105/SEQ ID NO. 106, SEQ ID NO. 107/SEQ ID NO. 108, SEQ ID NO. 109/SEQ ID NO.
   110, SEQ ID NO. 111/SEQ ID NO. 112, SEQ ID NO. 113/SEQ ID NO. 114, SEQ ID NO.
   115/SEQ ID NO. 116, SEQ ID NO. 117/SEQ ID NO. 118, SEQ ID NO. 119/SEQ ID NO.
   120, SEQ ID NO. 121/SEQ ID NO. 122, SEQ ID NO. 123/SEQ ID NO. 124, SEQ ID NO.
   125/SEQ ID NO. 126, SEQ ID NO. 127/SEQ ID NO. 128, SEQ ID NO. 129/SEQ ID NO.
10 130, SEQ ID NO. 131/SEQ ID NO. 132, SEQ ID NO. 133/SEQ ID NO. 134, SEQ ID NO.
   135/SEQ ID NO. 136, SEQ ID NO. 137/SEQ ID NO. 138, SEQ ID NO. 139/SEQ ID NO.
   140, SEQ ID NO. 141/SEQ ID NO. 142, SEQ ID NO. 143/SEQ ID NO. 144, SEQ ID NO.
   145/SEQ ID NO. 146, SEQ ID NO. 147/SEQ ID NO. 148, SEQ ID NO. 149/SEQ ID NO.
   150, SEQ ID NO. 151/SEQ ID NO. 152, SEQ ID NO. 153/SEQ ID NO. 154, SEQ ID NO.
15 155/SEQ ID NO. 156, SEQ ID NO. 157/SEQ ID NO. 158, SEQ ID NO. 159/SEQ ID NO.
   160, SEQ ID NO. 161/SEQ ID NO. 162, SEQ ID NO. 163/SEQ ID NO. 164, SEQ ID NO.
   165/SEQ ID NO. 166, SEQ ID NO. 167/SEQ ID NO. 168, SEQ ID NO. 169/SEQ ID NO.
   170, SEQ ID NO. 171/SEQ ID NO. 172, SEQ ID NO. 173/SEQ ID NO. 174, SEQ ID NO.
   175/SEQ ID NO. 176, SEQ ID NO. 177/SEQ ID NO. 178, SEQ ID NO. 179/SEQ ID NO.
20 180, SEQ ID NO. 181/SEQ ID NO. 182, SEQ ID NO. 183/SEQ ID NO. 184, SEQ ID NO.
   185/SEQ ID NO. 186, SEQ ID NO. 187/SEQ ID NO. 188, SEQ ID NO. 189/SEQ ID NO.
   190, SEQ ID NO. 191/SEQ ID NO. 192, SEQ ID NO. 193/SEQ ID NO. 194, SEQ ID NO.
   195/SEQ ID NO. 196, SEQ ID NO. 197/SEQ ID NO. 198, SEQ ID NO. 199/SEQ ID NO.
   200, SEQ ID NO. 201/SEQ ID NO. 202, SEQ ID NO. 203/SEQ ID NO. 204, SEQ ID NO.
25 205/SEQ ID NO. 206, SEQ ID NO. 207/SEQ ID NO. 208, SEQ ID NO. 209/SEQ ID NO.
   210, SEQ ID NO. 211/SEQ ID NO. 212, SEQ ID NO. 213/SEQ ID NO. 214, SEQ ID NO.
   215/SEQ ID NO. 216, SEQ ID NO. 217/SEQ ID NO. 218, SEQ ID NO. 219/SEQ ID NO.
   220, SEQ ID NO. 221/SEQ ID NO. 222, SEQ ID NO. 223/SEQ ID NO. 224, SEQ ID NO.
   225/SEQ ID NO. 226, SEQ ID NO. 227/SEQ ID NO. 228, SEQ ID NO. 229/SEQ ID NO.
30 230, SEQ ID NO. 231/SEQ ID NO. 232, SEQ ID NO. 233/SEQ ID NO. 234, SEQ ID NO.
   235/SEQ ID NO. 236, SEQ ID NO. 237/SEQ ID NO. 238, SEQ ID NO. 239/SEQ ID NO.
                                          47

   240, SEQ ID NO. 241/SEQ ID NO. 242, and combinations thereof. Preferably, the fully
   human single chain antibody has both a heavy chain variable domain region and a light
   chain variable domain region, wherein the single chain fully human antibody has a heavy
   chain/light chain variable domain sequence selected from the group consisting of SEQ ID
 5 NO. 1/SEQ ID NO. 2, SEQ ID NO. 3/SEQ ID NO. 4, SEQ ID NO. 5/SEQ ID NO. 6, SEQ
   ID NO. 7/SEQ ID NO. 8, SEQ ID NO. 9/SEQ ID NO. 10, SEQ ID NO. 11/SEQ ID NO. 12,
   SEQ ID NO. 13/SEQ ID NO. 14, SEQ ID NO. 15/SEQ ID NO. 16, SEQ ID NO. 17/SEQ ID
   NO. 18, SEQ ID NO. 19/SEQ ID NO. 20, SEQ ID NO. 21/SEQ ID NO. 22, SEQ ID NO.
   23/SEQ ID NO. 24, SEQ ID NO. 25/SEQ ID NO. 26, SEQ ID NO. 27/SEQ ID NO. 28,
10 SEQ ID NO. 29/SEQ ID NO. 30, SEQ ID NO. 31/SEQ ID NO. 32, SEQ ID NO. 33/SEQ ID
   NO. 34, SEQ ID NO. 35/SEQ ID NO. 36, SEQ ID NO. 37/SEQ ID NO. 38, SEQ ID NO.
   39/SEQ ID NO. 40, SEQ ID NO. 41/SEQ ID NO. 42, SEQ ID NO. 43/SEQ ID NO. 44,
   SEQ ID NO. 45/SEQ ID NO. 46, SEQ ID NO. 47/SEQ ID NO. 48, SEQ ID NO. 49/SEQ ID
   NO. 50, SEQ ID NO. 51/SEQ ID NO. 52, SEQ ID NO. 53/SEQ ID NO. 54, SEQ ID NO.
15 55/SEQ ID NO. 56, SEQ ID NO. 57/SEQ ID NO. 58, SEQ ID NO. 59/SEQ ID NO. 60,
   SEQ ID NO. 61/SEQ ID NO. 62, SEQ ID NO. 63/SEQ ID NO. 64, SEQ ID NO. 65/SEQ ID
   NO. 66, SEQ ID NO. 67/SEQ ID NO. 68, SEQ ID NO. 69/SEQ ID NO. 70, SEQ ID NO.
   71/SEQ ID NO. 72, SEQ ID NO. 73/SEQ ID NO. 74, SEQ ID NO. 75/SEQ ID NO. 76,
   SEQ ID NO. 77/SEQ ID NO. 78, SEQ ID NO. 79/SEQ ID NO. 80, SEQ ID NO. 81/SEQ ID
20 NO. 82, SEQ ID NO. 83/SEQ ID NO. 84, SEQ ID NO. 85/SEQ ID NO. 86, SEQ ID NO.
   87/SEQ ID NO. 88, SEQ ID NO. 89/SEQ ID NO. 90, SEQ ID NO. 91/SEQ ID NO. 92,
   SEQ ID NO. 93/SEQ ID NO. 94, SEQ ID NO. 95/SEQ ID NO. 96, SEQ ID NO. 97/SEQ ID
   NO. 98, SEQ ID NO. 99/SEQ ID NO. 100, SEQ ID NO. 101/SEQ ID NO. 102, SEQ ID
   NO. 103/SEQ ID NO. 104, SEQ ID NO. 105/SEQ ID NO. 106, SEQ ID NO. 107/SEQ ID
25 NO. 108, SEQ ID NO. 109/SEQ ID NO. 110, SEQ ID NO. 111/SEQ ID NO. 112, SEQ ID
   NO. 113/SEQ ID NO. 114, SEQ ID NO. 115/SEQ ID NO. 116, SEQ ID NO. 117/SEQ ID
   NO. 118, SEQ ID NO. 119/SEQ ID NO. 120, SEQ ID NO. 121/SEQ ID NO. 122, SEQ ID
   NO. 123/SEQ ID NO. 124, SEQ ID NO. 125/SEQ ID NO. 126, SEQ ID NO. 127/SEQ ID
   NO. 128, SEQ ID NO. 129/SEQ ID NO. 130, SEQ ID NO. 131/SEQ ID NO. 132, SEQ ID
30 NO. 133/SEQ ID NO. 134, SEQ ID NO. 135/SEQ ID NO. 136, SEQ ID NO. 137/SEQ ID
   NO. 138, SEQ ID NO. 139/SEQ ID NO. 140, SEQ ID NO. 141/SEQ ID NO. 142, SEQ ID
                                                48

   NO. 143/SEQ ID NO. 144, SEQ ID NO. 145/SEQ ID NO. 146, SEQ ID NO. 147/SEQ ID
   NO. 148, SEQ ID NO. 149/SEQ ID NO. 150, SEQ ID NO. 151/SEQ ID NO. 152, SEQ ID
   NO. 153/SEQ ID NO. 154, SEQ ID NO. 155/SEQ ID NO. 156, SEQ ID NO. 157/SEQ ID
   NO. 158, SEQ ID NO. 159/SEQ ID NO. 160, SEQ ID NO. 161/SEQ ID NO. 162, SEQ ID
 5 NO. 163/SEQ ID NO. 164, SEQ ID NO. 165/SEQ ID NO. 166, SEQ ID NO. 167/SEQ ID
   NO. 168, SEQ ID NO. 169/SEQ ID NO. 170, SEQ ID NO. 171/SEQ ID NO. 172, SEQ ID
   NO. 173/SEQ ID NO. 174, SEQ ID NO. 175/SEQ ID NO. 176, SEQ ID NO. 177/SEQ ID
   NO. 178, SEQ ID NO. 179/SEQ ID NO. 180, SEQ ID NO. 181/SEQ ID NO. 182, SEQ ID
   NO. 183/SEQ ID NO. 184, SEQ ID NO. 185/SEQ ID NO. 186, SEQ ID NO. 187/SEQ ID
10 NO. 188, SEQ ID NO. 189/SEQ ID NO. 190, SEQ ID NO. 191/SEQ ID NO. 192, SEQ ID
   NO. 193/SEQ ID NO. 194, SEQ ID NO. 195/SEQ ID NO. 196, SEQ ID NO. 197/SEQ ID
   NO. 198, SEQ ID NO. 199/SEQ ID NO. 200, SEQ ID NO. 201/SEQ ID NO. 202, SEQ ID
   NO. 203/SEQ ID NO. 204, SEQ ID NO. 205/SEQ ID NO. 206, SEQ ID NO. 207/SEQ ID
   NO. 208, SEQ ID NO. 209/SEQ ID NO. 210, SEQ ID NO. 211/SEQ ID NO. 212, SEQ ID
15 NO. 213/SEQ ID NO. 214, SEQ ID NO. 215/SEQ ID NO. 216, SEQ ID NO. 217/SEQ ID
   NO. 218, SEQ ID NO. 219/SEQ ID NO. 220, SEQ ID NO. 221/SEQ ID NO. 222, SEQ ID
   NO. 223/SEQ ID NO. 224, SEQ ID NO. 225/SEQ ID NO. 226, SEQ ID NO. 227/SEQ ID
   NO. 228, SEQ ID NO. 229/SEQ ID NO. 230, SEQ ID NO. 231/SEQ ID NO. 232, SEQ ID
   NO. 233/SEQ ID NO. 234, SEQ ID NO. 235/SEQ ID NO. 236, SEQ ID NO. 237/SEQ ID
20 NO. 238, SEQ ID NO. 239/SEQ ID NO. 240, SEQ ID NO. 241/SEQ ID NO. 242, and
   combinations thereof.
           Preferably, the broad spectrum of mammalian cancers to be treated is selected from
   the group consisting of ovarian, colon, breast, lung cancers, myelomas, neuroblastic-derived
   CNS tumors, monocytic leukemias, B-cell derived leukemias, T-cell derived leukemias, B
25 cell derived lymphomas, T-cell derived lymphomas, mast cell derived tumors, and
   combinations thereof. Preferably, the autoimmune disease or inflammatory disease is
   selected from the group consisting of intestinal mucosal inflammation, wasting disease
   associated with colitis, multiple sclerosis, systemic lupus erythematosus, viral infections,
   rheumatoid arthritis, osteoarthritis, psoriasis, Cohn's disease, and inflammatory bowel
30 disease.
                                                    49

            An "antigen binding protein" is a protein comprising a portion that binds to an
   antigen and, optionally, a scaffold or framework portion that allows the antigen binding
   portion to adopt a conformation that promotes binding of the antigen binding protein to the
   antigen. Examples of antigen binding proteins include antibodies, antibody fragments (e.g.,
 5 an antigen binding portion of an antibody), antibody derivatives, and antibody analogs. The
   antigen binding protein can comprise, for example, an alternative protein scaffold or
   artificial scaffold with grafted CDRs or CDR derivatives. Such scaffolds include, but are not
   limited to, antibody-derived scaffolds comprising mutations introduced to, for example,
   stabilize the three-dimensional structure of the antigen binding protein as well as wholly
10 synthetic scaffolds comprising, for example, a biocompatible polymer. See, for example,
   Korndorfer et al., 2003, Proteins:Structure,Function, and Bioinformatics,Volume 53,
   Issue 1:121-129; Roque et al., 2004, Biotechnol. Prog.20:639-654. In addition, peptide
   antibody mimetics ("PAMs") can be used, as well as scaffolds based on antibody mimetics
   utilizing fibronection components as a scaffold.
15          An antigen binding protein can have, for example, the structure of a naturally
   occurring immunoglobulin. An "immunoglobulin" is a tetrameric molecule. In a naturally
   occurring immunoglobulin, each tetramer is composed of two identical pairs of polypeptide
   chains, each pair having one "light" (about 25 kDa) and one "heavy" chain (about 50-70
   kDa). The amino-terminal portion of each chain includes a variable region of about 100 to
20 110 or more amino acids primarily responsible for antigen recognition. The carboxy
   terminal portion of each chain defines a constant region primarily responsible for effector
   function. Human light chains are classified as kappa or lambda light chains. Heavy chains
   are classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as
   IgM, IgD, IgG, IgA, and IgE, respectively. Within light and heavy chains, the variable and
25 constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy
   chain also including a "D" region of about 10 more amino acids. See generally,
   Fundamental Immunology Ch. 7 (Paul, W., ed., 2nd ed. Raven Press, N.Y. (1989))
   (incorporated by reference in its entirety for all purposes). The variable regions of each
   light/heavy chain pair form the antibody binding site such that an intact immunoglobulin has
30 two binding sites.
                                                   50

            The variable regions of naturally occurring immunoglobulin chains exhibit the same
   general structure of relatively conserved framework regions (FR) joined by three
   hypervariable regions, also called complementarity determining regions or CDRs. From N
   terminus to C-terminus, both light and heavy chains comprise the domains FRI, CDR1,
 5 FR2, CDR2, FR3, CDR3 and FR4. The assignment of amino acids to each domain is in
   accordance with the definitions of Kabat et al. in Sequences of Proteins of Immunological
   Interest, 5th Ed., US Dept. of Health and Human Services, PHS, NIH, NIH Publication no.
   91-3242, 1991. Other numbering systems for the amino acids in immunoglobulin chains
   include IMGT.RTM. (international ImMunoGeneTics information system; Lefranc et al,
10 Dev. Comp. Immunol. 29:185-203; 2005) and AHo (Honegger and Pluckthun, J Mol. Biol.
   309(3):657-670; 2001).
            Antibodies can be obtained from sources such as serum or plasma that contain
   immunoglobulins having varied antigenic specificity. If such antibodies are subjected to
   affinity purification, they can be enriched for a particular antigenic specificity. Such
15 enriched preparations of antibodies usually are made of less than about 10% antibody
   having specific binding activity for the particular antigen. Subjecting these preparations to
   several rounds of affinity purification can increase the proportion of antibody having
   specific binding activity for the antigen. Antibodies prepared in this manner are often
   referred to as "monospecific." Monospecfic antibody preparations can be made up of about
20 10%, 20%, 30%, 40%, 50%, 60%, 7 0%, 75%, 80%, 85%, 90%, 95%, 97%, 99%, or 99.9%
   antibody having specific binding activity for the particular antigen.
            An "antibody" refers to an intact immunoglobulin or to an antigen binding portion
   thereof that competes with the intact antibody for specific binding, unless otherwise
   specified. Antigen binding portions may be produced by recombinant DNA techniques or by
25 enzymatic or chemical cleavage of intact antibodies. Antigen binding portions include, inter
   alia, Fab, Fab', F(ab') 2 , Fv, domain antibodies (dAbs), and complementarity determining
   region (CDR) fragments, single-chain antibodies (scFv), chimeric antibodies, diabodies,
   triabodies, tetrabodies, and polypeptides that contain at least a portion of an
   immunoglobulin that is sufficient to confer specific antigen binding to the polypeptide.
30          A Fab fragment is a monovalent fragment having the VL, VH,      CL  and CHI domains; a
   F(ab') 2 fragment is a bivalent fragment having two Fab fragments linked by a disulfide
                                                    51

   bridge at the hinge region; a Fd fragment has the VH and CH1 domains; an Fv fragment has
   the VL and VH domains of a single arm of an antibody; and a dAb fragment has a VH
   domain, a VL domain, or an antigen-binding fragment of a VH or VL domain (U.S. Patents
   6,846,634; 6,696,245, US App. Pub.20/0202512; 2004/0202995; 2004/0038291;
 5 2004/0009507;20 03/0039958, and Ward et al., Nature 341:544-546, 1989).
            A single-chain antibody (scFv) is an antibody in which a VL and a VH region are
   joined via a linker (e.g., a synthetic sequence of amino acid residues) to form a continuous
   protein chain wherein the linker is long enough to allow the protein chain to fold back on
   itself and form a monovalent antigen binding site (see, e.g., Bird et al., 1988, Science
10 242:423-26 and Huston et al., 1988, Proc. NatI. Acad. Sci. USA 85:5879-83). Diabodies are
   bivalent antibodies comprising two polypeptide chains, wherein each polypeptide chain
   comprises VH and VL domains joined by a linker that is too short to allow for pairing
   between two domains on the same chain, thus allowing each domain to pair with a
   complementary domain on another polypeptide chain (see, e.g., Holliger et al., 1993, Proc.
15 Natl. Acad. Sci. USA 90:6444-48, and Poljak et al., 1994, Structure 2:1121-23). If the two
   polypeptide chains of a diabody are identical, then a diabody resulting from their pairing
   will have two identical antigen binding sites. Polypeptide chains having different sequences
   can be used to make a diabody with two different antigen binding sites. Similarly, tribodies
   and tetrabodies are antibodies comprising three and four polypeptide chains, respectively,
20 and forming three and four antigen binding sites, respectively, which can be the same or
   different.
            Complementarity determining regions (CDRs) and framework regions (FR) of a
   given antibody may be identified using the system described by Kabat et al. supra; Lefranc
   et al., supra and/or Honegger and Pluckthun, supra. One or more CDRs may be
25 incorporated into a molecule either covalently or noncovalently to make it an antigen
   binding protein. An antigen binding protein may incorporate the CDR(s) as part of a larger
   polypeptide chain, may covalently link the CDR(s) to another polypeptide chain, or may
   incorporate the CDR(s) noncovalently. The CDRs permit the antigen binding protein to
   specifically bind to a particular antigen of interest.
30          An antigen binding protein may have one or more binding sites. If there is more than
   one binding site, the binding sites may be identical to one another or may be different. For
                                                   52

   example, a naturally occurring human immunoglobulin typically has two identical binding
   sites, while a "bispecific" or "bifunctional" antibody has two different binding sites.
            The term "human antibody" includes all antibodies that have one or more variable
   and constant regions derived from human immunoglobulin sequences. In one embodiment,
 5 all of the variable and constant domains are derived from human immunoglobulin sequences
   (a fully human antibody). These antibodies may be prepared in a variety of ways, examples
   of which are described below, including through the immunization with an antigen of
   interest of a mouse that is genetically modified to express antibodies derived from human
   heavy and/or light chain-encoding genes.
10          A humanized antibody has a sequence that differs from the sequence of an antibody
   derived from a non-human species by one or more amino acid substitutions, deletions,
   and/or additions, such that the humanized antibody is less likely to induce an immune
   response, and/or induces a less severe immune response, as compared to the non-human
   species antibody, when it is administered to a human subject. In one embodiment, certain
15 amino acids in the framework and constant domains of the heavy and/or light chains of the
   non-human species antibody are mutated to produce the humanized antibody. In another
   embodiment, the constant domain(s) from a human antibody are fused to the variable
   domain(s) of a non-human species. In another embodiment, one or more amino acid
   residues in one or more CDR sequences of a non-human antibody are changed to reduce the
20 likely immunogenicity of the non-human antibody when it is administered to a human
   subject, wherein the changed amino acid residues either are not critical for immunospecific
   binding of the antibody to its antigen, or the changes to the amino acid sequence that are
   made are conservative changes, such that the binding of the humanized antibody to the
   antigen is not significantly worse than the binding of the non-human antibody to the antigen.
25 Examples of how to make humanized antibodies may be found in U.S. Patents 6,054,297,
   5,886,152 and 5,877,293.
            The term "chimeric antibody" refers to an antibody that contains one or more regions
   from one antibody and one or more regions from one or more other antibodies. In one
   embodiment, one or more of the CDRs are derived from a human anti-PD-LI antibody. In
30 another embodiment, all of the CDRs are derived from a human anti-PD-LI antibody. In
   another embodiment, the CDRs from more than one human anti-PD-LI antibodies are
                                                   53

   mixed and matched in a chimeric antibody. For instance, a chimeric antibody may comprise
   a CDRi from the light chain of a first human anti-PAR-2 antibody, a CDR2 and a CDR3
   from the light chain of a second human anti-PD-LI antibody, and the CDRs from the heavy
   chain from a third anti-PD-LI antibody. Other combinations are possible.
 5         Further, the framework regions may be derived from one of the same anti-PD-LI
   antibodies, from one or more different antibodies, such as a human antibody, or from a
   humanized antibody. In one example of a chimeric antibody, a portion of the heavy and/or
   light chain is identical with, homologous to, or derived from an antibody from a particular
   species or belonging to a particular antibody class or subclass, while the remainder of the
10 chain(s) is/are identical with, homologous to, or derived from an antibody (-ies) from
   another species or belonging to another antibody class or subclass. Also included are
   fragments of such antibodies that exhibit the desired biological activity (i.e., the ability to
   specifically bind PD-LI).
           A "neutralizing antibody" or an "inhibitory antibody" is an antibody that inhibits the
15 proteolytic activation of PD-Li when an excess of the anti-PD-Li antibody reduces the
   amount of activation by at least about 20% using an assay such as those described herein in
   the Examples. In various embodiments, the antigen binding protein reduces the amount of
   amount of proteolytic activation of PD-Li by at least 30%, 40%, 50%, 60%, 70%, 75%,
   80%, 85%, 90%, 95%, 97%, 99%, and 99.9%.
20         Fragments or analogs of antibodies can be readily prepared by those of ordinary skill
   in the art following the teachings of this specification and using techniques known in the art.
   Preferred amino- and carboxy-termini of fragments or analogs occur near boundaries of
   functional domains. Structural and functional domains can be identified by comparison of
   the nucleotide and/or amino acid sequence data to public or proprietary sequence databases.
25 Computerized comparison methods can be used to identify sequence motifs or predicted
   protein conformation domains that occur in other proteins of known structure and/or
   function. Methods to identify protein sequences that fold into a known three-dimensional
   structure are known. See, Bowie et al., 1991, Science 253:164.
           A "CDR grafted antibody" is an antibody comprising one or more CDRs derived
30 from an antibody of a particular species or isotype and the framework of another antibody of
   the same or different species or isotype.
                                                  54

            A "multi-specific antibody" is an antibody that recognizes more than one epitope on
   one or more antigens. A subclass of this type of antibody is a "bi-specific antibody" which
   recognizes two distinct epitopes on the same or different antigens.
            An antigen binding protein "specifically binds" to an antigen (e.g., human PD-LI) if
 5 it binds to the antigen with a dissociation constant of 1 nanomolar or less.
            An "antigen binding domain," "antigen binding region," or "antigen binding site" is a
   portion of an antigen binding protein that contains amino acid residues (or other moieties)
   that interact with an antigen and contribute to the antigen binding protein's specificity and
   affinity for the antigen. For an antibody that specifically binds to its antigen, this will
10 include at least part of at least one of its CDR domains.
            An "epitope" is the portion of a molecule that is bound by an antigen binding protein
   (e.g., by an antibody). An epitope can comprise non-contiguous portions of the molecule
   (e.g., in a polypeptide, amino acid residues that are not contiguous in the polypeptide's
   primary sequence but that, in the context of the polypeptide's tertiary and quaternary
15 structure, are near enough to each other to be bound by an antigen binding protein).
            The "percent identity" of two polynucleotide or two polypeptide sequences is
   determined by comparing the sequences using the GAP computer program (a part of the
   GCG Wisconsin Package, version 10.3 (Accelrys, San Diego, Calif.)) using its default
   parameters.
20          The terms "polynucleotide," "oligonucleotide" and "nucleic acid" are used
   interchangeably throughout and include DNA molecules (e.g., cDNA or genomic DNA),
   RNA molecules (e.g., mRNA), analogs of the DNA or RNA generated using nucleotide
   analogs (e.g., peptide nucleic acids and non-naturally occurring nucleotide analogs), and
   hybrids thereof. The nucleic acid molecule can be single-stranded or double-stranded. In one
25 embodiment, the nucleic acid molecules of the invention comprise a contiguous open
   reading frame encoding an antibody, or a fragment, derivative, mutein, or variant thereof.
            Two single-stranded polynucleotides are "the complement" of each other if their
   sequences can be aligned in an anti-parallel orientation such that every nucleotide in one
   polynucleotide is opposite its complementary nucleotide in the other polynucleotide,
30 without the introduction of gaps, and without unpaired nucleotides at the 5' or the 3' end of
   either sequence. A polynucleotide is "complementary" to another polynucleotide if the two
                                                   55

   polynucleotides can hybridize to one another under moderately stringent conditions. Thus, a
   polynucleotide can be complementary to another polynucleotide without being its
   complement.
            A "vector" is a nucleic acid that can be used to introduce another nucleic acid linked
 5 to it into a cell. One type of vector is a "plasmid," which refers to a linear or circular double
   stranded DNA molecule into which additional nucleic acid segments can be ligated. Another
   type of vector is a viral vector (e.g., replication defective retroviruses, adenoviruses and
   adeno-associated viruses), wherein additional DNA segments can be introduced into the
   viral genome. Certain vectors are capable of autonomous replication in a host cell into
10 which they are introduced (e.g., bacterial vectors comprising a bacterial origin of replication
   and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors)
   are integrated into the genome of a host cell upon introduction into the host cell, and thereby
   are replicated along with the host genome. An "expression vector" is a type of vector that
   can direct the expression of a chosen polynucleotide.
15          A nucleotide sequence is "operably linked" to a regulatory sequence if the regulatory
   sequence affects the expression (e.g., the level, timing, or location of expression) of the
   nucleotide sequence. A "regulatory sequence" is a nucleic acid that affects the expression
   (e.g., the level, timing, or location of expression) of a nucleic acid to which it is operably
   linked. The regulatory sequence can, for example, exert its effects directly on the regulated
20 nucleic acid, or through the action of one or more other molecules (e.g., polypeptides that
   bind to the regulatory sequence and/or the nucleic acid). Examples of regulatory sequences
   include promoters, enhancers and other expression control elements (e.g., polyadenylation
   signals). Further examples of regulatory sequences are described in, for example, Goeddel,
   1990, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San
25 Diego, Calif. and Baron et al., 1995, Nucleic Acids Res. 23:3605-06.
            A "host cell" is a cell that can be used to express a nucleic acid, e.g., a nucleic acid
   of the invention. A host cell can be a prokaryote, for example, E. coli, or it can be a
   eukaryote, for example, a single-celled eukaryote (e.g., a yeast or other fungus), a plant cell
   (e.g., a tobacco or tomato plant cell), an animal cell (e.g., a human cell, a monkey cell, a
30 hamster cell, a rat cell, a mouse cell, or an insect cell) or a hybridoma. Examples of host
   cells include the COS-7 line of monkey kidney cells (ATCC CRL 1651) (see Gluzman et
                                                     56

   al., 1981, Cell 23:175), L cells, C127 cells, 3T3 cells (ATCC CCL 163), Chinese hamster
   ovary (CHO) cells or their derivatives such as Veggie CHO and related cell lines which
   grow in serum-free media (see Rasmussen et al., 1998, Cytotechnology 28:31) or CHO
   strain DX-B 11, which is deficient in DHFR (see Urlaub et al., 1980, Proc. Natl. Acad. Sci.
 5 USA 77:4216-20), HeLa cells, BHK (ATCC CRL 10) cell lines, the CV1/EBNA cell line
   derived from the African green monkey kidney cell line CV1 (ATCC CCL 70) (see
   McMahan et al., 1991, EMBO J 10:2821), human embryonic kidney cells such as 293,293
   EBNA or MSR 293, human epidermal A431 cells, human Colo205 cells, other transformed
   primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary
10 tissue, primary explants, HL-60, U937, HaK or Jurkat cells. Typically, a host cell is a
   cultured cell that can be transformed or transfected with a polypeptide-encoding nucleic
   acid, which can then be expressed in the host cell. The phrase "recombinant host cell" can
   be used to denote a host cell that has been transformed or transfected with a nucleic acid to
   be expressed. A host cell also can be a cell that comprises the nucleic acid but does not
15 express it at a desired level unless a regulatory sequence is introduced into the host cell such
   that it becomes operably linked with the nucleic acid. It is understood that the term host cell
   refers not only to the particular subject cell but also to the progeny or potential progeny of
   such a cell. Because certain modifications may occur in succeeding generations due to, e.g.,
   mutation or environmental influence, such progeny may not, in fact, be identical to the
20 parent cell, but are still included within the scope of the term as used herein.
            Preferably, the mammalian cancer to be treated is selected from the group consisting
   of ovarian, colon, breast or hepatic carcinoma cell lines, myelomas, neuroblastic-derived
   CNS tumors, monocytic leukemias, B-cell derived leukemia's, T-cell derived leukemias, B
   cell derived lymphomas, T-cell derived lymphomas, mast cell derived tumors, and
25 combinations thereof.
            Polypeptides of the present disclosure can be produced using any standard methods
   known in the art. In one example, the polypeptides are produced by recombinant DNA
   methods by inserting a nucleic acid sequence (e.g., a cDNA) encoding the polypeptide into a
   recombinant expression vector and expressing the DNA sequence under conditions
30 promoting expression.
                                                    57

            Nucleic acids encoding any of the various polypeptides disclosed herein may be
   synthesized chemically. Codon usage may be selected so as to improve expression in a cell.
   Such codon usage will depend on the cell type selected. Specialized codon usage patterns
   have been developed for E. coli and other bacteria, as well as mammalian cells, plant cells,
 5 yeast cells and insect cells. See for example: Mayfield et al., Proc. Natl. Acad. Sci. USA.
   2003 100(2):438-42; Sinclair et al. ProteinExpr. Purif 2002 (1):96-105; Connell N D.
   Curr. Opin. Biotechnol. 2001 12(5):446-9; Makrides et al. Microbiol.Rev. 1996 60(3):512
   38; and Sharp et al. Yeast. 1991 7(7):657-78.
            General techniques for nucleic acid manipulation are described for example in
10 Sambrook et al., Molecular Cloning: A LaboratoryManual, Vols. 1-3, Cold Spring Harbor
   Laboratory Press, 2 ed., 1989, or F. Ausubel et al., CurrentProtocolsin Molecular Biology
   (Green Publishing and Wiley-Interscience: New York, 1987) and periodic updates, herein
   incorporated by reference. The DNA encoding the polypeptide is operably linked to suitable
   transcriptional or translational regulatory elements derived from mammalian, viral, or insect
15 genes. Such regulatory elements include a transcriptional promoter, an optional operator
   sequence to control transcription, a sequence encoding suitable mRNA ribosomal binding
   sites, and sequences that control the termination of transcription and translation. The ability
   to replicate in a host, usually conferred by an origin of replication, and a selection gene to
   facilitate recognition of transformants is additionally incorporated.
20          The recombinant DNA can also include any type of protein tag sequence that may be
   useful for purifying the protein. Examples of protein tags include but are not limited to a
   histidine tag, a FLAG tag, a myc tag, an HA tag, or a GST tag. Appropriate cloning and
   expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts can be
   found in Cloning Vectors: A LaboratoryManual, (Elsevier, N.Y., 1985).
25          The expression construct is introduced into the host cell using a method appropriate
   to the host cell. A variety of methods for introducing nucleic acids into host cells are known
   in the art, including, but not limited to, electroporation; transfection employing calcium
   chloride, rubidium chloride, calcium phosphate, DEAE-dextran, or other substances;
   microprojectile bombardment; lipofection; and infection (where the vector is an infectious
30 agent). Suitable host cells include prokaryotes, yeast, mammalian cells, or bacterial cells.
                                                    58

            Suitable bacteria include gram negative or gram positive organisms, for example, E.
   coli or Bacillus spp. Yeast, preferably from the Saccharomyces species, such as S.
   cerevisiae, may also be used for production of polypeptides. Various mammalian or insect
   cell culture systems can also be employed to express recombinant proteins. Baculovirus
 5 systems for production of heterologous proteins in insect cells are reviewed by Luckow and
   Summers, (Bio/Technology, 6:47, 1988). Examples of suitable mammalian host cell lines
   include endothelial cells, COS-7 monkey kidney cells, CV-1, L cells, C 127, 3T3, Chinese
   hamster ovary (CHO), human embryonic kidney cells, HeLa, 293, 293T, and BHK cell
   lines. Purified polypeptides are prepared by culturing suitable host/vector systems to express
10 the recombinant proteins. For many applications, the small size of many of the polypeptides
   disclosed herein would make expression in E. coli as the preferred method for expression.
   The protein is then purified from culture media or cell extracts.
           Proteins disclosed herein can also be produced using cell-translation systems. For
   such purposes the nucleic acids encoding the polypeptide must be modified to allow in vitro
15 transcription to produce mRNA and to allow cell-free translation of the mRNA in the
   particular cell-free system being utilized (eukaryotic such as a mammalian or yeast cell-free
   translation system or prokaryotic such as a bacterial cell-free translation system.
           PD-LI-binding polypeptides can also be produced by chemical synthesis (e.g., by
   the methods described in Solid Phase Peptide Synthesis, 2nd ed., 1984, The Pierce Chemical
20 Co., Rockford, Ill.). Modifications to the protein can also be produced by chemical
   synthesis.
           The polypeptides of the present disclosure can be purified by isolation/purification
   methods for proteins generally known in the field of protein chemistry. Non-limiting
   examples include extraction, recrystallization, salting out (e.g., with ammonium sulfate or
25 sodium sulfate), centrifugation, dialysis, ultrafiltration, adsorption chromatography, ion
   exchange chromatography, hydrophobic chromatography, normal phase chromatography,
   reversed-phase chromatography, gel filtration, gel permeation chromatography, affinity
   chromatography, electrophoresis, countercurrent distribution or any combinations of these.
   After purification, polypeptides may be exchanged into different buffers and/or concentrated
30 by any of a variety of methods known to the art, including, but not limited to, filtration and
   dialysis.
                                                   59

           The purified polypeptide is preferably at least 85% pure, more preferably at least
   95% pure, and most preferably at least 98% pure. Regardless of the exact numerical value of
   the purity, the polypeptide is sufficiently pure for use as a pharmaceutical product.
   Post-Translational Modifications of Polypeptides
 5         In certain embodiments, the binding polypeptides of the invention may further
   comprise post-translational modifications. Exemplary post-translational protein
   modifications include phosphorylation, acetylation, methylation, ADP-ribosylation,
   ubiquitination, glycosylation, carbonylation, sumoylation, biotinylation or addition of a
   polypeptide side chain or of a hydrophobic group. As a result, the modified soluble
10 polypeptides may contain non-amino acid elements, such as lipids, poly- or mono
   saccharide, and phosphates. A preferred form of glycosylation is sialylation, which
   conjugates one or more sialic acid moieties to the polypeptide. Sialic acid moieties improve
   solubility and serum half-life while also reducing the possible immunogeneticity of the
   protein. See Raju et al. Biochemistry. 2001 31; 40(30):8868-76. Effects of such non-amino
15 acid elements on the functionality of a polypeptide may be tested for its antagonizing role in
   PD-Li or PD-i function, e.g., its inhibitory effect on angiogenesis or on tumor growth.
           In one specific embodiment, modified forms of the subject soluble polypeptides
   comprise linking the subject soluble polypeptides to nonproteinaceous polymers. In one
   specific embodiment, the polymer is polyethylene glycol ("PEG"), polypropylene glycol, or
20 polyoxyalkylenes, in the manner as set forth in U.S. Patents 4,640,835; 4,496,689;
   4,301,144; 4,670,417; 4,791,192 or 4,179,337.
           PEG is a water soluble polymer that is commercially available or can be prepared by
   ring-opening polymerization of ethylene glycol according to methods well known in the art
   (Sandler and Karo, Polymer Synthesis, Academic Press, New York, Vol. 3, pages 138-161).
25 The term "PEG" is used broadly to encompass any polyethylene glycol molecule, without
   regard to size or to modification at an end of the PEG, and can be represented by the
   formula: X--O(CH 2 CH 20)n-ICH 2CH 2OH (1), where n is 20 to 2300 and X is H or a
   terminal modification, e.g., a C1 4 alkyl. In one embodiment, the PEG of the invention
   terminates on one end with hydroxy or methoxy, i.e., X is H or CH 3 ("methoxy PEG"). A
30 PEG can contain further chemical groups which are necessary for binding reactions; which
   results from the chemical synthesis of the molecule; or which is a spacer for optimal
                                                   60

   distance of parts of the molecule. In addition, such a PEG can consist of one or more PEG
   side-chains which are linked together. PEGs with more than one PEG chain are called
   multiarmed or branched PEGs. Branched PEGs can be prepared, for example, by the
   addition of polyethylene oxide to various polyols, including glycerol, pentaerythriol, and
 5 sorbitol. For example, a four-armed branched PEG can be prepared from pentaerythriol and
   ethylene oxide. Branched PEG are described in, for example, EP-A 0 473 084 and U.S.
   Patent. 5,932,462. One form of PEGs includes two PEG side-chains (PEG2) linked via the
   primary amino groups of a lysine (Monfardini et al., Bioconjugate Chem. 6 (1995) 62-69).
            Although PEG is well-known, this is, to our knowledge, the first demonstration that
10 a pegylated0F n3 polypeptide can be pegylated and retain ligand binding activity. In a
   preferred embodiment, the pegylated1       Fn3 polypeptide is produced by site-directed
   pegylation, particularly by conjugation of PEG to a cysteine moiety at the N- or C-terminus.
   Accordingly, the present disclosure provides a target-binding     1OFn3 polypeptide with
   improved pharmacokinetic properties, the polypeptide comprising: a        10Fn3 domain having
15 from about 80 to about 150 amino acids, wherein at least one of the loops of said      1OFn3
   domain participate in target binding; and a covalently bound PEG moiety, wherein said
   10Fn3  polypeptide binds to the target with a KD of less than 100 nM and has a clearance rate
   of less than 30 mL/hr/kg in a mammal. The PEG moiety may be attached to the          1OFn3
   polypeptide by site directed pegylation, such as by attachment to a Cys residue, where the
20 Cys residue may be positioned at the N-terminus of the OFn3 polypeptide or between the N
   terminus and the most N-terminal beta or beta-like strand or at the C-terminus of the 1OF    3
   polypeptide or between the C-terminus and the most C-terminal beta or beta-like strand. A
   Cys residue may be situated at other positions as well, particularly any of the loops that do
   not participate in target binding. A PEG moiety may also be attached by other chemistry,
25 including by conjugation to amines.
            PEG conjugation to peptides or proteins generally involves the activation of PEG
   and coupling of the activated PEG-intermediates directly to target proteins/peptides or to a
   linker, which is subsequently activated and coupled to target proteins/peptides (see
   Abuchowski et al., J Biol. Chem., 252, 3571 (1977) and J Biol. Chem., 252, 3582 (1977),
30 Zalipsky, et al., and Harris et. al., in: Poly(ethylene glycol) Chemistry: Biotechnicaland
   BiomedicalApplications; (J. M. Harris ed.) Plenum Press: New York, 1992; Chap.21 and
                                                    61

   22). It is noted that a binding polypeptide containing a PEG molecule is also known as a
   conjugated protein, whereas the protein lacking an attached PEG molecule can be referred to
   as unconjugated.
            A variety of molecular mass forms of PEG can be selected, e.g., from about 1,000
 5 Daltons (Da) to 100,000 Da (n is 20 to 2300), for conjugating to PD-Li-binding
   polypeptides. The number of repeating units "n" in the PEG is approximated for the
   molecular mass described in Daltons. It is preferred that the combined molecular mass of
   PEG on an activated linker is suitable for pharmaceutical use. Thus, in one embodiment, the
   molecular mass of the PEG molecules does not exceed 100,000 Da. For example, if three
10 PEG molecules are attached to a linker, where each PEG molecule has the same molecular
   mass of 12,000 Da (each n is about 270), then the total molecular mass of PEG on the linker
   is about 36,000 Da (total n is about 820). The molecular masses of the PEG attached to the
   linker can also be different, e.g., of three molecules on a linker two PEG molecules can be
   5,000 Da each (each n is about 110) and one PEG molecule can be 12,000 Da (n is about
15 270).
            In a specific embodiment of the disclosure an PD-LI binding polypeptide is
   covalently linked to one poly(ethylene glycol) group of the formula: --CO--(CH 2)x-
   (OCH 2 CH 2)m--OR, with the --CO (i.e. carbonyl) of the poly(ethylene glycol) group forming
   an amide bond with one of the amino groups of the binding polypeptide; R being lower
20 alkyl; x being 2 or 3; m being from about 450 to about 950; and n and m being chosen so
   that the molecular weight of the conjugate minus the binding polypeptide is from about 10
   to 40 kDa. In one embodiment, a binding polypeptide's 6-amino group of a lysine is the
   available (free) amino group.
            The above conjugates may be more specifically presented by formula (II): P-
25 NHCO--(CH 2)x--(OCH2 CH 2)m--OR (II) , wherein P is the group of a binding polypeptide as
   described herein, (i.e. without the amino group or amino groups which form an amide
   linkage with the carbonyl shown in formula (II); and wherein R is lower alkyl; x is 2 or 3; m
   is from about 450 to about 950 and is chosen so that the molecular weight of the conjugate
   minus the binding polypeptide is from about 10 to about 40 kDa. As used herein, the given
30 ranges of "m" have an orientational meaning. The ranges of "m" are determined in any case,
   and exactly, by the molecular weight of the PEG group.
                                                   62

           One skilled in the art can select a suitable molecular mass for PEG, e.g., based on
   how the pegylated binding polypeptide will be used therapeutically, the desired dosage,
   circulation time, resistance to proteolysis, immunogenicity, and other considerations. For a
   discussion of PEG and its use to enhance the properties of proteins, see Katre, Advanced
 5 DrugDelivery Reviews 10: 91-114 (1993).
           In one embodiment, PEG molecules may be activated to react with amino groups on
   a binding polypeptide, such as with lysines (Bencham et al., Anal. Biochem., 131, 25 (1983);
   Veronese et al., Appl. Biochem., 11, 141 (1985).; Zalipsky et al., Polymeric Drugs and Drug
   Delivery Systems, adrs 9-110 ACS Symposium Series 469 (1999); Zalipsky et al., Europ.
10 Polym. J, 19, 1177-1183 (1983); Delgado et al., Biotechnology and Applied Biochemistry,
   12, 119-128 (1990)).
           In one specific embodiment, carbonate esters of PEG are used to form the PEG
   binding polypeptide conjugates. N,N'-disuccinimidylcarbonate (DSC) may be used in the
   reaction with PEG to form active mixed PEG-succinimidyl carbonate that may be
15 subsequently reacted with a nucleophilic group of a linker or an amino group of a binding
   polypeptide (see U.S. Patents 5,281,698 and 5,932,462). In a similar type of reaction, 1,1'
   (dibenzotriazolyl)carbonate and di-(2-pyridyl)carbonate may be reacted with PEG to form
   PEG-benzotriazolyl and PEG-pyridyl mixed carbonate (U.S. Patent 5,382,657),
   respectively.
20         Pegylation of a   10Fn3 polypeptide can be performed according to the methods of the
   state of the art, for example by reaction of the binding polypeptide with electrophilically
   active PEGs (supplier: Shearwater Corp., USA, www.shearwatercorp.com). Preferred PEG
   reagents of the present invention are, e.g., N-hydroxysuccinimidyl propionates (PEG-SPA),
   butanoates (PEG-SBA), PEG-succinimidyl propionate or branched N-hydroxysuccinimides
25 such as mPEG2-NHS (Monfardini et al., Bioconjugate Chem. 6 (1995) 62-69). Such
   methods may used to pegylated at an f-amino group of a binding polypeptide lysine or the
   N-terminal amino group of the binding polypeptide.
           In another embodiment, PEG molecules may be coupled to sulfhydryl groups on a
   binding polypeptide (Sartore et al., Appl. Biochem. Biotechnol., 27, 45 (1991); Morpurgo et
30 al., Biocon. Chem., 7, 363-368 (1996); Goodson et al., Bio/Technology (1990) 8, 343; U.S.
                                                   63

   Patent 5,766,897). U.S. Patents 6,610,281 and 5,766,897 describes exemplary reactive PEG
   species that may be coupled to sulfhydryl groups.
           In some embodiments where PEG molecules are conjugated to cysteine residues on a
   binding polypeptide, the cysteine residues are native to the binding polypeptide, whereas in
 5 other embodiments, one or more cysteine residues are engineered into the binding
   polypeptide. Mutations may be introduced into a binding polypeptide coding sequence to
   generate cysteine residues. This might be achieved, for example, by mutating one or more
   amino acid residues to cysteine. Preferred amino acids for mutating to a cysteine residue
   include serine, threonine, alanine and other hydrophilic residues. Preferably, the residue to
10 be mutated to cysteine is a surface-exposed residue. Algorithms are well-known in the art
   for predicting surface accessibility of residues based on primary sequence or a protein.
   Alternatively, surface residues may be predicted by comparing the amino acid sequences of
   binding polypeptides, given that the crystal structure of the framework based on which
   binding polypeptides are designed and evolved has been solved (see Himanen et al., Nature.
15 (2001) 20-27; 414(6866):933-8) and thus the surface-exposed residues identified. In one
   embodiment, cysteine residues are introduced into binding polypeptides at or near the N
   and/or C-terminus, or within loop regions.
           In some embodiments, the pegylated binding polypeptide comprises a PEG molecule
   covalently attached to the alpha amino group of the N-terminal amino acid. Site specific N
20 terminal reductive amination is described in Pepinsky et al., (2001) JPET, 297, 1059, and
   U.S. Patent 5,824,784. The use of a PEG-aldehyde for the reductive amination of a protein
   utilizing other available nucleophilic amino groups is described in U.S. Patent 4,002,531, in
   Wieder et al., (1979) J Biol. Chem. 254,12579, and in Chamow et al., (1994) Bioconjugate
   Chem. 5, 133.
25         In another embodiment, pegylated binding polypeptide comprises one or more PEG
   molecules covalently attached to a linker, which in turn is attached to the alpha amino group
   of the amino acid residue at the N-terminus of the binding polypeptide. Such an approach is
   disclosed in U.S. Patent Publication 2002/0044921 and in W0094/01451.
           In one embodiment, a binding polypeptide is pegylated at the C-terminus. In a
30 specific embodiment, a protein is pegylated at the C-terminus by the introduction of C
   terminal azido-methionine and the subsequent conjugation of a methyl-PEG
                                                  64

   triarylphosphine compound via the Staudinger reaction. This C-terminal conjugation method
   is described in Cazalis et al., Bioconjug. Chem. 2004; 15(5):1005-1009.
           Monopegylation of a binding polypeptide can also be produced according to the
   general methods described in WO 94/01451. WO 94/01451 describes a method for
 5 preparing a recombinant polypeptide with a modified terminal amino acid alpha-carbon
   reactive group. The steps of the method involve forming the recombinant polypeptide and
   protecting it with one or more biologically added protecting groups at the N-terminal alpha
   amine and C-terminal alpha-carboxyl. The polypeptide can then be reacted with chemical
   protecting agents to selectively protect reactive side chain groups and thereby prevent side
10 chain groups from being modified. The polypeptide is then cleaved with a cleavage reagent
   specific for the biological protecting group to form an unprotected terminal amino acid
   alpha-carbon reactive group. The unprotected terminal amino acid alpha-carbon reactive
   group is modified with a chemical modifying agent. The side chain protected terminally
   modified single copy polypeptide is then deprotected at the side chain groups to form a
15 terminally modified recombinant single copy polypeptide. The number and sequence of
   steps in the method can be varied to achieve selective modification at the N- and/or C
   terminal amino acid of the polypeptide.
           The ratio of a binding polypeptide to activated PEG in the conjugation reaction can
   be from about 1:0.5 to 1:50, between from about 1:1 to 1:30, or from about 1:5 to 1:15.
20 Various aqueous buffers can be used in the present method to catalyze the covalent addition
   of PEG to the binding polypeptide. In one embodiment, the pH of a buffer used is from
   about 7.0 to 9.0. In another embodiment, the pH is in a slightly basic range, e.g., from about
   7.5 to 8.5. Buffers having a pKa close to neutral pH range may be used, e.g., phosphate
   buffer.
25         Conventional separation and purification techniques known in the art can be used to
   purify PEGylated binding polypeptide, such as size exclusion (e.g. gel filtration) and ion
   exchange chromatography. Products may also be separated using SDS-PAGE. Products that
   may be separated include mono-, di-, tri- poly- and un-pegylated binding polypeptide, as
   well as free PEG. The percentage of mono-PEG conjugates can be controlled by pooling
30 broader fractions around the elution peak to increase the percentage of mono-PEG in the
   composition. About ninety percent mono-PEG conjugates represents a good balance of yield
                                                   65

   and activity. Compositions in which, for example, at least ninety-two percent or at least
   ninety-six percent of the conjugates are mono-PEG species may be desired. In an
   embodiment of this invention the percentage of mono-PEG conjugates is from ninety
   percent to ninety-six percent.
 5               In one embodiment, PEGylated binding polypeptide of the invention contain one,
   two or more PEG moieties. In one embodiment, the PEG moiety(ies) are bound to an amino
   acid residue which is on the surface of the protein and/or away from the surface that
   contacts the target ligand. In one embodiment, the combined or total molecular mass of PEG
   in PEG- binding polypeptide is from about 3,000 Da to 60,000 Da, optionally from about
10 10,000 Da to 36,000 Da. In a one embodiment, the PEG in pegylated binding polypeptide is
   a substantially linear, straight-chain PEG.
                 In one embodiment of the invention, the PEG in pegylated binding polypeptide is not
   hydrolyzed from the pegylated amino acid residue using a hydroxylamine assay, e.g., 450
   mM hydroxylamine (pH 6.5) over 8 to 16 hours at room temperature, and is thus stable. In
15 one embodiment, greater than 80% of the composition is stable mono-PEG-binding
   polypeptide, more preferably at least 90%, and most preferably at least 95%.
                 In another embodiment, the pegylated binding polypeptides of the invention will
   preferably retain at least 25%, 50%, 60%, 7 0%, 80%, 85%, 90%, 95% or 100% of the
   biological activity associated with the unmodified protein. In one embodiment, biological
20 activity refers to its ability to bind to PD-LI, as assessed by KD, k.. or kff. In one specific
   embodiment, the pegylated binding polypeptide protein shows an increase in binding to PD
   LI relative to unpegylated binding polypeptide.
                 The serum clearance rate of PEG-modified polypeptide may be decreased by about
   10%, 20%, 30%, 40%, 50%, 60%, 7 0%, 80%, or even 90%, relative to the clearance rate of
25 the unmodified binding polypeptide. The PEG-modified polypeptide may have a half-life
   (t 1 / 2 )  which is enhanced relative to the half-life of the unmodified protein. The half-life of
   PEG-binding polypeptide may be enhanced by at least 10%, 20%, 30%, 40%, 50%, 60%,
   7 0%       , 80%, 9 0 %, 100%, 125%, 150%, 175%, 200%, 250%, 300%, 400% or 500%, or even
   by 1000% relative to the half-life of the unmodified binding polypeptide. In some
30 embodiments, the protein half-life is determined in vitro, such as in a buffered saline
                                                         66

   solution or in serum. In other embodiments, the protein half-life is an in vivo half life, such
   as the half-life of the protein in the serum or other bodily fluid of an animal.
   Therapeutic Formulations and Modes of Administration
           The present disclosure features methods for treating conditions or preventing pre
 5 conditions which respond to an inhibition of PD-Li biological activity. Preferred examples
   are conditions that are characterized by inflammation or cellular hyperproliferation.
   Techniques and dosages for administration vary depending on the type of specific
   polypeptide and the specific condition being treated but can be readily determined by the
   skilled artisan. In general, regulatory agencies require that a protein reagent to be used as a
10 therapeutic is formulated so as to have acceptably low levels of pyrogens. Accordingly,
   therapeutic formulations will generally be distinguished from other formulations in that they
   are substantially pyrogen free, or at least contain no more than acceptable levels of pyrogen
   as determined by the appropriate regulatory agency (e.g., FDA).
           Therapeutic compositions of the present disclosure may be administered with a
15 pharmaceutically acceptable diluent, carrier, or excipient, in unit dosage form.
   Administration may be parenteral (e.g., intravenous, subcutaneous), oral, or topical, as non
   limiting examples. In addition, any gene therapy technique, using nucleic acids encoding the
   polypeptides of the invention, may be employed, such as naked DNA delivery, recombinant
   genes and vectors, cell-based delivery, including ex vivo manipulation of patients' cells, and
20 the like.
           The composition can be in the form of a pill, tablet, capsule, liquid, or sustained
   release tablet for oral administration; or a liquid for intravenous, subcutaneous or parenteral
   administration; gel, lotion, ointment, cream, or a polymer or other sustained release vehicle
   for local administration.
25         Methods well known in the art for making formulations are found, for example, in
   "Remington: The Science and Practice of Pharmacy" (20th ed., ed. A. R. Gennaro A R.,
   2000, Lippincott Williams & Wilkins, Philadelphia, Pa.). Formulations for parenteral
   administration may, for example, contain excipients, sterile water, saline, polyalkylene
   glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated napthalenes.
30 Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or
   polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the
                                                   67

   compounds. Nanoparticulate formulations (e.g., biodegradable nanoparticles, solid lipid
   nanoparticles, liposomes) may be used to control the biodistribution of the compounds.
   Other potentially useful parenteral delivery systems include ethylene-vinyl acetate
   copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. The
 5 concentration of the compound in the formulation varies depending upon a number of
   factors, including the dosage of the drug to be administered, and the route of administration.
            The polypeptide may be optionally administered as a pharmaceutically acceptable
   salt, such as non-toxic acid addition salts or metal complexes that are commonly used in the
   pharmaceutical industry. Examples of acid addition salts include organic acids such as
10 acetic, lactic, pamoic, maleic, citric, malic, ascorbic, succinic, benzoic, palmitic, suberic,
   salicylic, tartaric, methanesulfonic, toluenesulfonic, or trifluoroacetic acids or the like;
   polymeric acids such as tannic acid, carboxymethyl cellulose, or the like; and inorganic acid
   such as hydrochloric acid, hydrobromic acid, sulfuric acid phosphoric acid, or the like.
   Metal complexes include zinc, iron, and the like. In one example, the polypeptide is
15 formulated in the presence of sodium acetate to increase thermal stability.
            Formulations for oral use include tablets containing the active ingredient(s) in a
   mixture with non-toxic pharmaceutically acceptable excipients. These excipients may be,
   for example, inert diluents or fillers (e.g., sucrose and sorbitol), lubricating agents, glidants,
   and anti-adhesives (e.g., magnesium stearate, zinc stearate, stearic acid, silicas,
20 hydrogenated vegetable oils, or talc).
            Formulations for oral use may also be provided as chewable tablets, or as hard
   gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, or as soft
   gelatin capsules wherein the active ingredient is mixed with water or an oil medium.
            A therapeutically effective dose refers to a dose that produces the therapeutic effects
25 for which it is administered. The exact dose will depend on the disorder to be treated, and
   may be ascertained by one skilled in the art using known techniques. In general, the
   polypeptide is administered at about 0.01 pg/kg to about 50 mg/kg per day, preferably 0.01
   mg/kg to about 30 mg/kg per day, most preferably 0.1 mg/kg to about 20 mg/kg per day.
   The polypeptide may be given daily (e.g., once, twice, three times, or four times daily) or
30 preferably less frequently (e.g., weekly, every two weeks, every three weeks, monthly, or
   quarterly). In addition, as is known in the art, adjustments for age as well as the body
                                                    68

   weight, general health, sex, diet, time of administration, drug interaction, and the severity of
   the disease may be necessary, and will be ascertainable with routine experimentation by
   those skilled in the art.
   Pharmaceutical Formulations of Disclosed Antibodies with Tumor Vaccines
 5         A combined therapeutic product or formulation of a disclosed anti-PD-LI antibody
   with a therapeutic vaccine provides synergistic oncologic therapeutic benefit. For example,
   the present disclosure provides a combination of a disclosed anti-PD-Li antibody with
   "Neuvax" which is a E75-derived 9 mer synthetic peptide isolated from HER2/neu
   combined with GM-CSF as an adjuvant as described in U.S. Patent 8,222,214, the
10 disclosure of which is incorporated by reference herein. In addition, the present disclosure
   provides a combination of a disclosed anti-PD-Li antibody with ALVAC-CEA vaccine,
   which is a canary pox virus combined with carcinoembryonic antigen.
   Exemplary Uses
           The PD-LI binding proteins described herein and their related variants are useful in
15 a number of therapeutic and diagnostic applications. These include the inhibition of the
   biological activity of PD-Li by competing for or blocking the binding to a PD-Li as well as
   the delivery of cytotoxic or imaging moieties to cells, preferably cells expressing PD-Li.
   The small size and stable structure of these molecules can be particularly valuable with
   respect to manufacturing of the drug, rapid clearance from the body for certain applications
20 where rapid clearance is desired or formulation into novel delivery systems that are suitable
   or improved using a molecule with such characteristics.
           On the basis of their efficacy as inhibitors of PD-Li biological activity, the
   polypeptides of this disclosure are effective against a number of cancer conditions as well as
   complications arising from cancer, such as pleural effusion and ascites. Preferably, the PD
25 LI-binding polypeptides of the disclosure can be used for the treatment of prevention of
   hyperproliferative diseases or cancer and the metastatic spread of cancers. Preferred
   indications for the disclosed anti-PD-LIantibodies include colorectal cancers, head and neck
   cancers, small cell lung cancer, non-small cell lung cancer (NSCLC) and pancreatic cancer.
   Non-limiting examples of cancers include bladder, blood, bone, brain, breast, cartilage,
30 colon kidney, liver, lung, lymph node, nervous tissue, ovary, pancreatic, prostate, skeletal
                                                   69

   muscle, skin, spinal cord, spleen, stomach, testes, thymus, thyroid, trachea, urogenital tract,
   ureter, urethra, uterus, or vaginal cancer.
            In addition, various inflammatory disorders can be treated with the disclosed anti
   PD-LI binding polypeptides disclosed herein. Such inflammatory disorders include, for
 5 example, intestinal mucosa inflammation wasting diseases associated with colitis, multiple
   sclerosis, systemic lupus erythematosus, viral infections, rheumatoid arthritis, osteoarthritis,
   psoriasis, and Crohn's disease.
            A PD-Li binding polypeptide can be administered alone or in combination with one
   or more additional therapies such as chemotherapy radiotherapy, immunotherapy, surgical
10 intervention, or any combination of these. Long-term therapy is equally possible as is
   adjuvant therapy in the context of other treatment strategies, as described above.
            In certain embodiments of such methods, one or more polypeptide therapeutic agents
   can be administered, together (simultaneously) or at different times (sequentially). In
   addition, polypeptide therapeutic agents can be administered with another type of
15 compounds for treating cancer or for inhibiting angiogenesis.
            In certain embodiments, the subject anti-PD-Ll antibodies agents of the invention
   can be used alone. Alternatively, the subject agents may be used in combination with other
   conventional anti-cancer therapeutic approaches directed to treatment or prevention of
   proliferative disorders (e.g., tumor). For example, such methods can be used in prophylactic
20 cancer prevention, prevention of cancer recurrence and metastases after surgery, and as an
   adjuvant of other conventional cancer therapy. The present disclosure recognizes that the
   effectiveness of conventional cancer therapies (e.g., chemotherapy, radiation therapy,
   phototherapy, immunotherapy, and surgery) can be enhanced through the use of a subject
   polypeptide therapeutic agent.
25          A wide array of conventional compounds have been shown to have anti-neoplastic
   activities. These compounds have been used as pharmaceutical agents in chemotherapy to
   shrink solid tumors, prevent metastases and further growth, or decrease the number of
   malignant cells in leukemic or bone marrow malignancies. Although chemotherapy has been
   effective in treating various types of malignancies, many anti-neoplastic compounds induce
30 undesirable side effects. It has been shown that when two or more different treatments are
   combined, the treatments may work synergistically and allow reduction of dosage of each of
                                                  70

   the treatments, thereby reducing the detrimental side effects exerted by each compound at
   higher dosages. In other instances, malignancies that are refractory to a treatment may
   respond to a combination therapy of two or more different treatments.
            When a polypeptide therapeutic agent of the present invention is administered in
 5 combination with another conventional anti-neoplastic agent, either concomitantly or
   sequentially, such therapeutic agent may be found to enhance the therapeutic effect of the
   anti-neoplastic agent or overcome cellular resistance to such anti-neoplastic agent. This
   allows decrease of dosage of an anti-neoplastic agent, thereby reducing the undesirable side
   effects, or restores the effectiveness of an anti-neoplastic agent in resistant cells.
10          Pharmaceutical compounds that may be used for combinatory anti-tumor therapy
   include, merely to illustrate: aminoglutethimide, amsacrine, anastrozole, asparaginase, bcg,
   bicalutamide, bleomycin, buserelin, busulfan, campothecin, capecitabine, carboplatin,
   carmustine, chlorambucil, cisplatin, cladribine, clodronate, colchicine, cyclophosphamide,
   cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, dienestrol,
15 diethylstilbestrol, docetaxel, doxorubicin, epirubicin, estradiol, estramustine, etoposide,
   exemestane, filgrastim, fludarabine, fludrocortisone, fluorouracil, fluoxymesterone,
   flutamide, gemcitabine, genistein, goserelin, hydroxyurea, idarubicin, ifosfamide, imatinib,
   interferon, irinotecan, ironotecan, letrozole, leucovorin, leuprolide, levamisole, lomustine,
   mechlorethamine, medroxyprogesterone, megestrol, melphalan, mercaptopurine, mesna,
20 methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, nocodazole, octreotide,
   oxaliplatin, paclitaxel, pamidronate, pentostatin, plicamycin, porfimer, procarbazine,
   raltitrexed, rituximab, streptozocin, suramin, tamoxifen, temozolomide, teniposide,
   testosterone, thioguanine, thiotepa, titanocene dichloride, topotecan, trastuzumab, tretinoin,
   vinblastine, vincristine, vindesine, and vinorelbine.
25          Certain chemotherapeutic anti-tumor compounds may be categorized by their
   mechanism of action into, for example, following groups: anti-metabolites/anti-cancer
   agents, such as pyrimidine analogs (5-fluorouracil, floxuridine, capecitabine, gemcitabine
   and cytarabine) and purine analogs, folate antagonists and related inhibitors
   (mercaptopurine, thioguanine, pentostatin and 2-chlorodeoxyadenosine (cladribine));
30 antiproliferative/antimitotic agents including natural products such as vinca alkaloids
   (vinblastine, vincristine, and vinorelbine), microtubule disruptors such as taxane (paclitaxel,
                                                   71

   docetaxel), vincristin, vinblastin, nocodazole, epothilones and navelbine,
   epidipodophyllotoxins (etoposide, teniposide), DNA damaging agents (actinomycin,
   amsacrine, anthracyclines, bleomycin, busulfan, camptothecin, carboplatin, chlorambucil,
   cisplatin, cyclophosphamide, cytoxan, dactinomycin, daunorubicin, doxorubicin, epirubicin,
 5 hexamethylmelamineoxaliplatin, iphosphamide, melphalan, merchlorehtamine, mitomycin,
   mitoxantrone, nitrosourea, plicamycin, procarbazine, taxol, taxotere, teniposide,
   triethylenethiophosphoramide and etoposide (VP 16)); antibiotics such as dactinomycin
   (actinomycin D), daunorubicin, doxorubicin (adriamycin), idarubicin, anthracyclines,
   mitoxantrone, bleomycins, plicamycin (mithramycin) and mitomycin; enzymes (L
10 asparaginase which systemically metabolizes L-asparagine and deprives cells which do not
   have the capacity to synthesize their own asparagine); antiplatelet agents;
   antiproliferative/antimitotic alkylating agents such as nitrogen mustards (mechlorethamine,
   cyclophosphamide and analogs, melphalan, chlorambucil), ethylenimines and
   methylmelamines (hexamethylmelamine and thiotepa), alkyl sulfonates-busulfan,
15 nitrosoureas (carmustine (BCNU) and analogs, streptozocin), trazenes--dacarbazinine
   (DTIC); antiproliferative/antimitotic antimetabolites such as folic acid analogs
   (methotrexate); platinum coordination complexes (cisplatin, carboplatin), procarbazine,
   hydroxyurea, mitotane, aminoglutethimide; hormones, hormone analogs (estrogen,
   tamoxifen, goserelin, bicalutamide, nilutamide) and aromatase inhibitors (letrozole,
20 anastrozole); anticoagulants (heparin, synthetic heparin salts and other inhibitors of
   thrombin); fibrinolytic agents (such as tissue plasminogen activator, streptokinase and
   urokinase), aspirin, dipyridamole, ticlopidine, clopidogrel, abciximab; antimigratory agents;
   antisecretory agents (breveldin); immunosuppressives (cyclosporine, tacrolimus (FK-506),
   sirolimus (rapamycin), azathioprine, mycophenolate mofetil); anti-angiogenic compounds
25 (TNP-470, genistein) and growth factor inhibitors (e.g., VEGF inhibitors, fibroblast growth
   factor (FGF) inhibitors); angiotensin receptor blocker; nitric oxide donors; anti-sense
   oligonucleotides; antibodies (trastuzumab); cell cycle inhibitors and differentiation inducers
   (tretinoin); mTOR inhibitors, topoisomerase inhibitors (doxorubicin (adriamycin),
   amsacrine, camptothecin, daunorubicin, dactinomycin, eniposide, epirubicin, etoposide,
30 idarubicin and mitoxantrone, topotecan, irinotecan), corticosteroids (cortisone,
   dexamethasone, hydrocortisone, methylpednisolone, prednisone, and prenisolone); growth
                                                  72

   factor signal transduction kinase inhibitors; mitochondrial dysfunction inducers and caspase
   activators; and chromatin disruptors.
           Depending on the nature of the combinatory therapy, administration of the
   polypeptide therapeutic agents may be continued while the other therapy is being
 5 administered and/or thereafter. Administration of the polypeptide therapeutic agents may be
   made in a single dose, or in multiple doses. In some instances, administration of the
   polypeptide therapeutic agents is commenced at least several days prior to the conventional
   therapy, while in other instances, administration is begun either immediately before or at the
   time of the administration of the conventional therapy.
10         In one example of a diagnostic application, a biological sample, such as serum or a
   tissue biopsy, from a patient suspected of having a condition characterized by inappropriate
   angiogenesis is contacted with a detectably labeled polypeptide of the disclosure to detect
   levels of PD-Li. The levels of PD-Li detected are then compared to levels of PD-Li
   detected in a normal sample also contacted with the labeled polypeptide. An increase of at
15 least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% in the levels of the PD-Li may
   be considered a diagnostic indicator.
           In certain embodiments, the PD-LI binding polypeptides are further attached to a
   label that is able to be detected (e.g., the label can be a radioisotope, fluorescent compound,
   enzyme or enzyme co-factor). The active moiety may be a radioactive agent, such as:
20 radioactive heavy metals such as iron chelates, radioactive chelates of gadolinium or
   manganese, positron emitters of oxygen, nitrogen, iron, carbon, or gallium,      4K, 52Fe, 5Co,
   67Cu, 67Ga, 68Ga, 123 1,25 1,31 132, or 99Tc. A binding
                                                              agent affixed to such a moiety may
   be used as an imaging agent and is administered in an amount effective for diagnostic use in
   a mammal such as a human and the localization and accumulation of the imaging agent is
25 then detected. The localization and accumulation of the imaging agent may be detected by
   radioscintigraphy, nuclear magnetic resonance imaging, computed tomography or positron
   emission tomography. Immunoscintigraphy using PD-LI binding polypeptides directed at
   PD-LI may be used to detect and/or diagnose cancers and vasculature. For example, any of
   the binding polypeptide against a PD-LI marker labeled with 99Technetium, IIndium, or
30 125Iodine  may be effectively used for such imaging. As will be evident to the skilled artisan,
   the amount of radioisotope to be administered is dependent upon the radioisotope. Those
                                                     73

   having ordinary skill in the art can readily formulate the amount of the imaging agent to be
   administered based upon the specific activity and energy of a given radionuclide used as the
   active moiety. Typically 0.1-100 millicuries per dose of imaging agent, preferably 1-10
   millicuries, most often 2-5 millicuries are administered. Thus, compositions according to the
 5 present invention useful as imaging agents comprising a targeting moiety conjugated to a
   radioactive moiety comprise 0.1-100 millicuries, in some embodiments preferably 1-10
   millicuries, in some embodiments preferably 2-5 millicuries, in some embodiments more
   preferably 1-5 millicuries.
           The PD-LI binding polypeptides can also be used to deliver additional therapeutic
10 agents (including but not limited to drug compounds, chemotherapeutic compounds, and
   radiotherapeutic compounds) to a cell or tissue expressing PD-LI. In one example, the PD
   LI binding polypeptide is fused to a chemotherapeutic agent for targeted delivery of the
   chemotherapeutic agent to a tumor cell or tissue expressing PD-LI.
           The PD-Li binding polypeptides are useful in a variety of applications, including
15 research, diagnostic and therapeutic applications. For instance, they can be used to isolate
   and/or purify receptor or portions thereof, and to study receptor structure (e.g.,
   conformation) and function.
           In certain aspects, the various binding polypeptides can be used to detect or measure
   the expression of PD-Li, for example, on endothelial cells (e.g., venous endothelial cells),
20 or on cells transfected with a PD-Li gene. Thus, they also have utility in applications such
   as cell sorting and imaging (e.g., flow cytometry, and fluorescence activated cell sorting),
   for diagnostic or research purposes.
           In certain embodiments, the binding polypeptides of fragments thereof can be
   labeled or unlabeled for diagnostic purposes. Typically, diagnostic assays entail detecting
25 the formation of a complex resulting from the binding of a binding polypeptide to PD-LI.
   The binding polypeptides or fragments can be directly labeled, similar to antibodies. A
   variety of labels can be employed, including, but not limited to, radionuclides, fluorescers,
   enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors and ligands (e.g., biotin,
   haptens). Numerous appropriate immunoassays are known to the skilled artisan (U.S.
30 Patents. 3,817,827; 3,850,752; 3,901,654; and 4,098,876). When unlabeled, the binding
   polypeptides can be used in assays, such as agglutination assays. Unlabeled binding
                                                   74

   polypeptides can also be used in combination with another (one or more) suitable reagent
   which can be used to detect the binding polypeptide, such as a labeled antibody reactive
   with the binding polypeptide or other suitable reagent (e.g., labeled protein A).
            In one embodiment, the binding polypeptides of the present invention can be utilized
 5 in enzyme immunoassays, wherein the subject polypeptides are conjugated to an enzyme.
   When a biological sample comprising a PD-Li protein is combined with the subject binding
   polypeptides, binding occurs between the binding polypeptides and the PD-Li protein. In
   one embodiment, a sample containing cells expressing a PD-Li protein (e.g., endothelial
   cells) is combined with the subject antibodies, and binding occurs between the binding
10 polypeptides and cells bearing a PD-LI protein recognized by the binding polypeptide.
   These bound cells can be separated from unbound reagents and the presence of the binding
   polypeptide-enzyme conjugate specifically bound to the cells can be determined, for
   example, by contacting the sample with a substrate of the enzyme which produces a color or
   other detectable change when acted on by the enzyme. In another embodiment, the subject
15 binding polypeptides can be unlabeled, and a second, labeled polypeptide (e.g., an antibody)
   can be added which recognizes the subject binding polypeptide.
            In certain aspects, kits for use in detecting the presence of a PD-LI protein in a
   biological sample can also be prepared. Such kits will include a PD-LI binding polypeptide
   which binds to a PD-LI protein or portion of said receptor, as well as one or more ancillary
20 reagents suitable for detecting the presence of a complex between the binding polypeptide
   and the receptor protein or portions thereof. The polypeptide compositions of the present
   invention can be provided in lyophilized form, either alone or in combination with
   additional antibodies specific for other epitopes. The binding polypeptides and/or
   antibodies, which can be labeled or unlabeled, can be included in the kits with adjunct
25 ingredients (e.g., buffers, such as Tris, phosphate and carbonate, stabilizers, excipients,
   biocides and/or inert proteins, e.g., bovine serum albumin). For example, the binding
   polypeptides and/or antibodies can be provided as a lyophilized mixture with the adjunct
   ingredients, or the adjunct ingredients can be separately provided for combination by the
   user. Generally these adjunct materials will be present in less than about 5% weight based
30 on the amount of active binding polypeptide or antibody, and usually will be present in a
   total amount of at least about 0.001% weight based on polypeptide or antibody
                                                     75

   concentration. Where a second antibody capable of binding to the binding polypeptide is
   employed, such antibody can be provided in the kit, for instance in a separate vial or
   container. The second antibody, if present, is typically labeled, and can be formulated in an
   analogous manner with the antibody formulations described above.
 5          Similarly, the present disclosure also provides a method of detecting and/or
   quantitating expression of PD-Li, wherein a composition comprising a cell or fraction
   thereof (e.g., membrane fraction) is contacted with a binding polypeptide which binds to a
   PD-LI or portion of the receptor under conditions appropriate for binding thereto, and the
   binding is monitored. Detection of the binding polypeptide, indicative of the formation of a
10 complex between binding polypeptide and PD-LI or a portion thereof, indicates the
   presence of the receptor. Binding of a polypeptide to the cell can be determined by standard
   methods, such as those described in the working examples. The method can be used to
   detect expression of PD-Li on cells from an individual. Optionally, a quantitative
   expression of PD-Li on the surface of endothelial cells can be evaluated, for instance, by
15 flow cytometry, and the staining intensity can be correlated with disease susceptibility,
   progression or risk.
            The present disclosure also provides a method of detecting the susceptibility of a
   mammal to certain diseases. To illustrate, the method can be used to detect the susceptibility
   of a mammal to diseases which progress based on the amount of PD-Li present on cells
20 and/or the number of PD-LI-positive cells in a mammal.
            Polypeptide sequences are indicated using standard one- or three-letter
   abbreviations. Unless otherwise indicated, each polypeptide sequence has amino termini at
   the left and a carboxy termini at the right; each single-stranded nucleic acid sequence, and
   the top strand of each double-stranded nucleic acid sequence, has a 5' termini at the left and
25 a 3' termini at the right. A particular polypeptide sequence also can be described by
   explaining how it differs from a reference sequence.
            The terms "PD-Li inhibitor" and "PD-Li antagonist" are used interchangeably. Each
   is a molecule that detectably inhibits at least one function of PD-Li. Conversely, a "PD-Li
   agonist" is a molecule that detectably increases at least one function of PD-Li. The
30 inhibition caused by a PD-Li inhibitor need not be complete so long as it is detectable using
   an assay. Any assay of a function of PD-Li can be used, examples of which are provided
                                                   76

   herein. Examples of functions of PD-Li that can be inhibited by a PD-Li inhibitor, or
   increased by a PD-LI agonist, include cancer cell growth or apoptosis (programmed cell
   death), and so on. Examples of types of PD-Li inhibitors and PD-Li agonists include, but
   are not limited to, PD-LI binding polypeptides such as antigen binding proteins (e.g., PD
 5 LI inhibiting antigen binding proteins), antibodies, antibody fragments, and antibody
   derivatives.
            The terms "peptide," "polypeptide" and "protein" each refers to a molecule
   comprising two or more amino acid residues joined to each other by peptide bonds. These
   terms encompass, e.g., native and artificial proteins, protein fragments and polypeptide
10 analogs (such as muteins, variants, and fusion proteins) of a protein sequence as well as
   post-translationally, or otherwise covalently or non-covalently, modified proteins. A
   peptide, polypeptide, or protein may be monomeric or polymeric.
            A "variant" of a polypeptide (for example, an antibody) comprises an amino acid
   sequence wherein one or more amino acid residues are inserted into, deleted from and/or
15 substituted into the amino acid sequence relative to another polypeptide sequence. Disclosed
   variants include, for example, fusion proteins.
            A "derivative" of a polypeptide is a polypeptide (e.g., an antibody) that has been
   chemically modified, e.g., via conjugation to another chemical moiety (such as, for example,
   polyethylene glycol or albumin, e.g., human serum albumin), phosphorylation, and
20 glycosylation. Unless otherwise indicated, the term "antibody" includes, in addition to
   antibodies comprising two full-length heavy chains and two full-length light chains,
   derivatives, variants, fragments, and muteins thereof, examples of which are described
   below.
            An "antigen binding protein" is a protein comprising a portion that binds to an
25 antigen and, optionally, a scaffold or framework portion that allows the antigen binding
   portion to adopt a conformation that promotes binding of the antigen binding protein to the
   antigen. Examples of antigen binding proteins include antibodies, antibody fragments (e.g.,
   an antigen binding portion of an antibody), antibody derivatives, and antibody analogs. The
   antigen binding protein can comprise, for example, an alternative protein scaffold or
30 artificial scaffold with grafted CDRs or CDR derivatives. Such scaffolds include, but are not
   limited to, antibody-derived scaffolds comprising mutations introduced to, for example,
                                                  77

   stabilize the three-dimensional structure of the antigen binding protein as well as wholly
   synthetic scaffolds comprising, for example, a biocompatible polymer. See, for example,
   Korndorfer et al., 2003, Proteins:Structure,Function, and Bioinformatics,Volume 53,
   Issue 1:121-129; Roque et al., 2004, Biotechnol. Prog.20:639-654. In addition, peptide
 5 antibody mimetics ("PAMs") can be used, as well as scaffolds based on antibody mimetics
   utilizing fibronection components as a scaffold.
           An antigen binding protein can have, for example, the structure of a naturally
   occurring immunoglobulin. An "immunoglobulin" is a tetrameric molecule. In a naturally
   occurring immunoglobulin, each tetramer is composed of two identical pairs of polypeptide
10 chains, each pair having one "light" (about 25 kDa) and one "heavy" chain (about 50-70
   kDa). The amino-terminal portion of each chain includes a variable region of about 100 to
   110 or more amino acids primarily responsible for antigen recognition. The carboxy
   terminal portion of each chain defines a constant region primarily responsible for effector
   function. Human light chains are classified as kappa or lambda light chains. Heavy chains
15 are classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as
   IgM, IgD, IgG, IgA, and IgE, respectively. Preferably, the anti-PD-Li antibodies disclosed
   herein are characterized by their variable domain region sequences in the heavy VH and light
   VL amino acid sequences. The preferred antibody is A6 which is a kappa IgG antibody.
   Within light and heavy chains, the variable and constant regions are joined by a "J"region
20 of about 12 or more amino acids, with the heavy chain also including a "D" region of about
   10 more amino acids. See generally, Fundamental Immunology Ch. 7 (Paul, W., ed., 2nd ed.
   Raven Press, N.Y. (1989)). The variable regions of each light/heavy chain pair form the
   antibody binding site such that an intact immunoglobulin has two binding sites.
           A "multi-specific antibody" is an antibody that recognizes more than one epitope on
25 one or more antigens. A subclass of this type of antibody is a "bi-specific antibody" which
   recognizes two distinct epitopes on the same or different antigens.
           An antigen binding protein "specifically binds" to an antigen (e.g., human PD-LI) if
   it binds to the antigen with a dissociation constant of 1 nanomolar or less.
           An "antigen binding domain, "antigen binding region," or "antigen binding site" is a
30 portion of an antigen binding protein that contains amino acid residues (or other moieties)
   that interact with an antigen and contribute to the antigen binding protein's specificity and
                                                  78

   affinity for the antigen. For an antibody that specifically binds to its antigen, this will
   include at least part of at least one of its CDR domains.
            An "epitope" is the portion of a molecule that is bound by an antigen binding protein
   (e.g., by an antibody). An epitope can comprise non-contiguous portions of the molecule
 5 (e.g., in a polypeptide, amino acid residues that are not contiguous in the polypeptide's
   primary sequence but that, in the context of the polypeptide's tertiary and quaternary
   structure, are near enough to each other to be bound by an antigen binding protein).
            The "percent homology" of two polynucleotide or two polypeptide sequences is
   determined by comparing the sequences using the GAP computer program (a part of the
10 GCG Wisconsin Package, version 10.3 (Accelrys, San Diego, Calif.)) using its default
   parameters.
            A "host cell" is a cell that can be used to express a nucleic acid. A host cell can be a
   prokaryote, for example, E. coli, or it can be a eukaryote, for example, a single-celled
   eukaryote (e.g., a yeast or other fungus), a plant cell (e.g., a tobacco or tomato plant cell), an
15 animal cell (e.g., a human cell, a monkey cell, a hamster cell, a rat cell, a mouse cell, or an
   insect cell) or a hybridoma. Examples of host cells include the COS-7 line of monkey
   kidney cells (ATCC CRL 1651) (Gluzman et al., 1981, Cell 23:175), L cells, C127 cells,
   3T3 cells (ATCC CCL 163), Chinese hamster ovary (CHO) cells or their derivatives such as
   Veggie CHO and related cell lines which grow in serum-free media (Rasmussen et al., 1998,
20 Cytotechnology 28:3 1) or CHO strain DX-B 11, which is deficient in DHFR (Urlaub et al.,
   1980, Proc.NatL. A cad. Sci. USA 77:4216-20), HeLa cells, BHK (ATCC CRL 10) cell lines,
   the CV1/EBNA cell line derived from the African green monkey kidney cell line CV1
   (ATCC CCL 70) (McMahan et al., 1991, EMBO J 10:2821), human embryonic kidney cells
   such as 293,293 EBNA or MSR 293, human epidermal A431 cells, human Colo205 cells,
25 other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro
   culture of primary tissue, primary explants, HL-60, U937, HaK or Jurkat cells. Typically, a
   host cell is a cultured cell that can be transformed or transfected with a polypeptide
   encoding nucleic acid, which can then be expressed in the host cell. The phrase
   "recombinant host cell" can be used to denote a host cell that has been transformed or
30 transfected with a nucleic acid to be expressed. A host cell also can be a cell that comprises
   the nucleic acid but does not express it at a desired level unless a regulatory sequence is
                                                    79

   introduced into the host cell such that it becomes operably linked with the nucleic acid. It is
   understood that the term host cell refers not only to the particular subject cell but also to the
   progeny or potential progeny of such a cell. Because certain modifications may occur in
   succeeding generations due to, e.g., mutation or environmental influence, such progeny may
 5 not, in fact, be identical to the parent cell, but are still included within the scope of the term
   as used herein.
   Antigen Binding Proteins
            Antigen binding proteins (e.g., antibodies, antibody fragments, antibody derivatives,
   antibody muteins, and antibody variants) are polypeptides that bind to PD-LI, (preferably,
10 human PD-Li). Antigen binding proteins include antigen binding proteins that inhibit a
   biological activity of PD-Li.
            Oligomers that contain one or more antigen binding proteins may be employed as
   PD-LI antagonists. Oligomers may be in the form of covalently-linked or non-covalently
   linked dimers, trimers, or higher oligomers. Oligomers comprising two or more antigen
15 binding protein are contemplated for use, with one example being a homodimer. Other
   oligomers include heterodimers, homotrimers, heterotrimers, homotetramers,
   heterotetramers, etc.
            One embodiment is directed to oligomers comprising multiple antigen binding
   proteins joined via covalent or non-covalent interactions between peptide moieties fused to
20 the antigen binding proteins. Such peptides may be peptide linkers (spacers), or peptides
   that have the property of promoting oligomerization. Leucine zippers and certain
   polypeptides derived from antibodies are among the peptides that can promote
   oligomerization of antigen binding proteins attached thereto, as described in more detail
   below.
25          In particular embodiments, the oligomers comprise from two to four antigen binding
   proteins. The antigen binding proteins of the oligomer may be in any form, such as any of
   the forms described above, e.g., variants or fragments. Preferably, the oligomers comprise
   antigen binding proteins that have PD-LI binding activity.
            In one embodiment, an oligomer is prepared using polypeptides derived from
30 immunoglobulins. Preparation of Fusion Proteins Comprising Certain Heterologous
   Polypeptides Fused to Various Portions of antibody-derived polypeptides (including the Fc
                                                     80

   domain) has been described, e.g., by Ashkenazi et al., 1991, Proc.Natl. Acad. Sci. USA
   88:10535; Byrn et al., 1990, Nature 344:677; and Hollenbaugh et al., 1992 "Construction of
   Immunoglobulin Fusion Proteins", in CurrentProtocolsin Immunology, Suppl. 4, pages
   10.19.1-10.19.11.
 5         One embodiment is directed to a dimer comprising two fusion proteins created by
   fusing a PD-LI binding fragment of an anti-PD-LI antibody to the Fc region of an antibody.
   The dimer can be made by, for example, inserting a gene fusion encoding the fusion protein
   into an appropriate expression vector, expressing the gene fusion in host cells transformed
   with the recombinant expression vector, and allowing the expressed fusion protein to
10 assemble much like antibody molecules, whereupon interchain disulfide bonds form
   between the Fc moieties to yield the dimer.
           The term "Fc polypeptide" includes native and mutein forms of polypeptides derived
   from the Fc region of an antibody. Truncated forms of such polypeptides containing the
   hinge region that promotes dimerization also are included. Fusion proteins comprising Fc
15 moieties (and oligomers formed therefrom) offer the advantage of facile purification by
   affinity chromatography over Protein A or Protein G columns.
           Another method for preparing oligomeric antigen binding proteins involves use of a
   leucine zipper. Leucine zipper domains are peptides that promote oligomerization of the
   proteins in which they are found. Leucine zippers were originally identified in several DNA
20 binding proteins (Landschulz et al., 1988, Science 240:1759), and have since been found in
   a variety of different proteins. Among the known leucine zippers are naturally occurring
   peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper
   domains suitable for producing soluble oligomeric proteins are described in WO 94/10308,
   and the leucine zipper derived from lung surfactant protein D (SPD) described in Hoppe et
25 al., 1994, FEBS Letters 344:191. The use of a modified leucine zipper that allows for stable
   trimerization of a heterologous protein fused thereto is described in Fanslow et al., 1994,
   Semin. Immunol. 6:267-78. In one approach, recombinant fusion proteins comprising an
   anti-PD-LI antibody fragment or derivative fused to a leucine zipper peptide are expressed
   in suitable host cells, and the soluble oligomeric anti-PD-LI antibody fragments or
30 derivatives that form are recovered from the culture supernatant.
                                                  81

            Antigen-binding fragments of antigen binding proteins of the invention may be
   produced by conventional techniques. Examples of such fragments include, but are not
   limited to, Fab and F(ab') 2 fragments.
            The present disclosure provides monoclonal antibodies that bind to PD-LI.
 5 Monoclonal antibodies may be produced using any technique known in the art, e.g., by
   immortalizing spleen cells harvested from the transgenic animal after completion of the
   immunization schedule. The spleen cells can be immortalized using any technique known in
   the art, e.g., by fusing them with myeloma cells to produce hybridomas. Myeloma cells for
   use in hybridoma-producing fusion procedures preferably are non-antibody-producing, have
10 high fusion efficiency, and enzyme deficiencies that render them incapable of growing in
   certain selective media which support the growth of only the desired fused cells
   (hybridomas). Examples of suitable cell lines for use in mouse fusions include Sp-20, P3
   X63/Ag8, P3-X63-Ag8.653, NSi/i.Ag 4 1, Sp210-AgI4, FO, NSO/U, MPC-i 1, MPC1 1
   X45-GTG 1.7 and S194/5XXO Bul; examples of cell lines used in rat fusions include
15 R210.RCY3, Y3-Ag 1.2.3, IR983F and 48210. Other cell lines useful for cell fusions are U
   266, GM1500-GRG2, LICR-LON-HMy2 and UC729-6.
            Antigen binding proteins directed against PD-LI can be used, for example, in assays
   to detect the presence of PD-Li polypeptides, either in vitro or in vivo. The antigen binding
   proteins also may be employed in purifying PD-LI proteins by immunoaffinity
20 chromatography. Blocking antigen binding proteins can be used in the methods disclosed
   herein. Such antigen binding proteins that function as PD-LI antagonists may be employed
   in treating any PD-LI-induced condition, including but not limited to various cancers.
            Antigen binding proteins may be employed in an in vitro procedure, or administered
   in vivo to inhibit PD-LI-induced biological activity. Disorders caused or exacerbated
25 (directly or indirectly) by the proteolytic activation of PD-Li, examples of which are
   provided herein, thus may be treated. In one embodiment, the present invention provides a
   therapeutic method comprising in vivo administration of a PD-LI blocking antigen binding
   protein to a mammal in need thereof in an amount effective for reducing an PD-LI-induced
   biological activity.
30          Antigen binding proteins include fully human monoclonal antibodies that inhibit a
   biological activity of PD-Li.
                                                   82

           Antigen binding proteins may be prepared by any of a number of conventional
   techniques. For example, they may be purified from cells that naturally express them (e.g.,
   an antibody can be purified from a hybridoma that produces it), or produced in recombinant
   expression systems, using any technique known in the art. See, for example, Monoclonal
 5 Antibodies, Hybridomas: A New Dimension in Biological Analyses, Kennet et al. (eds.),
   Plenum Press, New York (1980); and Antibodies: A Laboratory Manual, Harlow and Land
   (eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1988).
           Any expression system known in the art can be used to make the recombinant
   polypeptides of the invention. In general, host cells are transformed with a recombinant
10 expression vector that comprises DNA encoding a desired polypeptide. Among the host
   cells that may be employed are prokaryotes, yeast or higher eukaryotic cells. Prokaryotes
   include gram negative or gram positive organisms, for example E. coli or bacilli. Higher
   eukaryotic cells include insect cells and established cell lines of mammalian origin.
   Examples of suitable mammalian host cell lines include the COS-7 line of monkey kidney
15 cells (ATCC CRL 1651) (Gluzman et al., 1981, Cell 23:175), L cells, 293 cells, C127 cells,
   3T3 cells (ATCC CCL 163), Chinese hamster ovary (CHO) cells, HeLa cells, BHK (ATCC
   CRL 10) cell lines, and the CV1/EBNA cell line derived from the African green monkey
   kidney cell line CV1 (ATCC CCL 70) as described by McMahan et al., 1991, EMBO J. 10:
   2821. Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and
20 mammalian cellular hosts are described by Pouwels et al. (Cloning Vectors: A Laboratory
   Manual, Elsevier, N.Y., 1985).
           The transformed cells can be cultured under conditions that promote expression of
   the polypeptide, and the polypeptide recovered by conventional protein purification
   procedures. One such purification procedure includes the use of affinity chromatography,
25 e.g., over a matrix having all or a portion (e.g., the extracellular domain) of PD-Li bound
   thereto. Polypeptides contemplated for use herein include substantially homogeneous
   recombinant mammalian anti-PD-LI antibody polypeptides substantially free of
   contaminating endogenous materials.
           Antigen binding proteins may be prepared, and screened for desired properties, by
30 any of a number of known techniques. Certain of the techniques involve isolating a nucleic
   acid encoding a polypeptide chain (or portion thereof) of an antigen binding protein of
                                                   83

   interest (e.g., an anti-PD-Li antibody), and manipulating the nucleic acid through
   recombinant DNA technology. The nucleic acid may be fused to another nucleic acid of
   interest, or altered (e.g., by mutagenesis or other conventional techniques) to add, delete, or
   substitute one or more amino acid residues, for example.
 5          Single chain antibodies may be formed by linking heavy and light chain variable
   domain (Fv region) fragments via an amino acid bridge (short peptide linker), resulting in a
   single polypeptide chain. Such single-chain Fvs (scFvs) have been prepared by fusing DNA
   encoding a peptide linker between DNAs encoding the two variable domain polypeptides
   (VL and VH). The resulting polypeptides can fold back on themselves to form antigen
10 binding monomers, or they can form multimers (e.g., dimers, trimers, or tetramers),
   depending on the length of a flexible linker between the two variable domains (Kortt et al.,
   1997, Prot.Eng. 10:423; Kortt et al., 2001, Biomol. Eng. 18:95-108). By combining
   different VL and VH-comprising polypeptides, one can form multimeric scFvs that bind to
   different epitopes (Kriangkum et al., 2001, Biomol. Eng. 18:31-40). Techniques developed
15 for the production of single chain antibodies include those described in U.S. Patent
   4,946,778; Bird, 1988, Science 242:423; Huston et al., 1988, Proc.Natl. Acad. Sci. USA
   85:5879; Ward et al., 1989, Nature 334:544, de Graaf et al., 2002, Methods Mol. Biol.
   178:379-87.
            Techniques are known for deriving an antibody of a different subclass or isotype
20 from an antibody of interest, i.e., subclass switching. Thus, IgG antibodies may be derived
   from an IgM antibody, for example, and vice versa. Such techniques allow the preparation
   of new antibodies that possess the antigen-binding properties of a given antibody (the parent
   antibody), but also exhibit biological properties associated with an antibody isotype or
   subclass different from that of the parent antibody. Recombinant DNA techniques may be
25 employed. Cloned DNA encoding particular antibody polypeptides may be employed in
   such procedures, e.g., DNA encoding the constant domain of an antibody of the desired
   isotype (Lantto et al., 2002, Methods Mol. Biol. 178:303-16). Moreover, if an IgG4 is
   desired, it may also be desired to introduce a point mutation (CPSCP->CPPCP) in the hinge
   region (Bloom et al., 1997, Protein Science 6:407) to alleviate a tendency to form intra-H
30 chain disulfide bonds that can lead to heterogeneity in the IgG4 antibodies.
                                                   84

            In particular embodiments, antigen binding proteins of the present invention have a
   binding affinity (Ka) for PD-Li of at least 106. In other embodiments, the antigen binding
   proteins exhibit a Ka of at least 107 , at least 108, at least 109, or at least 1010. In another
   embodiment, the antigen binding protein exhibits a Ka substantially the same as that of an
 5 antibody described herein in the Examples.
            In another embodiment, the present disclosure provides an antigen binding protein
   that has a low dissociation rate from PD-LI. In one embodiment, the antigen binding protein
   has a Korf of 1 X 10-4 to -1 or lower. In another embodiment, the Korf is 5 X 10-5 to -1 or
   lower. In another embodiment, the Korf is substantially the same as an antibody described
10 herein. In another embodiment, the antigen binding protein binds to PD-LI with
   substantially the same Korf as an antibody described herein.
            In another aspect, the present disclosure provides an antigen binding protein that
   inhibits an activity of PD-Li. In one embodiment, the antigen binding protein has an IC5 0 of
   1000 nM or lower. In another embodiment, the IC 50 is 100 nM or lower; in another
15 embodiment, the IC 50 is 10 nM or lower. In another embodiment, the IC 50 is substantially
   the same as that of an antibody described herein in the Examples. In another embodiment,
   the antigen binding protein inhibits an activity of PD-Li with substantially the same IC 50 as
   an antibody described herein.
            In another aspect, the present disclosure provides an antigen binding protein that
20 binds to human PD-Li expressed on the surface of a cell and, when so bound, inhibits PD
   LI signaling activity in the cell without causing a significant reduction in the amount of PD
   LI on the surface of the cell. Any method for determining or estimating the amount of PD
   LI on the surface and/or in the interior of the cell can be used. In other embodiments,
   binding of the antigen binding protein to the PD-LI-expressing cell causes less than about
25 75%, 50%, 40%, 30%, 20%, 15%, 10%, 5%, 1%, or 0.1% of the cell-surface PD-Li to be
   internalized.
            In another aspect, the present disclosure provides an antigen binding protein having
   a half-life of at least one day in vitro or in vivo (e.g., when administered to a human subject).
   In one embodiment, the antigen binding protein has a half-life of at least three days. In
30 another embodiment, the antigen binding protein has a half-life of four days or longer. In
   another embodiment, the antigen binding protein has a half-life of eight days or longer. In
                                                     85

   another embodiment, the antigen binding protein is derivatized or modified such that it has a
   longer half-life as compared to the underivatized or unmodified antigen binding protein. In
   another embodiment, the antigen binding protein contains one or more point mutations to
   increase serum half life, such as described in WOOO/09560, incorporated by reference
 5 herein.
           The present disclosure further provides multi-specific antigen binding proteins, for
   example, bispecific antigen binding protein, e.g., antigen binding protein that bind to two
   different epitopes of PD-Li, or to an epitope of PD-Li and an epitope of another molecule,
   via two different antigen binding sites or regions. Moreover, bispecific antigen binding
10 protein as disclosed herein can comprise a PD-Li binding site from one of the herein
   described antibodies and a second PD-Li binding region from another of the herein
   described antibodies, including those described herein by reference to other publications.
   Alternatively, a bispecific antigen binding protein may comprise an antigen binding site
   from one of the herein described antibodies and a second antigen binding site from another
15 PD-LI antibody that is known in the art, or from an antibody that is prepared by known
   methods or the methods described herein.
           Numerous methods of preparing bispecific antibodies are known in the art. Such
   methods include the use of hybrid-hybridomas as described by Milstein et al., 1983, Nature
   305:537, and chemical coupling of antibody fragments (Brennan et al., 1985, Science
20 229:81; Glennie et al., 1987, J Immunol. 139:2367; U.S. Patent 6,010,902). Moreover,
   bispecific antibodies can be produced via recombinant means, for example by using leucine
   zipper moieties (i.e., from the Fos and Jun proteins, which preferentially form heterodimers;
   Kostelny et al., 1992, J Immunol. 148:1547) or other lock and key interactive domain
   structures as described in U.S. Patent 5,582,996. Additional useful techniques include those
25 described in U.S. Patents 5,959,083; and 5,807,706.
           In another aspect, the antigen binding protein comprises a derivative of an antibody.
   The derivatized antibody can comprise any molecule or substance that imparts a desired
   property to the antibody, such as increased half-life in a particular use. The derivatized
   antibody can comprise, for example, a detectable (or labeling) moiety (e.g., a radioactive,
30 colorimetric, antigenic or enzymatic molecule, a detectable bead (such as a magnetic or
   electrodense (e.g., gold bead), or a molecule that binds to another molecule (e.g., biotin or
                                                  86

   streptavidin), a therapeutic or diagnostic moiety (e.g., a radioactive, cytotoxic, or
   pharmaceutically active moiety), or a molecule that increases the suitability of the antibody
   for a particular use (e.g., administration to a subject, such as a human subject, or other in
   vivo or in vitro uses). Examples of molecules that can be used to derivatize an antibody
 5 include albumin (e.g., human serum albumin) and polyethylene glycol (PEG). Albumin
   linked and PEGylated derivatives of antibodies can be prepared using techniques well
   known in the art. In one embodiment, the antibody is conjugated or otherwise linked to
   transthyretin (TTR) or a TTR variant. The TTR or TTR variant can be chemically modified
   with, for example, a chemical selected from the group consisting of dextran, poly(n-vinyl
10 pyurrolidone), polyethylene glycols, propropylene glycol homopolymers, polypropylene
   oxide/ethylene oxide co-polymers, polyoxyethylated polyols and polyvinyl alcohols.
   Indications
           In one aspect, the present disclosure provides methods of treating a subject. The
   method can, for example, have a generally salubrious effect on the subject, e.g., it can
15 increase the subject's expected longevity. Alternatively, the method can, for example, treat,
   prevent, cure, relieve, or ameliorate ("treat") a disease, disorder, condition, or illness ("a
   condition"). Among the conditions to be treated are conditions characterized by
   inappropriate expression or activity of PD-Li. In some such conditions, the expression or
   activity level is too high, and the treatment comprises administering a PD-LI antagonist as
20 described herein. The disorders or conditions are cancer-related. In particular, those cancers
   include, but are not limited to, lung, ovarian and colon carcinoma and various myelomas.
            Specific medical conditions and diseases that are treatable or preventable with the
   antigen binding proteins of this disclosure include various cancers.
   Therapeutic Methods and Administration of Antigen Binding Proteins
25         Certain methods provided herein comprise administering a PD-Li binding antigen
   binding protein to a subject, thereby reducing a PD-Li -induced biological response that
   plays a role in a particular condition. In particular embodiments, methods of the invention
   involve contacting endogenous PD-Li with a PD-Li binding antigen binding protein, e.g.,
   via administration to a subject or in an ex vivo procedure.
30         The term "treatment" encompasses alleviation or prevention of at least one symptom
   or other aspect of a disorder, or reduction of disease severity, and the like. An antigen
                                                    87

   binding protein need not effect a complete cure, or eradicate every symptom or
   manifestation of a disease, to constitute a viable therapeutic agent. As is recognized in the
   pertinent field, drugs employed as therapeutic agents may reduce the severity of a given
   disease state, but need not abolish every manifestation of the disease to be regarded as
 5 useful therapeutic agents. Similarly, a prophylactically administered treatment need not be
   completely effective in preventing the onset of a condition in order to constitute a viable
   prophylactic agent. Simply reducing the impact of a disease (for example, by reducing the
   number or severity of its symptoms, or by increasing the effectiveness of another treatment,
   or by producing another beneficial effect), or reducing the likelihood that the disease will
10 occur or worsen in a subject, is sufficient. One embodiment of the invention is directed to a
   method comprising administering to a patient a PD-Li antagonist in an amount and for a
   time sufficient to induce a sustained improvement over baseline of an indicator that reflects
   the severity of the particular disorder.
           As is understood in the pertinent field, pharmaceutical compositions comprising the
15 antibodies and fragments thereof of the disclosure are administered to a subject in a manner
   appropriate to the indication. Pharmaceutical compositions may be administered by any
   suitable technique, including but not limited to, parenterally, topically, or by inhalation. If
   injected, the pharmaceutical composition can be administered, for example, via intra
   articular, intravenous, intramuscular, intralesional, intraperitoneal or subcutaneous routes,
20 by bolus injection, or continuous infusion. Localized administration, e.g. at a site of disease
   or injury is contemplated, as are transdermal delivery and sustained release from implants.
   Delivery by inhalation includes, for example, nasal or oral inhalation, use of a nebulizer,
   inhalation of the antagonist in aerosol form, and the like. Other alternatives include
   eyedrops; oral preparations including pills, syrups, lozenges or chewing gum; and topical
25 preparations such as lotions, gels, sprays, and ointments.
           Use of antigen binding proteins in ex vivo procedures also is contemplated. For
   example, a patient's blood or other bodily fluid may be contacted with an antigen binding
   protein that binds PD-Li ex vivo. The antigen binding protein may be bound to a suitable
   insoluble matrix or solid support material.
30         Advantageously, antigen binding proteins are administered in the form of a
   composition comprising one or more additional components such as a physiologically
                                                   88

   acceptable carrier, excipient or diluent. Optionally, the composition additionally comprises
   one or more physiologically active agents, for example, a second inflammation- or immune
   inhibiting substance, an anti-angiogenic substance, an analgesic substance, etc., non
   exclusive examples of which are provided herein. In various particular embodiments, the
 5 composition comprises one, two, three, four, five, or six physiologically active agents in
   addition to a PD-Li binding antigen binding protein
   Combination Therapy
           In another aspect, the present disclosure provides a method of treating a subject with
   a PD-LI inhibiting antigen binding protein and one or more other treatments. In one
10 embodiment, such a combination therapy achieves synergy or an additive effect by, for
   example, attacking multiple sites or molecular targets in a tumor. Types of combination
   therapies that can be used in connection with the present invention include inhibiting or
   activating (as appropriate) multiple nodes in a single disease-related pathway, multiple
   pathways in a target cell, and multiple cell types within a target tissue.
15         In another embodiment, a combination therapy method comprises administering to
   the subject two, three, four, five, six, or more of the PD-Li agonists or antagonists described
   herein. In another embodiment, the method comprises administering to the subject two or
   more treatments that together inhibit or activate (directly or indirectly) PD-LI-mediated
   signal transduction. Examples of such methods include using combinations of two or more
20 PD-Li inhibiting antigen binding proteins, of a PD-Li inhibiting antigen binding protein
   and one or more other therapeutic moiety having anti-cancer properties (for example,
   cytotoxic agents, and/or immunomodulators), or of a PD-LI inhibiting antigen binding
   protein and one or more other treatments (e.g., surgery, or radiation). Furthermore, one or
   more anti-PD-LI antibodies or antibody derivatives can be used in combination with one or
25 more molecules or other treatments, wherein the other molecule(s) and/or treatment(s) do
   not directly bind to or affect PD-LI, but which combination is effective for treating or
   preventing the condition being treated. In one embodiment, one or more of the molecule(s)
   and/or treatment(s) treats or prevents a condition that is caused by one or more of the other
   molecule(s) or treatment(s) in the course of therapy, e.g., nausea, fatigue, alopecia, cachexia,
30 insomnia, etc. In every case where a combination of molecules and/or other treatments is
   used, the individual molecule(s) and/or treatment(s) can be administered in any order, over
                                                   89

   any length of time, which is effective, e.g., simultaneously, consecutively, or alternately. In
   one embodiment, the method of treatment comprises completing a first course of treatment
   with one molecule or other treatment before beginning a second course of treatment. The
   length of time between the end of the first course of treatment and beginning of the second
 5 course of treatment can be any length of time that allows the total course of therapy to be
   effective, e.g., seconds, minutes, hours, days, weeks, months, or even years.
            In another embodiment, the method comprises administering one or more of the PD
   LI antagonists described herein and one or more other treatments (e.g., a therapeutic or
   palliative treatment). Where a method comprises administering more than one treatment to a
10 subject, it is to be understood that the order, timing, number, concentration, and volume of
   the administrations is limited only by the medical requirements and limitations of the
   treatment, i.e., two treatments can be administered to the subject, e.g., simultaneously,
   consecutively, alternately, or according to any other regimen.
                                               Example 1
15          This example provides a characterization of the disclosed anti-PD-LI antibodies
   binding to human PD-LI expressed on human lymphocytes. Human peripheral blood
   mononuclear cells were activated by culture with anti-CD3 for three days to promote
   expression of PD-Li. Binding was assessed by adding serial dilutions of the antibody to the
   activated lymphocytes. After washing, binding was detected by staining with a
20 phycoerythrin labeled anti-human Ig reagent followed by analysis using a FACS Aria
   (Becton Dickinson, San Jose, CA). Since the anti-human Ig reagent reacts with
   immunoglobulin on B lymphocytes the cells were co-staining with an anti-human CD19
   APC-Cy5 reagent. Data were obtained by gating on the CD 19 negative lymphocytes and the
   results are shown in Figure 1. Both H6 and H10 antibodies show potent binding activity
25 with an EC50 in the 100 pM range.
                                               Example 2
            This example provides the results from binding the disclosed anti-PD-LI antibodies
   to human lymphocytes. Anti-PD-LI antibodies were assayed for binding to non-activated
   lymphocytes. Peripheral blood mononuclear cells were incubated with anti-PD-Li
30 antibodies (I ptg/ml) followed by washing. Binding of the anti-PD-LI antibody was detected
   by staining with a phycoerythrin conjugated and human Ig reagent. To identify the stained
                                                    90

   populations the cells were co-stained with an anti-CD3 FITC or an anti-CD56 APC reagent.
   Since the anti-human Ig reagent reacts with immunoglobulin on B lymphocytes the cells
   were also stained with an anti-human CD19 APC-Cy5 reagent. The data in Figure 2 were
   derived from the CD19 negative lymphocytes following analysis using a FACSAria (Becton
 5 Dickinson, San Jose, CA). The results show that CD56 positive NK cells, but not CD3+ T
   cells, react with the anti-PD-LI antibodies.
                                              Example 3
            This example provides a showing of the effect of disclosed anti-PD-LI antibodies on
   lymphocyte proliferation. Anti-PD-LI antibodies were assayed for their ability to modulate
10 the response of lymphocytes to stimulation. The anti-PD-Li antibodies HI, H6 and HiO
   were added at 10 pg/ml to cultures of peripheral blood mononuclear cells labeled with the
   fluorescent dye carboxyfluorescein (CFSE) and stimulated with anti-CD3 (I ng/ml). After
   three days of culture, the cells were assayed for proliferative activity by flow cytometry
   using a FACS Aria (Becton Dickinson, San Jose, CA). The results, shown in Figure 3, show
15 that the anti-PD-Li antibodies inhibited lymphocyte proliferation.
                                              Example 4
            This example provides a showing of the effect of NK cells on the disclosed anti-PD
   LI antibodies on mediated inhibition of proliferation. With the anti-PD-Li antibodies
   showing a preferential binding to NK cells, the significance of this in the inhibition of
20 proliferation was tested. By cell sorting using a FACS Aria (Becton Dickinson, Dan Jose,
   CA) purified population of CD4+, CD8+, CD56+ (NK) and monocytes were obtained. As a
   base culture, 1.5 x 105 CD4+ cells and 3 x 104 monocytes were stimulated with anti-CD3 (I
   ng/ml) with or without H10 anti-PD-LI antibody (10 tg/ml). In separate cultures, either
   CD8+ cells or NK cells (both at 3 x 104 ) were added to this base culture. After three days of
25 culture, cells were stained for expression of CD25 as a measure of lymphocyte activation as
   measured by flow cytometry. The results shown in Figure 4 were compared to those
   obtained using whole, unfractionated PBMC (1.5 x 105). The anti-PD-Li antibody inhibited
   the activation of lymphocytes in the cultures containing whole PBMC and those where NK
   cells were added, but not in the absence of NK cells.
30                                            Example 5
                                                  91

           This example provides a showing of an effect of anti-PD-Li on NK cell activation.
   Disclosed anti-PD-LI antibodies were assayed for their ability to promote the activation of
   lymphocytes. Peripheral blood mononuclear cells or purified populations of lymphocyte
   subsets isolated by cell sorting were cultured with IL-2 (100 U/ml) in the presence or
 5 absence of added anti-PD-LI antibodies (10 pg/ml). After five days of culture, cells were
   stained for expression of CD25 as a measure of cell activation and analyzed by flow
   cytometry. The results shown in Figure 5 reveal that H6 and H10 enhance cell activation
   and that the responsive lymphocyte population is the NK cell.
                                             Example 6
10         This example provides a showing of an effect of disclosed anti-PD-Li antibodies on
   the progression of disease in a murine model of multiple sclerosis (MS). Anti-PD-Li
   antibodies were assayed for their ability to modulate the course of disease in mice induced
   to develop experimental autoimmune encephalitis (EAE) as a model of MS. Disease was
   induced in C57Bl/6 mice following injection of myelin oligodendrocyte glycoprotein
15 (MOG) peptide and pertussis toxin. Once symptoms of disease developed, the mice were
   treated every second day with an intraperitoneal injection of anti-PD-LI antibody (0.1 mg).
   The results shown in Figure 6 provide that both anti-PD-LI antibodies H6 and H10
   impacted the course of disease development with H6 greatly reducing disease severity.
                                             Example 7
20         This example provides a characterization of the disclosed G12 anti-PD-LI antibody.
   rhPD-LI was immobilized on CM5 sensor chip using standard NHS/EDC coupling
   methodology. All measurements were conducted in HBS-EP buffer with a flow rate of 30
   pL/min. Antibody was diluted so as to obtain a series of concentrations. A 1:1 (Langmuir)
   binding model was used to fit the data.
25 Table 1 provides the binding data for G12.
                                       G12
                   koj (M-' s-')    1.31E+07
       Biacore       koff (s-1)     4.90E-04
                     Kd (M)         3.74E-II
                                             Example 8
           This example provides the results from an experiment showing that G12 blocks the
   interaction between rhPD- 1 and rhPD-L 1. A 96-well ELISA plate was coated with 1 ng/pL
                                                  92

   PD1/His at 4 'C overnight, then blocked with casein in PBS. Pre-mixed 20 tl serial 2-fold
   diluted IgGs (started from 20 ptg/ml) and 20 pl 0.25 pl/ml PD-L1/Fc and incubated the
   mixtures 30 min. washed the plate with PBS-Tween (PBST) 3 times. Transferred 25 tl the
   mixtures to the ELISA plate and incubated 30 min with shaking. Washed 3 times with
 5 PBST. Added HRP conjugated Goat anti-human Fc (1:500 in casein), used TMB as
   substrate and developed 30 min. 2M H 2 SO 4 was added to stop the reaction. Read the OD at
   450nm.
   Table 2
                                                                 G12
      Blocking PD-1/PD-Li interaction (M)            IC50     7.288E-11
                                               Example 9
10          This example illustrates in vitro EC50 data for the binding of G12 to human PD-Li
   expressed on the surface of CHO cells. This example shows the binding characteristic for
   this antibody in terms of the maximal cell binding and the concentration at which 50%
   binding saturation (EC 5 o) is reached. In this example, the experimental procedure is as
   follows: 50,000 CHO-PD-L1 cells were aliquoted into the wells of a 96-well, v-bottom plate
15 in 100 tl FACS Buffer (PBS + 2% FBS). A dilution curve of the antibody was made in
   FACS Buffer encompassing the concentrations shown in Figure 7. Cells were spun down,
   washed Ix with FACS Buffer, and then resuspended in 25 tl of antibody solution in
   triplicate. After 0.5 hr incubation, cells were washed Ix with FACS Buffer and resuspended
   in 50 ptl PE-conjugated, goat anti-human IgG (y-chain specific) secondary antibody
20 (Southern Biotech Cat #2040-09). Cells were further incubated for 0.5 hr and then washed
   Ix with FACS Buffer. Cells were resuspended in 25 ptl FACS Buffer and the median
   fluorescence intensity in the FL2-H channel was determined using the Intellicyt HTFC flow
   cytometer.
            Results: As shown in Figure 7 and Table 3, the cell binding EC50 for the G12 anti
25 PD-Li antibody on CHO-PD-L1 cells was 1.71E-09 M. Data was collected on the Intellicyt
   HTFC flow cytometer, processed using FlowJo software, and analyzed and plotted in Graph
   Pad Prizm using non-linear regression fit. Data points are shown as the median fluorescence
   intensity (MFI) of positively labeled cells +/- Std Error.
   Table 3
                                                     G12
                                                    93

    Cell Binding EC50 (M) CHO-PD-LI1             1.7E-09
                                             Example 10
           This example provides in vitro IC5 o data for the blocking of the interaction between
 5 recombinant human PD-i (PD-i-Fc Chimera; Sino Biologics) and human PD-Li expressed
   CHO cells by anti-PD-Li antibody G12. Here, CHO cells expressing PD-Li were pre
   incubated with G12 prior to the addition of rhPD-I-Fc chimeric protein. After incubation
   and washing, PD-I binding to cell surface expressed PD-LI was detected using an Alexa
   Fluor 647 tagged anti-PD-I antibody by flow cytometry (Intellicyt HTFC; FL-4H). This
10 example shows that anti-PD-Li monoclonal antibody G12 was able to inhibit efficiently the
   binding of PD-i to PD-Li expressed on the surface of CHO cells.
           Results: As shown in Figure 8 and Table 4, the IC 50 for blocking of the PD-i/PD-Li
   cellular interaction by G12 is 1.76E-09 M. Data was collected on the Intellicyt HTFC flow
   cytometer, processed using FlowJo software, and analyzed and plotted in Graph Pad Prizm
15 using non-linear regression fit. Data points are shown as the median fluorescence detected in
   the FL-4H channel +/- Std Error.
   Table 4
                                                                        G12
         Inhibition of PD-1/PD-Li             CHO-PD-Li/             1.76E-09
           Interaction IC50 (M)                rhPD-I-Fc
                                                                                 20
                                             Example 11
   This example illustrates in vitro EC50 data for the binding of G12 to PD-Li expressed on the
   surface of ES-2 human ovarian carcinoma cells. This example shows the binding
   characteristic for this antibody in terms of the maximal cell binding and the concentration at
25 which 50% binding saturation (EC 5 o) is reached. In this example, the experimental
   procedure is as follows: ES-2 cells were treated with 500IU/ml IFNy for 18 hours to
   increase PD-Li levels above basal expression. After induction, 50,000 ES-2 cells were
   aliquoted into the wells of a 96-well, v-bottom plate in 100 Pl FACS Buffer (PBS + 2%
   FBS). A dilution curve of the antibody was made in FACS Buffer encompassing the
30 concentrations shown in Figure 9. Cells were spun down, washed Ix with FACS Buffer, and
   then resuspended in 25 pl of antibody solution in triplicate. After 0.5 hr incubation, cells
   were washed Ix with FACS Buffer and resuspended in 50 p1 PE-conjugated, goat anti
                                                   94

   human IgG (y-chain specific) secondary antibody (Southern Biotech Cat #2040-09). Cells
   were further incubated for 0.5 hr and then washed Ix with FACS Buffer. Cells were
   resuspended in 25 pl FACS Buffer and the median fluorescence intensity in the FL2-H
   channel was determined using the Intellicyt HTFC flow cytometer.
 5         Results: As shown in Figure 9 and Table 5, the cell binding EC50 for the G12 anti
   PD-Li antibody on ES-2 ovarian carcinoma cells was 4.58E-11 M. Data was collected on
   the Intellicyt HTFC flow cytometer, processed using FlowJo software, and analyzed and
   plotted in Graph Pad Prizm using non-linear regression fit. Data points are shown as the
   median fluorescence detected in the FL-2H channel +/- Std Error. Cell binding EC5 0 for
10 anti-PD-Li mAb G12 against human PD-Li expressed on ES-2 ovarian cancer cells after
   treatment with 500 IU/ml recombinant hIFNy for 18hr is shown in Table 5.
   Table 5
                                               G12    15
    Cell Binding EC50 (M)       ES-2        4.58E-11
                                             Example 12
20         This example provides a mixed lymphocyte reaction (MLR) to evaluate the effect of
   the antibodies on lymphocyte activity in lymphocyte effector cells. IL-2 secretion was
   measured in the presence or absence of an anti-PD-LI human monoclonal antibody (Figure
   10). The functional activity of the antibodies was assessed in an allogeneic mixed
   lymphocyte reaction (MLR) consisting of purified CD4+ T lymphocytes and allogeneic
25 dendritic cells. The antibodies used were the disclosed G12 antibody as compared to prior
   disclosed antibodies IOA5 and 12A4 (Bristol-Myers/Medarex) that were obtained via in
   house production from prior-disclosed antibody sequences (U.S. Patent Application
   2009/0055944 the disclosure of which is incorporated by reference herein). To prepare the
   dendritic cells, monocytes, purified using a discontinuous Percoll gradient, were cultured
30 with GM-CSF (1,000 U/ml) plus IL-4 (500 U/ml) for seven days. The CD4+ cells were
   prepared by negative selection using biotinylated antibodies reactive with CD8, CD16,
   CD19 and CD20. Removal of the reactive cells was achieved using biotin binding magnetic
   beads. The antibodies were added at the indicated concentrations to wells containing 105
                                                  95

   CD4+ cells labeled with carboxyfluorecein (CFSE) and 104 dendritic cells. After five days
   of culture, supernatants were harvested for cytokine determination.
                                               Example 13
            This example provides a mixed lymphocyte reaction (MLR) was employed to
 5 demonstrate the effect of blocking the PD-Li/PD-i pathway by the anti-PD-Li antibodies
   on lymphocyte effector cells. T cell activation was measured in the presence or absence of
   the anti-PD-Li human monoclonal antibody (Figure 12). The functional activity of the
   antibodies was assessed in an allogeneic mixed lymphocyte reaction (MLR) consisting of
   purified CD4+ T lymphocytes and allogeneic dendritic cells. The antibodies used were the
10 disclosed H6BiL, RSAi, RA3, RC5, SHiE2, SHiE4, SHiB 1i, and SHiC8 as compared to
   prior disclosed antibodies i0A5 (Bristol-Myers-Squibb/Medarex) and YW243.55S70
   (Roche/Genentech) that were obtained via in-house production from prior-disclosed
   antibody sequences (U.S. Patent Application 2009/0055944 and U.S. Patent Application US
   2010/0203056; the disclosure of which are incorporated by reference herein). To prepare
15 the dendritic cells, monocytes, purified using a discontinuous Percoll gradient, were cultured
   with GM-CSF (1,000 U/ml) plus IL-4 (500 U/ml) for seven days. The CD4+ cells were
   prepared by negative selection using biotinylated antibodies reactive with CD8, CD16,
   CD19 and CD20. Removal of the reactive cells was achieved using biotin binding magnetic
   beads. The antibodies were added at the indicated concentrations to wells containing 105
20 CD4+ cells labeled with carboxyfluorecein (CFSE) and 104 dendritic cells. After five days
   of culture, the cells were collected and stained for CD25 expression as a measure of cell
   activation. Cell activation was measured by flow cytometry.
            The results for cell activation are shown in Figure 13. With all anti-PD-Li antibodies
   there was an increase in cell activation. In Figure 13, the data are expressed as a percentage
25 of test value with of the respect to that obtained in the absence of any added antibody. In
   this way, the percent increase in cell activation was realized.
                                               Example 14
            The ability of anti-PD-Li antibodies to modulate immune responsiveness was
   assessed using a mixed lymphocyte reaction (MLR). With this assay, the effects anti-PD-LI
30 antibodies on cell activation and the production of IL-2 were measured. The MLR was
   performed by culturing 105 purified human CD4+ cells from one donor with 104 monocyte
                                                   96

   derived dendritic cells prepared from another donor. To prepare the dendritic cells, purified
   monocytes were cultured with GM-CSF (1,000 U/ml) and IL-4 (500 U/ml) for seven days.
   Anti-PD-Li or control antibodies were added to the allogeneic MLR cultures at 10 pg/ml
   unless stated otherwise. Parallel plates were set up to allow collection of supernatants at day
 5 3 and at day 5 to measure IL-2 using a commercial ELISA kit (Biolegend). The antibodies
   used were the disclosed H6B1L, RSA1, RA3, RC5, SH1E2, SH1E4, SHiBi 1, and SH1C8
   as compared to prior disclosed antibodies 1OA5 (Bristol-Myers-Squibb/Medarex) and
   YW243.55S70 (Roche/Genentech) that were obtained via in-house production from prior
   disclosed antibody sequences (U.S. Patent Application 2009/0055944 and U.S. Patent
10 Application US 2010/0203056; the disclosure of which are incorporated by reference
   herein).
            Production of IL-2 was enhanced by the addition of the anti-PD-LI antibodies.
                                            Example 15
                   This example provides a mixed lymphocyte reaction (MLR) was employed to
15 demonstrate the effect of blocking the PD-Li/PD-1 pathway by the anti-PD-Li antibodies
   on lymphocyte effector cells. IFN-y secretion was measured in the presence or absence of
   the anti-PD-LI human monoclonal antibody (Figure 11). The functional activity of the
   antibodies was assessed in an allogeneic mixed lymphocyte reaction (MLR) consisting of
   purified CD4+ T lymphocytes and allogeneic dendritic cells. The antibodies used were the
20 disclosed H6BIL, RSAI, RA3, RC5, SHIE2, SHIE4, SHiBi 1, and SH1C8 as compared to
   prior disclosed antibodies 10A5 (Bristol-Myers-Squibb/Medarex) and YW243.55S70
   (Roche/Genentech) that were obtained via in-house production from prior-disclosed
   antibody sequences (U.S. Patent Application 2009/0055944 and U.S. Patent Application US
   2010/0203056; the disclosure of which are incorporated by reference herein).
25 To prepare the dendritic cells, monocytes, purified using a discontinuous Percoll gradient,
   were cultured with GM-CSF (1,000 U/ml) plus IL-4 (500 U/ml) for seven days. The CD4+
   cells were prepared by negative selection using biotinylated antibodies reactive with CD8,
   CD 16, CD19 and CD20. Removal of the reactive cells was achieved using biotin binding
   magnetic beads. The antibodies were added at the indicated concentrations to wells
30 containing 105 CD4+ cells labeled with carboxyfluorecein (CFSE) and 104 dendritic cells.
   After five days of culture, supernatants were harvested for cytokine determination.
                                                 97

    Production of IFN-y was enhanced by the addition of the anti-PD-Li antibodies.
                                  Sequence Listing
          Heavy chain variable domain region            Light chain variable domain region
          QMQLVQSGAEVKKPGSSVKVSCKASGGTFNTYAIS           DIVMTQTPYSVSASVGDRVTITCRASQEVSR
          WVRQAPGQGLEWMGGIIPLFGKADYAQKFQDRVT            WVAWYQQKPGQAPKSLIYASSRLQSGVPS
          ITADESTSTAYMELSSLRSEDTAVYYCARDKGREELG         RFTASGSGTDFTLVISSLQPEDFATYYCQQYS
E6        GNYYYAVDVWGPGTTVTVSS SEQ ID NO. 1             RFPLTFGGGTKVEIK SEQ ID NO. 2
          QVQLQQLGPGLVKPSQTLSLTCAISGDSVSSNSAA           QPVLTQPASVSGSPGQSITISCTGTSSDVGG
          WNWIRQSPSRGLEWLGRTYYRSKWYTNYAVSMRS            YNYVSWYQQHPGKAPKLMVYDVSKRPSGV
          RITINPDTSKNQFSLQLNSVTPEDTAVYFCAGGNSSS         SNRFSGSKSGNTASLTISGLQTEDEADYYCSS
E7        HDDYWGQGTLVTVSS SEQ ID NO. 3                  YTSSNTRVFGTGTKLTVL SEQ ID NO. 4
          EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISW          DIVMTQSPSTLSASVGDRVTITCRASQSFTT
          VRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVT             YLAWYQQKPGKAPKLLIYQTSNLESGVPSRF
          MTTDTSTSTAYMELRSLRSDDTAVYYCARDLFPTIF          SGSGSGTEFTLTISSLQPDDFATYYCQQYSRY
E9        WEGGAFDIWGQGTMVTVSS SEQ ID NO. 5              WWSFGQGTRLEIK SEQ ID NO. 6
          EVQLVQSGAEVKKPGASLKVSCKASGYTFNSYDINW          AIQMTQSPSSLSASVGDRVTITCRASQSISSY
          VRQAPGQGLEWMGWINPNSGGTNYAQKFQGRV              LNWYQQKPGKAPKLLIYAASSLQSGVPSRFS
          TMTRDTSTSTVYMELSSLTSEDTAVYYCARDLFPHIY         GSGSGTDFTLTISSLQPEDFATYYCQQSSSTP
Eli       GNYYGMDIWGQGTTVTVSS SEQ ID NO. 7              LTFGQGTKVEIK SEQ ID NO. 8
          QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMH           QAVLTQPRSVSGSPGQSVTISCTGTSSDVG
          WVRQAPGKGLEWVAVISFDGSNKYYADSVRGRFTI           GYNYVSWYQQHPGKAPKLMIYDVRTRPSG
          SRDNSKNTLYLQMNSLRTEDTAVYYCARGWLDRDI           VSDRFSGSKSGNTASLSISGLQAEDEADYYC
Fl        DYWGQGTLVTVSS SEQ ID NO. 9                    SSHSSSTTVIFGGGTKLTVL SEQ ID NO. 10
          EVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYM H          DIVMTQSPSSLSASVGDRVTITCRASQSISSY
          WVRQAPGQGLEWMGWI NPNSDNTGSAQKFQGR             LNWYQQKPGKAPKLLIYAASSLQSGVPSRFS
          VFMTKTTSLNTAYM ELSGLRSEDTAIYYCARERSSGY        GSGSGTDFTLTISSLQPEDFATYYCQQSYSTP
F4        FDFWGQGTLVTVSS SEQ ID NO. 11                  ITFGQGTRLEIK SEQ ID NO. 12
          EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYWMS           QAVLTQPPSVSAAPGQRVTISCSGSNSN IAD
          WVRQAPGKGLEWVAN IKQDGSEKYYVDSVKGRFTI          TYVSWYQQLPGTAPRLLIYDN DQRPSGIPD
          SRDNAKNSLYLQMNSLRAEDTAVYYCAREGEHDAF           RFSGSKSGTSATLGITGLQTGDEADYYCGT
F7        DIWGQGTMVTVSS SEQ ID NO. 13                   WDSSLSGVFGTGTKVTVL SEQ ID NO. 14
          QVQLVQSGGGVVQPGRSPRLSCAASG FTFNTYGM           QSVLTQPASVSGSPGQSVTISCTGTSSDVGG
          HWVRQAPGKGLEWVAVISDGGNNKKYADSVKGRF            FNSVSWYQQHPGKAPKLMIYDVSKRPSEIS
          TISRDNAKNSLYLQM NSLRAEDTALYYCAKDIGESYY        DRFSGSKSGNTASLTISGLQPEDEADYYCSSY
F8        YYMDVWGKGTTVTVSS SEQ ID NO. 15                TSSSTLVFGGGTKLTVL SEQ ID NO. 16
          QVQLQQSGPGLVKPSQSLSLTCAISGDSLSSNSAAW          SYVLTQPPSVSVSPGQTASISCSGYKLENKYV
          NWIRQSPSGGLEWLGRTYYRSKWYNEYVESLKSRIT          SWYQQRAGQSPVLVIYQDNKRPSGIPERFS
          INSDISRNQFSLHLNSVTPEDTAVYYCASGTGARGM          GSNSGNTASLTITGLQPEDEADYYCSAWDS
Fl        DVWGQGTTVTVSS SEQ ID NO. 17                   SLRAWVFGGGTQLTVL SEQ ID NO. 18
                                          98

    QVQLQQSG PG LVKPS ETLS LTCAISG DSVS ENSAAW QPVLTQPPSVSVSPGQTASITCSG DELG NKY
    NWIRQSPSGGLEWLGRTYYRSKWYNEYVESLKSRIT       VYWYQQKPGRSPVLVIYQDSKRPSGFPARF
    INSDISRNQFSLH LNSVTPE DTAVYYCASGTGARG M    SGANSG NTATLTISGTQAM DEADYFCQAW
G4  DVWGQGTTVTVSS SEQ ID NO. 19                DSSTAWVFGGGTKLTVL SEQ ID NO. 20
    EVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYM H       DIVMTQSPSSLSASVGDRVTITCRASQSISSY
    WVRQAPGQGLEWMGWI NPNSDNTGSAQKFQGR          LNWYQQKPGKAPKLLIYAASSLQSGVPSRFS
    VFMTKTTSLNTAYM ELSGLRSEDTAIYYCARERSSGY     GSGSGTDFTLTISSLQPEDFATYYCQQSYSTP
G9  FDFWGQGTLVTVSS SEQ ID NO. 21               ITFGQGTRLEIK SEQ ID NO. 22
    QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRYGVH        LPVLTQPASVSGSPGQSVTISCTGTSSDVGG
    WVRQAPGQGLEWMG RLI PIVSMTNYAQKFQDRV        HNYVSWYQQHPGKAPKLM IYEVN KRPSGV
    SITTDKSTGTAYM ELRSLTSEDTALYYCASVGQQLP      PDRFSGSKSDYTASLTISGLQPDDEADYFCSS
G11 WVFFAWGQGTLVTVSS SEQ ID NO. 23             YTATTTGVVFGTGTKVTVL SEQ ID NO. 24
    EVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYM H       DIVMTQSPSSLSASVGDRVTITCRASQSISSY
    WVRQAPGQGLEWMGWI NPNSDNTGSAQKFQGR          LNWYQQKPGKAPKLLIYAASSLQSGVPSRFS
    VFMTKTTSLNTAYM ELSGLRSEDTAIYYCARERSSGY     GSGSGTDFTLTISSLQPEDFATYYCQQSYSTP
G12 FDFWGQGTLVTVSS SEQ ID NO. 25               ITFGQGTRLEIK SEQ ID NO. 26
    QVQLVQSGAEVKKPGASVKVSCKTSGNTFTNYYM H       DIVMTQSPPSLSASVGDRVTITCRASQSISSY
    WVRQAPGQGLEWMG IMNPSGGSTSYAQKFQGR          LNWYQQKPGKAPKLLIYAASSLQSGVPSRFS
    VTMTRDKSTSTVYM ELSSLTSEDTAVYYCARDLFPHI     GSGSGTDFTLTISSLQPEDFATYYCQQSYSTP
HI  YGNYYGMDIWGQGTTVTVSS SEQ ID NO. 27         YTFGQGTKVEIK SEQ ID NO. 28
    QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISW       QSVVTQPPSVSAAPGQKVTISCSGSTSNI EN
    VRQAPGQGLEWMGG1lPIFGTASYAQKFQGRVTIT        YSVSWYQQLPGTAPKLLIYDNNKRPSGIPDR
    ADESTTTAYM ELSSLRSEDTAVYYCAREGPEYCSGG      FSGSKSGTSATLGITGLQTGDEADYYCGTW
H3  TCYSADAFDIWGQGTMVTVSS SEQ ID NO. 29        DNRLSSVVFGGGTKVTVL SEQ ID NO. 30
                                               QPVLTQPPSVSAAPGQKVTISCSGSSSNIGN
    QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISW       SHVSWFQQLPGTAPKLVIYDNDKRPSGIAD
    VRQAPGQGLEWMGRIlPILGIANYAQKFQGRVTITA       RFSGSKSGTSATLGITGLQTGDEADYYCGT
    DKSTSTAYMELSSLRSEDTAVYYCARSESGSYSHDY       WDSSLSAGVFGGGTKLTVL SEQ ID NO.
H4  WGQGTTVTVSS SEQ ID NO. 31                  32
                                               QAVVTQPPSASGTPGQRVTISCSGSSSNVG
    QVQLVESGAEVKKPGASVKVSCKASGYTFTSYYIHW       VNHVFWYQHLPGMAPKLLIHRTNQWPSG
    VRQAPGQGLEWMGINPSGGSTTYAQKFQGRVSM          VPDRFSGSKSGTSATLGITGLQTGDEADYYC
    TRDTSTRTVYMELSGLISDDTAIYYCARDDDFYSGYP      GTWDSSLSAVFGGGTKLTVL SEQ ID NO.
H5  GDYWGQGTLVTVSS SEQ ID NO. 33               34
    QMQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIS        SYELMQPPSVSVAPGKTATIACGGENIGRKT
    WVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVT         VHWYQQKPGQAPVLVIYYDSDRPSGIPERF
    ITADESTSTAYMELSSLRSEDTAVYYCARGNIVATITP     SGSNSGNTATLTISRVEAGDEADYYCQVWD
H6  LDYWGQGTLVTVSS SEQ ID NO. 35               SSSDHRIFGGGTKLTVL SEQ ID NO. 36
    EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYSMN        EIVLTQSPSSLSASIGDRVTLTCRASQSIRRFL
    WVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISR      NWYQQKPGKAPELLIYTASSLQSGVPSRFSG
    DNAKNSLYLQMNSLRDEDTAVYYCARGDYYYGMD         SGSGTDFTLTINSLQPEDFATYYCQQSYAVS
HiO VWGQGTTVTVSS SEQ ID NO. 37                 PYTFGQGTKVEIR SEQ ID NO. 38
                                  99

        QM QLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIS     QSVVTQPPSVSAAPGQKVTISCSGSSSN IGN
        WVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVT       NYVSWYQQLPGTAPKLLIYDNNKRPSGIPD
        ITADESTSTAYM ELSSLRSEDTAVYYCARGD FWSGY   RFSGSKSGTSATLG ITG LQTGD EADYYCGT
H12     RTYYYYYGMDVWGQGTMVTVSS SEQ ID NO. 39     WDSSLSAVVFGGGTKLTVL SEQ ID NO. 40
        QVQLVQSGAEVKKPGASVKVSCKTSGYTFTS NAIG     ALTQPASVSGSLGQSITISCTGSSSDVGGYKY
        WVRQAPGQGLEWMGWISAYNGNTNYAQNLQGR         VSWYQQHPGKAPKLM IYDVINRPSGVSSRF
        VTMTTDTSTSTAYM ELRS LRSD DTAVFYCARKGTG L SGSKSANTASLTISG LQAEDEADYYCFSYSSR
PDL-D2  HFDYWGQGTLVTVSS SEQ ID NO. 41            STRIFGSGTKVTVL SEQ ID NO. 42
                                                 QTVVTQPPSVSKDLGQTATLTCTGNN NNV
        QVQLQQSG PG LVKPSQTLSLTCAISG DSVSSNSAA   GNHGAAWLQQHQG HPPKLLSYRN NNRPS
        WNWI RQSPSRG LEWLG RTYYRSKWYN DYAVSVKS   GISE RLSASRSG NTASLTITG LQPEDEADYYC
        RITI NPDTS KNQFSLQLNSVTPEDTAVYYCARGAAG   SAWDRSLSAWVFGGGTKLTVL SEQID
PDL-D11 RAFDIWGQGTMVTVSS SEQ ID NO. 43           NO. 44
        EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYSMN      EIVLTQSPSSLSASIGDRVTLTCRASQSIRRFL
        WVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISR    NWYQQKPGKAPELLIYTASSLQSGVPSRFSG
        DNAKNSLYLQMNSLRDEDTAVYYCARGDYYYGMD       SGSGTDFTLTINSLQPEDFATYYCQQSYAVS
PDL-H1  VWGQGTTVTVSS SEQ ID NO. 45               PYTFGQGTKVEIK SEQ ID NO. 46
        EVQLVESGGGLVQPGGSLRLSCAASGFYLGSYWMA      QSVLTQPASVSGSPGQSISVSCTGTSSDVGR
        WVRQAPGKGLEWVAAIRQDGSETYVDSVKGRFIIS      YNFVSWYQQHPGKAPKLMVFDVSNRPSGI
        RDNGGNSVTLQMTTLRAGDTAVYYCARAHYFGFD       SNRFSGSKSGNTASLTISGLQAEDEADYYCS
RB4     NWGQGTLVTVSS SEQ ID NO. 47               SYTTNSTYVFGSGTKVTVL SEQ ID NO. 48
                                                 QPVLTQPPSVSAAPGQKVTISCSGSSSN IAN
        QMQLVQSGAEVKKPGASVKISCKASGYPFRNYYIH      NYVSWYQQLPGTAPKLLIFANNKRPSGIPD
        WVRQAPGQGLEWVGINPDGGTITYAGKFQGRVS        RFSGSKSGTSAALDITGLQTGDEADYYCGT
        MTRDTSTSTVYMELSSLTSEDTAVYYCARDLFPHIYG    WDSDLRAGVFGGGTKLTVL SEQ ID NO.
RB11    NYYGMDIWGQGTTVTVSS SEQ ID NO. 49         50
        EVQLLESGGGVVQPGGSLRLSCAASGFTFSSYWMS      AIRMTQSPSSLSASVGDRVTITCRASQSISSY
        WVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTI      LNWYQQKPGKAPKLLIYTTSSLKSGVPSRFS
        SRDNSKNTVSLQMNSLRAEDTAVYYCAKDRYYNFP      GSGSGTDFTLTISRLQPEDFATYYCQQSYSST
RC5     LGMDVWGQGTTVTVSS SEQ ID NO. 51           WTFGRGTKVEIK SEQ ID NO. 52
        EVQLLESGAEVKKPGSSVKVSCKSSGDTFTNFAINWI    QSVLTQPASVSGSPGQSITISCTGTSSDVGSY
        RQAPGQGLEWMGRIIPLFGTTNYAQKFQGRVTITA      NLVSWYQQYPGKAPKLMIYEVSERPSGVPD
        DESTSTAFMDLNSLTSEDTAVYYCARTLGGDYYDSR     RFSGSKSGNTASLTVSGLQAEDEADYYCSSY
RF5     GYYNWGQGTLVTVSS SEQ ID NO. 53            TDSNNFRVFGGGTKLTVL SEQ ID NO. 54
        QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSVV      EIVMTQSPSSLYASVGDRVTITCRASQSISSY
        WNWFRQSPSRGLEWLGRAYYRSKWYNDYAVSVKS       LNWYQQKPGKVPKLLIYAASSLQSGVPSRFS
        RITINPDTSKNQLSLQLNSVTPEDTAVYYCAKGLDV     GSGSGTDFTLTISGLQPEDFATYYCQQSYTP
RG9     WGQGTTVTVSS SEQ ID NO. 55                AWTFGQGTKLEIK SEQ ID NO. 56
                                                 QSVVTQPPSVSAAPGQKVTISCSGSSSNIGN
        QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISW     NYVSWYQQVPGTAPKLLIYDNDKRPSGIPD
        VRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTIT      RFSGSKSGTSATLAITGLQTGDEADYYCGT
        ADESTSTAYMELSSLRSEDTAVYYCARDGIVADFQH     WDSSLNAWVFGGGTKLTVL SEQ ID NO.
RD1     WGQGTLVTVSS SEQ ID NO. 57                58
        QVQLVQSGAEVKKPGASVRVSCKASGGTFSSYAIS      QSVLTQPPSVSAAPGQKVTISCSGSSSNIEN
        WVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVT       NYVSWYQHLPGTAPKLLIYDDFKRPSGIPDR
        ITADESTSTAYMELSSLRSEDTAVYYCARDGIVADFQ    FSGSKSGTSATLGITGLQTGDEADYYCGTW
RF11    HWGQGTLVTVSS SEQ ID NO. 59               DSSLSAVVFGGGTKLTVL SEQ ID NO. 60
                                    100

                                               QSVLTQPPSASGSPGQSVTISCTGTSSDVGG
     QM QLVQSGAEVKKPGSSVKVSCKASGGTFNSYPIS      YNYVSWYQQH PGKAPKLM IYEVSKRPSGV
     WVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVT        PDRFSGSKSGNTASLTVSGLQAEDEADYYCS
     ITADESTSTAYMELSSLRSEDTAMYYCAKNHPTATL      SYAGSNNLGVFGGGTKLTVL SEQ ID NO.
RHI  DYWGQGTLVTVSS SEQ ID NO. 61               62
     QVQLVQSGG NLVKPGGSLRLSCAASG FSFSSYD MN    DIQLTQSPSSLSASVG DRVTITCRASQG ISS
     WVRQAPG RG LEWVSSISGTG RYEYYSPSVKG RFTIS  WLAWYQQKPG KAPKLLIYAASSLQSGVPSR
     RD NANTS LYLQM NSLTADDTAVYFCTRG DI LTGASA FSGSGSGTD FTLTISSLQPED FATYYCQQAN
RD9  MDVWGQGTTVTVSS SEQ ID NO. 63              SFPLTFGGGTKVEIK SEQ ID NO. 64
     EVQLLESGGNLVKPGGSLRLSCAASGFSFSSYDM N      DVVMTQSPSTLSASVG DRVTITCRASQSIGT
     WVRQAPG RG LEWVSSISGTG RYEYYSPSVKG RFTIS  WLAWYQQKPG KAPN LLIYKASSLESGVPS R
     RD NANTS LYLQM NSLTADDTAVYFCTRG DI LTGASA FSGSGSGTE FTLTISSLQPDD FATYYCQQAN
RE10 MDVWGQGTTVTVSS SEQ ID NO. 65              SFPLTFGGGTKVEIK SEQ ID NO. 66
     QM QLVQSGAEVKKPGSSVKVSCKASGGTFSRYGVH      DIQMTQSPSSLSASVG DRVTITCQASQD ISN
     WVRQAPGQG LEWMG RLI PIVSMTNYAQKFQDRV      YLNWYQQKPGKAPKLLIYDASTLQSGVPSR
     SITTDKSTGTAYM ELRSLTSEDTALYYCASVGQQLP     FSGSGSGTD FTLTISSLQPED FATYYCQQSYS
RA3  WVFFAWGQGTLVTVSS SEQ ID NO. 67            SHWTFGQGTKVEIK SEQ ID NO. 68
     EVQLVQSGAEVKKPGSSVKVSCKASGGTFSRYGVH       QSVVTQPPSVSGAPGQRVTISCTGSSSN IGA
     WVRQAPGQGLEWMGRLIPIVSMTNYAQKFQDRV         GYGVHWYQHLPGSAPKLLIYGNSNRPSGVT
     SITTDKSTGTAYM ELRSLTSEDTALYYCASVGQQLP     DRISGSKSGTSASLAITG LQAEDEAVYYCQSY
RG1  WVFFAWGQGTLVTVSS SEQ ID NO. 69            DSSLSTSVVFGGGTKLTVL SEQ ID NO. 70
     QMQLVQSGGGLIQPGGSLRLSCAASGFTFSSYAM H      QAG LTQPASVSGSPGQSITISCTGTSSDVGG
     WVRQAPG KG LEWVAVISFDGSN KYYADSVRG RFTI   YNYVSWYQQH PGKAPKLM IYDVTKRPSGV
     SRDNSKNTLYLQMNSLRTEDTAVYYCARGWLDRDI       SNRFSGSKSGNTASLTISGLQAEDEANYYCS
RB1  DYWGQGTLVTVSS SEQ ID NO. 71               SYTSRSTSVLFGGGTKLTVL SEQ ID NO. 72
     EVQLVESGGGVVLPGRSLRLSCAASGFTFSSYAMH       QPVLTQPPSVSEAPRQRVTISCSGSSSNIGH
     WVRQAPGKGLEWVAVISFDGSNKYYADSVRGRFTI       NAVTWYQQVPGKAPKLLIYYDDLLPSGVSD
     SRDNSKNTLYLQMNSLRTEDTAVYYCARGWLDRDI       RFSGSKSGTSASLAISGLQSEDEADYYCAAW
RG7  DYWGQGTLVTVSS SEQ ID NO. 73               DDSLNGWVFGGGTKLTVL SEQ ID NO. 74
                                               QAGLTQPASVSGSPGQSITISCTGTSSDVGG
     QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMH       YNYVSWYQQHPGKAPKLMIYDVSNRPSGV
     WVRQAPGKGLEWVAVISFDGSNKYYADSVRGRFTI       PDRFSGSKSGNTASLTISGLQAEDDADYYCA
     SRDNSKNTLYLQMNSLRTEDTAVYYCARGWLDRDI       SYTSTSTLGVVFGGGTKLTVL SEQ ID NO.
RA6  DYWGQGTLVTVSS SEQ ID NO. 75               76
     QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMH       QPVLTQPASVSGSPGQSITISCTGTSSDVGG
     WVRQAPGKGLEWVAVISFDGSNKYYADSVRGRFTI       YNYVSWYQHHPGKAPKLMIFDVNKRPSGV
     SRDNSKNTLYLQMNSLRTEDTAVYYCARGWLDRDI       SNRFSGSKSGNTASLTISGLQAEDEADYYCN
RA8  DYWGQGTLVTVSS SEQ ID NO. 77               SYTTSSTYVVFGGGTKLTVL SEQ ID NO. 78
                                               QSVLTQPPSASGTPGQRVTISCSGSSSNIGS
     QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMH       NTVHWYQQLPGTAPKVLYTNNQRPSGVP
     WVRQAPGKGLEWVAVISFDGSNKYYADSVRGRFTI       DRFSGSKSGTSASLAISGLQSEDEADYYCAA
     SRDNSKNTLYLQMNSLRTEDTAVYYCARGWLDRDI       WDGRLQGWVFGGGTKLTVL SEQ ID NO.
RA9  DYWGQGTLVTVSS SEQ ID NO. 79               80
     QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMH       QSVVTQPPSVSAAPGQKVTISCSGSNSN IAN
     WVRQAPGKGLEWVAVISFDGSNKYYADSVRGRFTI       NYVSWYQQLPGTAPKLLIYDSNKRPSGIPDR
     SRDNSKNTLYLQMNSLRTEDTAVYYCARGWLDRDI       FSGSKSGTSATLGITGLQTGDEADYYCGSW
RB5  DYWGQGTLVTVSS SEQ ID NO. 81               DSSLSVWMFGGGTKLTVL SEQ ID NO. 82
                                 101

                                               LPVLTQPRSVSGSPGQSVTISCTGTSSDVGG
      QVQLVESGGGVVQPG RSLRLSCAASG FTFSSYAM H YNYVSWYQQH PGKAPKLM IYDVTKRPSGV
      WVRQAPG KG LEWVAVISFDGSN KYYADSVRG RFTI  PDRFSGSKSG NTASLTISGLQAED EADYYCS
      SRDNSKNTLYLQMNSLRTEDTAVYYCARGWLD RDI     SYTGSSTLGPVFGGGTKLTVL SEQ ID NO.
RB8   DYWGQGTLVTVSS SEQ ID NO. 83              84
      EVQLVESGGGVVQPG RSLRLSCAASG FTFSSYAM H QSVLTQPPSVSAAPGQKVTISCSG NSSN IGN
      WVRQAPG KG LEWVAVISFDGSN KYYADSVRG RFTI  NYVSWYQQLPGTAPKLLIYDN DKRPSG IPD
      SRDNSKNTLYLQMNSLRTEDTAVYYCARGWLDRDI      RFSGSKSGTSASLAISELRFEDEADYYCAAW
RC8   DYWGQGTLVTVSS SEQ ID NO. 85              DDTLSGHVFGPGTKLTVL SEQ ID NO. 86
                                               SYELMQPPSVSVPPGETARITCGGN NIGNK
      EVQLVESGGGVVQPG RSLRLSCAASG FTFSSYAM H NVHWYQQKPGQAPVLVVREDSARPAG IPE
      WVRQAPG KG LEWVAVISFDGSN KYYADSVRG RFTI  RFSGSNSG NSATLTISRVEAG DEADYYCQV
      SRDNSKNTLYLQMNSLRTEDTAVYYCARGWLDRDI      WDNTSDHVVFGGGTKLTVL SEQ ID NO.
RC10  DYWGQGTLVTVSS SEQ ID NO. 87              88
                                               SYELMQPPSVSEVPGQRVTISCSGSSSN IGN
      QVQLVESGGGVVQPG RSLRLSCAASG FTFSSYAM H NAVNWFQQLPG KAPKLLVYYDDWVPSG IS
      WVRQAPG KG LEWVAVISFDGSN KYYADSVRG RFTI  GRFSASKSGTSASLAISG LQSG DEGDYYCAV
      SRDNSKNTLYLQMNSLRTEDTAVYYCARGWLDRDI      WDDRLSGVVFGGGTKLTVL SEQ ID NO.
RD2   DYWGQGTLVTVSS SEQ ID NO. 89              90
      QVQLVESGGGVVQPG RSLRLSCAASG FTFSSYAM H QSVVTQPPSVSAAPGQKVTISCSGSSSN IGN
      WVRQAPG KG LEWVAVISFDGSN KYYADSVRG RFTI  NYVSWYQQLPGTAPTLLIYDSN KRPSVI PD R
      SRDNSKNTLYLQMNSLRTEDTAVYYCARGWLDRDI      FSGSKSGTSATLGITGLQTGDEADYYCGTW
RE8   DYWGQGTLVTVSS SEQ ID NO. 91              DDSLNGWVFGGGTKLTVL SEQ ID NO. 92
      EVQLVESGGGVVQPG RSLRLSCAASG FTFSSYAM H QSALTQPASVSGSPGQSITISCTGTSSDVGG
      WVRQAPG KG LEWVAVISFDGSN KYYADSVRG RFTI  YNYVSWYQQH PGKAPKLM IYDVSNRPSGV
      SRDNSKNTLYLQMNSLRTEDTAVYYCARGWLDRDI      SNRFSGSKSGNTASLTISGLQAEDEADYYCS
RE9   DYWGQGTMVTVSS SEQ ID NO. 93              SYRSSTLGPVFGGGTKLTVL SEQ ID NO. 94
                                               QAG LTQPPSASGSPGQSVTISCTGTSSDVG
      QVQLVESGGGVVQPG RSLRLSCAASG FTFSSYAM H GYNYVSWYQQH PGKAPKLM IYDVSN RPSG
      WVRQAPG KG LEWVAVISFDGSN KYYADSVRG RFTI  VPDRFSGSKSG NTASLTISGLQAED EADYYC
      SRDNSKNTLYLQMNSLRTEDTAVYYCARGWLDRDI      SSYTSSSTLVVFGGGTKLTVL SEQ ID NO.
RG12  DYWGQGTLVTVSS SEQ ID NO. 95              96
      EVQLVQSGGG LVQPGGSLRLSCAASG FTFSSYSM N NIQMTQSPSSVSASVG DRVTITCRASQDISR
      WVRQAPG KG LEWVSYISSSSSTIYYADSVKG RFTISR WLAWYQQKPG KAPKLLIYAASSLQSGVPSR
      DNAKNSLYLQMNSLRDEDTAVYYCARGDYYYGMD       FSGSGSGTDFALTISSLQPEDFATYYCQQAD
RSA1  VWGQGTTVTVSS SEQ ID NO. 97               SFFSITFGQGTRLEIK SEQ ID NO. 98
      QVQLVQSGSEVKKPGASVKVSCRASGYLFTNYG IS     AlQLTQSPATLSLSPG ERATLSCRASQSVGVY
      WVRQAPGQGLEWMGWVSAHGEFTKYAPSLQDR         LAWYQQKPGQSPRLLIYDTSKRATG IPDRFS
      VTMTSDISTTTAYMELRSLRSDDAGVYYCARDRGA      ASGSGTDFTLTISRLEPEDFAVYYCHQRHSW
R2A7  DHFDTWGQGTLVTVSS SEQ ID NO. 99           PTTFGQGTRLEIK SEQ ID NO. 100
      EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYM H NIQMTQSPSSLSASVG DRVTITCRASQSISSY
      WVRQAPGQG LEWMG M INPSSATTTYTQKFQG RV LNWYQQKPG KAPKLLIYAASSLQSGVPS RFS
      SMTRDTSTSTVYM ELSSLTSEDTAVYYCARDLF PH IY GSGSGTD FTLTISSLQPED FATYYCQQSYSTL
R2B12 GNYYGMDIWGQGTTVTVSS SEQ ID NO. 101       TFGGGTKVEIK SEQ ID NO. 102
      EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSHVISW     QSVLTQPASVSGSPGQSITISCTGTSSDVG D
      VRQAPGQG LEWMGG IIPI FGTANYAQKFQG RVTIT  YN LVSWYQQH PG KAPKLI IYEVN KRPSGVS
      ADESTSTAYM ELSSM RSEDTAVYYCATSGVVAATH F NRFSGSKSG NTASLTISG LQAE DEADYYCSS
R2C9  GYWGQGTLVTVSS SEQ ID NO. 103             YAGYNNLYVFGTGTKVTVL SEQ ID NO.
                                  102

                                              104
                                              QSALTQPPSASGSPGQSVTISCTGTSSDVGG
      QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISW    YNYVSWYQQH PGKAPKLI IYDVN M RPSGV
      VRQAPGQG LEWMGG IIPI FGTANYAQKFQG RVTIT PDRFSGSKSG NTASLTISGLQAED EADYYCS
      ADESTSTAYM ELSSLRSEDTAVYYCARGASGSYF ITT SYAGLYFPLFGGGTQLTVL SEQ ID NO.
R2D5  YVDYWGQGTLVTVSS SEQ ID NO. 105          106
      EVQLVESGGG LVQPGGPLRLSCAASG FTLSSYWMS   DIVMTQSPSSLSASVG DRVTITCRASQSISSY
      WVRQAPG KG LEWVAN IKYDGSETYYADSVKG RFTI LNWYQQKPG KAPKLLIYAASSLQSGVPS RFS
      SRDNAKNSLYLQMNRLRLEDTAVYYCAREVSSAATS    GSGSGTDFTLTISSLQPEDFATYYCQQSHSS
R2D7  PLDRWGRGTLVTVSS SEQ ID NO. 107          RYTFGQGTKLEIK SEQ ID NO. 108
      EVQLVQSGAEVKKPGSSVKVSCKASGGTFSRYGVH     QSVVTQPPSVSGAPGQRVTISCTGSSSN IGA
      WVRQAPGQGLEWMGRLIPIVSMTNYAQKFQDRV       GYGVHWYQHLPGSAPKLLIYGNSNRPSGVT
      SITTDKSTGTAYM ELRSLTSEDTALYYCASVGQQLP   DRISGSKSGTSASLAITG LQAEDEAVYYCQSY
R2F4  WVFFAWGQGTLVTVSS SEQ ID NO. 109         DSSLSTSVVFGGGTKLTVL SEQ ID NO. 110
                                              QSVLTQPPSASGTPGQRVTISCSGSSSN IGS
      EVQLVESGGGVVQPGGSLRLSCAASG FTFSSYAM H   NTVHWYQQLPGTAPKVLYTN NQRPSGVP
      WVRQAPG KG LEWVAVISFDGSN KYYADSVRG RFTI DRFSGSKSGTSASLAISG LQSEDEADYYCAA
      SRDNSKNTLYLQMNSLRTEDTAVYYCARGWLD RDI    WDGRLQGWVFGGGTQLTVL SEQ ID NO.
R2A10 DYWGQGTLVTVSS SEQ ID NO. 111            112
                                              QAG LTQPPSASGTPGQRVTISCFGSSSDIGS
      EVQLVESGGGVVQPG RSLRLSCAASG FTFSSYAM H  NTVNWYQQVSGRAPKLLLYTNGQRPSGVP
      WVRQAPG KG LEWVAVISFDGSN KYYADSVRG RFTI DRFSGSKSGSSASLAISG LQSED EADYYCAS
      SRDNSKNTLYLQMNSLRTEDTAVYYCARGWLD RDI    WDDSLKGYVFGTGTKVTVL SEQ ID NO.
R2E2  DYWGQGTLVTVSS SEQ ID NO. 113            114
      EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISW    QSVLTQPPSVSAAPGQKVTISCSGSSSN IGN
      VRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITA    SYVSWYQHLPGTAPKLLIYDNNKRPSGIPDR
      DKSTSTAYM ELSSLRSEDTAVYYCARVGGGAQTPFD   FSGSKSATSATLG ITG LQTADEADYYCGTW
R3B8  YWGQGTLVTVSS SEQ ID NO. 115             DSSLGVVFGGGTKLTVL SEQ ID NO. 116
      QVQLVQSGSEVKRPGASVRVSCKASGYI FSQYTI HW  QSALTQPASVSGSPGQSITISCTGTSSDVGG
      VRQAPGE RLEWLGWI NAVTG NTKYAQKFQG RVTIT YNYVSWYQQH PGKAPKLM IYNVSKRPSGV
      M DSSASTAFM EMSSLRSEDAGVYFCARDMVPFGG    SNRFSGSKSGNTASLTISGLQAEDEADYYCS
R3C3  EIKYGFDFWGQGTMITVSS SEQ ID NO. 117      SYTSSSTFVFGTGTKVTVL SEQ ID NO. 118
      QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMH     SYELMQPPSVSVAPGETARITCGGNNIGSKS
      WVRQAPGKGLEWVALISYDGSNKYYADSMKGRFTI     VHWYQQKPGQAPILVIYYDSGRPSGIPERFS
      SRDNSKNTLFLQMNSLRAEDTAVYYCAKTLMPASI     GSNSGNTATLTISRAEAGDEADYYCHVWDS
R3E9  MGYFTHWGQGTLVTVSS SEQ ID NO. 119        YTDHVVFGGGTKLTVL SEQ ID NO. 120
      QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYM H    QPVLTQPPSLSVAPG KTASIACGG NNIGSKR
      WVRQAPGQGLEWMGIINPSDGSTSYAQKFQGRVT      VHWYQQKPGQAPVLVIYYESDRPSGIPERF
      MTRDTSTSTVYM ELSSLRS EDTAVYYCARGYYGSG I SGTISQNTATLSISRVEAG DEADYYCQVWD
R3E10 AMDVWGQGTTVTVSS SEQ ID NO. 121          RSSAHVVFGGGTKVTVL SEQ ID NO. 122
      QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISW    AIQMTQSPSSLSASVG DRVTITCRASQSISTY
      VRQAPGQG LEWMGG IIPI FGTANYAQKFQG RVTIT LNWYQQKPG KAPKLLIYAASSLQNGVPSRF
      ADESTSTAYMELSSLRPEDTAVYYCARDNGDLGFDY    SGSGSGTDFTLTISSLQPEDFATYYCQQSYST
R3F7  WGQGTLVTVSS SEQ ID NO. 123              PRTFGPGTKVDIK SEQ ID NO. 124
                                 103

          EVQLVESGGG LIQPGGSLRLSCAASG FTVSSNYM S  DIQMTQSPSSLSASVG DRVTITCQASQD ISN
          WVRQAPG KG LEWVSVIYSGGTIYYADSVKG RFTISR YLNWYQQKPGKAPKLLI FAGSN LQSGVPSR
          DSSKNTLYLH M NS LRAEDTGVYYCAKGVGSWS IFD FSGSGSGTD FTLTITSLQPE DFATYYCQQSYT
R3F10     YWGQGTLVTVSS SEQ ID NO. 125             TPTFGQGTKVEIK SEQ ID NO. 126
          EVQLVESGAELKKPGSSM KVSCKASGGTFSSYAISW   QSVVTQPASVSGSPGQSITISCTGTSSDVGS
          VRQAPGQGLEYIGRIlPI FGVTYYAQKFQGRVTISAD  YN LVSWYQQH PGKAPKLM IYEGSKRPSGVS
          KSTSTVYLDLRSLRSEDTAVYYCARDLGGGDG DWG    TRFSGSKSGNTASLTISGLQAEDESDYYCSSY
R4B10     QGTLVTVSS SEQ ID NO. 127                TGSAWVFGGGTKLTVL SEQ ID NO. 128
          EVQLVQSGAEVKKPGSSVKVSCKASGYTFTGYYM H    QSVVTQPPSVSATPGQKVTISCSGSDSN IGN
          WVRQAPGQGLEWMGRIllIPIFGTANYAQKFQGRVT    NYVSWFLQLPGTAPKLLIHNNDQRPSGVPD
          ITADESTSTAYM ELSSLRSEDTAVYFCVTSAWSDWG   RFSGSKSGTSASLAITGLQAED EADYYCQSF
R4H1      QGTLVTVSS SEQ ID NO. 129                DDSLRGYLFGTGTKVTVL SEQ ID NO. 130
                                                  QAVLTQPPSVSAAPGQKVTISCSGGSSN IAN
          EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMS     NYVSWYQHLPGTAPKLLIYDDNKRPSGIPD
          WVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTI     RFSGSKSGTSATLGITGLQTGDGADYYCGT
          SRDNSKNTLYLQMNSLGAEDTAVYYCAKGFYYPDH     WDNSLNSDWVFGGGTKL SEQ ID NO.
R4A11     WGQGTLVTVSS SEQ ID NO. 131              132
          EVQLVESGGGVVQPGGSLRLSCEVSGFIFSDYGMH     QSVLTQPPSVSVAPGKTARITCGGNNIGSKS
          WVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISR   VHWYQQKPGQAPVLVYYDSDRPSGIPERF
          DNAKNSLYLQMNSLRAEDTAMYYCARSWNYGRFF      SGSNSGNTATLTISRVEAGDEADYYCQVWD
R3D2      DYWDQGTLVTVSS SEQ ID NO. 133            SSSDHYVFGTGTKLTVL SEQ ID NO. 134
          EVQLVESGGGLVQPGGSLRLSCAASGFTSSRNWM      VIWMTQSPSSLSASVGDRVTITCRASQTISS
          HWVRLAPGKGLVWVSLIAPDGSLTTYADSVKGRFTI    YLNWYQQKPGKAPKLLIYAASSLQSGVPSRF
          SRDTAKNSVQLLLNSLRAEDTGLYFCAREAGVSGGL    SGSGSGTDFTLTISSLQPEDFATYYCQQANS
R5B8      DVWGQGTLVTVSS SEQ ID NO. 135            FPLTFGGGTKVEIK SEQ ID NO. 136
                                                  QSVLTQPPSVSAAPGQKVTISCSGNNSNIA
          EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISW    NNYVSWYQQLPGTAPKLLIYDNNYRPSGIP
          VRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTIT     DRFSGSKSGTSATLDITGLQTGDEADYYCGV
          ADKSTSTAYM ELSSLRSEDTAVYYCAREGTIYDSSGY  WDGSLTTGVFGGGTKLTVL SEQ ID NO.
SH1A1Q    SFDYWGQGTLVTVSS SEQ ID NO. 137          138
          EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISW    AIQMTQSPSSLSASVGDRVTITCRASQGISN
          VRQAPGQGLEWMG INPSGGSTSYAQKFQGRVSM      YLAWYQQKPGKVPKLLIYAASTLESGVPSRF
          TRDTSTSTVYM ELSSLTSEDTAVYYCARDLFPH IYGN SGSGSGTDFTLTISSLQPEDLATYYCQQLHTF
SH1B7B(K) YYGMDIWGQGTTVTVSS SEQ ID NO. 139        PLTFGGGTKVEIK SEQ ID NO. 140
                                                  QPVLTQPPSASGSPGQSVTISCTGTSSDVGA
          QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISW    YN FVSWYRQHPGKAPKLM IYEVN KRPSGV
          VRQAPGQGLEWMGG 11PI FGTANYAQKFQGRVTIT   PDRFSGSKSGNTASLTVSGLQAEDEADYYCS
          ADKSTSTAYM ELSSLRSEDTAVYYCARLAVPGAFDI   SYAGTNSLGIFGTGTKLTVL SEQ ID NO.
SHICI     WGQGTMVTVSS SEQ ID NO. 141              142
                                                  QSVVTQPPSVSAAPGQKVTISCSGSSSDIGN
          EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAM H    HYVSWYQQLPGTAPKLLIYDN NQRPSG IPD
          WVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTI     RFSGSKSGTSATLAITGLQTGDEADYYCGT
          SRDNSKNTLYLQMNSLRAEDTAVYYCARGQWLVTE     WDNSLSPHLLFGGGTKLTVL SEQ ID NO.
SH1C8     LDYWGQGTLVTVSS SEQ ID NO. 143           144
          EVQLVESGSEVEKPGSSVKVSCKASGGTFSDSG ISW   QSVLTQPPSVSAAPGQKVTISCSGSSSN MG
          VRQAPGQGLEWMGG 11PM FATPYYAQKFQDRVTi    NNYVSWYKQVPGTAPKLLIYEN DKRPSGI P
          TADESTSTVYMELSGLRSDDTAVFYCARDRGRGHLP    DRFSGSKSGTSATLGITGLQTGDEADYYCGT
SHIE10    WYFDLWGRGTLVTVSS SEQ ID NO. 145         WDNSLSGFVFASGTKVTVL SEQ ID NO.
                                      104

                                               146
       EVQLVESGAEVKKPGSSVKVSCKASGGTFSSYAISW    QSALTQPASVSGSLGQSVTISCTGSSSDVGS
       VRQAPGQG LEWMGG IIPI FGTANYAQKFQG RVTIT YN LVSWYQQH PGKAPN LM IYDVSKRSGVS
       ADESTSTAYM ELSSLRSEDTAVYYCARAPYYYYYM D  NRFSGSKSG NTASLTISG LQAE DEADYYCSS
SH1E2  VWGQGTTVTVSS SEQ ID NO. 147             YTGISTVVFGGGTKLTVL SEQ ID NO. 148
       EVQLLESGAEVKKPGSSVKVSCKASGGTLSRYALSW    QSVLTQPASVSGSPGQSITISCTGTSSDVGSY
       VRQAPGQGPEWVGAIIPIFGTPHYSKKFQDRVIlTV    NLVSWYQQHPGKAPKLMIYEVSKRPSGVS
       DTSTNTAFMELSSLRFEDTALYFCARGHDEYDISGYH   NRFSGSKSGNTASLTISGLQAEDEADYYCSS
SH1A9  RLDYWGQGTLVTVSS SEQ ID NO. 149          YGGFNNLLFGGGTKLTVL SEQ ID NO. 150
       QVQLVQSGSELKKPGSSVKVSCKASGYSFSGYYIHW    DIVMTQSPSSLSASIGDRVTITCRASQRISAY
       VRQAPGQGLEWMGWIDPNSGVTNYVRRFQGRVT       VNWYQQKPGKAPKVLIYAASSLRSGVPSRF
       MTRDTSLSTAYMELSGLTADDTAVYYCARDENLWQ     SGSGSGTDFTLTISSLQPEDFATYYCQQTYSS
SHIB1I FGYLDYWGQGTLVTVSS SEQ ID NO. 151        PWTFGQGTKVEIK SEQ ID NO. 152
                                               QSVLTQPPSASGSPGQSVTISCTGTSSDIGG
       QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRYGVH     YDSVSWYQQHPGKAPKLMIYDVSKRPSGV
       WVRQAPGQGLEWMGRLIPIVSMTNYAQKFQDRV       SNRFSGSKSGNTASLTISGLQAEDEADYYCS
       SITTDKSTGTAYMELRSLTSEDTALYYCASVGQQLP    SYTSSSIFFYVFGTGTKVTVL SEQ ID NO.
SH1E4  WVFFAWGQGTLVTVSS SEQ ID NO. 153         154
       QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMH     LPVLTQPASVSGSPGQSITISCTGTTSDIGGY
       WVRQAPGKGLEWVAVISFDGSNKYYADSVRGRFTI     DYVSWYQQHPGKAPKLMIYDVSKRPSGVS
       SRDNSKNTLYLQMNSLRTEDTAVYYCARGWLDRDI     NRFSGSKSGNTASLTISGLQAEDEADYYCSS
SH1B3  DYWGQGTLVTVSS SEQ ID NO. 155            YTSSSTHVFGTGTKLTVL SEQ ID NO. 156
                                               QSALTQPASVSGSPGQSITISCTGTSSDVGG
       EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMH     YNYVSWYQQHPGKAPKLMIYDVSNRPSGV
       WVRQAPGKGLEWVAVISFDGSNKYYADSVRGRFTI     SNRFSGSKSGNTASLTISGLQAEDEADYYCS
       SRDNSKNTLYLQMNSLRTEDTAVYYCARGWLDRDI     SYRSSTLGPVFGGGTKLTVL SEQ ID NO.
SHID1  DYWGQGTLVTVSS SEQ ID NO. 157            158
       QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMH     QAGLTQPPSVSEAPRQRVTISCSGSSSNIGN
       WVRQAPGKGLEWVAVISFDGSNKYYADSVRGRFTI     NAVNWYQQLPGKAPKLLIYYDDLLPSGVSD
       SRDNSKNTLYLQMNSLRTEDTAVYYCARGWLDRDI     RFSGSKSGTSASLAISGLQSEDEADYYCAAW
SH1D2  DYWGQGTLVTVSS SEQ ID NO. 159            DDSLNGYVFGTGTKLTVL SEQ ID NO. 160
       EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMH     QSALTQPRSVSGSPGQSVTISCTGTSSDVGG
       WVRQAPGKGLEWVAVISFDGSNKYYADSVRGRFTI     YNYVSWYQQHPGKAPKLMIYDVSKRPSGV
       SRDNSKNTLYLQMNSLRTEDTAVYYCARGWLDRDI     PDRFSGSKSGNTASLTISGLQAEDEADYYCS
SH1D12 DYWGQGTLVTVSS SEQ ID NO. 161            SYTSSTTHVFGTGTKVTVL SEQ ID NO. 162
                                               QSVVTQPPSVSAAPGQKVTISCSGSSSNIGN
       EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMH     NYVSWYQQLPGTAPKLLIYDNNKRPSGIPD
       WVRQAPGKGLEWVAVISFDGSNKYYADSVRGRFTI     RFSGSKSGTSATLGITGLQTGDEADYYCGT
       SRDNSKNTLYLQMNSLRTEDTAVYYCARGWLDRDI     WDSSLSVWVFGGGTQLTVL SEQ ID NO.
SHIE1  DYWGQGTLVTVSS SEQ ID NO. 163            164
                                               QSVLTQPASVSGSPGQSITISCTGTSSDVGG
       QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMH     YNYVSWYQQHPGRAPRLMIYDVSNRPSGV
       WVRQAPGKGLEWVAVISFDGSNKYYADSVRGRFTI     SNRFSGSKSGNTASLTISGLQAEDEGDYYCS
       SRDNSKNTLYLQMNSLRTEDTAVYYCARGWLDRDI     SYTSGGTLGPVFGGGTKLTVL SEQ ID NO.
SH1G9  DYWGQGTLVTVSS SEQ ID NO. 165            166
                                  105

                                                  QAG LTQPPSASGTPGQRVTISCSGSSSN IGS
          EVQLVQSGGG LVQPGGSLRLSCAASG FTFSDYGM H NTVNWYQQLPGTAPKLLIYSN NQRPSGVP
          WVRQPPGKG LEWLAVISYDGSYKI HADSVQGRFTIS  DRFSGSKSGTSASLAISG LQSEDEADYYCAA
          RDNAKNSVFLQMNSLKTEDTAVYYCTTDRKWLAW      WDDSLNGWVFGGGTKLTVL SEQ ID NO.
SHIAll    HGMDVWGQGTTVTVSS SEQ ID NO. 167         168
          EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISW    Al RMTQSPSSLSASVG DRVTITCRASQSISNY
          VRQAPGQG LEWMGG IIPI FGTANYAQKFQG RVTIT LNWYQQRPG KAPN LLIYAASSLQSGVPS RF
          ADESTSTAYM ELSSLRSEDTAVYYCARDGIVADFQH   SGSGSGTD FTLTISSLQPED FATYYCQQTYST
SH1C2     WGQGTLVTVSS SEQ ID NO. 169              PYTFGQGTKLEIK SEQ ID NO. 170
          EVQLVESGAEVKKPGASVKVSCKASG DTFSRYG ITW QSVLTQPASVSGSPGQSITISCTGTSSDVGG
          VRQAPGRG LEWM GNIVPF FGATNYAQKFQG RLTIT YNYVSWYRQH PGKAPKLM IYDVSYRPSGVS
          ADKSSYTSYM DLSSLRSDDTAVYYCARD HFYGSGGY NRFSGSKSG NTASLTISG LQAE DEADYYCSS
SH1G8     FDYWGQGTLVTVSS SEQ ID NO. 171           YTDSSTRYVFGTGTKLTVL SEQ ID NO. 172
                                                  QPVLTQPPSASGTPGQRVAISCSGSRSN IEl
          EVQLLESGAEVKKPGASVKVSCKASGYTF NSYDI NW NSVNWYQQLPGTAPKLLYD NN KRPSG IPD
          VRQAPGQG LEWMGG IIPVFGTANYAESFQG RVTM RFSGSKSGTSATLG ITG LQTGD EADYYCGS
          TADHSTSTAYMELNNLRSEDTAVYYCARDRWHYES     WDSSLSADVFGTGTKLTVL SEQ ID NO.
SH1H 2    RPMDVWGQGTTVTVSS SEQ ID NO. 173         174
                                                  QSVLTQPPSVSAAPG KKVTISCSGSSSN IGN
          EVQLVESGGG LVRPGGSLRLACAASG FSFSDYYMT   NYVSWYQQLPGTAPKLLIYRN NQRPSGVPD
          WIRQAPGRGLEWIAYISDSGQTVHYADSVKGRFTIS    RFSGSKSGTSASLAISGLQSEDEADYYCATW
          RDNTKNSLFLQVNTLRAEDTAVYYCAREDLLGYYLQ    DDSLNGWVFGGGTKLTVL SEQ ID NO.
SHIB1O    SWGQGTLVTVSS SEQ ID NO. 175             176
          QVQLQQSG PG LVKPSQTLSLTCAISG DSVSSNSAA  QSVVTQPPSVSGAPGQRVTISCTGSSSN IGA
          WNWI RQSPSRG LEWLG RTYYRSKWYN DYAVSVKS  GYDVHWYQQLPGTAPKLLIYG NNN RHSGV
          RITINPDTSKNQFSLQLNSVTPEDTAVYYCARDEPRA   PDRFSGSKSGTSASLAITGLQAEDEAEFFCG
          VAGSQAYYYYGMDVWGQGTTVTVSS SEQ ID NO. TWDSRLTTYVFGSGTKLTVL SEQ ID NO.
SH1B7A(L) 177                                     178
                                                  QSVVTQPPSVSAAPGQKVTISCSGSSSN IGN
          QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRYGVH     NYVSWYQQLPGTAPKLLIYDN NKRPSG IPD
          WVRQAPGQG LEWMG RLI PIVSMTNYAQKFQDRV    RFSGSKSGTSATLG ITG LQTGD EADYYCGT
          SITTDKSTGTAYM ELRSLTSEDTALYYCASVGQQLP   WDSSLSAVVFGGGTKLTVL SEQ ID NO.
SH1E6     WVFFAWGQGTLVTVSS SEQ ID NO. 179         180
          EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYM H VIWMTQSPSSLSASVGD RVTITCRASQSISS
          WVRQAPGQGLEWMGIINPSDGSTSYAQKFQGRVT      YLNWYQQKPGKAPKLLIYEASTLESGVPSRF
          MTRDTSTSTVH M ELSSLRSEDTAVYYCARDLFPH IY SGSGSGTE FTLTISSLQPED FATYYCQQSYST
SHIC11    GNYYGMDIWGQGTTVTVSS SEQ ID NO. 181      PYTFGQGTKLEIK SEQ ID NO. 182
                                                  QSVVTQPPSVSAAPGQKVTISCSGSSSN IGN
          QM QLVQSGGGVVQPG RSLRLSCAASG FTFSSYAM   NYVSWYQQVPGTAPKLLIYDN NKRPSG IPD
          HWVRQAPGKGLEWVAVISFDGSNKYYADSVRGRF      RFSGSNSDTSATLGITGLQTGDEADYYCGT
          TISRDNSKNTLYLQMNSLRTEDTAVYYCARGWLDR     WDSSLSAWVFGGGTKLTVL SEQ ID NO.
SH1A2     DIDYWGQGTLVTVSS SEQ ID NO. 183          184
                                                  QSVVTQPPSVSAAPGQKVTISCSGSSSN IGN
          QVQLVQSGGGVVQPG RSLRLSCAASG FTFSSYAM H NYVSWYQQLPGTAPKLLIYDN NKRPSG IPD
          WVRQAPG KG LEWVAVISFDGSN KYYADSVRG RFTI RFSGSKSGTSATLG ITG LQTGD EADYYCGT
          SRDNSKNTLYLQMNSLRTEDTAVYYCARGWLD RDI    WDSSLSAGSVVFGGGTKLTVL SEQ ID NO.
SHIBI     DYWGQGTLVTVSS SEQ ID NO. 185            186
                                     106

                                              QPVLTQPRSVSGSPGQSVTISCTGTSSDVGG
      EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISW    YN FVSWYQQNPGKAPKLM IYDVSKRPSGV
      VRQAPGQG LEWMGG IIPI FGTANYAQKFQG RVTIT PDRFSGSKSG NTASLTVSG LRAE DEADYYCA
      ADESTSTAYM ELSSLRS EDTAVYYCARDGIVADFQH  SYAGGRTFVFGGGTKVTVL SEQ ID NO.
R6B2  WGQGTLVTVSS SEQ ID NO. 187              188
      QM QLVQSGAEVKKPGSSVKVSCKASGGTFNSYPIS    QSVLTQSPSSFSASTG DRVTITCRASQG ISSY
      WVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVT      LAWYQQKPG KAPKLLIYAASTLQSGVPSRFS
      ITADESTSTAYMELSSLRSEDTAMYYCAKNHPTATL    GSGSGTDFTLTISCLQSEDFATYYCQQYYSYP
R6B7  DYWGQGTLVTVSS SEQ ID NO. 189            LTFGGGTKVTVL SEQ ID NO. 190
      QVQLVQSGGGVVQPGRSLRLSCAASGFPFRSYDM
      HWVRQAPGEGLEWVALISSDGSNKYYLDSVKGRFT     LPVLTQPASVSASAGQSIAISCTGISSDIGDY
      ISRDNSKNTLYLQMNSLRAEDTAVYYCAKDLLPYSSS   NSVSWYQRHPGKAPKLIIYDVSSRPSGVAD
      WDYYYYYGMDVWGQGTTVTVSS SEQ ID NO.       RFSGSKSGSTASLSISGLQAEDEADYYCASYT
R6B11 191                                     ASDNPVFGGGTKLTVL SEQ ID NO. 192
      EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHW    SYELMQPPSVSVAPGKTATIACGGENIGRKT
      VRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISA    VHWYQQKPGQAPVLVIYYDSDRPSGIPERF
      DTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYA      SGSNSGNTATLTISRVEAGDEADYYCQVWD
R6D1  MDYWGQGTLVTVSS SEQ ID NO. 193           SSSDHRIFGGGTKLTVL SEQ ID NO. 194
                                              QSVLTQPPSVSAAPGQEVTISCSGSNSNIGN
      EVQLVESGGGLVKPGGSRKLSCAASGFTFSNYGMH     NYVSWYQQLPGTAPKLLIYDNNERPSGIPD
      WVRQAPEKGLEWVAYISSGSSTIYYADTVKGRFTISR   RFSGSKSGTSATLGITGLQTGDEADYYCGT
      DNAKNTLFLQMTSLRSEDTAMYYCARRGLLLDYWG     WDSSLSAGVFGGGTKLTVL SEQ ID NO.
R6C8  QGTTLTVSS SEQ ID NO. 195                196
                                              QSVLTQPPSVSAAPGQEVTISCSGSNSNIGN
      EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISW    NYVSWYQQLPGTAPKLLIYDNNERPSGIPD
      VRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVT       RFSGSKSGTSATLGITGLQTGDEADYYCGT
      MTTDTSTSTAYMELRSLRSDDTAVYYCARDLFPTIF    WDSSLSAGVFGGGTKLTVL SEQ ID NO.
R9G8  WEGGAFDIWGQGTMVTVSS SEQ ID NO. 197      198
                                              QSVLTQPPSVSAAPGQEVTISCSGSNSNIGN
      QVQLVQSGSEVEKPGSSVKVSCKASGGTFSDSGISW    NYVSWYQQLPGTAPKLLIYDNNERPSGIPD
      VRQAPGQGLEWMGGllPMFATPYYAQKFQDRVTI      RFSGSKSGTSATLGITGLQTGDEADYYCGT
      TADESTSTVYMELSGLRSDDTAVFYCARDRGRGHLP    WDSSLSAGVFGGGTKLTVL SEQ ID NO.
R7D1  WYFDLWGRGTLVTVSS SEQ ID NO. 199         200
      QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISW    AIRMTQSPSSLSASVGDRVTITCRASQSISNY
      VRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTIT     LNWYQQRPGKAPNLLIYAASSLQSGVPSRF
      ADESTSTAYMELSSLRSEDTAVYYCARDGIVADFQH    SGSGSGTDFTLTISSLQPEDFATYYCQQTYST
R7D2  WGQGTLVTVSS SEQ ID NO. 201              PYTFGQGTKLEIK SEQ ID NO. 202
                                              QSVLTQPPSVSAAPGQEVTISCSGSNSNIGN
      EVQLLESGAEVKKPGSSVKVSCKASGGTFSSYAISWV   NYVSWYQQLPGTAPKLLIYDNNERPSGIPD
      RQAPGQGLEWMGRIlPILGIADYAQKFQGRVTITAD    RFSGSKSGTSATLGITGLQTGDEADYYCGT
      KFTSTAYMELSSLRSEDTAVYYCATVEGWGAVTTFD    WDSSLSAGVFGGGTKLTVL SEQ ID NO.
R7E7  YWGQGTLVTVSS SEQ ID NO. 203             204
      QVQLVQSGAEVKKPGSSVKVSCKASGGTLSSYAISW    QSVLTQPPSVSGAPGQRVTISCTGSSSNIGA
      VRQVPGHGLEWMGRIISMLGVSNYAQNFQGRVT       GYDVYWYQHLLGKAPKLLIYGNSNRPSGVS
      TADKSTSTAYMELRSLTSDDTAVYYCATVTIFDGDYY   DRFSASKSGTSVSLAITGLQAEDEADYYCQS
R7F2  AMDVWGQGTTVTVSS SEQ ID NO. 205          YDSSLSGYVFGTGTKLTVL SEQ ID NO. 206
                                  107

       EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSHVISW       QPVLTQPASVSGSPGQSITISCTGTSSDVGS
       VRQAPGQG LEWMG II LPS FG KTNYAQKFQG RVTM   YN LVSWYQQH PGKAPKLM IYEVSKRPSGVS
       TGDTSTSTVYMELSSLTSEDTAVYYCVREFSGGYFDY      NRFSGSKSGNTASLTISGLQAEDEADYYCNT
R7F7   WGQGTLVTVSS SEQ ID NO. 207                 YTSSGTYVIGTGTKVTVL SEQ ID NO. 208
       QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVI H       QPVLTQPASVSGSPGQSITISCTGTSSDIGRY
       WVRQAPGQRLEWMGWI HAG NG HTKYAQN FQGR       NYVSWYQQH PG KAPKVM IYDVSN RPSGVS
       VTITRDTSATTAYVEVSSLGSEDTALYYCAREGSDIGL     NRFSGSKSGNTASLTISGLQAEDEADYYCSS
R9H2   DLHYWGQGTLVTVSS SEQ ID NO. 209             YTSSSTWVFGGGTKLTVL SEQ ID NO. 210
       EVQLVQSGGGVVQPG RSLRLSCEASG FTFRN FAM H    QSVVTQPPSVSAAPGQKVTISCSGSSSN IGN
       WVRQAPGKGLEWAAVISVDGSREHYADSVKGRFTI        NYVSWYQQLPGTAPKILIYDNDKRPSGIPDR
       SRDNSQNTVYLQMNGLRPEDTAEYYCAREGEGST         FSGSKSGTSATLGITGLQTGDEADYYCGTW
R9H6   WSSFDYWGQGTLVTVSS SEQ ID NO. 211           DRSLSGYVFGTGTKVTVL SEQ ID NO. 212
       QM QLVQSGAEVKKPGSSVKVSCKASGGTFSSYAYS       SYE LMQPPSVSVAPG KTATIACGG EN IGRKT
       WVRQAPGQGLEWMGGIIPSFGTANYAQKFQGRV          VHWYQQKPGQAPVLVIYYDSDRPSGIPERF
       TITADESTSTAYM ELSSLRSEDTAVYYCARGPIVATIT    SGSNSG NTATLTISRVEAGD EADYYCLVWD
H6B1L  PLDYWGQGTLVTVSS SEQ ID NO. 213             SSSDHRIFGGGTKLTVL SEQ ID NO. 214
       QM QLVQSGAEVKKPGSSVKVSCKASGGTFSSYAYS       SYE LMQPPSVSVAPG KTATIACGG EN IGRKT
       WVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVT         VHWYQQKPGQAPVLVIYYDSDRPSGIPERF
       ITADESTSTAYM ELSSLRSEDTAVYYCARGPIVATITP    SGSNSG NTATLTISRVEAGD EADYYCQVWD
H6A1   LDYWGQGTLVTVSS SEQ ID NO. 215              SSSDHRIFGGGTKLTVL SEQ ID NO. 216
       QM QLVQSGAEVKKPGSSVKVSCKASGGTFSSYAYS       SYE LMQPPSVSVAPG KTATIACGG EN IGRKT
       WVRQAPGQGLEWMGGIIPSFGTANYAQKFQGRV          VHWYQQKPGQAPVLVIYYDSDRPSGIPERF
       TITADESTSTAYM ELSSLRSEDTAVYYCARGPIVATIT    SGSNSG NTATLTISRVEAGD EADYYCQVWD
H6B1   PLDYWGQGTLVTVSS SEQ ID NO. 217             SSSDHRIFGGGTKLTVL SEQ ID NO. 218
       QM QLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIS       SYE LMQPPSVSVAPG KTATIACGG EN IGRKT
       WVRQAPGQGLEWMGGIIPAFGTANYAQKFQGRV          VHWYQQKPGQAPVLVIYYDSDRPSGIPERF
       TITADESTSTAYM ELSSLRSEDTAVYYCARGPIVATIT    SGSNSG NTATLTISRVEAGD EADYYCQVWD
H6B2   PLDYWGQGTLVTVSS SEQ ID NO. 219             SSSDHRIFGGGTKLTVL SEQ ID NO. 220
       QVQLVQSGAEVKKPGASVKVSCKTSG NTFTNYALH       DIVMTQSPPSLSASVGD RVTITCRASQSISSY
       WVRQAPGQG LEWMGGM KPSGGSTSIAQKFQG R        LNWYQQKPG KAPKLLIYATSSLQYGVPS RFS
       VTMTRD KSTSTVYM ELSSLTSEDTAVYYCARDLFPH I   GSGSGTD FTLTISSLQPED FATYYCQGSYSTP
H19C   FGNYYGMDIWGQGTTVTVSS SEQ ID NO. 221        YTFGQGTKVEIK SEQ ID NO. 222
       QVQLVQSGAEVKKPGASVKVSCKTSG NTFTNYYM H      DIVMTQSPPSLSASVGD RVTITCRASQSISSY
       WVRQAPGQGLEWMGSMQPSGGSTSLAQKFQGR           LNWYQQKPG KAPKLLIYAASSLQSGVPS RFS
       VTMTRD KSTSTVYM ELSSLTSE DTAVYYCARD LFPH I GSGSGTD FTLTISSLQPED FATYYCQGSYSTP
HIOD   LGNYYGMDIWGQGTTVTVSS SEQ ID NO. 223        YTFGQGTKVEIK SEQ ID NO. 224
       QVQLVQSGAEVKKPGASVKVSCKTSG NTFTNYPM        DIVMTQSPPSLSASVGD RVTITCRASQSISSY
       HWVRQAPGQGLEWMGSM KPSGGSTSLAPKFQG R        LNWYQQKPG KAPKLLIYAASSLQYGVPS RFS
       VTMTRD KSTSTVYM ELSSLTSE DTAVYYCARD LFPH I GSGSGTD FTLTISSLQPED FATYYCQGSYSTP
H11F   IGNYYGMDIWGQGTTVTVSS SEQ ID NO. 225        YTFGQGTKVEIK SEQ ID NO. 226
       QVQLVQSGAEVKKPGASVKVSCKTSG NTFTNYSM H      DIVMTQSPPSLSASVGD RVTITCRASQSISSY
       WVRQAPGQG LEWMG IMN PSGGSTSYAQKFQG R       LNWYQQKPG KAPKLLIYAASSLQSGVPS RFS
       VTMTRD KSTSTVYM ELSSLTSE DTAVYYCARD LFPH I GSGSGTD FTLTISSLQPED FATYYCQQSYSTP
HICI   YGNYYGMDIWGQGTTVTVSS SEQ ID NO. 227        YTFGQGTKVEIK SEQ ID NO. 228
       EVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYM H       DIVMTQSPSSLSASVGDRVTITCRASQSISSF
       WVRQAPGQGLEWMGWI NPNSDNTGSAQKFQGR          LNWYQQKPGKAPKLLIYAASSLQSGVPSRFS
       VFMTKTTSLNTAYM ELSGLRSEDTAIYYCARERSSGY     GSGSGTDFTLTISSLQPEDFATYYCQQSYSTP
GPG1A2 FDFWGQGTLVTVSS SEQ ID NO. 229              ITFGQGTKVEIK SEQ ID NO. 230
                                    108

        QVQLVQSGAEVKKLGASVKVSCKASGYP FTGYYM H  DIVMTQSPSSLSASVG DRVTITCRATPSTSSY
        WVRQAPGQG LEWMGWI NPNG DNTG LAQKFQG R  LNWYQQKPG KAPKLLIYAASSLQSGVPS RFS
        VFMTKTTSLNTAYM ELSGLRSEDTAIYYCARERSSGY GSGSGTD FTLTISSLQPED FATYYCQQSYSTP
GPGG8   FDFWGQGTLVTVSS SEQ ID NO. 231          ITFGQGTKLEIK SEQ ID NO. 232
        QVQLVQSGAEVKKPGASVKVSCKTSGYPFTGYYM H   DIVMTQSPSSLSASVG DRVTITCRASQSISSY
        WVRQAPGQG LEWMGWI NPLSDTTGSAQKFQG R    LNWYQQKPG KAPKLLIYAASSLQSGVPS RFS
        VFMTKTTSLNTAYM ELSGLRSEDTAIYYCARERSSGY GSGSGTDFTLTISSLQPEDFATYYCQQSYSTP
GPGG1O  FDFWGQGTLVTVSS SEQ ID NO. 233          ITFGQGTKLEIK SEQ ID NO. 234
        QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYM H   DIVMTQSPSSLSASVG DRVTITCRASQSISSF
        WVRQAPGQG LEWMGWI NPLSDNTGSAQKFQG R    LNWYQQKPG KAPKLLIYLASSLQSGVPSRFS
        VFMTKTTSLNTAYM ELSGLRSEDTAIYYCARERSSGY GSGSGTDFTLTISSLQPEDFATYYCQQSYSTP
GPGH7   FDFWGQGTLVTVSS SEQ ID NO. 235          ITFGQGTKVEIK SEQ ID NO. 236
        QVQLVQSGAEVKKPGASVKVSCKTSGYTFTGYYM H   DIVMTQSPSSLSASVG DRVTITCRASQSISSF
        WVRQAPGQG LEWMGWI NPNS DNTGYAQKFQG R   LNWYQQKPG KAPKLLIYAASSLQSGVPS RFS
        VFMTKTTSLNTAYM ELSGLRSEDTAIYYCARERSSGY GSGSGTDFTLTISSLQPEDFATYYCQQAYST
GPGH1O  FDFWGQGTLVTVSS SEQ ID NO. 237          PITFGQGTKVEIK SEQ ID NO. 238
        QVQLVQSGAEVKKPGASVKVSCKASGYPFTGYYM H
        WVRQAPGQGLEWMGWI NPLSDSTGSAQKFQGRV     DIVMTQSPSSLSASVGDRVTITCRASQSISSY
        FMTKTTSLNTAYM ELSGLRSEDTAIYYCARERSSGYF LNWYQQKPGKAPKLLIYAASSLQSGVPSRFS
        DFWGQGTLVTVSS SEQ ID NO. 2 SEQ ID NO.  GSGSGTDFTLTISSLQPEDFATYYCQQSYSTP
GPGH11  239                                    ITFGQGTKLEIK SEQ ID NO. 240
        QVQLVQSGAEVKKPGASVKVSCKTSGYTFTGYYM H   DIVMTQSPSSLSASVG DRVTITCRASQSISSF
        WVRQAPGQG LEWMGWI NPNS DNTGYAQKFQG R   LNWYQQKPG KAPKLLIYAASSLQSGVPS RFS
        VFMTKTTSLNTAYM ELSGLRSEDTAIYYCARERSSGY GSGSGTDFTLTISSLQPEDFATYYCQQPYSTP
GPGH1OP FDFWGQGTLVTVSS SEQ ID NO. 241          ITFGQGTKVEIK SEQ ID NO. 242
                                   109

   We claim:
           1.      A fully human antibody of an IgG class that binds to a PD-Li epitope with a
   binding affinity of at least 10-6M, that has a heavy chain variable domain sequence that is at
   least 95% identical to the amino acid sequences selected from the group consisting of SEQ
 5 ID NO. 1, SEQ ID NO. 3, SEQ ID NO. 5, SEQ ID NO. 7, SEQ ID NO. 9, SEQ ID NO. 11,
   SEQ ID NO. 13, SEQ ID NO. 15, SEQ ID NO. 17, SEQ ID NO. 19, SEQ ID NO. 21, SEQ
   ID NO. 23, SEQ ID NO. 25, SEQ ID NO. 27, SEQ ID NO. 29, SEQ ID NO. 31, SEQ ID
   NO. 33, SEQ ID NO. 35, SEQ ID NO. 37, SEQ ID NO. 39, SEQ ID NO. 41, SEQ ID NO.
   43, SEQ ID NO. 45, SEQ ID NO. 47, SEQ ID NO. 49, SEQ ID NO. 51, SEQ ID NO. 53,
10 SEQ ID NO. 55, SEQ ID NO. 57, SEQ ID NO. 59, SEQ ID NO. 61, SEQ ID NO. 63, SEQ
   ID NO. 65, SEQ ID NO. 67, SEQ ID NO. 69, SEQ ID NO. 71, SEQ ID NO. 73, SEQ ID
   NO. 75, SEQ ID NO. 77, SEQ ID NO. 79, SEQ ID NO. 81, SEQ ID NO. 83, SEQ ID NO.
   85, SEQ ID NO. 87, SEQ ID NO. 89, SEQ ID NO. 91, SEQ ID NO. 93, SEQ ID NO. 95,
   SEQ ID NO. 97, SEQ ID NO. 99, SEQ ID NO. 101, SEQ ID NO. 103, SEQ ID NO. 105,
15 SEQ ID NO. 107, SEQ ID NO. 109, SEQ ID NO. 111, SEQ ID NO. 113, SEQ ID NO. 115,
   SEQ ID NO. 117, SEQ ID NO. 119, SEQ ID NO. 121, SEQ ID NO. 123, SEQ ID NO. 125,
   SEQ ID NO. 127, SEQ ID NO. 129, SEQ ID NO. 131, SEQ ID NO. 133, SEQ ID NO. 135,
   SEQ ID NO. 137, SEQ ID NO. 139, SEQ ID NO. 141, SEQ ID NO. 143, SEQ ID NO. 145,
   SEQ ID NO. 147, SEQ ID NO. 149, SEQ ID NO. 151, SEQ ID NO. 153, SEQ ID NO. 155,
20 SEQ ID NO. 157, SEQ ID NO. 159, SEQ ID NO. 161, SEQ ID NO. 163, SEQ ID NO. 165,
   SEQ ID NO. 167, SEQ ID NO. 169, SEQ ID NO. 171, SEQ ID NO. 173, SEQ ID NO. 175,
   SEQ ID NO. 177, SEQ ID NO. 179, SEQ ID NO. 181, SEQ ID NO. 183, SEQ ID NO. 185,
   SEQ ID NO. 187, SEQ ID NO. 189, SEQ ID NO. 191, SEQ ID NO. 193, SEQ ID NO. 195,
   SEQ ID NO. 197, SEQ ID NO. 199, SEQ ID NO. 201, SEQ ID NO. 203, SEQ ID NO. 205,
25 SEQ ID NO. 207, SEQ ID NO. 209, SEQ ID NO. 211, SEQ ID NO. 213, SEQ ID NO. 215,
   SEQ ID NO. 217, SEQ ID NO. 219, SEQ ID NO. 221, SEQ ID NO. 223, SEQ ID NO. 225,
   SEQ ID NO. 227, SEQ ID NO. 229, SEQ ID NO. 231, SEQ ID NO. 233, SEQ ID NO. 235,
   SEQ ID NO. 237, SEQ ID NO. 239, SEQ ID NO. 241, and combinations thereof, and that
   has a light chain variable domain sequence that is at least 95% identical to the amino acid
30 sequences selected from the group consisting of SEQ ID NO. 2, SEQ ID NO. 4, SEQ ID
   NO. 6, SEQ ID NO. 8, SEQ ID NO. 10, SEQ ID NO. 12, SEQ ID NO. 14, SEQ ID NO. 16,
                                                   110

   SEQ ID NO. 18, SEQ ID NO. 20, SEQ ID NO. 22, SEQ ID NO. 24, SEQ ID NO. 26, SEQ
   ID NO. 28, SEQ ID NO. 30, SEQ ID NO. 32, SEQ ID NO. 34, SEQ ID NO. 36, SEQ ID
   NO. 38, SEQ ID NO. 40, SEQ ID NO. 42, SEQ ID NO. 44, SEQ ID NO. 46, SEQ ID NO.
   48, SEQ ID NO. 50, SEQ ID NO. 52, SEQ ID NO. 54, SEQ ID NO. 56, SEQ ID NO. 58,
 5 SEQ ID NO. 60, SEQ ID NO. 62, SEQ ID NO. 64, SEQ ID NO. 66, SEQ ID NO. 68, SEQ
   ID NO. 70, SEQ ID NO. 72, SEQ ID NO. 74, SEQ ID NO. 76, SEQ ID NO. 78, SEQ ID
   NO. 80, SEQ ID NO. 82, SEQ ID NO. 84, SEQ ID NO. 86, SEQ ID NO. 88, SEQ ID NO.
   90, SEQ ID NO. 92, SEQ ID NO. 94, SEQ ID NO. 96, SEQ ID NO. 98, SEQ ID NO. 100,
   SEQ ID NO. 102, SEQ ID NO. 104, SEQ ID NO. 106, SEQ ID NO. 108, SEQ ID NO. 110,
10 SEQ ID NO. 112, SEQ ID NO. 114, SEQ ID NO. 116, SEQ ID NO. 118, SEQ ID NO. 120,
   SEQ ID NO. 122, SEQ ID NO. 124, SEQ ID NO. 126, SEQ ID NO. 128, SEQ ID NO. 130,
   SEQ ID NO. 132, SEQ ID NO. 134, SEQ ID NO. 136, SEQ ID NO. 138, SEQ ID NO. 140,
   SEQ ID NO. 142, SEQ ID NO. 144, SEQ ID NO. 146, SEQ ID NO. 148, SEQ ID NO. 150,
   SEQ ID NO. 152, SEQ ID NO. 154, SEQ ID NO. 156, SEQ ID NO. 158, SEQ ID NO. 160,
15 SEQ ID NO. 162, SEQ ID NO. 164, SEQ ID NO. 166, SEQ ID NO. 168, SEQ ID NO. 170,
   SEQ ID NO. 172, SEQ ID NO. 174, SEQ ID NO. 176, SEQ ID NO. 178, SEQ ID NO. 180,
   SEQ ID NO. 182, SEQ ID NO. 184, SEQ ID NO. 186, SEQ ID NO. 188, SEQ ID NO. 190,
   SEQ ID NO. 192, SEQ ID NO. 194, SEQ ID NO. 196, SEQ ID NO. 198, SEQ ID NO. 200,
   SEQ ID NO. 202, SEQ ID NO. 204, SEQ ID NO. 206, SEQ ID NO. 208, SEQ ID NO. 210,
20 SEQ ID NO. 212, SEQ ID NO. 214, SEQ ID NO. 216, SEQ ID NO. 218, SEQ ID NO. 220,
   SEQ ID NO. 222, SEQ ID NO. 224, SEQ ID NO. 226, SEQ ID NO. 228, SEQ ID NO. 230,
   SEQ ID NO. 232, SEQ ID NO. 234, SEQ ID NO. 236, SEQ ID NO. 238, SEQ ID NO. 240,
   SEQ ID NO. 242, and combinations thereof.
           2.     The fully human antibody of claim 1, wherein the antibody has a heavy
25 chain/light chain variable domain sequence selected from the group consisting of SEQ ID
   NO. 1/SEQ ID NO. 2 (called E6 herein), SEQ ID NO. 3/SEQ ID NO. 4 (called E7 herein),
   SEQ ID NO. 5/SEQ ID NO. 6 (called E9 herein), SEQ ID NO. 7/SEQ ID NO. 8 (called EI1
   herein), SEQ ID NO. 9/SEQ ID NO. 10 (called Fl herein), SEQ ID NO. 11/SEQ ID NO. 12
   (called F4 herein), SEQ ID NO. 13/SEQ ID NO. 14 (called F7 herein), SEQ ID NO. 15/SEQ
30 ID NO. 16 (called F8 herein), SEQ ID NO. 17/SEQ ID NO. 18 (called F 11 herein), SEQ ID
   NO. 19/SEQ ID NO. 20 (called G4 herein), SEQ ID NO. 21/SEQ ID NO. 22 (called G9
                                               111

   herein), SEQ ID NO. 23/SEQ ID NO. 24 (called GIl herein), SEQ ID NO. 25/SEQ ID NO.
   26 (called G12 herein), SEQ ID NO. 27/SEQ ID NO. 28 (called HI herein), SEQ ID NO.
   29/SEQ ID NO. 30 (called H3 herein), SEQ ID NO. 3 i/SEQ ID NO. 32 (called H4 herein),
   SEQ ID NO. 33/SEQ ID NO. 34 (called H5 herein), SEQ ID NO. 35/SEQ ID NO. 36 (called
 5 H6 herein), SEQ ID NO. 37/SEQ ID NO. 38 (called HiO herein), SEQ ID NO. 39/SEQ ID
   NO. 40 (called H12 herein), SEQ ID NO. 41/SEQ ID NO. 42 (called PDL-D2 herein), SEQ
   ID NO. 43/SEQ ID NO. 44 (called PDL-D I1herein), SEQ ID NO. 45/SEQ ID NO. 46
   (called PDL-Hi herein), SEQ ID NO. 47/SEQ ID NO. 48 (called RB4 herein), SEQ ID NO.
   49/SEQ ID NO. 50 (called RB I1herein), SEQ ID NO. 5i/SEQ ID NO. 52 (called RC5
10 herein), SEQ ID NO. 53/SEQ ID NO. 54 (called RF5 herein), SEQ ID NO. 55/SEQ ID NO.
   56 (called RG9 herein), SEQ ID NO. 57/SEQ ID NO. 58 (called RDi herein), SEQ ID NO.
   59/SEQ ID NO. 60 (called RF I1herein), SEQ ID NO. 6 1/SEQ ID NO. 62 (called RH I1
   herein), SEQ ID NO. 63/SEQ ID NO. 64 (called RD9 herein), SEQ ID NO. 65/SEQ ID NO.
   66 (called RE10 herein), SEQ ID NO. 67/SEQ ID NO. 68 (called RA3 herein), SEQ ID NO.
15 69/SEQ ID NO. 70 (called RGI herein), SEQ ID NO. 7 1/SEQ ID NO. 72 (called RBI
   herein), SEQ ID NO. 73/SEQ ID NO. 74 (called RG7 herein), SEQ ID NO. 75/SEQ ID NO.
   76 (called RA6 herein), SEQ ID NO. 77/SEQ ID NO. 78 (called RA8 herein), SEQ ID NO.
   79/SEQ ID NO. 80 (called RA9 herein), SEQ ID NO. 81/SEQ ID NO. 82 (called RB5
   herein), SEQ ID NO. 83/SEQ ID NO. 84 (called RB8 herein), SEQ ID NO. 85/SEQ ID NO.
20 86 (called RC8 herein), SEQ ID NO. 87/SEQ ID NO. 88 (called RC10 herein), SEQ ID NO.
   89/SEQ ID NO. 90 (called RD2 herein), SEQ ID NO. 91/SEQ ID NO. 92 (called RE8
   herein), SEQ ID NO. 93/SEQ ID NO. 94 (called RE9 herein), SEQ ID NO. 95/SEQ ID NO.
   96 (called RG12 herein), SEQ ID NO. 97/SEQ ID NO. 98 (called RSAi herein), SEQ ID
   NO. 99/SEQ ID NO. 100 (called R2A7 herein), SEQ ID NO. i0i/SEQ ID NO. 102 (called
25 R2B12 herein), SEQ ID NO. 103/SEQ ID NO. 104 (called R2C9 herein), SEQ ID NO.
   105/SEQ ID NO. 106 (called R2D5 herein), SEQ ID NO. 107/SEQ ID NO. 108 (called
   R2D7 herein), SEQ ID NO. 109/SEQ ID NO. 110 (called R2F4 herein), SEQ ID NO.
   I 11/SEQ ID NO. 112 (called R2A10 herein), SEQ ID NO. I I3/SEQ ID NO. 114 (called
   R2E2 herein), SEQ ID NO. 115/SEQ ID NO. 116 (called R3B8 herein), SEQ ID NO.
30 117/SEQ ID NO. 118 (called R3C3 herein), SEQ ID NO. 119/SEQ ID NO. 120 (called
   R3E9 herein), SEQ ID NO. 121/SEQ ID NO. 122 (called R3EiO herein), SEQ ID NO.
                                             112

   123/SEQ ID NO. 124 (called R3F7 herein), SEQ ID NO. 125/SEQ ID NO. 126 (called
   R3F1O herein), SEQ ID NO. 127/SEQ ID NO. 128 (called R4B1O herein), SEQ ID NO.
   129/SEQ ID NO. 130 (called R4H1 herein), SEQ ID NO. 131/SEQ ID NO. 132 (called
   R4A1 1 herein), SEQ ID NO. 133/SEQ ID NO. 134 (called R3D2 herein), SEQ ID NO.
 5 135/SEQ ID NO. 136 (called R5B8 herein), SEQ ID NO. 137/SEQ ID NO. 138 (called
   SH1A1Q herein), SEQ ID NO. 139/SEQ ID NO. 140 (called SH1B7B(K) herein), SEQ ID
   NO. 141/SEQ ID NO. 142 (called SHICI herein), SEQ ID NO. 143/SEQ ID NO. 144
   (called SH1C8 herein), SEQ ID NO. 145/SEQ ID NO. 146 (called SHIE10 herein), SEQ ID
   NO. 147/SEQ ID NO. 148 (called SH1E2 herein), SEQ ID NO. 149/SEQ ID NO. 150
10 (called SH1A9 herein), SEQ ID NO. 151/SEQ ID NO. 152 (called SHIB 11 herein), SEQ ID
   NO. 153/SEQ ID NO. 154 (called SH1E4 herein), SEQ ID NO. 155/SEQ ID NO. 156
   (called SH1B3 herein), SEQ ID NO. 157/SEQ ID NO. 158 (called SHID1 herein), SEQ ID
   NO. 159/SEQ ID NO. 160 (called SH1D2 herein), SEQ ID NO. 161/SEQ ID NO. 162
   (called SH1D12 herein), SEQ ID NO. 163/SEQ ID NO. 164 (called SHIE1 herein), SEQ ID
15 NO. 165/SEQ ID NO. 166 (called SH1G9 herein), SEQ ID NO. 167/SEQ ID NO. 168
   (called SHIA 11 herein), SEQ ID NO. 169/SEQ ID NO. 170 (called SH1C2 herein), SEQ ID
   NO. 171/SEQ ID NO. 172 (called SH1G8 herein), SEQ ID NO. 173/SEQ ID NO. 174
   (called SH1H2 herein), SEQ ID NO. 175/SEQ ID NO. 176 (called SHIB10 herein), SEQ ID
   NO. 177/SEQ ID NO. 178 (called SH1B7A(L) herein), SEQ ID NO. 179/SEQ ID NO. 180
20 (called SH1E6 herein), SEQ ID NO. 181/SEQ ID NO. 182 (called SHIC 11 herein), SEQ ID
   NO. 183/SEQ ID NO. 184 (called SH1A2 herein), SEQ ID NO. 185/SEQ ID NO. 186
   (called SHIBI herein), SEQ ID NO. 187/SEQ ID NO. 188 (called R6B2 herein), SEQ ID
   NO. 189/SEQ ID NO. 190 (called R6B7 herein), SEQ ID NO. 191/SEQ ID NO. 192 (called
   R6B1 1 herein), SEQ ID NO. 193/SEQ ID NO. 194 (called R6D1 herein), SEQ ID NO.
25 195/SEQ ID NO. 196 (called R6C8 herein), SEQ ID NO. 197/SEQ ID NO. 198 (called
   R9G8 herein), SEQ ID NO. 199/SEQ ID NO. 200 (called R7D1 herein), SEQ ID NO.
   201/SEQ ID NO. 202 (called R7D2 herein), SEQ ID NO. 203/SEQ ID NO. 204 (called
   R7E7 herein), SEQ ID NO. 205/SEQ ID NO. 206 (called R7F2 herein), SEQ ID NO.
   207/SEQ ID NO. 208 (called R7F7 herein), SEQ ID NO. 209/SEQ ID NO. 210 (called
30 R9H2 herein), SEQ ID NO. 211/SEQ ID NO. 212 (called R9H6 herein), SEQ ID NO.
   213/SEQ ID NO. 214 (called H6B1L herein), SEQ ID NO. 215/SEQ ID NO. 216 (called
                                            113

   H6A1 herein), SEQ ID NO. 217/SEQ ID NO. 218 (called H6B1 herein), SEQ ID NO.
   219/SEQ ID NO. 220 (called H6B2 herein), SEQ ID NO. 221/SEQ ID NO. 222 (called
   H19C herein), SEQ ID NO. 223/SEQ ID NO. 224 (called H1 OD herein), SEQ ID NO.
   225/SEQ ID NO. 226 (called HI IF herein), SEQ ID NO. 227/SEQ ID NO. 228 (called
 5 HICI herein), SEQ ID NO. 229/SEQ ID NO. 230 (called GPG1A2 herein), SEQ ID NO.
   231/SEQ ID NO. 232 (called GPGG8 herein), SEQ ID NO. 233/SEQ ID NO. 234 (called
   GPGG10 herein), SEQ ID NO. 235/SEQ ID NO. 236 (called GPGH7 herein), SEQ ID NO.
   237/SEQ ID NO. 238 (called GPGH10 herein), SEQ ID NO. 239/SEQ ID NO. 240 (called
   GPGH1 1 herein), SEQ ID NO. 241/SEQ ID NO. 242 (called GPGH OP herein), and
10 combinations thereof.
           3.     A Fab fully human antibody fragment, having a variable domain region from
   a heavy chain and a variable domain region from a light chain, wherein the heavy chain
   variable domain sequence that is at least 95% identical to the amino acid sequences selected
   from the group consisting of SEQ ID NO. 1, SEQ ID NO. 3, SEQ ID NO. 5, SEQ ID NO. 7,
15 SEQ ID NO. 9, SEQ ID NO. 11, SEQ ID NO. 13, SEQ ID NO. 15, SEQ ID NO. 17, SEQ
   ID NO. 19, SEQ ID NO. 21, SEQ ID NO. 23, SEQ ID NO. 25, SEQ ID NO. 27, SEQ ID
   NO. 29, SEQ ID NO. 31, SEQ ID NO. 33, SEQ ID NO. 35, SEQ ID NO. 37, SEQ ID NO.
   39, SEQ ID NO. 41, SEQ ID NO. 43, SEQ ID NO. 45, SEQ ID NO. 47, SEQ ID NO. 49,
   SEQ ID NO. 51, SEQ ID NO. 53, SEQ ID NO. 55, SEQ ID NO. 57, SEQ ID NO. 59, SEQ
20 ID NO. 61, SEQ ID NO. 63, SEQ ID NO. 65, SEQ ID NO. 67, SEQ ID NO. 69, SEQ ID
   NO. 71, SEQ ID NO. 73, SEQ ID NO. 75, SEQ ID NO. 77, SEQ ID NO. 79, SEQ ID NO.
   81, SEQ ID NO. 83, SEQ ID NO. 85, SEQ ID NO. 87, SEQ ID NO. 89, SEQ ID NO. 91,
   SEQ ID NO. 93, SEQ ID NO. 95, SEQ ID NO. 97, SEQ ID NO. 99, SEQ ID NO. 101, SEQ
   ID NO. 103, SEQ ID NO. 105, SEQ ID NO. 107, SEQ ID NO. 109, SEQ ID NO. 111, SEQ
25 ID NO. 113, SEQ ID NO. 115, SEQ ID NO. 117, SEQ ID NO. 119, SEQ ID NO. 121, SEQ
   ID NO. 123, SEQ ID NO. 125, SEQ ID NO. 127, SEQ ID NO. 129, SEQ ID NO. 131, SEQ
   ID NO. 133, SEQ ID NO. 135, SEQ ID NO. 137, SEQ ID NO. 139, SEQ ID NO. 141, SEQ
   ID NO. 143, SEQ ID NO. 145, SEQ ID NO. 147, SEQ ID NO. 149, SEQ ID NO. 151, SEQ
   ID NO. 153, SEQ ID NO. 155, SEQ ID NO. 157, SEQ ID NO. 159, SEQ ID NO. 161, SEQ
30 ID NO. 163, SEQ ID NO. 165, SEQ ID NO. 167, SEQ ID NO. 169, SEQ ID NO. 171, SEQ
   ID NO. 173, SEQ ID NO. 175, SEQ ID NO. 177, SEQ ID NO. 179, SEQ ID NO. 181, SEQ
                                                114

   ID NO. 183, SEQ ID NO. 185, SEQ ID NO. 187, SEQ ID NO. 189, SEQ ID NO. 191, SEQ
   ID NO. 193, SEQ ID NO. 195, SEQ ID NO. 197, SEQ ID NO. 199, SEQ ID NO. 201, SEQ
   ID NO. 203, SEQ ID NO. 205, SEQ ID NO. 207, SEQ ID NO. 209, SEQ ID NO. 211, SEQ
   ID NO. 213, SEQ ID NO. 215, SEQ ID NO. 217, SEQ ID NO. 219, SEQ ID NO. 221, SEQ
 5 ID NO. 223, SEQ ID NO. 225, SEQ ID NO. 227, SEQ ID NO. 229, SEQ ID NO. 231, SEQ
   ID NO. 233, SEQ ID NO. 235, SEQ ID NO. 237, SEQ ID NO. 239, SEQ ID NO. 241, and
   combinations thereof, and that has a light chain variable domain sequence that is at least
   95% identical to the amino acid sequences selected from the group consisting of SEQ ID
   NO. 2, SEQ ID NO. 4, SEQ ID NO. 6, SEQ ID NO. 8, SEQ ID NO. 10, SEQ ID NO. 12,
10 SEQ ID NO. 14, SEQ ID NO. 16, SEQ ID NO. 18, SEQ ID NO. 20, SEQ ID NO. 22, SEQ
   ID NO. 24, SEQ ID NO. 26, SEQ ID NO. 28, SEQ ID NO. 30, SEQ ID NO. 32, SEQ ID
   NO. 34, SEQ ID NO. 36, SEQ ID NO. 38, SEQ ID NO. 40, SEQ ID NO. 42, SEQ ID NO.
   44, SEQ ID NO. 46, SEQ ID NO. 48, SEQ ID NO. 50, SEQ ID NO. 52, SEQ ID NO. 54,
   SEQ ID NO. 56, SEQ ID NO. 58, SEQ ID NO. 60, SEQ ID NO. 62, SEQ ID NO. 64, SEQ
15 ID NO. 66, SEQ ID NO. 68, SEQ ID NO. 70, SEQ ID NO. 72, SEQ ID NO. 74, SEQ ID
   NO. 76, SEQ ID NO. 78, SEQ ID NO. 80, SEQ ID NO. 82, SEQ ID NO. 84, SEQ ID NO.
   86, SEQ ID NO. 88, SEQ ID NO. 90, SEQ ID NO. 92, SEQ ID NO. 94, SEQ ID NO. 96,
   SEQ ID NO. 98, SEQ ID NO. 100, SEQ ID NO. 102, SEQ ID NO. 104, SEQ ID NO. 106,
   SEQ ID NO. 108, SEQ ID NO. 110, SEQ ID NO. 112, SEQ ID NO. 114, SEQ ID NO. 116,
20 SEQ ID NO. 118, SEQ ID NO. 120, SEQ ID NO. 122, SEQ ID NO. 124, SEQ ID NO. 126,
   SEQ ID NO. 128, SEQ ID NO. 130, SEQ ID NO. 132, SEQ ID NO. 134, SEQ ID NO. 136,
   SEQ ID NO. 138, SEQ ID NO. 140, SEQ ID NO. 142, SEQ ID NO. 144, SEQ ID NO. 146,
   SEQ ID NO. 148, SEQ ID NO. 150, SEQ ID NO. 152, SEQ ID NO. 154, SEQ ID NO. 156,
   SEQ ID NO. 158, SEQ ID NO. 160, SEQ ID NO. 162, SEQ ID NO. 164, SEQ ID NO. 166,
25 SEQ ID NO. 168, SEQ ID NO. 170, SEQ ID NO. 172, SEQ ID NO. 174, SEQ ID NO. 176,
   SEQ ID NO. 178, SEQ ID NO. 180, SEQ ID NO. 182, SEQ ID NO. 184, SEQ ID NO. 186,
   SEQ ID NO. 188, SEQ ID NO. 190, SEQ ID NO. 192, SEQ ID NO. 194, SEQ ID NO. 196,
   SEQ ID NO. 198, SEQ ID NO. 200, SEQ ID NO. 202, SEQ ID NO. 204, SEQ ID NO. 206,
   SEQ ID NO. 208, SEQ ID NO. 210, SEQ ID NO. 212, SEQ ID NO. 214, SEQ ID NO. 216,
30 SEQ ID NO. 218, SEQ ID NO. 220, SEQ ID NO. 222, SEQ ID NO. 224, SEQ ID NO. 226,
                                                115

   SEQ ID NO. 228, SEQ ID NO. 230, SEQ ID NO. 232, SEQ ID NO. 234, SEQ ID NO. 236,
   SEQ ID NO. 238, SEQ ID NO. 240, SEQ ID NO. 242, and combinations thereof.
          4.      The fully human antibody Fab fragment of claim 3, wherein the antibody has
   a heavy chain/light chain variable domain sequence selected from the group consisting of
 5 SEQ ID NO. 1/SEQ ID NO. 2, SEQ ID NO. 3/SEQ ID NO. 4, SEQ ID NO. 5/SEQ ID NO.
   6, SEQ ID NO. 7/SEQ ID NO. 8, SEQ ID NO. 9/SEQ ID NO. 10, SEQ ID NO. 11/SEQ ID
   NO. 12, SEQ ID NO. 13/SEQ ID NO. 14, SEQ ID NO. 15/SEQ ID NO. 16, SEQ ID NO.
   17/SEQ ID NO. 18, SEQ ID NO. 19/SEQ ID NO. 20, SEQ ID NO. 21/SEQ ID NO. 22,
   SEQ ID NO. 23/SEQ ID NO. 24, SEQ ID NO. 25/SEQ ID NO. 26, SEQ ID NO. 27/SEQ ID
10 NO. 28, SEQ ID NO. 29/SEQ ID NO. 30, SEQ ID NO. 31/SEQ ID NO. 32, SEQ ID NO.
   33/SEQ ID NO. 34, SEQ ID NO. 35/SEQ ID NO. 36, SEQ ID NO. 37/SEQ ID NO. 38,
   SEQ ID NO. 39/SEQ ID NO. 40, SEQ ID NO. 41/SEQ ID NO. 42, SEQ ID NO. 43/SEQ ID
   NO. 44, SEQ ID NO. 45/SEQ ID NO. 46, SEQ ID NO. 47/SEQ ID NO. 48, SEQ ID NO.
   49/SEQ ID NO. 50, SEQ ID NO. 51/SEQ ID NO. 52, SEQ ID NO. 53/SEQ ID NO. 54,
15 SEQ ID NO. 55/SEQ ID NO. 56, SEQ ID NO. 57/SEQ ID NO. 58, SEQ ID NO. 59/SEQ ID
   NO. 60, SEQ ID NO. 61/SEQ ID NO. 62, SEQ ID NO. 63/SEQ ID NO. 64, SEQ ID NO.
   65/SEQ ID NO. 66, SEQ ID NO. 67/SEQ ID NO. 68, SEQ ID NO. 69/SEQ ID NO. 70,
   SEQ ID NO. 71/SEQ ID NO. 72, SEQ ID NO. 73/SEQ ID NO. 74, SEQ ID NO. 75/SEQ ID
   NO. 76, SEQ ID NO. 77/SEQ ID NO. 78, SEQ ID NO. 79/SEQ ID NO. 80, SEQ ID NO.
20 81/SEQ ID NO. 82, SEQ ID NO. 83/SEQ ID NO. 84, SEQ ID NO. 85/SEQ ID NO. 86,
   SEQ ID NO. 87/SEQ ID NO. 88, SEQ ID NO. 89/SEQ ID NO. 90, SEQ ID NO. 91/SEQ ID
   NO. 92, SEQ ID NO. 93/SEQ ID NO. 94, SEQ ID NO. 95/SEQ ID NO. 96, SEQ ID NO.
   97/SEQ ID NO. 98, SEQ ID NO. 99/SEQ ID NO. 100, SEQ ID NO. 101/SEQ ID NO. 102,
   SEQ ID NO. 103/SEQ ID NO. 104, SEQ ID NO. 105/SEQ ID NO. 106, SEQ ID NO.
25 107/SEQ ID NO. 108, SEQ ID NO. 109/SEQ ID NO. 110, SEQ ID NO. 111/SEQ ID NO.
   112, SEQ ID NO. 113/SEQ ID NO. 114, SEQ ID NO. 115/SEQ ID NO. 116, SEQ ID NO.
   117/SEQ ID NO. 118, SEQ ID NO. 119/SEQ ID NO. 120, SEQ ID NO. 121/SEQ ID NO.
   122, SEQ ID NO. 123/SEQ ID NO. 124, SEQ ID NO. 125/SEQ ID NO. 126, SEQ ID NO.
   127/SEQ ID NO. 128, SEQ ID NO. 129/SEQ ID NO. 130, SEQ ID NO. 131/SEQ ID NO.
30 132, SEQ ID NO. 133/SEQ ID NO. 134, SEQ ID NO. 135/SEQ ID NO. 136, SEQ ID NO.
   137/SEQ ID NO. 138, SEQ ID NO. 139/SEQ ID NO. 140, SEQ ID NO. 141/SEQ ID NO.
                                               116

   142, SEQ ID NO. 143/SEQ ID NO. 144, SEQ ID NO. 145/SEQ ID NO. 146, SEQ ID NO.
   147/SEQ ID NO. 148, SEQ ID NO. 149/SEQ ID NO. 150, SEQ ID NO. 151/SEQ ID NO.
   152, SEQ ID NO. 153/SEQ ID NO. 154, SEQ ID NO. 155/SEQ ID NO. 156, SEQ ID NO.
   157/SEQ ID NO. 158, SEQ ID NO. 159/SEQ ID NO. 160, SEQ ID NO. 161/SEQ ID NO.
 5 162, SEQ ID NO. 163/SEQ ID NO. 164, SEQ ID NO. 165/SEQ ID NO. 166, SEQ ID NO.
   167/SEQ ID NO. 168, SEQ ID NO. 169/SEQ ID NO. 170, SEQ ID NO. 171/SEQ ID NO.
   172, SEQ ID NO. 173/SEQ ID NO. 174, SEQ ID NO. 175/SEQ ID NO. 176, SEQ ID NO.
   177/SEQ ID NO. 178, SEQ ID NO. 179/SEQ ID NO. 180, SEQ ID NO. 181/SEQ ID NO.
   182, SEQ ID NO. 183/SEQ ID NO. 184, SEQ ID NO. 185/SEQ ID NO. 186, SEQ ID NO.
10 187/SEQ ID NO. 188, SEQ ID NO. 189/SEQ ID NO. 190, SEQ ID NO. 191/SEQ ID NO.
   192, SEQ ID NO. 193/SEQ ID NO. 194, SEQ ID NO. 195/SEQ ID NO. 196, SEQ ID NO.
   197/SEQ ID NO. 198, SEQ ID NO. 199/SEQ ID NO. 200, SEQ ID NO. 201/SEQ ID NO.
   202, SEQ ID NO. 203/SEQ ID NO. 204, SEQ ID NO. 205/SEQ ID NO. 206, SEQ ID NO.
   207/SEQ ID NO. 208, SEQ ID NO. 209/SEQ ID NO. 210, SEQ ID NO. 211/SEQ ID NO.
15 212, SEQ ID NO. 213/SEQ ID NO. 214, SEQ ID NO. 215/SEQ ID NO. 216, SEQ ID NO.
   217/SEQ ID NO. 218, SEQ ID NO. 219/SEQ ID NO. 220, SEQ ID NO. 221/SEQ ID NO.
   222, SEQ ID NO. 223/SEQ ID NO. 224, SEQ ID NO. 225/SEQ ID NO. 226, SEQ ID NO.
   227/SEQ ID NO. 228, SEQ ID NO. 229/SEQ ID NO. 230, SEQ ID NO. 231/SEQ ID NO.
   232, SEQ ID NO. 233/SEQ ID NO. 234, SEQ ID NO. 235/SEQ ID NO. 236, SEQ ID NO.
20 237/SEQ ID NO. 238, SEQ ID NO. 239/SEQ ID NO. 240, SEQ ID NO. 241/SEQ ID NO.
   242, and combinations thereof.
          5.      A single chain human antibody, having a variable domain region from a
   heavy chain and a variable domain region from a light chain and a peptide linker connection
   the heavy chain and light chain variable domain regions, wherein the heavy chain variable
25 domain sequence that is at least 95% identical to the amino acid sequences selected from the
   group consisting of SEQ ID NO. 1, SEQ ID NO. 3, SEQ ID NO. 5, SEQ ID NO. 7, SEQ ID
   NO. 9, SEQ ID NO. 11, SEQ ID NO. 13, SEQ ID NO. 15, SEQ ID NO. 17, SEQ ID NO.
   19, SEQ ID NO. 21, SEQ ID NO. 23, SEQ ID NO. 25, SEQ ID NO. 27, SEQ ID NO. 29,
   SEQ ID NO. 31, SEQ ID NO. 33, SEQ ID NO. 35, SEQ ID NO. 37, SEQ ID NO. 39, SEQ
30 ID NO. 41, SEQ ID NO. 43, SEQ ID NO. 45, SEQ ID NO. 47, SEQ ID NO. 49, SEQ ID
   NO. 51, SEQ ID NO. 53, SEQ ID NO. 55, SEQ ID NO. 57, SEQ ID NO. 59, SEQ ID NO.
                                                117

   61, SEQ ID NO. 63, SEQ ID NO. 65, SEQ ID NO. 67, SEQ ID NO. 69, SEQ ID NO. 71,
   SEQ ID NO. 73, SEQ ID NO. 75, SEQ ID NO. 77, SEQ ID NO. 79, SEQ ID NO. 81, SEQ
   ID NO. 83, SEQ ID NO. 85, SEQ ID NO. 87, SEQ ID NO. 89, SEQ ID NO. 91, SEQ ID
   NO. 93, SEQ ID NO. 95, SEQ ID NO. 97, SEQ ID NO. 99, SEQ ID NO. 101, SEQ ID NO.
 5 103, SEQ ID NO. 105, SEQ ID NO. 107, SEQ ID NO. 109, SEQ ID NO. 111, SEQ ID NO.
   113, SEQ ID NO. 115, SEQ ID NO. 117, SEQ ID NO. 119, SEQ ID NO. 121, SEQ ID NO.
   123, SEQ ID NO. 125, SEQ ID NO. 127, SEQ ID NO. 129, SEQ ID NO. 131, SEQ ID NO.
   133, SEQ ID NO. 135, SEQ ID NO. 137, SEQ ID NO. 139, SEQ ID NO. 141, SEQ ID NO.
   143, SEQ ID NO. 145, SEQ ID NO. 147, SEQ ID NO. 149, SEQ ID NO. 151, SEQ ID NO.
10 153, SEQ ID NO. 155, SEQ ID NO. 157, SEQ ID NO. 159, SEQ ID NO. 161, SEQ ID NO.
   163, SEQ ID NO. 165, SEQ ID NO. 167, SEQ ID NO. 169, SEQ ID NO. 171, SEQ ID NO.
   173, SEQ ID NO. 175, SEQ ID NO. 177, SEQ ID NO. 179, SEQ ID NO. 181, SEQ ID NO.
   183, SEQ ID NO. 185, SEQ ID NO. 187, SEQ ID NO. 189, SEQ ID NO. 191, SEQ ID NO.
   193, SEQ ID NO. 195, SEQ ID NO. 197, SEQ ID NO. 199, SEQ ID NO. 201, SEQ ID NO.
15 203, SEQ ID NO. 205, SEQ ID NO. 207, SEQ ID NO. 209, SEQ ID NO. 211, SEQ ID NO.
   213, SEQ ID NO. 215, SEQ ID NO. 217, SEQ ID NO. 219, SEQ ID NO. 221, SEQ ID NO.
   223, SEQ ID NO. 225, SEQ ID NO. 227, SEQ ID NO. 229, SEQ ID NO. 231, SEQ ID NO.
   233, SEQ ID NO. 235, SEQ ID NO. 237, SEQ ID NO. 239, SEQ ID NO. 241, and
   combinations thereof, and that has a light chain variable domain sequence that is at least
20 95% identical to the amino acid sequences selected from the group consisting of SEQ ID
   NO. 2, SEQ ID NO. 4, SEQ ID NO. 6, SEQ ID NO. 8, SEQ ID NO. 10, SEQ ID NO. 12,
   SEQ ID NO. 14, SEQ ID NO. 16, SEQ ID NO. 18, SEQ ID NO. 20, SEQ ID NO. 22, SEQ
   ID NO. 24, SEQ ID NO. 26, SEQ ID NO. 28, SEQ ID NO. 30, SEQ ID NO. 32, SEQ ID
   NO. 34, SEQ ID NO. 36, SEQ ID NO. 38, SEQ ID NO. 40, SEQ ID NO. 42, SEQ ID NO.
25 44, SEQ ID NO. 46, SEQ ID NO. 48, SEQ ID NO. 50, SEQ ID NO. 52, SEQ ID NO. 54,
   SEQ ID NO. 56, SEQ ID NO. 58, SEQ ID NO. 60, SEQ ID NO. 62, SEQ ID NO. 64, SEQ
   ID NO. 66, SEQ ID NO. 68, SEQ ID NO. 70, SEQ ID NO. 72, SEQ ID NO. 74, SEQ ID
   NO. 76, SEQ ID NO. 78, SEQ ID NO. 80, SEQ ID NO. 82, SEQ ID NO. 84, SEQ ID NO.
   86, SEQ ID NO. 88, SEQ ID NO. 90, SEQ ID NO. 92, SEQ ID NO. 94, SEQ ID NO. 96,
30 SEQ ID NO. 98, SEQ ID NO. 100, SEQ ID NO. 102, SEQ ID NO. 104, SEQ ID NO. 106,
   SEQ ID NO. 108, SEQ ID NO. 110, SEQ ID NO. 112, SEQ ID NO. 114, SEQ ID NO. 116,
                                                118

   SEQ ID NO. 118, SEQ ID NO. 120, SEQ ID NO. 122, SEQ ID NO. 124, SEQ ID NO. 126,
   SEQ ID NO. 128, SEQ ID NO. 130, SEQ ID NO. 132, SEQ ID NO. 134, SEQ ID NO. 136,
   SEQ ID NO. 138, SEQ ID NO. 140, SEQ ID NO. 142, SEQ ID NO. 144, SEQ ID NO. 146,
   SEQ ID NO. 148, SEQ ID NO. 150, SEQ ID NO. 152, SEQ ID NO. 154, SEQ ID NO. 156,
 5 SEQ ID NO. 158, SEQ ID NO. 160, SEQ ID NO. 162, SEQ ID NO. 164, SEQ ID NO. 166,
   SEQ ID NO. 168, SEQ ID NO. 170, SEQ ID NO. 172, SEQ ID NO. 174, SEQ ID NO. 176,
   SEQ ID NO. 178, SEQ ID NO. 180, SEQ ID NO. 182, SEQ ID NO. 184, SEQ ID NO. 186,
   SEQ ID NO. 188, SEQ ID NO. 190, SEQ ID NO. 192, SEQ ID NO. 194, SEQ ID NO. 196,
   SEQ ID NO. 198, SEQ ID NO. 200, SEQ ID NO. 202, SEQ ID NO. 204, SEQ ID NO. 206,
10 SEQ ID NO. 208, SEQ ID NO. 210, SEQ ID NO. 212, SEQ ID NO. 214, SEQ ID NO. 216,
   SEQ ID NO. 218, SEQ ID NO. 220, SEQ ID NO. 222, SEQ ID NO. 224, SEQ ID NO. 226,
   SEQ ID NO. 228, SEQ ID NO. 230, SEQ ID NO. 232, SEQ ID NO. 234, SEQ ID NO. 236,
   SEQ ID NO. 238, SEQ ID NO. 240, SEQ ID NO. 242, and combinations thereof.
           6.     The fully human single chain antibody of claim 5, wherein the single chain
15 fully human antibody has a heavy chain/light chain variable domain sequence selected from
   the group consisting of SEQ ID NO. 1/SEQ ID NO. 2, SEQ ID NO. 3/SEQ ID NO. 4, SEQ
   ID NO. 5/SEQ ID NO. 6, SEQ ID NO. 7/SEQ ID NO. 8, SEQ ID NO. 9/SEQ ID NO. 10,
   SEQ ID NO. 11/SEQ ID NO. 12, SEQ ID NO. 13/SEQ ID NO. 14, SEQ ID NO. 15/SEQ ID
   NO. 16, SEQ ID NO. 17/SEQ ID NO. 18, SEQ ID NO. 19/SEQ ID NO. 20, SEQ ID NO.
20 21/SEQ ID NO. 22, SEQ ID NO. 23/SEQ ID NO. 24, SEQ ID NO. 25/SEQ ID NO. 26,
   SEQ ID NO. 27/SEQ ID NO. 28, SEQ ID NO. 29/SEQ ID NO. 30, SEQ ID NO. 31/SEQ ID
   NO. 32, SEQ ID NO. 33/SEQ ID NO. 34, SEQ ID NO. 35/SEQ ID NO. 36, SEQ ID NO.
   37/SEQ ID NO. 38, SEQ ID NO. 39/SEQ ID NO. 40, SEQ ID NO. 41/SEQ ID NO. 42,
   SEQ ID NO. 43/SEQ ID NO. 44, SEQ ID NO. 45/SEQ ID NO. 46, SEQ ID NO. 47/SEQ ID
25 NO. 48, SEQ ID NO. 49/SEQ ID NO. 50, SEQ ID NO. 51/SEQ ID NO. 52, SEQ ID NO.
   53/SEQ ID NO. 54, SEQ ID NO. 55/SEQ ID NO. 56, SEQ ID NO. 57/SEQ ID NO. 58,
   SEQ ID NO. 59/SEQ ID NO. 60, SEQ ID NO. 61/SEQ ID NO. 62, SEQ ID NO. 63/SEQ ID
   NO. 64, SEQ ID NO. 65/SEQ ID NO. 66, SEQ ID NO. 67/SEQ ID NO. 68, SEQ ID NO.
   69/SEQ ID NO. 70, SEQ ID NO. 71/SEQ ID NO. 72, SEQ ID NO. 73/SEQ ID NO. 74,
30 SEQ ID NO. 75/SEQ ID NO. 76, SEQ ID NO. 77/SEQ ID NO. 78, SEQ ID NO. 79/SEQ ID
   NO. 80, SEQ ID NO. 81/SEQ ID NO. 82, SEQ ID NO. 83/SEQ ID NO. 84, SEQ ID NO.
                                               119

   85/SEQ ID NO. 86, SEQ ID NO. 87/SEQ ID NO. 88, SEQ ID NO. 89/SEQ ID NO. 90,
   SEQ ID NO. 91/SEQ ID NO. 92, SEQ ID NO. 93/SEQ ID NO. 94, SEQ ID NO. 95/SEQ ID
   NO. 96, SEQ ID NO. 97/SEQ ID NO. 98, SEQ ID NO. 99/SEQ ID NO. 100, SEQ ID NO.
   101/SEQ ID NO. 102, SEQ ID NO. 103/SEQ ID NO. 104, SEQ ID NO. 105/SEQ ID NO.
 5 106, SEQ ID NO. 107/SEQ ID NO. 108, SEQ ID NO. 109/SEQ ID NO. 110, SEQ ID NO.
   111/SEQ ID NO. 112, SEQ ID NO. 113/SEQ ID NO. 114, SEQ ID NO. 115/SEQ ID NO.
   116, SEQ ID NO. 117/SEQ ID NO. 118, SEQ ID NO. 119/SEQ ID NO. 120, SEQ ID NO.
   121/SEQ ID NO. 122, SEQ ID NO. 123/SEQ ID NO. 124, SEQ ID NO. 125/SEQ ID NO.
   126, SEQ ID NO. 127/SEQ ID NO. 128, SEQ ID NO. 129/SEQ ID NO. 130, SEQ ID NO.
10 131/SEQ ID NO. 132, SEQ ID NO. 133/SEQ ID NO. 134, SEQ ID NO. 135/SEQ ID NO.
   136, SEQ ID NO. 137/SEQ ID NO. 138, SEQ ID NO. 139/SEQ ID NO. 140, SEQ ID NO.
   141/SEQ ID NO. 142, SEQ ID NO. 143/SEQ ID NO. 144, SEQ ID NO. 145/SEQ ID NO.
   146, SEQ ID NO. 147/SEQ ID NO. 148, SEQ ID NO. 149/SEQ ID NO. 150, SEQ ID NO.
   151/SEQ ID NO. 152, SEQ ID NO. 153/SEQ ID NO. 154, SEQ ID NO. 155/SEQ ID NO.
15 156, SEQ ID NO. 157/SEQ ID NO. 158, SEQ ID NO. 159/SEQ ID NO. 160, SEQ ID NO.
   161/SEQ ID NO. 162, SEQ ID NO. 163/SEQ ID NO. 164, SEQ ID NO. 165/SEQ ID NO.
   166, SEQ ID NO. 167/SEQ ID NO. 168, SEQ ID NO. 169/SEQ ID NO. 170, SEQ ID NO.
   171/SEQ ID NO. 172, SEQ ID NO. 173/SEQ ID NO. 174, SEQ ID NO. 175/SEQ ID NO.
   176, SEQ ID NO. 177/SEQ ID NO. 178, SEQ ID NO. 179/SEQ ID NO. 180, SEQ ID NO.
20 181/SEQ ID NO. 182, SEQ ID NO. 183/SEQ ID NO. 184, SEQ ID NO. 185/SEQ ID NO.
   186, SEQ ID NO. 187/SEQ ID NO. 188, SEQ ID NO. 189/SEQ ID NO. 190, SEQ ID NO.
   191/SEQ ID NO. 192, SEQ ID NO. 193/SEQ ID NO. 194, SEQ ID NO. 195/SEQ ID NO.
   196, SEQ ID NO. 197/SEQ ID NO. 198, SEQ ID NO. 199/SEQ ID NO. 200, SEQ ID NO.
   201/SEQ ID NO. 202, SEQ ID NO. 203/SEQ ID NO. 204, SEQ ID NO. 205/SEQ ID NO.
25 206, SEQ ID NO. 207/SEQ ID NO. 208, SEQ ID NO. 209/SEQ ID NO. 210, SEQ ID NO.
   211/SEQ ID NO. 212, SEQ ID NO. 213/SEQ ID NO. 214, SEQ ID NO. 215/SEQ ID NO.
   216, SEQ ID NO. 217/SEQ ID NO. 218, SEQ ID NO. 219/SEQ ID NO. 220, SEQ ID NO.
   221/SEQ ID NO. 222, SEQ ID NO. 223/SEQ ID NO. 224, SEQ ID NO. 225/SEQ ID NO.
   226, SEQ ID NO. 227/SEQ ID NO. 228, SEQ ID NO. 229/SEQ ID NO. 230, SEQ ID NO.
30 231/SEQ ID NO. 232, SEQ ID NO. 233/SEQ ID NO. 234, SEQ ID NO. 235/SEQ ID NO.
                                          120

   236, SEQ ID NO. 237/SEQ ID NO. 238, SEQ ID NO. 239/SEQ ID NO. 240, SEQ ID NO.
   241/SEQ ID NO. 242, and combinations thereof.
           7.     The fully human single chain antibody of claim 5, wherein the fully human
   single chain antibody has both a heavy chain variable domain region and a light chain
 5 variable domain region, wherein the single chain fully human antibody has a heavy
   chain/light chain variable domain sequence selected from the group consisting of SEQ ID
   NO. 1/SEQ ID NO. 2, SEQ ID NO. 3/SEQ ID NO. 4, SEQ ID NO. 5/SEQ ID NO. 6, SEQ
   ID NO. 7/SEQ ID NO. 8, SEQ ID NO. 9/SEQ ID NO. 10, SEQ ID NO. 11/SEQ ID NO. 12,
   SEQ ID NO. 13/SEQ ID NO. 14, SEQ ID NO. 15/SEQ ID NO. 16, SEQ ID NO. 17/SEQ ID
10 NO. 18, SEQ ID NO. 19/SEQ ID NO. 20, SEQ ID NO. 21/SEQ ID NO. 22, SEQ ID NO.
   23/SEQ ID NO. 24, SEQ ID NO. 25/SEQ ID NO. 26, SEQ ID NO. 27/SEQ ID NO. 28,
   SEQ ID NO. 29/SEQ ID NO. 30, SEQ ID NO. 31/SEQ ID NO. 32, SEQ ID NO. 33/SEQ ID
   NO. 34, SEQ ID NO. 35/SEQ ID NO. 36, SEQ ID NO. 37/SEQ ID NO. 38, SEQ ID NO.
   39/SEQ ID NO. 40, SEQ ID NO. 41/SEQ ID NO. 42, SEQ ID NO. 43/SEQ ID NO. 44,
15 SEQ ID NO. 45/SEQ ID NO. 46, SEQ ID NO. 47/SEQ ID NO. 48, SEQ ID NO. 49/SEQ ID
   NO. 50, SEQ ID NO. 51/SEQ ID NO. 52, SEQ ID NO. 53/SEQ ID NO. 54, SEQ ID NO.
   55/SEQ ID NO. 56, SEQ ID NO. 57/SEQ ID NO. 58, SEQ ID NO. 59/SEQ ID NO. 60,
   SEQ ID NO. 61/SEQ ID NO. 62, SEQ ID NO. 63/SEQ ID NO. 64, SEQ ID NO. 65/SEQ ID
   NO. 66, SEQ ID NO. 67/SEQ ID NO. 68, SEQ ID NO. 69/SEQ ID NO. 70, SEQ ID NO.
20 71/SEQ ID NO. 72, SEQ ID NO. 73/SEQ ID NO. 74, SEQ ID NO. 75/SEQ ID NO. 76,
   SEQ ID NO. 77/SEQ ID NO. 78, SEQ ID NO. 79/SEQ ID NO. 80, SEQ ID NO. 81/SEQ ID
   NO. 82, SEQ ID NO. 83/SEQ ID NO. 84, SEQ ID NO. 85/SEQ ID NO. 86, SEQ ID NO.
   87/SEQ ID NO. 88, SEQ ID NO. 89/SEQ ID NO. 90, SEQ ID NO. 91/SEQ ID NO. 92,
   SEQ ID NO. 93/SEQ ID NO. 94, SEQ ID NO. 95/SEQ ID NO. 96, SEQ ID NO. 97/SEQ ID
25 NO. 98, SEQ ID NO. 99/SEQ ID NO. 100, SEQ ID NO. 101/SEQ ID NO. 102, SEQ ID
   NO. 103/SEQ ID NO. 104, SEQ ID NO. 105/SEQ ID NO. 106, SEQ ID NO. 107/SEQ ID
   NO. 108, SEQ ID NO. 109/SEQ ID NO. 110, SEQ ID NO. 111/SEQ ID NO. 112, SEQ ID
   NO. 113/SEQ ID NO. 114, SEQ ID NO. 115/SEQ ID NO. 116, SEQ ID NO. 117/SEQ ID
   NO. 118, SEQ ID NO. 119/SEQ ID NO. 120, SEQ ID NO. 121/SEQ ID NO. 122, SEQ ID
30 NO. 123/SEQ ID NO. 124, SEQ ID NO. 125/SEQ ID NO. 126, SEQ ID NO. 127/SEQ ID
   NO. 128, SEQ ID NO. 129/SEQ ID NO. 130, SEQ ID NO. 131/SEQ ID NO. 132, SEQ ID
                                               121

   NO. 133/SEQ ID NO. 134, SEQ ID NO. 135/SEQ ID NO. 136, SEQ ID NO. 137/SEQ ID
   NO. 138, SEQ ID NO. 139/SEQ ID NO. 140, SEQ ID NO. 141/SEQ ID NO. 142, SEQ ID
   NO. 143/SEQ ID NO. 144, SEQ ID NO. 145/SEQ ID NO. 146, SEQ ID NO. 147/SEQ ID
   NO. 148, SEQ ID NO. 149/SEQ ID NO. 150, SEQ ID NO. 151/SEQ ID NO. 152, SEQ ID
 5 NO. 153/SEQ ID NO. 154, SEQ ID NO. 155/SEQ ID NO. 156, SEQ ID NO. 157/SEQ ID
   NO. 158, SEQ ID NO. 159/SEQ ID NO. 160, SEQ ID NO. 161/SEQ ID NO. 162, SEQ ID
   NO. 163/SEQ ID NO. 164, SEQ ID NO. 165/SEQ ID NO. 166, SEQ ID NO. 167/SEQ ID
   NO. 168, SEQ ID NO. 169/SEQ ID NO. 170, SEQ ID NO. 171/SEQ ID NO. 172, SEQ ID
   NO. 173/SEQ ID NO. 174, SEQ ID NO. 175/SEQ ID NO. 176, SEQ ID NO. 177/SEQ ID
10 NO. 178, SEQ ID NO. 179/SEQ ID NO. 180, SEQ ID NO. 181/SEQ ID NO. 182, SEQ ID
   NO. 183/SEQ ID NO. 184, SEQ ID NO. 185/SEQ ID NO. 186, SEQ ID NO. 187/SEQ ID
   NO. 188, SEQ ID NO. 189/SEQ ID NO. 190, SEQ ID NO. 191/SEQ ID NO. 192, SEQ ID
   NO. 193/SEQ ID NO. 194, SEQ ID NO. 195/SEQ ID NO. 196, SEQ ID NO. 197/SEQ ID
   NO. 198, SEQ ID NO. 199/SEQ ID NO. 200, SEQ ID NO. 201/SEQ ID NO. 202, SEQ ID
15 NO. 203/SEQ ID NO. 204, SEQ ID NO. 205/SEQ ID NO. 206, SEQ ID NO. 207/SEQ ID
   NO. 208, SEQ ID NO. 209/SEQ ID NO. 210, SEQ ID NO. 211/SEQ ID NO. 212, SEQ ID
   NO. 213/SEQ ID NO. 214, SEQ ID NO. 215/SEQ ID NO. 216, SEQ ID NO. 217/SEQ ID
   NO. 218, SEQ ID NO. 219/SEQ ID NO. 220, SEQ ID NO. 221/SEQ ID NO. 222, SEQ ID
   NO. 223/SEQ ID NO. 224, SEQ ID NO. 225/SEQ ID NO. 226, SEQ ID NO. 227/SEQ ID
20 NO. 228, SEQ ID NO. 229/SEQ ID NO. 230, SEQ ID NO. 231/SEQ ID NO. 232, SEQ ID
   NO. 233/SEQ ID NO. 234, SEQ ID NO. 235/SEQ ID NO. 236, SEQ ID NO. 237/SEQ ID
   NO. 238, SEQ ID NO. 239/SEQ ID NO. 240, SEQ ID NO. 241/SEQ ID NO. 242, and
   combinations thereof.
           8.      A method for treating a broad spectrum of mammalian cancers or treating
25 inflammatory diseases or autoimmune diseases, comprising administering an effective
   amount of an anti-PD-Li polypeptide, wherein the anti-PD-Li polypeptide is selected from
   the group consisting of a fully human antibody of an IgG class that binds to a PD-LI epitope
   with a binding affinity of at least 10-6 M, a Fab fully human antibody fragment, having a
   variable domain region from a heavy chain and a variable domain region from a light chain,
30 a single chain human antibody, having a variable domain region from a heavy chain and a
                                                  122

   variable domain region from a light chain and a peptide linker connection the heavy chain
   and light chain variable domain regions, and combinations thereof;
            wherein the fully human antibody has a heavy chain variable domain sequence that
   is at least 95% identical to the amino acid sequences selected from the group consisting of
 5 SEQ ID NO. 1, SEQ ID NO. 3, SEQ ID NO. 5, SEQ ID NO. 7, SEQ ID NO. 9, SEQ ID NO.
   11, SEQ ID NO. 13, SEQ ID NO. 15, SEQ ID NO. 17, SEQ ID NO. 19, SEQ ID NO. 21,
   SEQ ID NO. 23, SEQ ID NO. 25, SEQ ID NO. 27, SEQ ID NO. 29, SEQ ID NO. 31, SEQ
   ID NO. 33, SEQ ID NO. 35, SEQ ID NO. 37, SEQ ID NO. 39, SEQ ID NO. 41, SEQ ID
   NO. 43, SEQ ID NO. 45, SEQ ID NO. 47, SEQ ID NO. 49, SEQ ID NO. 51, SEQ ID NO.
10 53, SEQ ID NO. 55, SEQ ID NO. 57, SEQ ID NO. 59, SEQ ID NO. 61, SEQ ID NO. 63,
   SEQ ID NO. 65, SEQ ID NO. 67, SEQ ID NO. 69, SEQ ID NO. 71, SEQ ID NO. 73, SEQ
   ID NO. 75, SEQ ID NO. 77, SEQ ID NO. 79, SEQ ID NO. 81, SEQ ID NO. 83, SEQ ID
   NO. 85, SEQ ID NO. 87, SEQ ID NO. 89, SEQ ID NO. 91, SEQ ID NO. 93, SEQ ID NO.
   95, SEQ ID NO. 97, SEQ ID NO. 99, SEQ ID NO. 101, SEQ ID NO. 103, SEQ ID NO.
15 105, SEQ ID NO. 107, SEQ ID NO. 109, SEQ ID NO. 111, SEQ ID NO. 113, SEQ ID NO.
   115, SEQ ID NO. 117, SEQ ID NO. 119, SEQ ID NO. 121, SEQ ID NO. 123, SEQ ID NO.
   125, SEQ ID NO. 127, SEQ ID NO. 129, SEQ ID NO. 131, SEQ ID NO. 133, SEQ ID NO.
   135, SEQ ID NO. 137, SEQ ID NO. 139, SEQ ID NO. 141, SEQ ID NO. 143, SEQ ID NO.
   145, SEQ ID NO. 147, SEQ ID NO. 149, SEQ ID NO. 151, SEQ ID NO. 153, SEQ ID NO.
20 155, SEQ ID NO. 157, SEQ ID NO. 159, SEQ ID NO. 161, SEQ ID NO. 163, SEQ ID NO.
   165, SEQ ID NO. 167, SEQ ID NO. 169, SEQ ID NO. 171, SEQ ID NO. 173, SEQ ID NO.
   175, SEQ ID NO. 177, SEQ ID NO. 179, SEQ ID NO. 181, SEQ ID NO. 183, SEQ ID NO.
   185, SEQ ID NO. 187, SEQ ID NO. 189, SEQ ID NO. 191, SEQ ID NO. 193, SEQ ID NO.
   195, SEQ ID NO. 197, SEQ ID NO. 199, SEQ ID NO. 201, SEQ ID NO. 203, SEQ ID NO.
25 205, SEQ ID NO. 207, SEQ ID NO. 209, SEQ ID NO. 211, SEQ ID NO. 213, SEQ ID NO.
   215, SEQ ID NO. 217, SEQ ID NO. 219, SEQ ID NO. 221, SEQ ID NO. 223, SEQ ID NO.
   225, SEQ ID NO. 227, SEQ ID NO. 229, SEQ ID NO. 231, SEQ ID NO. 233, SEQ ID NO.
   235, SEQ ID NO. 237, SEQ ID NO. 239, SEQ ID NO. 241, and combinations thereof, and
   that has a light chain variable domain sequence that is at least 95% identical to the amino
30 acid sequences selected from the group consisting of SEQ ID NO. 2, SEQ ID NO. 4, SEQ
   ID NO. 6, SEQ ID NO. 8, SEQ ID NO. 10, SEQ ID NO. 12, SEQ ID NO. 14, SEQ ID NO.
                                                 123

   16, SEQ ID NO. 18, SEQ ID NO. 20, SEQ ID NO. 22, SEQ ID NO. 24, SEQ ID NO. 26,
   SEQ ID NO. 28, SEQ ID NO. 30, SEQ ID NO. 32, SEQ ID NO. 34, SEQ ID NO. 36, SEQ
   ID NO. 38, SEQ ID NO. 40, SEQ ID NO. 42, SEQ ID NO. 44, SEQ ID NO. 46, SEQ ID
   NO. 48, SEQ ID NO. 50, SEQ ID NO. 52, SEQ ID NO. 54, SEQ ID NO. 56, SEQ ID NO.
 5 58, SEQ ID NO. 60, SEQ ID NO. 62, SEQ ID NO. 64, SEQ ID NO. 66, SEQ ID NO. 68,
   SEQ ID NO. 70, SEQ ID NO. 72, SEQ ID NO. 74, SEQ ID NO. 76, SEQ ID NO. 78, SEQ
   ID NO. 80, SEQ ID NO. 82, SEQ ID NO. 84, SEQ ID NO. 86, SEQ ID NO. 88, SEQ ID
   NO. 90, SEQ ID NO. 92, SEQ ID NO. 94, SEQ ID NO. 96, SEQ ID NO. 98, SEQ ID NO.
   100, SEQ ID NO. 102, SEQ ID NO. 104, SEQ ID NO. 106, SEQ ID NO. 108, SEQ ID NO.
10 110, SEQ ID NO. 112, SEQ ID NO. 114, SEQ ID NO. 116, SEQ ID NO. 118, SEQ ID NO.
   120, SEQ ID NO. 122, SEQ ID NO. 124, SEQ ID NO. 126, SEQ ID NO. 128, SEQ ID NO.
   130, SEQ ID NO. 132, SEQ ID NO. 134, SEQ ID NO. 136, SEQ ID NO. 138, SEQ ID NO.
   140, SEQ ID NO. 142, SEQ ID NO. 144, SEQ ID NO. 146, SEQ ID NO. 148, SEQ ID NO.
   150, SEQ ID NO. 152, SEQ ID NO. 154, SEQ ID NO. 156, SEQ ID NO. 158, SEQ ID NO.
15 160, SEQ ID NO. 162, SEQ ID NO. 164, SEQ ID NO. 166, SEQ ID NO. 168, SEQ ID NO.
   170, SEQ ID NO. 172, SEQ ID NO. 174, SEQ ID NO. 176, SEQ ID NO. 178, SEQ ID NO.
   180, SEQ ID NO. 182, SEQ ID NO. 184, SEQ ID NO. 186, SEQ ID NO. 188, SEQ ID NO.
   190, SEQ ID NO. 192, SEQ ID NO. 194, SEQ ID NO. 196, SEQ ID NO. 198, SEQ ID NO.
   200, SEQ ID NO. 202, SEQ ID NO. 204, SEQ ID NO. 206, SEQ ID NO. 208, SEQ ID NO.
20 210, SEQ ID NO. 212, SEQ ID NO. 214, SEQ ID NO. 216, SEQ ID NO. 218, SEQ ID NO.
   220, SEQ ID NO. 222, SEQ ID NO. 224, SEQ ID NO. 226, SEQ ID NO. 228, SEQ ID NO.
   230, SEQ ID NO. 232, SEQ ID NO. 234, SEQ ID NO. 236, SEQ ID NO. 238, SEQ ID NO.
   240, SEQ ID NO. 242, and combinations thereof;
           wherein the Fab fully human antibody fragment has the heavy chain variable domain
25 sequence that is at least 95% identical to the amino acid sequences selected from the group
   consisting of SEQ ID NO. 1, SEQ ID NO. 3, SEQ ID NO. 5, SEQ ID NO. 7, SEQ ID NO. 9,
   SEQ ID NO. 11, SEQ ID NO. 13, SEQ ID NO. 15, SEQ ID NO. 17, SEQ ID NO. 19, SEQ
   ID NO. 21, SEQ ID NO. 23, SEQ ID NO. 25, SEQ ID NO. 27, SEQ ID NO. 29, SEQ ID
   NO. 31, SEQ ID NO. 33, SEQ ID NO. 35, SEQ ID NO. 37, SEQ ID NO. 39, SEQ ID NO.
30 41, SEQ ID NO. 43, SEQ ID NO. 45, SEQ ID NO. 47, SEQ ID NO. 49, SEQ ID NO. 51,
   SEQ ID NO. 53, SEQ ID NO. 55, SEQ ID NO. 57, SEQ ID NO. 59, SEQ ID NO. 61, SEQ
                                                  124

   ID NO. 63, SEQ ID NO. 65, SEQ ID NO. 67, SEQ ID NO. 69, SEQ ID NO. 71, SEQ ID
   NO. 73, SEQ ID NO. 75, SEQ ID NO. 77, SEQ ID NO. 79, SEQ ID NO. 81, SEQ ID NO.
   83, SEQ ID NO. 85, SEQ ID NO. 87, SEQ ID NO. 89, SEQ ID NO. 91, SEQ ID NO. 93,
   SEQ ID NO. 95, SEQ ID NO. 97, SEQ ID NO. 99, SEQ ID NO. 101, SEQ ID NO. 103,
 5 SEQ ID NO. 105, SEQ ID NO. 107, SEQ ID NO. 109, SEQ ID NO. 111, SEQ ID NO. 113,
   SEQ ID NO. 115, SEQ ID NO. 117, SEQ ID NO. 119, SEQ ID NO. 121, SEQ ID NO. 123,
   SEQ ID NO. 125, SEQ ID NO. 127, SEQ ID NO. 129, SEQ ID NO. 131, SEQ ID NO. 133,
   SEQ ID NO. 135, SEQ ID NO. 137, SEQ ID NO. 139, SEQ ID NO. 141, SEQ ID NO. 143,
   SEQ ID NO. 145, SEQ ID NO. 147, SEQ ID NO. 149, SEQ ID NO. 151, SEQ ID NO. 153,
10 SEQ ID NO. 155, SEQ ID NO. 157, SEQ ID NO. 159, SEQ ID NO. 161, SEQ ID NO. 163,
   SEQ ID NO. 165, SEQ ID NO. 167, SEQ ID NO. 169, SEQ ID NO. 171, SEQ ID NO. 173,
   SEQ ID NO. 175, SEQ ID NO. 177, SEQ ID NO. 179, SEQ ID NO. 181, SEQ ID NO. 183,
   SEQ ID NO. 185, SEQ ID NO. 187, SEQ ID NO. 189, SEQ ID NO. 191, SEQ ID NO. 193,
   SEQ ID NO. 195, SEQ ID NO. 197, SEQ ID NO. 199, SEQ ID NO. 201, SEQ ID NO. 203,
15 SEQ ID NO. 205, SEQ ID NO. 207, SEQ ID NO. 209, SEQ ID NO. 211, SEQ ID NO. 213,
   SEQ ID NO. 215, SEQ ID NO. 217, SEQ ID NO. 219, SEQ ID NO. 221, SEQ ID NO. 223,
   SEQ ID NO. 225, SEQ ID NO. 227, and combinations thereof, and that has the light chain
   variable domain sequence that is at least 95% identical to the amino acid sequences selected
   from the group consisting of SEQ ID NO. 2, SEQ ID NO. 4, SEQ ID NO. 6, SEQ ID NO. 8,
20 SEQ ID NO. 10, SEQ ID NO. 12, SEQ ID NO. 14, SEQ ID NO. 16, SEQ ID NO. 18, SEQ
   ID NO. 20, SEQ ID NO. 22, SEQ ID NO. 24, SEQ ID NO. 26, SEQ ID NO. 28, SEQ ID
   NO. 30, SEQ ID NO. 32, SEQ ID NO. 34, SEQ ID NO. 36, SEQ ID NO. 38, SEQ ID NO.
   40, SEQ ID NO. 42, SEQ ID NO. 44, SEQ ID NO. 46, SEQ ID NO. 48, SEQ ID NO. 50,
   SEQ ID NO. 52, SEQ ID NO. 54, SEQ ID NO. 56, SEQ ID NO. 58, SEQ ID NO. 60, SEQ
25 ID NO. 62, SEQ ID NO. 64, SEQ ID NO. 66, SEQ ID NO. 68, SEQ ID NO. 70, SEQ ID
   NO. 72, SEQ ID NO. 74, SEQ ID NO. 76, SEQ ID NO. 78, SEQ ID NO. 80, SEQ ID NO.
   82, SEQ ID NO. 84, SEQ ID NO. 86, SEQ ID NO. 88, SEQ ID NO. 90, SEQ ID NO. 92,
   SEQ ID NO. 94, SEQ ID NO. 96, SEQ ID NO. 98, SEQ ID NO. 100, SEQ ID NO. 102,
   SEQ ID NO. 104, SEQ ID NO. 106, SEQ ID NO. 108, SEQ ID NO. 110, SEQ ID NO. 112,
30 SEQIDNO. 114, SEQIDNO. 116, SEQIDNO. 118, SEQIDNO. 120, SEQIDNO. 122,
   SEQ ID NO. 124, SEQ ID NO. 126, SEQ ID NO. 128, SEQ ID NO. 130, SEQ ID NO. 132,
                                                125

   SEQ ID NO. 134, SEQ ID NO. 136, SEQ ID NO. 138, SEQ ID NO. 140, SEQ ID NO. 142,
   SEQ ID NO. 144, SEQ ID NO. 146, SEQ ID NO. 148, SEQ ID NO. 150, SEQ ID NO. 152,
   SEQ ID NO. 154, SEQ ID NO. 156, SEQ ID NO. 158, SEQ ID NO. 160, SEQ ID NO. 162,
   SEQ ID NO. 164, SEQ ID NO. 166, SEQ ID NO. 168, SEQ ID NO. 170, SEQ ID NO. 172,
 5 SEQ ID NO. 174, SEQ ID NO. 176, SEQ ID NO. 178, SEQ ID NO. 180, SEQ ID NO. 182,
   SEQ ID NO. 184, SEQ ID NO. 186, SEQ ID NO. 188, SEQ ID NO. 190, SEQ ID NO. 192,
   SEQ ID NO. 194, SEQ ID NO. 196, SEQ ID NO. 198, SEQ ID NO. 200, SEQ ID NO. 202,
   SEQ ID NO. 204, SEQ ID NO. 206, SEQ ID NO. 208, SEQ ID NO. 210, SEQ ID NO. 212,
   SEQ ID NO. 214, SEQ ID NO. 216, SEQ ID NO. 218, SEQ ID NO. 220, SEQ ID NO. 222,
10 SEQ ID NO. 224, SEQ ID NO. 226, SEQ ID NO. 228, SEQ ID NO. 230, SEQ ID NO. 232,
   SEQ ID NO. 234, SEQ ID NO. 236, SEQ ID NO. 238, SEQ ID NO. 240, SEQ ID NO. 242,
   and combinations thereof; and
           wherein the single chain human antibody has the heavy chain variable domain
   sequence that is at least 95% identical to the amino acid sequences selected from the group
15 consisting of SEQ ID NO. 1, SEQ ID NO. 3, SEQ ID NO. 5, SEQ ID NO. 7, SEQ ID NO. 9,
   SEQ ID NO. 11, SEQ ID NO. 13, SEQ ID NO. 15, SEQ ID NO. 17, SEQ ID NO. 19, SEQ
   ID NO. 21, SEQ ID NO. 23, SEQ ID NO. 25, SEQ ID NO. 27, SEQ ID NO. 29, SEQ ID
   NO. 31, SEQ ID NO. 33, SEQ ID NO. 35, SEQ ID NO. 37, SEQ ID NO. 39, SEQ ID NO.
   41, SEQ ID NO. 43, SEQ ID NO. 45, SEQ ID NO. 47, SEQ ID NO. 49, SEQ ID NO. 51,
20 SEQ ID NO. 53, SEQ ID NO. 55, SEQ ID NO. 57, SEQ ID NO. 59, SEQ ID NO. 61, SEQ
   ID NO. 63, SEQ ID NO. 65, SEQ ID NO. 67, SEQ ID NO. 69, SEQ ID NO. 71, SEQ ID
   NO. 73, SEQ ID NO. 75, SEQ ID NO. 77, SEQ ID NO. 79, SEQ ID NO. 81, SEQ ID NO.
   83, SEQ ID NO. 85, SEQ ID NO. 87, SEQ ID NO. 89, SEQ ID NO. 91, SEQ ID NO. 93,
   SEQ ID NO. 95, SEQ ID NO. 97, SEQ ID NO. 99, SEQ ID NO. 101, SEQ ID NO. 103,
25 SEQ ID NO. 105, SEQ ID NO. 107, SEQ ID NO. 109, SEQ ID NO. 111, SEQ ID NO. 113,
   SEQ ID NO. 115, SEQ ID NO. 117, SEQ ID NO. 119, SEQ ID NO. 121, SEQ ID NO. 123,
   SEQ ID NO. 125, SEQ ID NO. 127, SEQ ID NO. 129, SEQ ID NO. 131, SEQ ID NO. 133,
   SEQ ID NO. 135, SEQ ID NO. 137, SEQ ID NO. 139, SEQ ID NO. 141, SEQ ID NO. 143,
   SEQ ID NO. 145, SEQ ID NO. 147, SEQ ID NO. 149, SEQ ID NO. 151, SEQ ID NO. 153,
30 SEQ ID NO. 155, SEQ ID NO. 157, SEQ ID NO. 159, SEQ ID NO. 161, SEQ ID NO. 163,
   SEQ ID NO. 165, SEQ ID NO. 167, SEQ ID NO. 169, SEQ ID NO. 171, SEQ ID NO. 173,
                                                  126

   SEQ ID NO. 175, SEQ ID NO. 177, SEQ ID NO. 179, SEQ ID NO. 181, SEQ ID NO. 183,
   SEQ ID NO. 185, SEQ ID NO. 187, SEQ ID NO. 189, SEQ ID NO. 191, SEQ ID NO. 193,
   SEQ ID NO. 195, SEQ ID NO. 197, SEQ ID NO. 199, SEQ ID NO. 201, SEQ ID NO. 203,
   SEQ ID NO. 205, SEQ ID NO. 207, SEQ ID NO. 209, SEQ ID NO. 211, SEQ ID NO. 213,
 5 SEQ ID NO. 215, SEQ ID NO. 217, SEQ ID NO. 219, SEQ ID NO. 221, SEQ ID NO. 223,
   SEQ ID NO. 225, SEQ ID NO. 227, SEQ ID NO. 229, SEQ ID NO. 231, SEQ ID NO. 233,
   SEQ ID NO. 235, SEQ ID NO. 237, SEQ ID NO. 239, SEQ ID NO. 241, and combinations
   thereof, and that has the light chain variable domain sequence that is at least 95% identical
   to the amino acid sequences selected from the group consisting of SEQ ID NO. 2, SEQ ID
10 NO. 4, SEQ ID NO. 6, SEQ ID NO. 8, SEQ ID NO. 10, SEQ ID NO. 12, SEQ ID NO. 14,
   SEQ ID NO. 16, SEQ ID NO. 18, SEQ ID NO. 20, SEQ ID NO. 22, SEQ ID NO. 24, SEQ
   ID NO. 26, SEQ ID NO. 28, SEQ ID NO. 30, SEQ ID NO. 32, SEQ ID NO. 34, SEQ ID
   NO. 36, SEQ ID NO. 38, SEQ ID NO. 40, SEQ ID NO. 42, SEQ ID NO. 44, SEQ ID NO.
   46, SEQ ID NO. 48, SEQ ID NO. 50, SEQ ID NO. 52, SEQ ID NO. 54, SEQ ID NO. 56,
15 SEQ ID NO. 58, SEQ ID NO. 60, SEQ ID NO. 62, SEQ ID NO. 64, SEQ ID NO. 66, SEQ
   ID NO. 68, SEQ ID NO. 70, SEQ ID NO. 72, SEQ ID NO. 74, SEQ ID NO. 76, SEQ ID
   NO. 78, SEQ ID NO. 80, SEQ ID NO. 82, SEQ ID NO. 84, SEQ ID NO. 86, SEQ ID NO.
   88, SEQ ID NO. 90, SEQ ID NO. 92, SEQ ID NO. 94, SEQ ID NO. 96, SEQ ID NO. 98,
   SEQ ID NO. 100, SEQ ID NO. 102, SEQ ID NO. 104, SEQ ID NO. 106, SEQ ID NO. 108,
20 SEQ ID NO. 110, SEQ ID NO. 112, SEQ ID NO. 114, SEQ ID NO. 116, SEQ ID NO. 118,
   SEQ ID NO. 120, SEQ ID NO. 122, SEQ ID NO. 124, SEQ ID NO. 126, SEQ ID NO. 128,
   SEQ ID NO. 130, SEQ ID NO. 132, SEQ ID NO. 134, SEQ ID NO. 136, SEQ ID NO. 138,
   SEQ ID NO. 140, SEQ ID NO. 142, SEQ ID NO. 144, SEQ ID NO. 146, SEQ ID NO. 148,
   SEQ ID NO. 150, SEQ ID NO. 152, SEQ ID NO. 154, SEQ ID NO. 156, SEQ ID NO. 158,
25 SEQ ID NO. 160, SEQ ID NO. 162, SEQ ID NO. 164, SEQ ID NO. 166, SEQ ID NO. 168,
   SEQ ID NO. 170, SEQ ID NO. 172, SEQ ID NO. 174, SEQ ID NO. 176, SEQ ID NO. 178,
   SEQ ID NO. 180, SEQ ID NO. 182, SEQ ID NO. 184, SEQ ID NO. 186, SEQ ID NO. 188,
   SEQ ID NO. 190, SEQ ID NO. 192, SEQ ID NO. 194, SEQ ID NO. 196, SEQ ID NO. 198,
   SEQ ID NO. 200, SEQ ID NO. 202, SEQ ID NO. 204, SEQ ID NO. 206, SEQ ID NO. 208,
30 SEQ ID NO. 210, SEQ ID NO. 212, SEQ ID NO. 214, SEQ ID NO. 216, SEQ ID NO. 218,
   SEQ ID NO. 220, SEQ ID NO. 222, SEQ ID NO. 224, SEQ ID NO. 226, SEQ ID NO. 228,
                                                  127

   SEQ ID NO. 230, SEQ ID NO. 232, SEQ ID NO. 234, SEQ ID NO. 236, SEQ ID NO. 238,
   SEQ ID NO. 240, SEQ ID NO. 242, and combinations thereof.
           9.     The method for treating a broad spectrum of mammalian cancers of claim 8,
   wherein the fully human antibody has a heavy chain/light chain variable domain sequence
 5 selected from the group consisting of SEQ ID NO. 1/SEQ ID NO. 2, SEQ ID NO. 3/SEQ ID
   NO. 4, SEQ ID NO. 5/SEQ ID NO. 6, SEQ ID NO. 7/SEQ ID NO. 8, SEQ ID NO. 9/SEQ
   ID NO. 10, SEQ ID NO. 11/SEQ ID NO. 12, SEQ ID NO. 13/SEQ ID NO. 14, SEQ ID NO.
   15/SEQ ID NO. 16, SEQ ID NO. 17/SEQ ID NO. 18, SEQ ID NO. 19/SEQ ID NO. 20,
   SEQ ID NO. 21/SEQ ID NO. 22, SEQ ID NO. 23/SEQ ID NO. 24, SEQ ID NO. 25/SEQ ID
10 NO. 26, SEQ ID NO. 27/SEQ ID NO. 28, SEQ ID NO. 29/SEQ ID NO. 30, SEQ ID NO.
   31/SEQ ID NO. 32, SEQ ID NO. 33/SEQ ID NO. 34, SEQ ID NO. 35/SEQ ID NO. 36,
   SEQ ID NO. 37/SEQ ID NO. 38, SEQ ID NO. 39/SEQ ID NO. 40, SEQ ID NO. 41/SEQ ID
   NO. 42, SEQ ID NO. 43/SEQ ID NO. 44, SEQ ID NO. 45/SEQ ID NO. 46, SEQ ID NO.
   47/SEQ ID NO. 48, SEQ ID NO. 49/SEQ ID NO. 50, SEQ ID NO. 51/SEQ ID NO. 52,
15 SEQ ID NO. 53/SEQ ID NO. 54, SEQ ID NO. 55/SEQ ID NO. 56, SEQ ID NO. 57/SEQ ID
   NO. 58, SEQ ID NO. 59/SEQ ID NO. 60, SEQ ID NO. 61/SEQ ID NO. 62, SEQ ID NO.
   63/SEQ ID NO. 64, SEQ ID NO. 65/SEQ ID NO. 66, SEQ ID NO. 67/SEQ ID NO. 68,
   SEQ ID NO. 69/SEQ ID NO. 70, SEQ ID NO. 71/SEQ ID NO. 72, SEQ ID NO. 73/SEQ ID
   NO. 74, SEQ ID NO. 75/SEQ ID NO. 76, SEQ ID NO. 77/SEQ ID NO. 78, SEQ ID NO.
20 79/SEQ ID NO. 80, SEQ ID NO. 81/SEQ ID NO. 82, SEQ ID NO. 83/SEQ ID NO. 84,
   SEQ ID NO. 85/SEQ ID NO. 86, SEQ ID NO. 87/SEQ ID NO. 88, SEQ ID NO. 89/SEQ ID
   NO. 90, SEQ ID NO. 91/SEQ ID NO. 92, SEQ ID NO. 93/SEQ ID NO. 94, SEQ ID NO.
   95/SEQ ID NO. 96, SEQ ID NO. 97/SEQ ID NO. 98, SEQ ID NO. 99/SEQ ID NO. 100,
   SEQ ID NO. 101/SEQ ID NO. 102, SEQ ID NO. 103/SEQ ID NO. 104, SEQ ID NO.
25 105/SEQ ID NO. 106, SEQ ID NO. 107/SEQ ID NO. 108, SEQ ID NO. 109/SEQ ID NO.
   110, SEQ ID NO. 111/SEQ ID NO. 112, SEQ ID NO. 113/SEQ ID NO. 114, SEQ ID NO.
   115/SEQ ID NO. 116, SEQ ID NO. 117/SEQ ID NO. 118, SEQ ID NO. 119/SEQ ID NO.
   120, SEQ ID NO. 121/SEQ ID NO. 122, SEQ ID NO. 123/SEQ ID NO. 124, SEQ ID NO.
   125/SEQ ID NO. 126, SEQ ID NO. 127/SEQ ID NO. 128, SEQ ID NO. 129/SEQ ID NO.
30 130, SEQ ID NO. 131/SEQ ID NO. 132, SEQ ID NO. 133/SEQ ID NO. 134, SEQ ID NO.
   135/SEQ ID NO. 136, SEQ ID NO. 137/SEQ ID NO. 138, SEQ ID NO. 139/SEQ ID NO.
                                               128

   140, SEQ ID NO. 141/SEQ ID NO. 142, SEQ ID NO. 143/SEQ ID NO. 144, SEQ ID NO.
   145/SEQ ID NO. 146, SEQ ID NO. 147/SEQ ID NO. 148, SEQ ID NO. 149/SEQ ID NO.
   150, SEQ ID NO. 151/SEQ ID NO. 152, SEQ ID NO. 153/SEQ ID NO. 154, SEQ ID NO.
   155/SEQ ID NO. 156, SEQ ID NO. 157/SEQ ID NO. 158, SEQ ID NO. 159/SEQ ID NO.
 5 160, SEQ ID NO. 161/SEQ ID NO. 162, SEQ ID NO. 163/SEQ ID NO. 164, SEQ ID NO.
   165/SEQ ID NO. 166, SEQ ID NO. 167/SEQ ID NO. 168, SEQ ID NO. 169/SEQ ID NO.
   170, SEQ ID NO. 171/SEQ ID NO. 172, SEQ ID NO. 173/SEQ ID NO. 174, SEQ ID NO.
   175/SEQ ID NO. 176, SEQ ID NO. 177/SEQ ID NO. 178, SEQ ID NO. 179/SEQ ID NO.
   180, SEQ ID NO. 181/SEQ ID NO. 182, SEQ ID NO. 183/SEQ ID NO. 184, SEQ ID NO.
10 185/SEQ ID NO. 186, SEQ ID NO. 187/SEQ ID NO. 188, SEQ ID NO. 189/SEQ ID NO.
   190, SEQ ID NO. 191/SEQ ID NO. 192, SEQ ID NO. 193/SEQ ID NO. 194, SEQ ID NO.
   195/SEQ ID NO. 196, SEQ ID NO. 197/SEQ ID NO. 198, SEQ ID NO. 199/SEQ ID NO.
   200, SEQ ID NO. 201/SEQ ID NO. 202, SEQ ID NO. 203/SEQ ID NO. 204, SEQ ID NO.
   205/SEQ ID NO. 206, SEQ ID NO. 207/SEQ ID NO. 208, SEQ ID NO. 209/SEQ ID NO.
15 210, SEQ ID NO. 211/SEQ ID NO. 212, SEQ ID NO. 213/SEQ ID NO. 214, SEQ ID NO.
   215/SEQ ID NO. 216, SEQ ID NO. 217/SEQ ID NO. 218, SEQ ID NO. 219/SEQ ID NO.
   220, SEQ ID NO. 221/SEQ ID NO. 222, SEQ ID NO. 223/SEQ ID NO. 224, SEQ ID NO.
   225/SEQ ID NO. 226, SEQ ID NO. 227/SEQ ID NO. 228, SEQ ID NO. 229/SEQ ID NO.
   230, SEQ ID NO. 231/SEQ ID NO. 232, SEQ ID NO. 233/SEQ ID NO. 234, SEQ ID NO.
20 235/SEQ ID NO. 236, SEQ ID NO. 237/SEQ ID NO. 238, SEQ ID NO. 239/SEQ ID NO.
   240, SEQ ID NO. 241/SEQ ID NO. 242, and combinations thereof.
           10.    The method for treating a broad spectrum of mammalian cancers of claim 8,
   wherein the fully human antibody Fab fragment has both a heavy chain variable domain
   region and a light chain variable domain region wherein the antibody has a heavy chain/light
25 chain variable domain sequence selected from the group consisting of SEQ ID NO. 1/SEQ
   ID NO. 2, SEQ ID NO. 3/SEQ ID NO. 4, SEQ ID NO. 5/SEQ ID NO. 6, SEQ ID NO.
   7/SEQ ID NO. 8, SEQ ID NO. 9/SEQ ID NO. 10, SEQ ID NO. 11/SEQ ID NO. 12, SEQ ID
   NO. 13/SEQ ID NO. 14, SEQ ID NO. 15/SEQ ID NO. 16, SEQ ID NO. 17/SEQ ID NO. 18,
   SEQ ID NO. 19/SEQ ID NO. 20, SEQ ID NO. 21/SEQ ID NO. 22, SEQ ID NO. 23/SEQ ID
30 NO. 24, SEQ ID NO. 25/SEQ ID NO. 26, SEQ ID NO. 27/SEQ ID NO. 28, SEQ ID NO.
   29/SEQ ID NO. 30, SEQ ID NO. 31/SEQ ID NO. 32, SEQ ID NO. 33/SEQ ID NO. 34,
                                                129

   SEQ ID NO. 35/SEQ ID NO. 36, SEQ ID NO. 37/SEQ ID NO. 38, SEQ ID NO. 39/SEQ ID
   NO. 40, SEQ ID NO. 41/SEQ ID NO. 42, SEQ ID NO. 43/SEQ ID NO. 44, SEQ ID NO.
   45/SEQ ID NO. 46, SEQ ID NO. 47/SEQ ID NO. 48, SEQ ID NO. 49/SEQ ID NO. 50,
   SEQ ID NO. 51/SEQ ID NO. 52, SEQ ID NO. 53/SEQ ID NO. 54, SEQ ID NO. 55/SEQ ID
 5 NO. 56, SEQ ID NO. 57/SEQ ID NO. 58, SEQ ID NO. 59/SEQ ID NO. 60, SEQ ID NO.
   61/SEQ ID NO. 62, SEQ ID NO. 63/SEQ ID NO. 64, SEQ ID NO. 65/SEQ ID NO. 66,
   SEQ ID NO. 67/SEQ ID NO. 68, SEQ ID NO. 69/SEQ ID NO. 70, SEQ ID NO. 71/SEQ ID
   NO. 72, SEQ ID NO. 73/SEQ ID NO. 74, SEQ ID NO. 75/SEQ ID NO. 76, SEQ ID NO.
   77/SEQ ID NO. 78, SEQ ID NO. 79/SEQ ID NO. 80, SEQ ID NO. 81/SEQ ID NO. 82,
10 SEQ ID NO. 83/SEQ ID NO. 84, SEQ ID NO. 85/SEQ ID NO. 86, SEQ ID NO. 87/SEQ ID
   NO. 88, SEQ ID NO. 89/SEQ ID NO. 90, SEQ ID NO. 91/SEQ ID NO. 92, SEQ ID NO.
   93/SEQ ID NO. 94, SEQ ID NO. 95/SEQ ID NO. 96, SEQ ID NO. 97/SEQ ID NO. 98,
   SEQ ID NO. 99/SEQ ID NO. 100, SEQ ID NO. 101/SEQ ID NO. 102, SEQ ID NO.
   103/SEQ ID NO. 104, SEQ ID NO. 105/SEQ ID NO. 106, SEQ ID NO. 107/SEQ ID NO.
15 108, SEQ ID NO. 109/SEQ ID NO. 110, SEQ ID NO. 111/SEQ ID NO. 112, SEQ ID NO.
   113/SEQ ID NO. 114, SEQ ID NO. 115/SEQ ID NO. 116, SEQ ID NO. 117/SEQ ID NO.
   118, SEQ ID NO. 119/SEQ ID NO. 120, SEQ ID NO. 121/SEQ ID NO. 122, SEQ ID NO.
   123/SEQ ID NO. 124, SEQ ID NO. 125/SEQ ID NO. 126, SEQ ID NO. 127/SEQ ID NO.
   128, SEQ ID NO. 129/SEQ ID NO. 130, SEQ ID NO. 131/SEQ ID NO. 132, SEQ ID NO.
20 133/SEQ ID NO. 134, SEQ ID NO. 135/SEQ ID NO. 136, SEQ ID NO. 137/SEQ ID NO.
   138, SEQ ID NO. 139/SEQ ID NO. 140, SEQ ID NO. 141/SEQ ID NO. 142, SEQ ID NO.
   143/SEQ ID NO. 144, SEQ ID NO. 145/SEQ ID NO. 146, SEQ ID NO. 147/SEQ ID NO.
   148, SEQ ID NO. 149/SEQ ID NO. 150, SEQ ID NO. 151/SEQ ID NO. 152, SEQ ID NO.
   153/SEQ ID NO. 154, SEQ ID NO. 155/SEQ ID NO. 156, SEQ ID NO. 157/SEQ ID NO.
25 158, SEQ ID NO. 159/SEQ ID NO. 160, SEQ ID NO. 161/SEQ ID NO. 162, SEQ ID NO.
   163/SEQ ID NO. 164, SEQ ID NO. 165/SEQ ID NO. 166, SEQ ID NO. 167/SEQ ID NO.
   168, SEQ ID NO. 169/SEQ ID NO. 170, SEQ ID NO. 171/SEQ ID NO. 172, SEQ ID NO.
   173/SEQ ID NO. 174, SEQ ID NO. 175/SEQ ID NO. 176, SEQ ID NO. 177/SEQ ID NO.
   178, SEQ ID NO. 179/SEQ ID NO. 180, SEQ ID NO. 181/SEQ ID NO. 182, SEQ ID NO.
30 183/SEQ ID NO. 184, SEQ ID NO. 185/SEQ ID NO. 186, SEQ ID NO. 187/SEQ ID NO.
   188, SEQ ID NO. 189/SEQ ID NO. 190, SEQ ID NO. 191/SEQ ID NO. 192, SEQ ID NO.
                                          130

   193/SEQ ID NO. 194, SEQ ID NO. 195/SEQ ID NO. 196, SEQ ID NO. 197/SEQ ID NO.
   198, SEQ ID NO. 199/SEQ ID NO. 200, SEQ ID NO. 201/SEQ ID NO. 202, SEQ ID NO.
   203/SEQ ID NO. 204, SEQ ID NO. 205/SEQ ID NO. 206, SEQ ID NO. 207/SEQ ID NO.
   208, SEQ ID NO. 209/SEQ ID NO. 210, SEQ ID NO. 211/SEQ ID NO. 212, SEQ ID NO.
 5 213/SEQ ID NO. 214, SEQ ID NO. 215/SEQ ID NO. 216, SEQ ID NO. 217/SEQ ID NO.
   218, SEQ ID NO. 219/SEQ ID NO. 220, SEQ ID NO. 221/SEQ ID NO. 222, SEQ ID NO.
   223/SEQ ID NO. 224, SEQ ID NO. 225/SEQ ID NO. 226, SEQ ID NO. 227/SEQ ID NO.
   228, SEQ ID NO. 229/SEQ ID NO. 230, SEQ ID NO. 231/SEQ ID NO. 232, SEQ ID NO.
   233/SEQ ID NO. 234, SEQ ID NO. 235/SEQ ID NO. 236, SEQ ID NO. 237/SEQ ID NO.
10 238, SEQ ID NO. 239/SEQ ID NO. 240, SEQ ID NO. 241/SEQ ID NO. 242, and
   combinations thereof.
           11.    The method for treating a broad spectrum of mammalian cancers of claim 8,
   wherein the fully human single chain antibody has both a heavy chain variable domain
   region and a light chain variable domain region, wherein the single chain fully human
15 antibody has a heavy chain/light chain variable domain sequence selected from the group
   consisting of SEQ ID NO. 1/SEQ ID NO. 2, SEQ ID NO. 3/SEQ ID NO. 4, SEQ ID NO.
   5/SEQ ID NO. 6, SEQ ID NO. 7/SEQ ID NO. 8, SEQ ID NO. 9/SEQ ID NO. 10, SEQ ID
   NO. 11/SEQ ID NO. 12, SEQ ID NO. 13/SEQ ID NO. 14, SEQ ID NO. 15/SEQ ID NO. 16,
   SEQ ID NO. 17/SEQ ID NO. 18, SEQ ID NO. 19/SEQ ID NO. 20, SEQ ID NO. 21/SEQ ID
20 NO. 22, SEQ ID NO. 23/SEQ ID NO. 24, SEQ ID NO. 25/SEQ ID NO. 26, SEQ ID NO.
   27/SEQ ID NO. 28, SEQ ID NO. 29/SEQ ID NO. 30, SEQ ID NO. 31/SEQ ID NO. 32,
   SEQ ID NO. 33/SEQ ID NO. 34, SEQ ID NO. 35/SEQ ID NO. 36, SEQ ID NO. 37/SEQ ID
   NO. 38, SEQ ID NO. 39/SEQ ID NO. 40, SEQ ID NO. 41/SEQ ID NO. 42, SEQ ID NO.
   43/SEQ ID NO. 44, SEQ ID NO. 45/SEQ ID NO. 46, SEQ ID NO. 47/SEQ ID NO. 48,
25 SEQ ID NO. 49/SEQ ID NO. 50, SEQ ID NO. 51/SEQ ID NO. 52, SEQ ID NO. 53/SEQ ID
   NO. 54, SEQ ID NO. 55/SEQ ID NO. 56, SEQ ID NO. 57/SEQ ID NO. 58, SEQ ID NO.
   59/SEQ ID NO. 60, SEQ ID NO. 61/SEQ ID NO. 62, SEQ ID NO. 63/SEQ ID NO. 64,
   SEQ ID NO. 65/SEQ ID NO. 66, SEQ ID NO. 67/SEQ ID NO. 68, SEQ ID NO. 69/SEQ ID
   NO. 70, SEQ ID NO. 71/SEQ ID NO. 72, SEQ ID NO. 73/SEQ ID NO. 74, SEQ ID NO.
30 75/SEQ ID NO. 76, SEQ ID NO. 77/SEQ ID NO. 78, SEQ ID NO. 79/SEQ ID NO. 80,
   SEQ ID NO. 81/SEQ ID NO. 82, SEQ ID NO. 83/SEQ ID NO. 84, SEQ ID NO. 85/SEQ ID
                                                131

   NO. 86, SEQ ID NO. 87/SEQ ID NO. 88, SEQ ID NO. 89/SEQ ID NO. 90, SEQ ID NO.
   91/SEQ ID NO. 92, SEQ ID NO. 93/SEQ ID NO. 94, SEQ ID NO. 95/SEQ ID NO. 96,
   SEQ ID NO. 97/SEQ ID NO. 98, SEQ ID NO. 99/SEQ ID NO. 100, SEQ ID NO. 101/SEQ
   ID NO. 102, SEQ ID NO. 103/SEQ ID NO. 104, SEQ ID NO. 105/SEQ ID NO. 106, SEQ
 5 ID NO. 107/SEQ ID NO. 108, SEQ ID NO. 109/SEQ ID NO. 110, SEQ ID NO. 111/SEQ
   ID NO. 112, SEQ ID NO. 113/SEQ ID NO. 114, SEQ ID NO. 115/SEQ ID NO. 116, SEQ
   ID NO. 117/SEQ ID NO. 118, SEQ ID NO. 119/SEQ ID NO. 120, SEQ ID NO. 121/SEQ
   ID NO. 122, SEQ ID NO. 123/SEQ ID NO. 124, SEQ ID NO. 125/SEQ ID NO. 126, SEQ
   ID NO. 127/SEQ ID NO. 128, SEQ ID NO. 129/SEQ ID NO. 130, SEQ ID NO. 131/SEQ
10 ID NO. 132, SEQ ID NO. 133/SEQ ID NO. 134, SEQ ID NO. 135/SEQ ID NO. 136, SEQ
   ID NO. 137/SEQ ID NO. 138, SEQ ID NO. 139/SEQ ID NO. 140, SEQ ID NO. 141/SEQ
   ID NO. 142, SEQ ID NO. 143/SEQ ID NO. 144, SEQ ID NO. 145/SEQ ID NO. 146, SEQ
   ID NO. 147/SEQ ID NO. 148, SEQ ID NO. 149/SEQ ID NO. 150, SEQ ID NO. 151/SEQ
   ID NO. 152, SEQ ID NO. 153/SEQ ID NO. 154, SEQ ID NO. 155/SEQ ID NO. 156, SEQ
15 ID NO. 157/SEQ ID NO. 158, SEQ ID NO. 159/SEQ ID NO. 160, SEQ ID NO. 161/SEQ
   ID NO. 162, SEQ ID NO. 163/SEQ ID NO. 164, SEQ ID NO. 165/SEQ ID NO. 166, SEQ
   ID NO. 167/SEQ ID NO. 168, SEQ ID NO. 169/SEQ ID NO. 170, SEQ ID NO. 171/SEQ
   ID NO. 172, SEQ ID NO. 173/SEQ ID NO. 174, SEQ ID NO. 175/SEQ ID NO. 176, SEQ
   ID NO. 177/SEQ ID NO. 178, SEQ ID NO. 179/SEQ ID NO. 180, SEQ ID NO. 181/SEQ
20 ID NO. 182, SEQ ID NO. 183/SEQ ID NO. 184, SEQ ID NO. 185/SEQ ID NO. 186, SEQ
   ID NO. 187/SEQ ID NO. 188, SEQ ID NO. 189/SEQ ID NO. 190, SEQ ID NO. 191/SEQ
   ID NO. 192, SEQ ID NO. 193/SEQ ID NO. 194, SEQ ID NO. 195/SEQ ID NO. 196, SEQ
   ID NO. 197/SEQ ID NO. 198, SEQ ID NO. 199/SEQ ID NO. 200, SEQ ID NO. 201/SEQ
   ID NO. 202, SEQ ID NO. 203/SEQ ID NO. 204, SEQ ID NO. 205/SEQ ID NO. 206, SEQ
25 ID NO. 207/SEQ ID NO. 208, SEQ ID NO. 209/SEQ ID NO. 210, SEQ ID NO. 211/SEQ
   ID NO. 212, SEQ ID NO. 213/SEQ ID NO. 214, SEQ ID NO. 215/SEQ ID NO. 216, SEQ
   ID NO. 217/SEQ ID NO. 218, SEQ ID NO. 219/SEQ ID NO. 220, SEQ ID NO. 221/SEQ
   ID NO. 222, SEQ ID NO. 223/SEQ ID NO. 224, SEQ ID NO. 225/SEQ ID NO. 226, SEQ
   ID NO. 227/SEQ ID NO. 228, SEQ ID NO. 229/SEQ ID NO. 230, SEQ ID NO. 231/SEQ
30 ID NO. 232, SEQ ID NO. 233/SEQ ID NO. 234, SEQ ID NO. 235/SEQ ID NO. 236, SEQ
                                          132

   ID NO. 237/SEQ ID NO. 238, SEQ ID NO. 239/SEQ ID NO. 240, SEQ ID NO. 241/SEQ
   ID NO. 242, and combinations thereof.
            12.    The method for treating a broad spectrum of mammalian cancers or
   inflammatory diseases or autoimmune diseases of claim 8, wherein the broad spectrum of
 5 mammalian cancers to be treated is selected from the group consisting of ovarian, colon,
   breast, lung cancers, myelomas, neuroblastic-derived CNS tumors, monocytic leukemias, B
   cell derived leukemias, T-cell derived leukemias, B-cell derived lymphomas, T-cell derived
   lymphomas, mast cell derived tumors, and combinations thereof.
            13.    The method for treating a broad spectrum of mammalian cancers or
10 inflammatory diseases or autoimmune diseases of claim 8, wherein the broad the
   autoimmune disease or inflammatory disease is selected from the group consisting of
   intestinal mucosal inflammation, wasting disease associated with colitis, multiple sclerosis,
   systemic lupus erythematosus, viral infections, rheumatoid arthritis, osteoarthritis, psoriasis,
   Cohn's disease, and inflammatory bowel disease.
15
                                                133

<removed-apn>   <removed-date>
                      <U+274B><U+2710><U+2763><U+2709>r<U+2761> <U+2736>

<removed-apn>   <removed-date>
                      <U+274B><U+2710><U+2763><U+2709>r<U+2761> <U+2737>

              <U+274B><U+2710><U+2763><U+2709>r<U+2761> <U+2738>
<removed-date>
                               <U+273A><U+272A>         <U+273E><U+272A>
<removed-apn>
                         <U+2739><U+273E><U+272A>        <U+273A><U+273E><U+272A>        <U+273A><U+273D><U+272A>

<removed-apn>   <removed-date>
                      <U+274B><U+2710><U+2763><U+2709>r<U+2761> <U+2739>

<removed-apn>   <removed-date>
                      <U+274B><U+2710><U+2763><U+2709>r<U+2761> <U+273A>

<removed-apn>   <removed-date>
                      <U+274B><U+2710><U+2763><U+2709>r<U+2761> <U+273B>

              <U+274B><U+2710><U+2763><U+2709>r<U+2761> <U+273C>
<removed-date>
                                          <U+25CF><U+2736><U+2737>
                         <U+2738><U+2735><U+2735><U+2735><U+2735><U+2735>
<removed-apn>
                         <U+2701><U+2735><U+2735><U+2735><U+2735><U+2735>
                          <U+2735><U+2735><U+2735><U+2735><U+2735>
                             <U+2735>
                              <U+2732> <U+2739>   <U+2732> <U+2701>    <U+2732> <U+2735>   <U+2732><U+273D>   <U+2732><U+273B>

<removed-apn>   <removed-date>
                      <U+274B><U+2710><U+2763><U+2709>r<U+2761> <U+273D>

<removed-apn>   <removed-date>
                      <U+274B><U+2710><U+2763><U+2709>r<U+2761> <U+273E>

         <removed-apn>   <removed-date>
                 !
                               <U+274B><U+2710><U+2763><U+2709>r<U+2761> <U+2736><U+2735>
!
!
! "# $
!
%!

<removed-apn>        <removed-date>
             "#      !
                           <U+274B><U+2710><U+2763><U+2709>r<U+2761> <U+2736><U+2736>

              <U+274B><U+2710><U+2763><U+2709>r<U+2761> <U+2736><U+2737>
<removed-date>
                          &   '          %             (   )
                                       * %
<removed-apn>
                 %!
                 $
                                  !         !   "# $   !       %!
                                      & '       & '

      <removed-apn>   <removed-date>
()
*                           <U+274B><U+2710><U+2763><U+2709>r<U+2761> <U+2736><U+2738>
)
)
+,-
.

           <removed-apn>   <removed-date>
/
)                                <U+274B><U+2710><U+2763><U+2709>r<U+2761> <U+2736><U+2739>
* '0 1 &

            <removed-apn>   <removed-date>
/
)                                 <U+274B><U+2710><U+2763><U+2709>r<U+2761> <U+2736><U+273A>
* 23<U+2763> 1 &

                                                       PDl 1s eql i s t . t x t
<removed-date>
              Or gani z at i on Appl i c ant
              ----------------------
                      St r eet :
                      Ci t y :
                      St at e :
                      Count r y :
                      Pos t al Code :
                      PhoneNumber :
                      Fax Number :
                      Emai l Addr es s :
              <110> Or gani z at i onName : Sor r ent o Ther apeut i c s I nc .
<removed-apn>
              Appl i c at i on Pr oj ec t
              -------------------
              <120> Ti t l e : Ant i gen Bi ndi ng Pr ot ei ns t hat Bi nd PD- L1
              <130> AppFi l eRef er enc e : PD- L1- 1A
              <140> Cur r ent AppNumber :
              <141> Cur r ent Fi l i ngDat e : 2013- 05- 31
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QMQLVQSGAE VKKPGSSVKV SCKASGGTFN TYAI SWVRQA PGQGLEWMGG I I PLFGKADY    60
              AQKFQDRVTI TADESTSTAY MELSSLRSED TAVYYCARDK GREELGGNYY YAVDVWGPGT      120
              TVTVSS                                                                 126
              <212> Ty pe : PRT
              <211> Lengt h : 126
                    Sequenc eName : SEQ I D NO: 1
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              DI VMTQTPYS VSASVGDRVT I TCRASQEVS RWVAWYQQKP GQAPKSLI YA SSRLQSGVPS    60
              RFTASGSGTD FTLVI SSLQP EDFATYYCQQ YSRFPLTFGG GTKVEI K                  107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 2
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLQQLGPG LVKPSQTLSL TCAI SGDSVS SNSAAWNWI R QSPSRGLEWL GRTYYRSKWY     60
              TNYAVSMRSR I TI NPDTSKN QFSLQLNSVT PEDTAVYFCA GGNSSSHDDY WGQGTLVTVS    120
              S                                                                      121
              <212> Ty pe : PRT
              <211> Lengt h : 121
                    Sequenc eName : SEQ I D NO: 3
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QPVLTQPASV SGSPGQSI TI SCTGTSSDVG GYNYVSWYQQ HPGKAPKLMV YDVSKRPSGV      60
              SNRFSGSKSG NTASLTI SGL QTEDEADYYC SSYTSSNTRV FGTGTKLTVL                110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                                                    Page 1

                                                 PDl 1s eql i s t . t x t
<removed-date>
                    Sequenc eName : SEQ I D NO: 4
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVQSGAE VKKPGASVKV SCKASGYTFT SYGI SWVRQA PGQGLEWMGW I SAYNGNTNY      60
              AQKLQGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARDL FPTI FWEGGA FDI WGQGTMV     120
              TVSS                                                                    124
<removed-apn>
              <212> Ty pe : PRT
              <211> Lengt h : 124
                    Sequenc eName : SEQ I D NO: 5
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              DI VMTQSPST LSASVGDRVT I TCRASQSFT TYLAWYQQKP GKAPKLLI YQ TSNLESGVPS     60
              RFSGSGSGTE FTLTI SSLQP DDFATYYCQQ YSRYWWSFGQ GTRLEI K                   107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 6
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVQSGAE VKKPGASLKV SCKASGYTFN SYDI NWVRQA PGQGLEWMGW I NPNSGGTNY      60
              AQKFQGRVTM TRDTSTSTVY MELSSLTSED TAVYYCARDL FPHI YGNYYG MDI WGQGTTV     120
              TVSS                                                                    124
              <212> Ty pe : PRT
              <211> Lengt h : 124
                    Sequenc eName : SEQ I D NO: 7
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              AI QMTQSPSS LSASVGDRVT I TCRASQSI S SYLNWYQQKP GKAPKLLI YA ASSLQSGVPS    60
              RFSGSGSGTD FTLTI SSLQP EDFATYYCQQ SSSTPLTFGQ GTKVEI K                   107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 8
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV I SFDGSNKYY       60
              ADSVRGRFTI SRDNSKNTLY LQMNSLRTED TAVYYCARGW LDRDI DYWGQ GTLVTVSS        118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 9
                    Sequenc eDes c r i pt i on :
                                                            Page 2

                                                      PDl 1s eql i s t . t x t
<removed-date>
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QAVLTQPRSV SGSPGQSVTI SCTGTSSDVG GYNYVSWYQQ HPGKAPKLMI YDVRTRPSGV        60
              SDRFSGSKSG NTASLSI SGL QAEDEADYYC SSHSSSTTVI FGGGTKLTVL                 110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 10
                    Sequenc eDes c r i pt i on :
<removed-apn>
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVQSGAE VKKPGASVKV SCKASGYTFT GYYMHWVRQA PGQGLEWMGW I NPNSDNTGS       60
              AQKFQGRVFM TKTTSLNTAY MELSGLRSED TAI YYCARER SSGYFDFWGQ GTLVTVSS        118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 11
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              DI VMTQSPSS LSASVGDRVT I TCRASQSI S SYLNWYQQKP GKAPKLLI YA ASSLQSGVPS    60
              RFSGSGSGTD FTLTI SSLQP EDFATYYCQQ SYSTPI TFGQ GTRLEI K                  107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 12
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVESGGG VVQPGRSLRL SCAASGFTFS SYWMSWVRQA PGKGLEWVAN I KQDGSEKYY       60
              VDSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCAREG EHDAFDI WGQ GTMVTVSS        118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 13
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QAVLTQPPSV SAAPGQRVTI SCSGSNSNI A DTYVSWYQQL PGTAPRLLI Y DNDQRPSGI P     60
              DRFSGSKSGT SATLGI TGLQ TGDEADYYCG TWDSSLSGVF GTGTKVTVL                  109
              <212> Ty pe : PRT
              <211> Lengt h : 109
                    Sequenc eName : SEQ I D NO: 14
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
                                                             Page 3

                                               PDl 1s eql i s t . t x t
<removed-date>
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGGG VVQPGRSPRL SCAASGFTFN TYGMHWVRQA PGKGLEWVAV I SDGGNNKKY      60
              ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TALYYCAKDI GESYYYYMDV WGKGTTVTVS      120
              S                                                                      121
              <212> Ty pe : PRT
              <211> Lengt h : 121
                    Sequenc eName : SEQ I D NO: 15
                    Sequenc eDes c r i pt i on :
              Sequenc e
<removed-apn>
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVLTQPASV SGSPGQSVTI SCTGTSSDVG GFNSVSWYQQ HPGKAPKLMI YDVSKRPSEI       60
              SDRFSGSKSG NTASLTI SGL QPEDEADYYC SSYTSSSTLV FGGGTKLTVL                110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 16
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLQQSGPG LVKPSQSLSL TCAI SGDSLS SNSAAWNWI R QSPSGGLEWL GRTYYRSKWY     60
              NEYVESLKSR I TI NSDI SRN QFSLHLNSVT PEDTAVYYCA SGTGARGMDV WGQGTTVTVS   120
              S                                                                      121
              <212> Ty pe : PRT
              <211> Lengt h : 121
                    Sequenc eName : SEQ I D NO: 17
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              SYVLTQPPSV SVSPGQTASI SCSGYKLENK YVSWYQQRAG QSPVLVI YQD NKRPSGI PER     60
              FSGSNSGNTA SLTI TGLQPE DEADYYCSAW DSSLRAWVFG GGTQLTVL                  108
              <212> Ty pe : PRT
              <211> Lengt h : 108
                    Sequenc eName : SEQ I D NO: 18
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLQQSGPG LVKPSETLSL TCAI SGDSVS ENSAAWNWI R QSPSGGLEWL GRTYYRSKWY     60
              NEYVESLKSR I TI NSDI SRN QFSLHLNSVT PEDTAVYYCA SGTGARGMDV WGQGTTVTVS   120
              S                                                                      121
              <212> Ty pe : PRT
              <211> Lengt h : 121
                    Sequenc eName : SEQ I D NO: 19
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QPVLTQPPSV SVSPGQTASI TCSGDELGNK YVYWYQQKPG RSPVLVI YQD SKRPSGFPAR      60
                                                             Page 4

                                                PDl 1s eql i s t . t x t
<removed-date>
              FSGANSGNTA TLTI SGTQAM DEADYFCQAW DSSTAWVFGG GTKLTVL                    107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 20
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVQSGAE VKKPGASVKV SCKASGYTFT GYYMHWVRQA PGQGLEWMGW I NPNSDNTGS       60
<removed-apn>
              AQKFQGRVFM TKTTSLNTAY MELSGLRSED TAI YYCARER SSGYFDFWGQ GTLVTVSS        118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 21
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              DI VMTQSPSS LSASVGDRVT I TCRASQSI S SYLNWYQQKP GKAPKLLI YA ASSLQSGVPS    60
              RFSGSGSGTD FTLTI SSLQP EDFATYYCQQ SYSTPI TFGQ GTRLEI K                  107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 22
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGAE VKKPGSSVKV SCKASGGTFS RYGVHWVRQA PGQGLEWMGR LI PI VSMTNY      60
              AQKFQDRVSI TTDKSTGTAY MELRSLTSED TALYYCASVG QQLPWVFFAW GQGTLVTVSS       120
              <212> Ty pe : PRT
              <211> Lengt h : 120
                    Sequenc eName : SEQ I D NO: 23
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              LPVLTQPASV SGSPGQSVTI SCTGTSSDVG GHNYVSWYQQ HPGKAPKLMI YEVNKRPSGV        60
              PDRFSGSKSD YTASLTI SGL QPDDEADYFC SSYTATTTGV VFGTGTKVTV L               111
              <212> Ty pe : PRT
              <211> Lengt h : 111
                    Sequenc eName : SEQ I D NO: 24
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVQSGAE VKKPGASVKV SCKASGYTFT GYYMHWVRQA PGQGLEWMGW I NPNSDNTGS       60
              AQKFQGRVFM TKTTSLNTAY MELSGLRSED TAI YYCARER SSGYFDFWGQ GTLVTVSS        118
                                                    Page 5

                                                PDl 1s eql i s t . t x t
<removed-date>
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 25
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              DI VMTQSPSS LSASVGDRVT I TCRASQSI S SYLNWYQQKP GKAPKLLI YA ASSLQSGVPS    60
<removed-apn>
              RFSGSGSGTD FTLTI SSLQP EDFATYYCQQ SYSTPI TFGQ GTRLEI K                  107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 26
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGAE VKKPGASVKV SCKTSGNTFT NYYMHWVRQA PGQGLEWMGI MNPSGGSTSY        60
              AQKFQGRVTM TRDKSTSTVY MELSSLTSED TAVYYCARDL FPHI YGNYYG MDI WGQGTTV     120
              TVSS                                                                    124
              <212> Ty pe : PRT
              <211> Lengt h : 124
                    Sequenc eName : SEQ I D NO: 27
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              DI VMTQSPPS LSASVGDRVT I TCRASQSI S SYLNWYQQKP GKAPKLLI YA ASSLQSGVPS    60
              RFSGSGSGTD FTLTI SSLQP EDFATYYCQQ SYSTPYTFGQ GTKVEI K                   107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 28
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAI SWVRQA PGQGLEWMGG I I PI FGTASY    60
              AQKFQGRVTI TADESTTTAY MELSSLRSED TAVYYCAREG PEYCSGGTCY SADAFDI WGQ      120
              GTMVTVSS                                                                128
              <212> Ty pe : PRT
              <211> Lengt h : 128
                    Sequenc eName : SEQ I D NO: 29
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVVTQPPSV SAAPGQKVTI SCSGSTSNI E NYSVSWYQQL PGTAPKLLI Y DNNKRPSGI P     60
              DRFSGSKSGT SATLGI TGLQ TGDEADYYCG TWDNRLSSVV FGGGTKVTVL                 110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 30
                    Sequenc eDes c r i pt i on :
                                                       Page 6

                                                         PDl 1s eql i s t . t x t
<removed-date>
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAI SWVRQA PGQGLEWMGR I I PI LGI ANY    60
              AQKFQGRVTI TADKSTSTAY MELSSLRSED TAVYYCARSE SGSYSHDYWG QGTTVTVSS         119
              <212> Ty pe : PRT
              <211> Lengt h : 119
                    Sequenc eName : SEQ I D NO: 31
<removed-apn>
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QPVLTQPPSV SAAPGQKVTI SCSGSSSNI G NSHVSWFQQL PGTAPKLVI Y DNDKRPSGI A      60
              DRFSGSKSGT SATLGI TGLQ TGDEADYYCG TWDSSLSAGV FGGGTKLTVL                  110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 32
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVESGAE VKKPGASVKV SCKASGYTFT SYYI HWVRQA PGQGLEWMGI I NPSGGSTTY       60
              AQKFQGRVSM TRDTSTRTVY MELSGLI SDD TAI YYCARDD DFYSGYPGDY WGQGTLVTVS      120
              S                                                                        121
              <212> Ty pe : PRT
              <211> Lengt h : 121
                    Sequenc eName : SEQ I D NO: 33
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QAVVTQPPSA SGTPGQRVTI SCSGSSSNVG VNHVFWYQHL PGMAPKLLI H RTNQWPSGVP        60
              DRFSGSKSGT SATLGI TGLQ TGDEADYYCG TWDSSLSAVF GGGTKLTVL                   109
              <212> Ty pe : PRT
              <211> Lengt h : 109
                    Sequenc eName : SEQ I D NO: 34
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QMQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAI SWVRQA PGQGLEWMGG I I PI FGTANY     60
              AQKFQGRVTI TADESTSTAY MELSSLRSED TAVYYCARGN I VATI TPLDY WGQGTLVTVS      120
              S                                                                        121
              <212> Ty pe : PRT
              <211> Lengt h : 121
                    Sequenc eName : SEQ I D NO: 35
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              SYELMQPPSV SVAPGKTATI ACGGENI GRK TVHWYQQKPG QAPVLVI YYD SDRPSGI PER      60
                                                     Page 7

                                                 PDl 1s eql i s t . t x t
<removed-date>
              FSGSNSGNTA TLTI SRVEAG DEADYYCQVW DSSSDHRI FG GGTKLTVL                  108
              <212> Ty pe : PRT
              <211> Lengt h : 108
                    Sequenc eName : SEQ I D NO: 36
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVQSGGG LVQPGGSLRL SCAASGFTFS SYSMNWVRQA PGKGLEWVSY I SSSSSTI YY      60
<removed-apn>
              ADSVKGRFTI SRDNAKNSLY LQMNSLRDED TAVYYCARGD YYYGMDVWGQ GTTVTVSS         118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 37
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EI VLTQSPSS LSASI GDRVT LTCRASQSI R RFLNWYQQKP GKAPELLI YT ASSLQSGVPS    60
              RFSGSGSGTD FTLTI NSLQP EDFATYYCQQ SYAVSPYTFG QGTKVEI R                  108
              <212> Ty pe : PRT
              <211> Lengt h : 108
                    Sequenc eName : SEQ I D NO: 38
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QMQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAI SWVRQA PGQGLEWMGG I I PI FGTANY    60
              AQKFQGRVTI TADESTSTAY MELSSLRSED TAVYYCARGD FWSGYRTYYY YYGMDVWGQG       120
              TMVTVSS                                                                 127
              <212> Ty pe : PRT
              <211> Lengt h : 127
                    Sequenc eName : SEQ I D NO: 39
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVVTQPPSV SAAPGQKVTI SCSGSSSNI G NNYVSWYQQL PGTAPKLLI Y DNNKRPSGI P     60
              DRFSGSKSGT SATLGI TGLQ TGDEADYYCG TWDSSLSAVV FGGGTKLTVL                 110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 40
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGAE VKKPGASVKV SCKTSGYTFT SNAI GWVRQA PGQGLEWMGW I SAYNGNTNY      60
              AQNLQGRVTM TTDTSTSTAY MELRSLRSDD TAVFYCARKG TGLHFDYWGQ GTLVTVSS         118
              <212> Ty pe : PRT
                                                        Page 8

                                                 PDl 1s eql i s t . t x t
<removed-date>
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 41
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              ALTQPASVSG SLGQSI TI SC TGSSSDVGGY KYVSWYQQHP GKAPKLMI YD VI NRPSGVSS    60
              RFSGSKSANT ASLTI SGLQA EDEADYYCFS YSSRSTRI FG SGTKVTVL                  108
              <212> Ty pe : PRT
<removed-apn>
              <211> Lengt h : 108
                    Sequenc eName : SEQ I D NO: 42
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLQQSGPG LVKPSQTLSL TCAI SGDSVS SNSAAWNWI R QSPSRGLEWL GRTYYRSKWY      60
              NDYAVSVKSR I TI NPDTSKN QFSLQLNSVT PEDTAVYYCA RGAAGRAFDI WGQGTMVTVS     120
              S                                                                       121
              <212> Ty pe : PRT
              <211> Lengt h : 121
                    Sequenc eName : SEQ I D NO: 43
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QTVVTQPPSV SKDLGQTATL TCTGNNNNVG NHGAAWLQQH QGHPPKLLSY RNNNRPSGI S       60
              ERLSASRSGN TASLTI TGLQ PEDEADYYCS AWDRSLSAWV FGGGTKLTVL                 110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 44
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVQSGGG LVQPGGSLRL SCAASGFTFS SYSMNWVRQA PGKGLEWVSY I SSSSSTI YY      60
              ADSVKGRFTI SRDNAKNSLY LQMNSLRDED TAVYYCARGD YYYGMDVWGQ GTTVTVSS         118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 45
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EI VLTQSPSS LSASI GDRVT LTCRASQSI R RFLNWYQQKP GKAPELLI YT ASSLQSGVPS    60
              RFSGSGSGTD FTLTI NSLQP EDFATYYCQQ SYAVSPYTFG QGTKVEI K                  108
              <212> Ty pe : PRT
              <211> Lengt h : 108
                    Sequenc eName : SEQ I D NO: 46
                    Sequenc eDes c r i pt i on :
                                                            Page 9

                                                         PDl 1s eql i s t . t x t
<removed-date>
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVESGGG LVQPGGSLRL SCAASGFYLG SYWMAWVRQA PGKGLEWVAA I RQDGSETI Y     60
              VDSVKGRFI I SRDNGGNSVT LQMTTLRAGD TAVYYCARAH YFGFDNWGQG TLVTVSS        117
              <212> Ty pe : PRT
              <211> Lengt h : 117
                    Sequenc eName : SEQ I D NO: 47
<removed-apn>
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVLTQPASV SGSPGQSI SV SCTGTSSDVG RYNFVSWYQQ HPGKAPKLMV FDVSNRPSGI      60
              SNRFSGSKSG NTASLTI SGL QAEDEADYYC SSYTTNSTYV FGSGTKVTVL                110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 48
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QMQLVQSGAE VKKPGASVKI SCKASGYPFR NYYI HWVRQA PGQGLEWVGI I NPDGGTI TY    60
              AGKFQGRVSM TRDTSTSTVY MELSSLTSED TAVYYCARDL FPHI YGNYYG MDI WGQGTTV    120
              TVSS                                                                   124
              <212> Ty pe : PRT
              <211> Lengt h : 124
                    Sequenc eName : SEQ I D NO: 49
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QPVLTQPPSV SAAPGQKVTI SCSGSSSNI A NNYVSWYQQL PGTAPKLLI F ANNKRPSGI P    60
              DRFSGSKSGT SAALDI TGLQ TGDEADYYCG TWDSDLRAGV FGGGTKLTVL                110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 50
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLLESGGG VVQPGGSLRL SCAASGFTFS SYWMSWVRQA PGKGLEWVAN I KQDGSEKYY      60
              VDSVKGRFTI SRDNSKNTVS LQMNSLRAED TAVYYCAKDR YYNFPLGMDV WGQGTTVTVS      120
              S                                                                      121
              <212> Ty pe : PRT
              <211> Lengt h : 121
                    Sequenc eName : SEQ I D NO: 51
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
                                                     Page 10

                                                         PDl 1s eql i s t . t x t
<removed-date>
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              AI RMTQSPSS LSASVGDRVT I TCRASQSI S SYLNWYQQKP GKAPKLLI YT TSSLKSGVPS    60
              RFSGSGSGTD FTLTI SRLQP EDFATYYCQQ SYSSTWTFGR GTKVEI K                   107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 52
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
<removed-apn>
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLLESGAE VKKPGSSVKV SCKSSGDTFT NFAI NWI RQA PGQGLEWMGR I I PLFGTTNY    60
              AQKFQGRVTI TADESTSTAF MDLNSLTSED TAVYYCARTL GGDYYDSRGY YNWGQGTLVT       120
              VSS                                                                     123
              <212> Ty pe : PRT
              <211> Lengt h : 123
                    Sequenc eName : SEQ I D NO: 53
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVLTQPASV SGSPGQSI TI SCTGTSSDVG SYNLVSWYQQ YPGKAPKLMI YEVSERPSGV       60
              PDRFSGSKSG NTASLTVSGL QAEDEADYYC SSYTDSNNFR VFGGGTKLTV L                111
              <212> Ty pe : PRT
              <211> Lengt h : 111
                    Sequenc eName : SEQ I D NO: 54
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLQQSGPG LVKPSQTLSL TCAI SGDSVS SNSVVWNWFR QSPSRGLEWL GRAYYRSKWY       60
              NDYAVSVKSR I TI NPDTSKN QLSLQLNSVT PEDTAVYYCA KGLDVWGQGT TVTVSS         116
              <212> Ty pe : PRT
              <211> Lengt h : 116
                    Sequenc eName : SEQ I D NO: 55
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EI VMTQSPSS LYASVGDRVT I TCRASQSI S SYLNWYQQKP GKVPKLLI YA ASSLQSGVPS    60
              RFSGSGSGTD FTLTI SGLQP EDFATYYCQQ SYTPAWTFGQ GTKLEI K                   107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 56
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
                                                             Page 11

                                               PDl 1s eql i s t . t x t
<removed-date>
              QVQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAI SWVRQA PGQGLEWMGG I I PI FGTANY    60
              AQKFQGRVTI TADESTSTAY MELSSLRSED TAVYYCARDG I VADFQHWGQ GTLVTVSS        118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 57
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
<removed-apn>
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVVTQPPSV SAAPGQKVTI SCSGSSSNI G NNYVSWYQQV PGTAPKLLI Y DNDKRPSGI P     60
              DRFSGSKSGT SATLAI TGLQ TGDEADYYCG TWDSSLNAWV FGGGTKLTVL                 110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 58
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGAE VKKPGASVRV SCKASGGTFS SYAI SWVRQA PGQGLEWMGG I I PI FGTANY    60
              AQKFQGRVTI TADESTSTAY MELSSLRSED TAVYYCARDG I VADFQHWGQ GTLVTVSS        118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 59
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVLTQPPSV SAAPGQKVTI SCSGSSSNI E NNYVSWYQHL PGTAPKLLI Y DDFKRPSGI P     60
              DRFSGSKSGT SATLGI TGLQ TGDEADYYCG TWDSSLSAVV FGGGTKLTVL                 110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 60
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QMQLVQSGAE VKKPGSSVKV SCKASGGTFN SYPI SWVRQA PGQGLEWMGG I I PI FGTANY    60
              AQKFQGRVTI TADESTSTAY MELSSLRSED TAMYYCAKNH PTATLDYWGQ GTLVTVSS         118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 61
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVLTQPPSA SGSPGQSVTI SCTGTSSDVG GYNYVSWYQQ HPGKAPKLMI YEVSKRPSGV        60
                                                     Page 12

                                               PDl 1s eql i s t . t x t
<removed-date>
              PDRFSGSKSG NTASLTVSGL QAEDEADYYC SSYAGSNNLG VFGGGTKLTV L                111
              <212> Ty pe : PRT
              <211> Lengt h : 111
                    Sequenc eName : SEQ I D NO: 62
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
<removed-apn>
              QVQLVQSGGN LVKPGGSLRL SCAASGFSFS SYDMNWVRQA PGRGLEWVSS I SGTGRYEYY       60
              SPSVKGRFTI SRDNANTSLY LQMNSLTADD TAVYFCTRGD I LTGASAMDV WGQGTTVTVS      120
              S                                                                       121
              <212> Ty pe : PRT
              <211> Lengt h : 121
                    Sequenc eName : SEQ I D NO: 63
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              DI QLTQSPSS LSASVGDRVT I TCRASQGI S SWLAWYQQKP GKAPKLLI YA ASSLQSGVPS    60
              RFSGSGSGTD FTLTI SSLQP EDFATYYCQQ ANSFPLTFGG GTKVEI K                   107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 64
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLLESGGN LVKPGGSLRL SCAASGFSFS SYDMNWVRQA PGRGLEWVSS I SGTGRYEYY       60
              SPSVKGRFTI SRDNANTSLY LQMNSLTADD TAVYFCTRGD I LTGASAMDV WGQGTTVTVS      120
              S                                                                       121
              <212> Ty pe : PRT
              <211> Lengt h : 121
                    Sequenc eName : SEQ I D NO: 65
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              DVVMTQSPST LSASVGDRVT I TCRASQSI G TWLAWYQQKP GKAPNLLI YK ASSLESGVPS     60
              RFSGSGSGTE FTLTI SSLQP DDFATYYCQQ ANSFPLTFGG GTKVEI K                   107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 66
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QMQLVQSGAE VKKPGSSVKV SCKASGGTFS RYGVHWVRQA PGQGLEWMGR LI PI VSMTNY      60
              AQKFQDRVSI TTDKSTGTAY MELRSLTSED TALYYCASVG QQLPWVFFAW GQGTLVTVSS       120
                                                     Page 13

                                                PDl 1s eql i s t . t x t
<removed-date>
              <212> Ty pe : PRT
              <211> Lengt h : 120
                    Sequenc eName : SEQ I D NO: 67
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              DI QMTQSPSS LSASVGDRVT I TCQASQDI S NYLNWYQQKP GKAPKLLI YD ASTLQSGVPS    60
<removed-apn>
              RFSGSGSGTD FTLTI SSLQP EDFATYYCQQ SYSSHWTFGQ GTKVEI K                   107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 68
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVQSGAE VKKPGSSVKV SCKASGGTFS RYGVHWVRQA PGQGLEWMGR LI PI VSMTNY      60
              AQKFQDRVSI TTDKSTGTAY MELRSLTSED TALYYCASVG QQLPWVFFAW GQGTLVTVSS       120
              <212> Ty pe : PRT
              <211> Lengt h : 120
                    Sequenc eName : SEQ I D NO: 69
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVVTQPPSV SGAPGQRVTI SCTGSSSNI G AGYGVHWYQH LPGSAPKLLI YGNSNRPSGV       60
              TDRI SGSKSG TSASLAI TGL QAEDEAVYYC QSYDSSLSTS VVFGGGTKLT VL             112
              <212> Ty pe : PRT
              <211> Lengt h : 112
                    Sequenc eName : SEQ I D NO: 70
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QMQLVQSGGG LI QPGGSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV I SFDGSNKYY      60
              ADSVRGRFTI SRDNSKNTLY LQMNSLRTED TAVYYCARGW LDRDI DYWGQ GTLVTVSS        118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 71
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QAGLTQPASV SGSPGQSI TI SCTGTSSDVG GYNYVSWYQQ HPGKAPKLMI YDVTKRPSGV       60
              SNRFSGSKSG NTASLTI SGL QAEDEANYYC SSYTSRSTSV LFGGGTKLTV L               111
                                                      Page 14

                                                PDl 1s eql i s t . t x t
<removed-date>
              <212> Ty pe : PRT
              <211> Lengt h : 111
                    Sequenc eName : SEQ I D NO: 72
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVESGGG VVLPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV I SFDGSNKYY     60
<removed-apn>
              ADSVRGRFTI SRDNSKNTLY LQMNSLRTED TAVYYCARGW LDRDI DYWGQ GTLVTVSS      118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 73
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QPVLTQPPSV SEAPRQRVTI SCSGSSSNI G HNAVTWYQQV PGKAPKLLI Y YDDLLPSGVS    60
              DRFSGSKSGT SASLAI SGLQ SEDEADYYCA AWDDSLNGWV FGGGTKLTVL               110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 74
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV I SFDGSNKYY     60
              ADSVRGRFTI SRDNSKNTLY LQMNSLRTED TAVYYCARGW LDRDI DYWGQ GTLVTVSS      118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 75
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QAGLTQPASV SGSPGQSI TI SCTGTSSDVG GYNYVSWYQQ HPGKAPKLMI YDVSNRPSGV     60
              PDRFSGSKSG NTASLTI SGL QAEDDADYYC ASYTSTSTLG VVFGGGTKLT VL            112
              <212> Ty pe : PRT
              <211> Lengt h : 112
                    Sequenc eName : SEQ I D NO: 76
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV I SFDGSNKYY     60
              ADSVRGRFTI SRDNSKNTLY LQMNSLRTED TAVYYCARGW LDRDI DYWGQ GTLVTVSS      118
                                                      Page 15

                                                PDl 1s eql i s t . t x t
<removed-date>
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 77
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QPVLTQPASV SGSPGQSI TI SCTGTSSDVG GYNYVSWYQH HPGKAPKLMI FDVNKRPSGV      60
<removed-apn>
              SNRFSGSKSG NTASLTI SGL QAEDEADYYC NSYTTSSTYV VFGGGTKLTV L              111
              <212> Ty pe : PRT
              <211> Lengt h : 111
                    Sequenc eName : SEQ I D NO: 78
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV I SFDGSNKYY      60
              ADSVRGRFTI SRDNSKNTLY LQMNSLRTED TAVYYCARGW LDRDI DYWGQ GTLVTVSS       118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 79
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVLTQPPSA SGTPGQRVTI SCSGSSSNI G SNTVHWYQQL PGTAPKVLI Y TNNQRPSGVP     60
              DRFSGSKSGT SASLAI SGLQ SEDEADYYCA AWDGRLQGWV FGGGTKLTVL                110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 80
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV I SFDGSNKYY      60
              ADSVRGRFTI SRDNSKNTLY LQMNSLRTED TAVYYCARGW LDRDI DYWGQ GTLVTVSS       118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 81
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVVTQPPSV SAAPGQKVTI SCSGSNSNI A NNYVSWYQQL PGTAPKLLI Y DSNKRPSGI P    60
              DRFSGSKSGT SATLGI TGLQ TGDEADYYCG SWDSSLSVWM FGGGTKLTVL                110
              <212> Ty pe : PRT
                                                    Page 16

                                                 PDl 1s eql i s t . t x t
<removed-date>
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 82
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV I SFDGSNKYY      60
              ADSVRGRFTI SRDNSKNTLY LQMNSLRTED TAVYYCARGW LDRDI DYWGQ GTLVTVSS       118
<removed-apn>
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 83
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              LPVLTQPRSV SGSPGQSVTI SCTGTSSDVG GYNYVSWYQQ HPGKAPKLMI YDVTKRPSGV       60
              PDRFSGSKSG NTASLTI SGL QAEDEADYYC SSYTGSSTLG PVFGGGTKLT VL             112
              <212> Ty pe : PRT
              <211> Lengt h : 112
                    Sequenc eName : SEQ I D NO: 84
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV I SFDGSNKYY      60
              ADSVRGRFTI SRDNSKNTLY LQMNSLRTED TAVYYCARGW LDRDI DYWGQ GTLVTVSS       118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 85
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVLTQPPSV SAAPGQKVTI SCSGNSSNI G NNYVSWYQQL PGTAPKLLI Y DNDKRPSGI P    60
              DRFSGSKSGT SASLAI SELR FEDEADYYCA AWDDTLSGHV FGPGTKLTVL                110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 86
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV I SFDGSNKYY      60
              ADSVRGRFTI SRDNSKNTLY LQMNSLRTED TAVYYCARGW LDRDI DYWGQ GTLVTVSS       118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                                                           Page 17

                                                 PDl 1s eql i s t . t x t
<removed-date>
                    Sequenc eName : SEQ I D NO: 87
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              SYELMQPPSV SVPPGETARI TCGGNNI GNK NVHWYQQKPG QAPVLVVRED SARPAGI PER     60
              FSGSNSGNSA TLTI SRVEAG DEADYYCQVW DNTSDHVVFG GGTKLTVL                  108
              <212> Ty pe : PRT
              <211> Lengt h : 108
<removed-apn>
                    Sequenc eName : SEQ I D NO: 88
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV I SFDGSNKYY      60
              ADSVRGRFTI SRDNSKNTLY LQMNSLRTED TAVYYCARGW LDRDI DYWGQ GTLVTVSS       118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 89
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              SYELMQPPSV SEVPGQRVTI SCSGSSSNI G NNAVNWFQQL PGKAPKLLVY YDDWVPSGI S     60
              GRFSASKSGT SASLAI SGLQ SGDEGDYYCA VWDDRLSGVV FGGGTKLTVL                110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 90
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV I SFDGSNKYY      60
              ADSVRGRFTI SRDNSKNTLY LQMNSLRTED TAVYYCARGW LDRDI DYWGQ GTLVTVSS       118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 91
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVVTQPPSV SAAPGQKVTI SCSGSSSNI G NNYVSWYQQL PGTAPTLLI Y DSNKRPSVI P    60
              DRFSGSKSGT SATLGI TGLQ TGDEADYYCG TWDDSLNGWV FGGGTKLTVL                110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 92
                    Sequenc eDes c r i pt i on :
              Sequenc e
                                                           Page 18

                                                         PDl 1s eql i s t . t x t
<removed-date>
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV I SFDGSNKYY     60
              ADSVRGRFTI SRDNSKNTLY LQMNSLRTED TAVYYCARGW LDRDI DYWGQ GTMVTVSS      118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 93
                    Sequenc eDes c r i pt i on :
<removed-apn>
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSALTQPASV SGSPGQSI TI SCTGTSSDVG GYNYVSWYQQ HPGKAPKLMI YDVSNRPSGV     60
              SNRFSGSKSG NTASLTI SGL QAEDEADYYC SSYRSSTLGP VFGGGTKLTV L             111
              <212> Ty pe : PRT
              <211> Lengt h : 111
                    Sequenc eName : SEQ I D NO: 94
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV I SFDGSNKYY     60
              ADSVRGRFTI SRDNSKNTLY LQMNSLRTED TAVYYCARGW LDRDI DYWGQ GTLVTVSS      118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 95
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QAGLTQPPSA SGSPGQSVTI SCTGTSSDVG GYNYVSWYQQ HPGKAPKLMI YDVSNRPSGV      60
              PDRFSGSKSG NTASLTI SGL QAEDEADYYC SSYTSSSTLV VFGGGTKLTV L             111
              <212> Ty pe : PRT
              <211> Lengt h : 111
                    Sequenc eName : SEQ I D NO: 96
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVQSGGG LVQPGGSLRL SCAASGFTFS SYSMNWVRQA PGKGLEWVSY I SSSSSTI YY    60
              ADSVKGRFTI SRDNAKNSLY LQMNSLRDED TAVYYCARGD YYYGMDVWGQ GTTVTVSS       118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 97
                    Sequenc eDes c r i pt i on :
                                                     Page 19

                                                      PDl 1s eql i s t . t x t
<removed-date>
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              NI QMTQSPSS VSASVGDRVT I TCRASQDI S RWLAWYQQKP GKAPKLLI YA ASSLQSGVPS    60
              RFSGSGSGTD FALTI SSLQP EDFATYYCQQ ADSFFSI TFG QGTRLEI K                 108
              <212> Ty pe : PRT
              <211> Lengt h : 108
                    Sequenc eName : SEQ I D NO: 98
                    Sequenc eDes c r i pt i on :
<removed-apn>
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGSE VKKPGASVKV SCRASGYLFT NYGI SWVRQA PGQGLEWMGW VSAHGEFTKY       60
              APSLQDRVTM TSDI STTTAY MELRSLRSDD AGVYYCARDR GADHFDTWGQ GTLVTVSS        118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 99
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              AI QLTQSPAT LSLSPGERAT LSCRASQSVG VYLAWYQQKP GQSPRLLI YD TSKRATGI PD     60
              RFSASGSGTD FTLTI SRLEP EDFAVYYCHQ RHSWPTTFGQ GTRLEI K                   107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 100
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVQSGAE VKKPGASVKV SCKASGYTFT SYYMHWVRQA PGQGLEWMGM I NPSSATTTY       60
              TQKFQGRVSM TRDTSTSTVY MELSSLTSED TAVYYCARDL FPHI YGNYYG MDI WGQGTTV     120
              TVSS                                                                    124
              <212> Ty pe : PRT
              <211> Lengt h : 124
                    Sequenc eName : SEQ I D NO: 101
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              NI QMTQSPSS LSASVGDRVT I TCRASQSI S SYLNWYQQKP GKAPKLLI YA ASSLQSGVPS    60
              RFSGSGSGTD FTLTI SSLQP EDFATYYCQQ SYSTLTFGGG TKVEI K                    106
              <212> Ty pe : PRT
              <211> Lengt h : 106
                    Sequenc eName : SEQ I D NO: 102
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
                                                             Page 20

                                               PDl 1s eql i s t . t x t
<removed-date>
              <400> Pr eSequenc eSt r i ng :
              EVQLVQSGAE VKKPGSSVKV SCKASGGTFS SHVI SWVRQA PGQGLEWMGG I I PI FGTANY    60
              AQKFQGRVTI TADESTSTAY MELSSMRSED TAVYYCATSG VVAATHFGYW GQGTLVTVSS       120
              <212> Ty pe : PRT
              <211> Lengt h : 120
                    Sequenc eName : SEQ I D NO: 103
                    Sequenc eDes c r i pt i on :
              Sequenc e
<removed-apn>
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVLTQPASV SGSPGQSI TI SCTGTSSDVG DYNLVSWYQQ HPGKAPKLI I YEVNKRPSGV      60
              SNRFSGSKSG NTASLTI SGL QAEDEADYYC SSYAGYNNLY VFGTGTKVTV L               111
              <212> Ty pe : PRT
              <211> Lengt h : 111
                    Sequenc eName : SEQ I D NO: 104
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAI SWVRQA PGQGLEWMGG I I PI FGTANY    60
              AQKFQGRVTI TADESTSTAY MELSSLRSED TAVYYCARGA SGSYFI TTYV DYWGQGTLVT      120
              VSS                                                                     123
              <212> Ty pe : PRT
              <211> Lengt h : 123
                    Sequenc eName : SEQ I D NO: 105
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSALTQPPSA SGSPGQSVTI SCTGTSSDVG GYNYVSWYQQ HPGKAPKLI I YDVNMRPSGV       60
              PDRFSGSKSG NTASLTI SGL QAEDEADYYC SSYAGLYFPL FGGGTQLTVL                 110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 106
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVESGGG LVQPGGPLRL SCAASGFTLS SYWMSWVRQA PGKGLEWVAN I KYDGSETYY       60
              ADSVKGRFTI SRDNAKNSLY LQMNRLRLED TAVYYCAREV SSAATSPLDR WGRGTLVTVS       120
              S                                                                       121
              <212> Ty pe : PRT
              <211> Lengt h : 121
                    Sequenc eName : SEQ I D NO: 107
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
                                                             Page 21

                                                  PDl 1s eql i s t . t x t
<removed-date>
              <400> Pr eSequenc eSt r i ng :
              DI VMTQSPSS LSASVGDRVT I TCRASQSI S SYLNWYQQKP GKAPKLLI YA ASSLQSGVPS    60
              RFSGSGSGTD FTLTI SSLQP EDFATYYCQQ SHSSRYTFGQ GTKLEI K                   107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 108
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
<removed-apn>
              <400> Pr eSequenc eSt r i ng :
              EVQLVQSGAE VKKPGSSVKV SCKASGGTFS RYGVHWVRQA PGQGLEWMGR LI PI VSMTNY      60
              AQKFQDRVSI TTDKSTGTAY MELRSLTSED TALYYCASVG QQLPWVFFAW GQGTLVTVSS       120
              <212> Ty pe : PRT
              <211> Lengt h : 120
                    Sequenc eName : SEQ I D NO: 109
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVVTQPPSV SGAPGQRVTI SCTGSSSNI G AGYGVHWYQH LPGSAPKLLI YGNSNRPSGV       60
              TDRI SGSKSG TSASLAI TGL QAEDEAVYYC QSYDSSLSTS VVFGGGTKLT VL             112
              <212> Ty pe : PRT
              <211> Lengt h : 112
                    Sequenc eName : SEQ I D NO: 110
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVESGGG VVQPGGSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV I SFDGSNKYY       60
              ADSVRGRFTI SRDNSKNTLY LQMNSLRTED TAVYYCARGW LDRDI DYWGQ GTLVTVSS        118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 111
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVLTQPPSA SGTPGQRVTI SCSGSSSNI G SNTVHWYQQL PGTAPKVLI Y TNNQRPSGVP      60
              DRFSGSKSGT SASLAI SGLQ SEDEADYYCA AWDGRLQGWV FGGGTQLTVL                 110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 112
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV I SFDGSNKYY       60
                                                             Page 22

                                                 PDl 1s eql i s t . t x t
<removed-date>
              ADSVRGRFTI SRDNSKNTLY LQMNSLRTED TAVYYCARGW LDRDI DYWGQ GTLVTVSS         118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 113
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
<removed-apn>
              <400> Pr eSequenc eSt r i ng :
              QAGLTQPPSA SGTPGQRVTI SCFGSSSDI G SNTVNWYQQV SGRAPKLLLY TNGQRPSGVP        60
              DRFSGSKSGS SASLAI SGLQ SEDEADYYCA SWDDSLKGYV FGTGTKVTVL                  110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 114
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAI SWVRQA PGQGLEWMGR I I PI LGI ANY    60
              AQKFQGRVTI TADKSTSTAY MELSSLRSED TAVYYCARVG GGAQTPFDYW GQGTLVTVSS        120
              <212> Ty pe : PRT
              <211> Lengt h : 120
                    Sequenc eName : SEQ I D NO: 115
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVLTQPPSV SAAPGQKVTI SCSGSSSNI G NSYVSWYQHL PGTAPKLLI Y DNNKRPSGI P      60
              DRFSGSKSAT SATLGI TGLQ TADEADYYCG TWDSSLGVVF GGGTKLTVL                   109
              <212> Ty pe : PRT
              <211> Lengt h : 109
                    Sequenc eName : SEQ I D NO: 116
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGSE VKRPGASVRV SCKASGYI FS QYTI HWVRQA PGERLEWLGW I NAVTGNTKY      60
              AQKFQGRVTI TMDSSASTAF MEMSSLRSED AGVYFCARDM VPFGGEI KYG FDFWGQGTMI       120
              TVSS                                                                     124
              <212> Ty pe : PRT
              <211> Lengt h : 124
                    Sequenc eName : SEQ I D NO: 117
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSALTQPASV SGSPGQSI TI SCTGTSSDVG GYNYVSWYQQ HPGKAPKLMI YNVSKRPSGV        60
              SNRFSGSKSG NTASLTI SGL QAEDEADYYC SSYTSSSTFV FGTGTKVTVL                  110
              <212> Ty pe : PRT
                                                    Page 23

                                                 PDl 1s eql i s t . t x t
<removed-date>
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 118
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVAL I SYDGSNKYY       60
              ADSMKGRFTI SRDNSKNTLF LQMNSLRAED TAVYYCAKTL MPASI MGYFT HWGQGTLVTV      120
<removed-apn>
              SS                                                                      122
              <212> Ty pe : PRT
              <211> Lengt h : 122
                    Sequenc eName : SEQ I D NO: 119
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              SYELMQPPSV SVAPGETARI TCGGNNI GSK SVHWYQQKPG QAPI LVI YYD SGRPSGI PER    60
              FSGSNSGNTA TLTI SRAEAG DEADYYCHVW DSYTDHVVFG GGTKLTVL                   108
              <212> Ty pe : PRT
              <211> Lengt h : 108
                    Sequenc eName : SEQ I D NO: 120
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYYMHWVRQA PGQGLEWMGI I NPSDGSTSY       60
              AQKFQGRVTM TRDTSTSTVY MELSSLRSED TAVYYCARGY YGSGI AMDVW GQGTTVTVSS      120
              <212> Ty pe : PRT
              <211> Lengt h : 120
                    Sequenc eName : SEQ I D NO: 121
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QPVLTQPPSL SVAPGKTASI ACGGNNI GSK RVHWYQQKPG QAPVLVI YYE SDRPSGI PER     60
              FSGTI SQNTA TLSI SRVEAG DEADYYCQVW DRSSAHVVFG GGTKVTVL                  108
              <212> Ty pe : PRT
              <211> Lengt h : 108
                     Sequenc eName : SEQ I D NO: 122
                     Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAI SWVRQA PGQGLEWMGG I I PI FGTANY    60
              AQKFQGRVTI TADESTSTAY MELSSLRPED TAVYYCARDN GDLGFDYWGQ GTLVTVSS         118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 123
                    Sequenc eDes c r i pt i on :
              Sequenc e
                                                           Page 24

                                                         PDl 1s eql i s t . t x t
<removed-date>
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              AI QMTQSPSS LSASVGDRVT I TCRASQSI S TYLNWYQQKP GKAPKLLI YA ASSLQNGVPS     60
              RFSGSGSGTD FTLTI SSLQP EDFATYYCQQ SYSTPRTFGP GTKVDI K                    107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 124
                    Sequenc eDes c r i pt i on :
              Sequenc e
<removed-apn>
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVESGGG LI QPGGSLRL SCAASGFTVS SNYMSWVRQA PGKGLEWVSV I YSGGTI YYA      60
              DSVKGRFTI S RDSSKNTLYL HMNSLRAEDT GVYYCAKGVG SWSI FDYWGQ GTLVTVSS        118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 125
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              DI QMTQSPSS LSASVGDRVT I TCQASQDI S NYLNWYQQKP GKAPKLLI FA GSNLQSGVPS     60
              RFSGSGSGTD FTLTI TSLQP EDFATYYCQQ SYTTPTFGQG TKVEI K                     106
              <212> Ty pe : PRT
              <211> Lengt h : 106
                    Sequenc eName : SEQ I D NO: 126
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVESGAE LKKPGSSMKV SCKASGGTFS SYAI SWVRQA PGQGLEYI GR I I PI FGVTYY    60
              AQKFQGRVTI SADKSTSTVY LDLRSLRSED TAVYYCARDL GGGDGDWGQG TLVTVSS           117
              <212> Ty pe : PRT
              <211> Lengt h : 117
                    Sequenc eName : SEQ I D NO: 127
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVVTQPASV SGSPGQSI TI SCTGTSSDVG SYNLVSWYQQ HPGKAPKLMI YEGSKRPSGV        60
              STRFSGSKSG NTASLTI SGL QAEDESDYYC SSYTGSAWVF GGGTKLTVL                   109
              <212> Ty pe : PRT
              <211> Lengt h : 109
                    Sequenc eName : SEQ I D NO: 128
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVQSGAE VKKPGSSVKV SCKASGYTFT GYYMHWVRQA PGQGLEWMGR I I PI FGTANY      60
                                                             Page 25

                                                PDl 1s eql i s t . t x t
<removed-date>
              AQKFQGRVTI TADESTSTAY MELSSLRSED TAVYFCVTSA WSDWGQGTLV TVSS            114
              <212> Ty pe : PRT
              <211> Lengt h : 114
                    Sequenc eName : SEQ I D NO: 129
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
<removed-apn>
              <400> Pr eSequenc eSt r i ng :
              QSVVTQPPSV SATPGQKVTI SCSGSDSNI G NNYVSWFLQL PGTAPKLLI H NNDQRPSGVP     60
              DRFSGSKSGT SASLAI TGLQ AEDEADYYCQ SFDDSLRGYL FGTGTKVTVL                110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 130
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYWMSWVRQA PGKGLEWVAN I KQDGSEKYY      60
              VDSVKGRFTI SRDNSKNTLY LQMNSLGAED TAVYYCAKGF YYPDHWGQGT LVTVSS          116
              <212> Ty pe : PRT
              <211> Lengt h : 116
                    Sequenc eName : SEQ I D NO: 131
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QAVLTQPPSV SAAPGQKVTI SCSGGSSNI A NNYVSWYQHL PGTAPKLLI Y DDNKRPSGI P    60
              DRFSGSKSGT SATLGI TGLQ TGDGADYYCG TWDNSLNSDW VFGGGTKL                  108
              <212> Ty pe : PRT
              <211> Lengt h : 108
                    Sequenc eName : SEQ I D NO: 132
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVESGGG VVQPGGSLRL SCEVSGFI FS DYGMHWVRQA PGKGLEWVSS I SSSSSYI YY    60
              ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAMYYCARSW NYGRFFDYWD QGTLVTVSS       119
              <212> Ty pe : PRT
              <211> Lengt h : 119
                    Sequenc eName : SEQ I D NO: 133
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVLTQPPSV SVAPGKTARI TCGGNNI GSK SVHWYQQKPG QAPVLVI YYD SDRPSGI PER    60
              FSGSNSGNTA TLTI SRVEAG DEADYYCQVW DSSSDHYVFG TGTKLTVL                  108
                                                    Page 26

                                                 PDl 1s eql i s t . t x t
<removed-date>
              <212> Ty pe : PRT
              <211> Lengt h : 108
                    Sequenc eName : SEQ I D NO: 134
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVESGGG LVQPGGSLRL SCAASGFTSS RNWMHWVRLA PGKGLVWVSL I APDGSLTTY       60
              ADSVKGRFTI SRDTAKNSVQ LLLNSLRAED TGLYFCAREA GVSGGLDVWG QGTLVTVSS        119
<removed-apn>
              <212> Ty pe : PRT
              <211> Lengt h : 119
                    Sequenc eName : SEQ I D NO: 135
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              VI WMTQSPSS LSASVGDRVT I TCRASQTI S SYLNWYQQKP GKAPKLLI YA ASSLQSGVPS    60
              RFSGSGSGTD FTLTI SSLQP EDFATYYCQQ ANSFPLTFGG GTKVEI K                   107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 136
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAI SWVRQA PGQGLEWMGG I I PI FGTANY    60
              AQKFQGRVTI TADKSTSTAY MELSSLRSED TAVYYCAREG TI YDSSGYSF DYWGQGTLVT      120
              VSS                                                                     123
              <212> Ty pe : PRT
              <211> Lengt h : 123
                    Sequenc eName : SEQ I D NO: 137
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVLTQPPSV SAAPGQKVTI SCSGNNSNI A NNYVSWYQQL PGTAPKLLI Y DNNYRPSGI P     60
              DRFSGSKSGT SATLDI TGLQ TGDEADYYCG VWDGSLTTGV FGGGTKLTVL                 110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 138
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAI SWVRQA PGQGLEWMGI I NPSGGSTSY      60
              AQKFQGRVSM TRDTSTSTVY MELSSLTSED TAVYYCARDL FPHI YGNYYG MDI WGQGTTV     120
              TVSS                                                                    124
              <212> Ty pe : PRT
              <211> Lengt h : 124
                                                           Page 27

                                                 PDl 1s eql i s t . t x t
<removed-date>
                    Sequenc eName : SEQ I D NO: 139
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              AI QMTQSPSS LSASVGDRVT I TCRASQGI S NYLAWYQQKP GKVPKLLI YA ASTLESGVPS    60
              RFSGSGSGTD FTLTI SSLQP EDLATYYCQQ LHTFPLTFGG GTKVEI K                   107
              <212> Ty pe : PRT
              <211> Lengt h : 107
<removed-apn>
                    Sequenc eName : SEQ I D NO: 140
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAI SWVRQA PGQGLEWMGG I I PI FGTANY    60
              AQKFQGRVTI TADKSTSTAY MELSSLRSED TAVYYCARLA VPGAFDI WGQ GTMVTVSS        118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 141
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QPVLTQPPSA SGSPGQSVTI SCTGTSSDVG AYNFVSWYRQ HPGKAPKLMI YEVNKRPSGV        60
              PDRFSGSKSG NTASLTVSGL QAEDEADYYC SSYAGTNSLG I FGTGTKLTV L               111
              <212> Ty pe : PRT
              <211> Lengt h : 111
                    Sequenc eName : SEQ I D NO: 142
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV I SYDGSNKYY       60
              ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARGQ WLVTELDYWG QGTLVTVSS        119
              <212> Ty pe : PRT
              <211> Lengt h : 119
                    Sequenc eName : SEQ I D NO: 143
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVVTQPPSV SAAPGQKVTI SCSGSSSDI G NHYVSWYQQL PGTAPKLLI Y DNNQRPSGI P     60
              DRFSGSKSGT SATLAI TGLQ TGDEADYYCG TWDNSLSPHL LFGGGTKLTV L               111
              <212> Ty pe : PRT
              <211> Lengt h : 111
                                                           Page 28

                                                 PDl 1s eql i s t . t x t
<removed-date>
                    Sequenc eName : SEQ I D NO: 144
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVESGSE VEKPGSSVKV SCKASGGTFS DSGI SWVRQA PGQGLEWMGG I I PMFATPYY     60
              AQKFQDRVTI TADESTSTVY MELSGLRSDD TAVFYCARDR GRGHLPWYFD LWGRGTLVTV       120
              SS                                                                      122
<removed-apn>
              <212> Ty pe : PRT
              <211> Lengt h : 122
                    Sequenc eName : SEQ I D NO: 145
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVLTQPPSV SAAPGQKVTI SCSGSSSNMG NNYVSWYKQV PGTAPKLLI Y ENDKRPSGI P      60
              DRFSGSKSGT SATLGI TGLQ TGDEADYYCG TWDNSLSGFV FASGTKVTVL                 110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 146
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVESGAE VKKPGSSVKV SCKASGGTFS SYAI SWVRQA PGQGLEWMGG I I PI FGTANY    60
              AQKFQGRVTI TADESTSTAY MELSSLRSED TAVYYCARAP YYYYYMDVWG QGTTVTVSS        119
              <212> Ty pe : PRT
              <211> Lengt h : 119
                    Sequenc eName : SEQ I D NO: 147
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSALTQPASV SGSLGQSVTI SCTGSSSDVG SYNLVSWYQQ HPGKAPNLMI YDVSKRSGVS        60
              NRFSGSKSGN TASLTI SGLQ AEDEADYYCS SYTGI STVVF GGGTKLTVL                 109
              <212> Ty pe : PRT
              <211> Lengt h : 109
                    Sequenc eName : SEQ I D NO: 148
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLLESGAE VKKPGSSVKV SCKASGGTLS RYALSWVRQA PGQGPEWVGA I I PI FGTPHY     60
              SKKFQDRVI I TVDTSTNTAF MELSSLRFED TALYFCARGH DEYDI SGYHR LDYWGQGTLV     120
              TVSS                                                                    124
              <212> Ty pe : PRT
              <211> Lengt h : 124
                    Sequenc eName : SEQ I D NO: 149
                    Sequenc eDes c r i pt i on :
                                                           Page 29

                                                 PDl 1s eql i s t . t x t
<removed-date>
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVLTQPASV SGSPGQSI TI SCTGTSSDVG SYNLVSWYQQ HPGKAPKLMI YEVSKRPSGV        60
              SNRFSGSKSG NTASLTI SGL QAEDEADYYC SSYGGFNNLL FGGGTKLTVL                  110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 150
                    Sequenc eDes c r i pt i on :
<removed-apn>
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGSE LKKPGSSVKV SCKASGYSFS GYYI HWVRQA PGQGLEWMGW I DPNSGVTNY       60
              VRRFQGRVTM TRDTSLSTAY MELSGLTADD TAVYYCARDE NLWQFGYLDY WGQGTLVTVS        120
              S                                                                        121
              <212> Ty pe : PRT
              <211> Lengt h : 121
                    Sequenc eName : SEQ I D NO: 151
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              DI VMTQSPSS LSASI GDRVT I TCRASQRI S AYVNWYQQKP GKAPKVLI YA ASSLRSGVPS    60
              RFSGSGSGTD FTLTI SSLQP EDFATYYCQQ TYSSPWTFGQ GTKVEI K                    107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 152
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGAE VKKPGSSVKV SCKASGGTFS RYGVHWVRQA PGQGLEWMGR LI PI VSMTNY       60
              AQKFQDRVSI TTDKSTGTAY MELRSLTSED TALYYCASVG QQLPWVFFAW GQGTLVTVSS        120
              <212> Ty pe : PRT
              <211> Lengt h : 120
                    Sequenc eName : SEQ I D NO: 153
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVLTQPPSA SGSPGQSVTI SCTGTSSDI G GYDSVSWYQQ HPGKAPKLMI YDVSKRPSGV        60
              SNRFSGSKSG NTASLTI SGL QAEDEADYYC SSYTSSSI FF YVFGTGTKVT VL              112
              <212> Ty pe : PRT
              <211> Lengt h : 112
                    Sequenc eName : SEQ I D NO: 154
                    Sequenc eDes c r i pt i on :
              Sequenc e
                                                       Page 30

                                                         PDl 1s eql i s t . t x t
<removed-date>
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV I SFDGSNKYY     60
              ADSVRGRFTI SRDNSKNTLY LQMNSLRTED TAVYYCARGW LDRDI DYWGQ GTLVTVSS      118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 155
                    Sequenc eDes c r i pt i on :
<removed-apn>
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              LPVLTQPASV SGSPGQSI TI SCTGTTSDI G GYDYVSWYQQ HPGKAPKLMI YDVSKRPSGV    60
              SNRFSGSKSG NTASLTI SGL QAEDEADYYC SSYTSSSTHV FGTGTKLTVL               110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 156
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV I SFDGSNKYY     60
              ADSVRGRFTI SRDNSKNTLY LQMNSLRTED TAVYYCARGW LDRDI DYWGQ GTLVTVSS      118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 157
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSALTQPASV SGSPGQSI TI SCTGTSSDVG GYNYVSWYQQ HPGKAPKLMI YDVSNRPSGV     60
              SNRFSGSKSG NTASLTI SGL QAEDEADYYC SSYRSSTLGP VFGGGTKLTV L             111
              <212> Ty pe : PRT
              <211> Lengt h : 111
                    Sequenc eName : SEQ I D NO: 158
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV I SFDGSNKYY     60
              ADSVRGRFTI SRDNSKNTLY LQMNSLRTED TAVYYCARGW LDRDI DYWGQ GTLVTVSS      118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 159
                    Sequenc eDes c r i pt i on :
              Sequenc e
                                                      Page 31

                                                         PDl 1s eql i s t . t x t
<removed-date>
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QAGLTQPPSV SEAPRQRVTI SCSGSSSNI G NNAVNWYQQL PGKAPKLLI Y YDDLLPSGVS     60
              DRFSGSKSGT SASLAI SGLQ SEDEADYYCA AWDDSLNGYV FGTGTKLTVL                110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 160
                    Sequenc eDes c r i pt i on :
              Sequenc e
<removed-apn>
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV I SFDGSNKYY      60
              ADSVRGRFTI SRDNSKNTLY LQMNSLRTED TAVYYCARGW LDRDI DYWGQ GTLVTVSS       118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 161
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSALTQPRSV SGSPGQSVTI SCTGTSSDVG GYNYVSWYQQ HPGKAPKLMI YDVSKRPSGV       60
              PDRFSGSKSG NTASLTI SGL QAEDEADYYC SSYTSSTTHV FGTGTKVTVL                110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 162
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV I SFDGSNKYY      60
              ADSVRGRFTI SRDNSKNTLY LQMNSLRTED TAVYYCARGW LDRDI DYWGQ GTLVTVSS       118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 163
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVVTQPPSV SAAPGQKVTI SCSGSSSNI G NNYVSWYQQL PGTAPKLLI Y DNNKRPSGI P    60
              DRFSGSKSGT SATLGI TGLQ TGDEADYYCG TWDSSLSVWV FGGGTQLTVL                110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 164
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV I SFDGSNKYY      60
              ADSVRGRFTI SRDNSKNTLY LQMNSLRTED TAVYYCARGW LDRDI DYWGQ GTLVTVSS       118
                                                             Page 32

                                                PDl 1s eql i s t . t x t
<removed-date>
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 165
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVLTQPASV SGSPGQSI TI SCTGTSSDVG GYNYVSWYQQ HPGRAPRLMI YDVSNRPSGV       60
              SNRFSGSKSG NTASLTI SGL QAEDEGDYYC SSYTSGGTLG PVFGGGTKLT VL              112
<removed-apn>
              <212> Ty pe : PRT
              <211> Lengt h : 112
                    Sequenc eName : SEQ I D NO: 166
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVQSGGG LVQPGGSLRL SCAASGFTFS DYGMHWVRQP PGKGLEWLAV I SYDGSYKI H      60
              ADSVQGRFTI SRDNAKNSVF LQMNSLKTED TAVYYCTTDR KWLAWHGMDV WGQGTTVTVS       120
              S                                                                       121
              <212> Ty pe : PRT
              <211> Lengt h : 121
                    Sequenc eName : SEQ I D NO: 167
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QAGLTQPPSA SGTPGQRVTI SCSGSSSNI G SNTVNWYQQL PGTAPKLLI Y SNNQRPSGVP      60
              DRFSGSKSGT SASLAI SGLQ SEDEADYYCA AWDDSLNGWV FGGGTKLTVL                 110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 168
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAI SWVRQA PGQGLEWMGG I I PI FGTANY    60
              AQKFQGRVTI TADESTSTAY MELSSLRSED TAVYYCARDG I VADFQHWGQ GTLVTVSS        118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 169
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              AI RMTQSPSS LSASVGDRVT I TCRASQSI S NYLNWYQQRP GKAPNLLI YA ASSLQSGVPS    60
              RFSGSGSGTD FTLTI SSLQP EDFATYYCQQ TYSTPYTFGQ GTKLEI K                   107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 170
                    Sequenc eDes c r i pt i on :
                                                      Page 33

                                                         PDl 1s eql i s t . t x t
<removed-date>
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVESGAE VKKPGASVKV SCKASGDTFS RYGI TWVRQA PGRGLEWMGN I VPFFGATNY      60
              AQKFQGRLTI TADKSSYTSY MDLSSLRSDD TAVYYCARDH FYGSGGYFDY WGQGTLVTVS       120
              S                                                                       121
              <212> Ty pe : PRT
              <211> Lengt h : 121
                    Sequenc eName : SEQ I D NO: 171
<removed-apn>
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVLTQPASV SGSPGQSI TI SCTGTSSDVG GYNYVSWYRQ HPGKAPKLMI YDVSYRPSGV       60
              SNRFSGSKSG NTASLTI SGL QAEDEADYYC SSYTDSSTRY VFGTGTKLTV L               111
              <212> Ty pe : PRT
              <211> Lengt h : 111
                    Sequenc eName : SEQ I D NO: 172
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLLESGAE VKKPGASVKV SCKASGYTFN SYDI NWVRQA PGQGLEWMGG I I PVFGTANY     60
              AESFQGRVTM TADHSTSTAY MELNNLRSED TAVYYCARDR WHYESRPMDV WGQGTTVTVS       120
              S                                                                       121
              <212> Ty pe : PRT
              <211> Lengt h : 121
                    Sequenc eName : SEQ I D NO: 173
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QPVLTQPPSA SGTPGQRVAI SCSGSRSNI E I NSVNWYQQL PGTAPKLLI Y DNNKRPSGI P    60
              DRFSGSKSGT SATLGI TGLQ TGDEADYYCG SWDSSLSADV FGTGTKLTVL                 110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 174
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVESGGG LVRPGGSLRL ACAASGFSFS DYYMTWI RQA PGRGLEWI AY I SDSGQTVHY     60
              ADSVKGRFTI SRDNTKNSLF LQVNTLRAED TAVYYCARED LLGYYLQSWG QGTLVTVSS        119
              <212> Ty pe : PRT
              <211> Lengt h : 119
                    Sequenc eName : SEQ I D NO: 175
                    Sequenc eDes c r i pt i on :
                                                      Page 34

                                                         PDl 1s eql i s t . t x t
<removed-date>
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVLTQPPSV SAAPGKKVTI SCSGSSSNI G NNYVSWYQQL PGTAPKLLI Y RNNQRPSGVP     60
              DRFSGSKSGT SASLAI SGLQ SEDEADYYCA TWDDSLNGWV FGGGTKLTVL                110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 176
                    Sequenc eDes c r i pt i on :
<removed-apn>
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLQQSGPG LVKPSQTLSL TCAI SGDSVS SNSAAWNWI R QSPSRGLEWL GRTYYRSKWY     60
              NDYAVSVKSR I TI NPDTSKN QFSLQLNSVT PEDTAVYYCA RDEPRAVAGS QAYYYYGMDV    120
              WGQGTTVTVS S                                                           131
              <212> Ty pe : PRT
              <211> Lengt h : 131
                    Sequenc eName : SEQ I D NO: 177
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVVTQPPSV SGAPGQRVTI SCTGSSSNI G AGYDVHWYQQ LPGTAPKLLI YGNNNRHSGV      60
              PDRFSGSKSG TSASLAI TGL QAEDEAEFFC GTWDSRLTTY VFGSGTKLTV L              111
              <212> Ty pe : PRT
              <211> Lengt h : 111
                    Sequenc eName : SEQ I D NO: 178
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGAE VKKPGSSVKV SCKASGGTFS RYGVHWVRQA PGQGLEWMGR LI PI VSMTNY     60
              AQKFQDRVSI TTDKSTGTAY MELRSLTSED TALYYCASVG QQLPWVFFAW GQGTLVTVSS      120
              <212> Ty pe : PRT
              <211> Lengt h : 120
                    Sequenc eName : SEQ I D NO: 179
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVVTQPPSV SAAPGQKVTI SCSGSSSNI G NNYVSWYQQL PGTAPKLLI Y DNNKRPSGI P    60
              DRFSGSKSGT SATLGI TGLQ TGDEADYYCG TWDSSLSAVV FGGGTKLTVL                110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 180
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
                                                      Page 35

                                                         PDl 1s eql i s t . t x t
<removed-date>
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVQSGAE VKKPGASVKV SCKASGYTFT SYYMHWVRQA PGQGLEWMGI I NPSDGSTSY       60
              AQKFQGRVTM TRDTSTSTVH MELSSLRSED TAVYYCARDL FPHI YGNYYG MDI WGQGTTV     120
              TVSS                                                                    124
              <212> Ty pe : PRT
              <211> Lengt h : 124
                    Sequenc eName : SEQ I D NO: 181
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
<removed-apn>
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              VI WMTQSPSS LSASVGDRVT I TCRASQSI S SYLNWYQQKP GKAPKLLI YE ASTLESGVPS    60
              RFSGSGSGTE FTLTI SSLQP EDFATYYCQQ SYSTPYTFGQ GTKLEI K                   107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                     Sequenc eName : SEQ I D NO: 182
                     Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QMQLVQSGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV I SFDGSNKYY       60
              ADSVRGRFTI SRDNSKNTLY LQMNSLRTED TAVYYCARGW LDRDI DYWGQ GTLVTVSS        118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 183
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVVTQPPSV SAAPGQKVTI SCSGSSSNI G NNYVSWYQQV PGTAPKLLI Y DNNKRPSGI P     60
              DRFSGSNSDT SATLGI TGLQ TGDEADYYCG TWDSSLSAWV FGGGTKLTVL                 110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 184
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV I SFDGSNKYY       60
              ADSVRGRFTI SRDNSKNTLY LQMNSLRTED TAVYYCARGW LDRDI DYWGQ GTLVTVSS        118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 185
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVVTQPPSV SAAPGQKVTI SCSGSSSNI G NNYVSWYQQL PGTAPKLLI Y DNNKRPSGI P     60
              DRFSGSKSGT SATLGI TGLQ TGDEADYYCG TWDSSLSAGS VVFGGGTKLT VL              112
                                                    Page 36

                                                PDl 1s eql i s t . t x t
<removed-date>
              <212> Ty pe : PRT
              <211> Lengt h : 112
                    Sequenc eName : SEQ I D NO: 186
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAI SWVRQA PGQGLEWMGG I I PI FGTANY    60
<removed-apn>
              AQKFQGRVTI TADESTSTAY MELSSLRSED TAVYYCARDG I VADFQHWGQ GTLVTVSS        118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 187
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QPVLTQPRSV SGSPGQSVTI SCTGTSSDVG GYNFVSWYQQ NPGKAPKLMI YDVSKRPSGV        60
              PDRFSGSKSG NTASLTVSGL RAEDEADYYC ASYAGGRTFV FGGGTKVTVL                  110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 188
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QMQLVQSGAE VKKPGSSVKV SCKASGGTFN SYPI SWVRQA PGQGLEWMGG I I PI FGTANY    60
              AQKFQGRVTI TADESTSTAY MELSSLRSED TAMYYCAKNH PTATLDYWGQ GTLVTVSS         118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 189
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVLTQSPSS FSASTGDRVT I TCRASQGI S SYLAWYQQKP GKAPKLLI YA ASTLQSGVPS     60
              RFSGSGSGTD FTLTI SCLQS EDFATYYCQQ YYSYPLTFGG GTKVTVL                    107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 190
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGGG VVQPGRSLRL SCAASGFPFR SYDMHWVRQA PGEGLEWVAL I SSDGSNKYY       60
              LDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDL LPYSSSWDYY YYYGMDVWGQ       120
              GTTVTVSS                                                                128
                                                      Page 37

                                                 PDl 1s eql i s t . t x t
<removed-date>
              <212> Ty pe : PRT
              <211> Lengt h : 128
                    Sequenc eName : SEQ I D NO: 191
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              LPVLTQPASV SASAGQSI AI SCTGI SSDI G DYNSVSWYQR HPGKAPKLI I YDVSSRPSGV    60
              ADRFSGSKSG STASLSI SGL QAEDEADYYC ASYTASDNPV FGGGTKLTVL                 110
<removed-apn>
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 192
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVESGGG LVQPGGSLRL SCAASGFNI K DTYI HWVRQA PGKGLEWVAR I YPTNGYTRY     60
              ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCSRWG GDGFYAMDYW GQGTLVTVSS       120
              <212> Ty pe : PRT
              <211> Lengt h : 120
                    Sequenc eName : SEQ I D NO: 193
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              SYELMQPPSV SVAPGKTATI ACGGENI GRK TVHWYQQKPG QAPVLVI YYD SDRPSGI PER     60
              FSGSNSGNTA TLTI SRVEAG DEADYYCQVW DSSSDHRI FG GGTKLTVL                  108
              <212> Ty pe : PRT
              <211> Lengt h : 108
                    Sequenc eName : SEQ I D NO: 194
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVESGGG LVKPGGSRKL SCAASGFTFS NYGMHWVRQA PEKGLEWVAY I SSGSSTI YY      60
              ADTVKGRFTI SRDNAKNTLF LQMTSLRSED TAMYYCARRG LLLDYWGQGT TLTVSS           116
              <212> Ty pe : PRT
              <211> Lengt h : 116
                    Sequenc eName : SEQ I D NO: 195
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVLTQPPSV SAAPGQEVTI SCSGSNSNI G NNYVSWYQQL PGTAPKLLI Y DNNERPSGI P     60
              DRFSGSKSGT SATLGI TGLQ TGDEADYYCG TWDSSLSAGV FGGGTKLTVL                 110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 196
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
                                                             Page 38

                                                 PDl 1s eql i s t . t x t
<removed-date>
              <400> Pr eSequenc eSt r i ng :
              EVQLVQSGAE VKKPGASVKV SCKASGYTFT SYGI SWVRQA PGQGLEWMGW I SAYNGNTNY      60
              AQKLQGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARDL FPTI FWEGGA FDI WGQGTMV     120
              TVSS                                                                    124
              <212> Ty pe : PRT
              <211> Lengt h : 124
                    Sequenc eName : SEQ I D NO: 197
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
<removed-apn>
              <400> Pr eSequenc eSt r i ng :
              QSVLTQPPSV SAAPGQEVTI SCSGSNSNI G NNYVSWYQQL PGTAPKLLI Y DNNERPSGI P     60
              DRFSGSKSGT SATLGI TGLQ TGDEADYYCG TWDSSLSAGV FGGGTKLTVL                 110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 198
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGSE VEKPGSSVKV SCKASGGTFS DSGI SWVRQA PGQGLEWMGG I I PMFATPYY     60
              AQKFQDRVTI TADESTSTVY MELSGLRSDD TAVFYCARDR GRGHLPWYFD LWGRGTLVTV       120
              SS                                                                      122
              <212> Ty pe : PRT
              <211> Lengt h : 122
                    Sequenc eName : SEQ I D NO: 199
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVLTQPPSV SAAPGQEVTI SCSGSNSNI G NNYVSWYQQL PGTAPKLLI Y DNNERPSGI P     60
              DRFSGSKSGT SATLGI TGLQ TGDEADYYCG TWDSSLSAGV FGGGTKLTVL                 110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 200
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAI SWVRQA PGQGLEWMGG I I PI FGTANY    60
              AQKFQGRVTI TADESTSTAY MELSSLRSED TAVYYCARDG I VADFQHWGQ GTLVTVSS        118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 201
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              AI RMTQSPSS LSASVGDRVT I TCRASQSI S NYLNWYQQRP GKAPNLLI YA ASSLQSGVPS    60
              RFSGSGSGTD FTLTI SSLQP EDFATYYCQQ TYSTPYTFGQ GTKLEI K                   107
                                                    Page 39

                                                 PDl 1s eql i s t . t x t
<removed-date>
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 202
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLLESGAE VKKPGSSVKV SCKASGGTFS SYAI SWVRQA PGQGLEWMGR I I PI LGI ADY    60
              AQKFQGRVTI TADKFTSTAY MELSSLRSED TAVYYCATVE GWGAVTTFDY WGQGTLVTVS        120
<removed-apn>
              S                                                                        121
              <212> Ty pe : PRT
              <211> Lengt h : 121
                    Sequenc eName : SEQ I D NO: 203
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVLTQPPSV SAAPGQEVTI SCSGSNSNI G NNYVSWYQQL PGTAPKLLI Y DNNERPSGI P      60
              DRFSGSKSGT SATLGI TGLQ TGDEADYYCG TWDSSLSAGV FGGGTKLTVL                  110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 204
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGAE VKKPGSSVKV SCKASGGTLS SYAI SWVRQV PGHGLEWMGR I I SMLGVSNY      60
              AQNFQGRVTI TADKSTSTAY MELRSLTSDD TAVYYCATVT I FDGDYYAMD VWGQGTTVTV       120
              SS                                                                       122
              <212> Ty pe : PRT
              <211> Lengt h : 122
                    Sequenc eName : SEQ I D NO: 205
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVLTQPPSV SGAPGQRVTI SCTGSSSNI G AGYDVYWYQH LLGKAPKLLI YGNSNRPSGV        60
              SDRFSASKSG TSVSLAI TGL QAEDEADYYC QSYDSSLSGY VFGTGTKLTV L                111
              <212> Ty pe : PRT
              <211> Lengt h : 111
                    Sequenc eName : SEQ I D NO: 206
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVQSGAE VKKPGSSVKV SCKASGGTFS SHVI SWVRQA PGQGLEWMGI I LPSFGKTNY       60
              AQKFQGRVTM TGDTSTSTVY MELSSLTSED TAVYYCVREF SGGYFDYWGQ GTLVTVSS          118
                                                           Page 40

                                                 PDl 1s eql i s t . t x t
<removed-date>
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 207
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QPVLTQPASV SGSPGQSI TI SCTGTSSDVG SYNLVSWYQQ HPGKAPKLMI YEVSKRPSGV       60
              SNRFSGSKSG NTASLTI SGL QAEDEADYYC NTYTSSGTYV I GTGTKVTVL                110
<removed-apn>
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 208
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYVI HWVRQA PGQRLEWMGW I HAGNGHTKY      60
              AQNFQGRVTI TRDTSATTAY VEVSSLGSED TALYYCAREG SDI GLDLHYW GQGTLVTVSS      120
              <212> Ty pe : PRT
              <211> Lengt h : 120
                    Sequenc eName : SEQ I D NO: 209
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QPVLTQPASV SGSPGQSI TI SCTGTSSDI G RYNYVSWYQQ HPGKAPKVMI YDVSNRPSGV      60
              SNRFSGSKSG NTASLTI SGL QAEDEADYYC SSYTSSSTWV FGGGTKLTVL                 110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 210
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVQSGGG VVQPGRSLRL SCEASGFTFR NFAMHWVRQA PGKGLEWAAV I SVDGSREHY       60
              ADSVKGRFTI SRDNSQNTVY LQMNGLRPED TAEYYCAREG EGSTWSSFDY WGQGTLVTVS       120
              S                                                                       121
              <212> Ty pe : PRT
              <211> Lengt h : 121
                    Sequenc eName : SEQ I D NO: 211
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QSVVTQPPSV SAAPGQKVTI SCSGSSSNI G NNYVSWYQQL PGTAPKI LI Y DNDKRPSGI P    60
              DRFSGSKSGT SATLGI TGLQ TGDEADYYCG TWDRSLSGYV FGTGTKVTVL                 110
              <212> Ty pe : PRT
              <211> Lengt h : 110
                    Sequenc eName : SEQ I D NO: 212
                    Sequenc eDes c r i pt i on :
                                                    Page 41

                                                PDl 1s eql i s t . t x t
<removed-date>
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QMQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAYSWVRQA PGQGLEWMGG I I PSFGTANY     60
              AQKFQGRVTI TADESTSTAY MELSSLRSED TAVYYCARGP I VATI TPLDY WGQGTLVTVS    120
              S                                                                      121
              <212> Ty pe : PRT
              <211> Lengt h : 121
<removed-apn>
                    Sequenc eName : SEQ I D NO: 213
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              SYELMQPPSV SVAPGKTATI ACGGENI GRK TVHWYQQKPG QAPVLVI YYD SDRPSGI PER    60
              FSGSNSGNTA TLTI SRVEAG DEADYYCLVW DSSSDHRI FG GGTKLTVL                 108
              <212> Ty pe : PRT
              <211> Lengt h : 108
                    Sequenc eName : SEQ I D NO: 214
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QMQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAYSWVRQA PGQGLEWMGG I I PI FGTANY    60
              AQKFQGRVTI TADESTSTAY MELSSLRSED TAVYYCARGP I VATI TPLDY WGQGTLVTVS    120
              S                                                                      121
              <212> Ty pe : PRT
              <211> Lengt h : 121
                    Sequenc eName : SEQ I D NO: 215
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              SYELMQPPSV SVAPGKTATI ACGGENI GRK TVHWYQQKPG QAPVLVI YYD SDRPSGI PER    60
              FSGSNSGNTA TLTI SRVEAG DEADYYCQVW DSSSDHRI FG GGTKLTVL                 108
              <212> Ty pe : PRT
              <211> Lengt h : 108
                    Sequenc eName : SEQ I D NO: 216
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QMQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAYSWVRQA PGQGLEWMGG I I PSFGTANY     60
              AQKFQGRVTI TADESTSTAY MELSSLRSED TAVYYCARGP I VATI TPLDY WGQGTLVTVS    120
              S                                                                      121
              <212> Ty pe : PRT
              <211> Lengt h : 121
                    Sequenc eName : SEQ I D NO: 217
                    Sequenc eDes c r i pt i on :
              Sequenc e
                                                      Page 42

                                                         PDl 1s eql i s t . t x t
<removed-date>
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              SYELMQPPSV SVAPGKTATI ACGGENI GRK TVHWYQQKPG QAPVLVI YYD SDRPSGI PER     60
              FSGSNSGNTA TLTI SRVEAG DEADYYCQVW DSSSDHRI FG GGTKLTVL                  108
              <212> Ty pe : PRT
              <211> Lengt h : 108
                    Sequenc eName : SEQ I D NO: 218
                    Sequenc eDes c r i pt i on :
              Sequenc e
<removed-apn>
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QMQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAI SWVRQA PGQGLEWMGG I I PAFGTANY     60
              AQKFQGRVTI TADESTSTAY MELSSLRSED TAVYYCARGP I VATI TPLDY WGQGTLVTVS     120
              S                                                                       121
              <212> Ty pe : PRT
              <211> Lengt h : 121
                    Sequenc eName : SEQ I D NO: 219
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              SYELMQPPSV SVAPGKTATI ACGGENI GRK TVHWYQQKPG QAPVLVI YYD SDRPSGI PER     60
              FSGSNSGNTA TLTI SRVEAG DEADYYCQVW DSSSDHRI FG GGTKLTVL                  108
              <212> Ty pe : PRT
              <211> Lengt h : 108
                    Sequenc eName : SEQ I D NO: 220
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGAE VKKPGASVKV SCKTSGNTFT NYALHWVRQA PGQGLEWMGG MKPSGGSTSI        60
              AQKFQGRVTM TRDKSTSTVY MELSSLTSED TAVYYCARDL FPHI FGNYYG MDI WGQGTTV     120
              TVSS                                                                    124
              <212> Ty pe : PRT
              <211> Lengt h : 124
                    Sequenc eName : SEQ I D NO: 221
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              DI VMTQSPPS LSASVGDRVT I TCRASQSI S SYLNWYQQKP GKAPKLLI YA TSSLQYGVPS    60
              RFSGSGSGTD FTLTI SSLQP EDFATYYCQG SYSTPYTFGQ GTKVEI K                   107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 222
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGAE VKKPGASVKV SCKTSGNTFT NYYMHWVRQA PGQGLEWMGS MQPSGGSTSL        60
                                                             Page 43

                                                PDl 1s eql i s t . t x t
<removed-date>
              AQKFQGRVTM TRDKSTSTVY MELSSLTSED TAVYYCARDL FPHI LGNYYG MDI WGQGTTV     120
              TVSS                                                                    124
              <212> Ty pe : PRT
              <211> Lengt h : 124
                    Sequenc eName : SEQ I D NO: 223
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
<removed-apn>
              <400> Pr eSequenc eSt r i ng :
              DI VMTQSPPS LSASVGDRVT I TCRASQSI S SYLNWYQQKP GKAPKLLI YA ASSLQSGVPS    60
              RFSGSGSGTD FTLTI SSLQP EDFATYYCQG SYSTPYTFGQ GTKVEI K                   107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 224
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGAE VKKPGASVKV SCKTSGNTFT NYPMHWVRQA PGQGLEWMGS MKPSGGSTSL        60
              APKFQGRVTM TRDKSTSTVY MELSSLTSED TAVYYCARDL FPHI I GNYYG MDI WGQGTTV    120
              TVSS                                                                    124
              <212> Ty pe : PRT
              <211> Lengt h : 124
                    Sequenc eName : SEQ I D NO: 225
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              DI VMTQSPPS LSASVGDRVT I TCRASQSI S SYLNWYQQKP GKAPKLLI YA ASSLQYGVPS    60
              RFSGSGSGTD FTLTI SSLQP EDFATYYCQG SYSTPYTFGQ GTKVEI K                   107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 226
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGAE VKKPGASVKV SCKTSGNTFT NYSMHWVRQA PGQGLEWMGI MNPSGGSTSY        60
              AQKFQGRVTM TRDKSTSTVY MELSSLTSED TAVYYCARDL FPHI YGNYYG MDI WGQGTTV     120
              TVSS                                                                    124
              <212> Ty pe : PRT
              <211> Lengt h : 124
                    Sequenc eName : SEQ I D NO: 227
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              DI VMTQSPPS LSASVGDRVT I TCRASQSI S SYLNWYQQKP GKAPKLLI YA ASSLQSGVPS    60
              RFSGSGSGTD FTLTI SSLQP EDFATYYCQQ SYSTPYTFGQ GTKVEI K                   107
              <212> Ty pe : PRT
                                                             Page 44

                                                 PDl 1s eql i s t . t x t
<removed-date>
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 228
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              EVQLVQSGAE VKKPGASVKV SCKASGYTFT GYYMHWVRQA PGQGLEWMGW I NPNSDNTGS       60
              AQKFQGRVFM TKTTSLNTAY MELSGLRSED TAI YYCARER SSGYFDFWGQ GTLVTVSS        118
              <212> Ty pe : PRT
<removed-apn>
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 229
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              DI VMTQSPSS LSASVGDRVT I TCRASQSI S SFLNWYQQKP GKAPKLLI YA ASSLQSGVPS    60
              RFSGSGSGTD FTLTI SSLQP EDFATYYCQQ SYSTPI TFGQ GTKVEI K                  107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 230
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGAE VKKLGASVKV SCKASGYPFT GYYMHWVRQA PGQGLEWMGW I NPNGDNTGL       60
              AQKFQGRVFM TKTTSLNTAY MELSGLRSED TAI YYCARER SSGYFDFWGQ GTLVTVSS        118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 231
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              DI VMTQSPSS LSASVGDRVT I TCRATPSTS SYLNWYQQKP GKAPKLLI YA ASSLQSGVPS     60
              RFSGSGSGTD FTLTI SSLQP EDFATYYCQQ SYSTPI TFGQ GTKLEI K                  107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 232
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGAE VKKPGASVKV SCKTSGYPFT GYYMHWVRQA PGQGLEWMGW I NPLSDTTGS       60
              AQKFQGRVFM TKTTSLNTAY MELSGLRSED TAI YYCARER SSGYFDFWGQ GTLVTVSS        118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 233
                    Sequenc eDes c r i pt i on :
                                                           Page 45

                                                         PDl 1s eql i s t . t x t
<removed-date>
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              DI VMTQSPSS LSASVGDRVT I TCRASQSI S SYLNWYQQKP GKAPKLLI YA ASSLQSGVPS    60
              RFSGSGSGTD FTLTI SSLQP EDFATYYCQQ SYSTPI TFGQ GTKLEI K                  107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 234
                    Sequenc eDes c r i pt i on :
<removed-apn>
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGAE VKKPGASVKV SCKASGYTFT GYYMHWVRQA PGQGLEWMGW I NPLSDNTGS       60
              AQKFQGRVFM TKTTSLNTAY MELSGLRSED TAI YYCARER SSGYFDFWGQ GTLVTVSS        118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 235
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              DI VMTQSPSS LSASVGDRVT I TCRASQSI S SFLNWYQQKP GKAPKLLI YL ASSLQSGVPS    60
              RFSGSGSGTD FTLTI SSLQP EDFATYYCQQ SYSTPI TFGQ GTKVEI K                  107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 236
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGAE VKKPGASVKV SCKTSGYTFT GYYMHWVRQA PGQGLEWMGW I NPNSDNTGY       60
              AQKFQGRVFM TKTTSLNTAY MELSGLRSED TAI YYCARER SSGYFDFWGQ GTLVTVSS        118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 237
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              DI VMTQSPSS LSASVGDRVT I TCRASQSI S SFLNWYQQKP GKAPKLLI YA ASSLQSGVPS    60
              RFSGSGSGTD FTLTI SSLQP EDFATYYCQQ AYSTPI TFGQ GTKVEI K                  107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 238
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
                                                             Page 46

                                               PDl 1s eql i s t . t x t
<removed-date>
              QVQLVQSGAE VKKPGASVKV SCKASGYPFT GYYMHWVRQA PGQGLEWMGW I NPLSDSTGS           60
              AQKFQGRVFM TKTTSLNTAY MELSGLRSED TAI YYCARER SSGYFDFWGQ GTLVTVSS            118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 239
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
<removed-apn>
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              DI VMTQSPSS LSASVGDRVT I TCRASQSI S SYLNWYQQKP GKAPKLLI YA ASSLQSGVPS        60
              RFSGSGSGTD FTLTI SSLQP EDFATYYCQQ SYSTPI TFGQ GTKLEI K                      107
              <212> Ty pe : PRT
              <211> Lengt h : 107
                    Sequenc eName : SEQ I D NO: 240
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              QVQLVQSGAE VKKPGASVKV SCKTSGYTFT GYYMHWVRQA PGQGLEWMGW I NPNSDNTGY           60
              AQKFQGRVFM TKTTSLNTAY MELSGLRSED TAI YYCARER SSGYFDFWGQ GTLVTVSS            118
              <212> Ty pe : PRT
              <211> Lengt h : 118
                    Sequenc eName : SEQ I D NO: 241
                    Sequenc eDes c r i pt i on :
              Sequenc e
              --------
              <213> Or gani s mName : Ar t i f i c i al Sequenc e
              <400> Pr eSequenc eSt r i ng :
              DI VMTQSPSSLSASVGDRVTI TCRASQSI SSFLNWYQQKPGKAPKLLI YAASSLQSGVPSRFSGSGSGTDFTLTI SSLQP
              EDFATYYCQQPYSTPI TFGQGTKVEI K
              <212> Ty pe : PRT
              <211> Lengt h : 107
                     Sequenc eName : SEQ I D NO: 242
                     Sequenc eDes c r i pt i on :
                                                      Page 47

